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Abstract 
This thesis addresses current issues regarding assessment of physical activity (PA) 
and physical function (PF) status of haemodialysis (HD) patients, specifically: What 
is the recommended wear time to provide a reliable accelerometer estimate of 
habitual PA and sedentary behaviour? Can similar outcomes from different 
accelerometers be used interchangeably? Do subjectively and objectively estimated 
PA outcomes agree closely enough to be pooled? Which PF assessments are 
potentially most ‘useful’? This thesis also explores potential risk factors of arterial 
stiffness, a strong predictor of mortality in this population.  
A PA reliability study involving 70 maintenance HD patients (55.9 ± 15.7 years) over 
a seven-day monitoring period indicated one dialysis day and two non-diaysis days 
with a minimum of eight hours wear per day would provide reliable estimates of PA 
and sedentary behaviour regardless of accelerometer employed, and allowed 90% 
sample retention. Concordance studies indicated broad agreement for similar 
outcomes obtained via ActivPAL and Actigraph GT3X accelerometers but they were 
not interchangeable. ActivPAL is recommended for monitoring steps taken and time 
seated, Actigraph activity count output for total/overall PA. Questionnaire and 
accelerometer estimated PA outcomes may not be used interchangeably or pooled. 
More of the shared variance of physical performance was explained by clinical, 
demographic and habitual PA factors than for self-reported functional status thus 
recommending the former. Age, blood pressure and HD vintage were determinants 
of arterial stiffness, however PA and cardiorespiratory fitness did not appear to be 
risk factors in this sample.  
This thesis makes clear recommendations regarding implementation of PA and PF 
assessment methods, and illustrates their application on sample retention, as well 
as characterising and potentially identifying individuals at risk of poor outcomes. 
Emergence of HD vintage as a risk factor for arterial stiffness underscores the need 
for further research into adjunctive lifestyle interventions to manage health threats in 
this population.  
Key words: physical activity, physical function, arterial stiffness, chronic kidney 
disease 
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Chapter 1: General Introduction and Literature Review 
1.1 Introduction and background 
Chronic kidney disease (CKD) is a long term condition in which the ability remove 
waste solutes, regulate fluid volume and electrolyte balance, and produce 
erythropoietin necessary for red blood cell production is irreversibly degraded. This 
condition is classified according to five stages of progressive organ impairment 
defined by thresholds of glomerular filtration rate (GFR) (table 1.1). Chronic kidney 
disease stage 5 represents the most severe stage, and is defined as little or no 
residual kidney function (<15 ml/min/1.73m2), at which point survival is dependent 
on renal replacement therapy (RRT) (National Kidney Foundation 2002).  
Table 1.1 Stages of CKD according to severity of kidney impairment. 
CKD Stage  GFR* Description  
1 >90 Normal kidney function but urine findings or structural 
abnormalities or genetic trait indicate kidney disease. 
2 60 - 89 Mildly impaired kidney function, and other findings (as for 
stage 1) indicate kidney disease.  
3A 45 - 59 Moderately impaired kidney function  
  3B 30 - 34 
4 15 - 29 Severely impaired kidney function  
5 <15 or 
dialysis 
Very severe impairment, or ‘established renal failure’.  
*GFR values are normalised to a surface area of 1.73 m2 (The Renal Association 2009). 
Of the three treatment options available for RRT (peritoneal dialysis, haemodialysis, 
kidney transplant) haemodialysis (HD) therapy is the most common first modality 
(USRDS 2010; SRRR 2011; UKRR 2012).  Maintenance HD is typically four to five 
hours in duration and provided in a hospital setting thrice weekly. Although renal 
transplants have increased, 42% of the prevalent stage 5 CKD population continue 
with maintenance HD, a proportion unchanged over the last decade (SRRR 2013). 
Haemodialysis is likely to remain a lifelong therapy for many individuals.  
1.1.1 Prevalence and health burden of chronic kidney disease 
It is estimated that prevalence of stages 3 to 5 CKD is 6% in the UK population 
(Roderick et al. 2011) and 10 - 16% for all stages of impairment worldwide making 
this condition a global health problem (Hallan et al. 2006; Coresh et al. 2007; 
Couser et al. 2011). Approximately 55,000 people in the UK currently receive RRT, 
of who 4,501 are Scottish residents (SRRR 2013). Alarmingly, annual incidence of 
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RRT in Scotland has more than doubled from 41 to 101 per million population since 
1983 (SRRR 2013). Projected yearly population growth of around 5% is forecast for 
the UK (UKRR 2010) and North America (USRDS 2010). Not only is HD therapy the 
most common mode of RRT, it is also the most expensive in developed countries 
(Salonen et al. 2007; Just et al. 2008; Arrieta et al. 2011). The average cost of UK 
hospital based HD therapy per person has been calculated at £35,023 (Baboolal et 
al. 2008). Although people with stage 5 CKD represent less than 0.01% of the UK 
NHS patient population 3% of its annual budget is devoted to RRT (UKRR 2010). 
Similarly, in North America RRT accounts for 5.9% of Medicare expenditure (26.8 
billion USD) with the majority devoted to HD (USRDS 2010).  
Historically, glomerulonephritis, multisystem diseases, interstitial nephropathies 
have been the predominant primary renal diagnoses. However, stage 5 CKD is 
increasingly being driven by a rising tide of diabetes which has increased more than 
threefold over the last 30 years and now accounts for at least a quarter of primary 
renal diagnoses (USRDS 2012; UKRR 2012; SRRR 2013). In addition the last three 
decades have witnessed a dramatic shift in age demographic as the incidence rate 
for RRT acceptance among older adults (>64 years) has ballooned since 1980 
(figure 1.1). Median age of the HD population is now around 65 years (UKRR 2012; 
SRRR 2013), with men accounting for 63% of those starting RRT (UKRR 2012). 
Figure 1.1 UK RRT incidence rate from 1980 to 2011 (UKRR 2012).  
 
1.1.2 Life expectancy in stage 5 CKD 
Maintenance HD for stage 5 CKD is life-saving, however longevity is still 
considerably reduced compared to non-uraemic peers. Illustratively, average life 
expectancy for an asymptomatic 55 year old in the UK is 26 years, but just five 
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years for a person receiving dialysis therapy in Scotland (SRRR 2010). This 
disparity is even more profound for younger adults who experience an alarming 18 
fold relative reduction in life expectancy (figure 1.2) compared to non-uraemic 
individuals (UKRR 2012).  
Figure 1.2 Relative risk of death for prevalent RRT population compared to the 
general population (UKRR 2012). 
 
First year survival rates for the dialysis population have continued to improve 
incrementally, however five-year survival rate remains as low as 35% (Breidhardt et 
al. 2011; UKRR 2012; USRDS 2012; SRRR 2013). Such statistics are a sobering 
reminder that despite advances in medical management, living with stage 5 CKD 
and HD therapy is still a fragile existence. Moreover UK renal registry data indicate 
mortality rate among older adults receiving HD in Scotland are significantly higher 
compared to the rest of the UK (figure 1.3). 
Figure 1.3 Mortality rate per 1000 patients years by UK country and age group 
for prevalent dialysis patients (UKRR 2012).  
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1.1.3 Cardiovascular health and mortality in stage 5 CKD 
Shorter life expectancy in this clinical population is mediated largely by 
cardiovascular (CV) causes. Disproportionately high CV morbidity and mortality in 
this population is largely attributed to increased stiffness of central and conduit 
arteries (London et al. 2011; Verbeke et al. 2011). Adverse haemodynamic 
consequences of large artery stiffening include widening of pulse pressure and 
isolated systolic hypertension (O’Rourke and Hashimoto 2007). In the CKD 
population this invariably leads to left ventricular hypertrophy (LVH) (Marchais et al. 
1993; Nitta et al. 2004; Wang et al. 2007), and reduced coronary perfusion during 
diastole (O’Rourke and Hashimoto 2007). These outcomes are all independent 
predictors of CV morbidity and mortality of HD patients (Silberberg et al. 1989; 
Parfrey et al. 1996; Iseki et al. 1997). 
1.1.4 Risk factors for CVD in stage 5 
Vascular aging is accelerated in people with stage 5 CKD (Pannier et al. 2005; 
Sigrist et al. 2007; Suzuki et al. 2011), and it is believed this is due to greater burden 
of traditional and non-traditional CV risk factors (Zoccali 2000; UKRR 2012). Level 
of physical activity (PA) and cardiorespiratory fitness (CRF) are important CV and all 
cause mortality risk factors (Blair et al. 2001) and are similarly implicated in survival 
of HD patients. Individuals starting HD who are sedentary, frail or report severe 
difficulties with moderate activities are most at risk of poor outcomes (O’Hare et al. 
2003; Stack et al. 2005; Johansen et al. 2007). Equally, higher levels of PA and a 
fitness level sufficient to walk up a moderate incline significantly ameliorate mortality 
risk in this population (Sietsema et al. 2004; Stack et al. 2005; Tentori et al. 2010). 
Worryingly, the dialysis population is characterised by high prevalence of low PA 
and CRF (Stack et al. 2005; Parsons and King-van Vlack 2009; Painter et al. 2011). 
1.1.5 Health management in stage 5 CKD 
Haemodialysis therapy for stage 5 CKD can prolong life and ameliorate some of the 
symptoms associated with this condition. However, there are indications that 
commencement of HD also coincides with a decline towards frailty (Johansen et al. 
2010a), which is also predictive of poor short-term prognosis (Johansen et al. 2007). 
In light of their robust associations with health outcomes, routine monitoring of 
physical function and encouragement of PA by all nephrology staff is recommended 
by the Kidney Disease Outcomes and Quality Initiative (KDOQI) as part of health 
management (National Kidney Foundation 2005). However, PA counselling 
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practices among renal healthcare providers remain inconsistent (Delgado and 
Johansen 2010). This could reflect low awareness, but it may be difficult to 
operationalise recommendations when there is little information to support renal 
healthcare providers on how they may be implemented. There is a pressing need for 
clear guidance in this stagnant area of health management. 
1.1.6 Monitoring physical activity and physical function in stage 5 CKD 
Selection of the most useful assessment instruments to monitor PA and level of 
physical function is hampered by the bewildering array of subjective and objective 
outcomes that have already been employed in the CKD literature. Questionnaires 
have been widely used to monitor PA due to their low cost and expediency but they 
have recognised limitations. Consequently, participant mounted activity monitors 
that objectively estimate activity are increasingly being adopted in CKD health 
research for PA surveillance, however data reduction criteria are infrequently stated. 
Variable compliance with monitor wear has been observed in PA studies (Rich et al. 
2013), therefore minimum wear time recommendations are necessary to ensure 
data are sufficiently reliable for meaningful analysis (Baranowski et al. 2008). 
Importantly, wear criteria need to be stringent enough to ensure data integrity while 
at the same time allowing retention of an adequately representative sample 
(Catellier et al. 2005; Hinkley et al. 2012). Moreover, there are indications that wear 
time requirements for clinical populations characterised by low PA differ to current 
recommendations developed in samples of asymptomatic adults (Chen et al. 2009; 
Miller et al. 2013). Reliable characterisation of PA is crucial to enable clinicians to 
identify individuals at risk of poor outcomes and for investigators exploring 
behaviour and health outcomes in CKD. In addition, given the implications for 
analyses and conclusions, which form the basis of health recommendations, 
research to inform activity monitor data reduction criteria in stage 5 CKD is strongly 
indicated.  
A single question regarding exercise frequency is prognostic of mortality among 
dialysis patients (O’Hare et al. 2003; Tentori et al. 2010). However, PA data 
obtained via activity monitors provide greater information density regarding 
behaviour indices and patterns. Moreover, they are better able to estimate activity at 
the lower end of the spectrum where many clinical populations tend to operate as 
well as quantify sedentary time, which is now a putative health risk factor 
independent of PA (Owen et al. 2010; Thorp et al. 2011). Physical activity is a 
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burgeoning area of research in CKD but there is little uniformity of activity monitors 
employed and few data from clinical populations to guide device selection. In 
addition, a considerable amount of PA data has been obtained via self-report 
questionnaires already. It would be advantageous to determine whether this bank of 
information could be meaningfully synthesised with data obtained via contemporary 
objective PA assessment methods. Research in this area is warranted in order that 
recommendations can be made regarding utility and standardisation of PA 
assessment instruments appropriate to outcomes of interest. 
Routine monitoring of physical function (PF) is a KDOQI recommendation but there 
is limited guidance as to how this may be achieved. Cardiorespiratory fitness 
determined via cardiopulmonary exercise test is predictive of survival across the 
CKD trajectory (Sietsema et al. 2004; Gulati et al. 2012) but is not feasible as a 
routine outcome and may not adequately indicate functional limitations. Physical 
performance tests that replicate common activities (chair stands, walk tests) provide 
more feasible proxy measures of fitness and strength in the clinical setting and are 
predictive of mortality, falls, hospitalisations and dependency in asymptomatic older 
adults (Buatois et al. 2008; Tiedeman et al. 2008; Braden 2012). Functional mobility 
testing is similarly predictive of health outcomes (bone fractures, mortality, 
dependency) in the CKD population (Jamal et al. 2006, Cook and Jassal 2008; 
Roshanraven et al. 2013). An important ‘person centred’ perspective of an 
individual’s level of function can be obtained by questionnaires, which have 
prognostic utility comparable to or better than clinical biomarkers of health status in 
stage 5 CKD (DeOreo et al. 1997; Lowrie et al. 2003; Knight et al. 2003; Mapes et 
al. 2003). There is now growing awareness of the prognostic utility of PF and its 
contribution to frailty (Fried et al. 2001). Consequently, there is a pressing need to 
identify the most useful PF outcomes to support healthcare providers in nephrology 
with implementation of KDOQI recommendations and current government health 
strategies.  
Augmentation index (AI) and aortic pulse wave velocity (PWV) are commonly used 
as indicators of increased arterial stiffness, which is implicated in premature 
mortality of people with stage 5 CKD. Both vascular indices are associated with LVH 
(Marchais et al. 1993; Nitta et al. 2004) and have prognostic utility in the stage 5 
CKD population (London et al. 2001a; Blacher et al. 2003; Verbeke et al. 2011). 
Importantly, accumulating evidence indicates PA that improves or maintains CRF 
attenuates vascular stiffening of non-uraemic adults of all ages (Vaitkevicius et al. 
 7 
1993; Tanaka et al. 2000; Boreham et al. 2004; Gando et al. 2010b; Aoyagi et al. 
2010). Physical activity and CRF are implicated in longevity of HD patients and form 
part of KDOQI recommendations for CV health management. However, the 
relationship between PA, CRF and arterial stiffness in this population has received 
little attention. Exploration in this area would seem a prerequisite for structured PA 
interventions aimed at reducing CV mortality and morbidity. In addition, although AI 
and PWV both measure arterial stiffness they are not interchangeable (Laurent et al. 
2006; Sharman et al. 2009). Guidance regarding whether one or both outcomes are 
most appropriate for stage 5 CKD would be timely given that arterial stiffness is now 
being employed as an intermediate endpoint in studies targeting vascular health. 
1.1.7 Summary 
Despite medical advances people living with stage 5 CKD and maintenance HD 
experience shorter life expectancies. Encouraging PA and monitoring physical 
function are recognised as important in augmenting health management in stage 5 
CKD. However, the literature shows little uniformity of assessment methods and 
even less exploration of their clinical utility. Although PA and CRF are implicated in 
survival of HD patients there is a paucity of data regarding their relative contribution 
to arterial stiffness an important CV risk factor.  Exploration of these relationships 
may also help inform timely selection of the most appropriate index of arterial 
stiffness for the stage 5 CKD population. The overarching aims of this project are to:  
x Provide substantive recommendations to support healthcare providers and 
investigators with informed selection of PA and PF assessment instruments 
that reflect the current shift towards to ‘person-focused’ care.  
x Explore whether lower mortality observed with higher levels of PA and CRF 
is potentially mediated via a direct effect on arterial stiffness in this 
population. 
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1.2 Literature Review 
1.2.1 Epidemiology of physical activity in stage 5 CKD 
1.2.1.1 Prevalence of low physical activity in stage 5 CKD 
There is general agreement from a large body of studies that low levels of physical 
activity (PA) are highly prevalent among people with stage 5 CKD (table 1.2). Early 
research indicated 59% were not capable of PA more strenuous than basic ADLs 
(Painter et al. 2001) a statistic that appears to have changed very little. Large-scale 
epidemiological studies such as the Dialysis Mortality and Morbidity Study (DMMS) 
and the more recent international Dialysis Outcomes and Practice Patterns Study 
(DOPPS) agree that 56% to 63% of dialysis patients exercised once a week or less 
(O’Hare et al. 2003; Stack et al. 2005; Tentori et al. 2010). Worryingly, this figure 
appears to be higher (75%) among women receiving HD (Winkler et al. 2002). 
These findings are consistent with pooled accelerometry data from single centre 
studies in different countries that classified almost two thirds of HD patients as 
sedentary or low-active (Cupisti et al. 2011; Avesani et al. 2012).  
Just 14% of incident HD patients in the Choices for Healthy Outcomes in Caring for 
ESRD Study reported exercising three or more times per week (Longenecker et al. 
2002). Smaller cohort studies, using non-standardised questionnaires (Painter et al. 
2000; Allen and Gappelmaier 2001) found that even fewer patients (10.4% to 12%) 
met contemporary exercise guidelines, with exercise frequency even lower for 
female HD patients (Allen and Gappelmair 2001; Nielens et al. 2001; Brenner and 
Brohart 2008; Sridharan et al. 2013) as observed in the general population 
(Townsend et al. 2012). Although exercise frequency is predictive of survival in 
stage 5 CKD (O’Hare et al. 2003; Stack et al. 2005; Tentori et al. 2010) it does not 
accurately characterise other aspects of habitual PA that may also endow health 
protective benefits (Ainsworth et al. 2011). Furthermore, exercise is often used 
interchangeably with PA. Although both terms involve movement and energy 
expenditure above basal metabolic rate, exercise is a subcategory of PA and is 
defined as: “Physical activity that is planned, structured, repetitive and purposive in 
the sense that the improvement or maintenance of one or more components of 
physical fitness is the objective” (Caspersen et al 1985, p. 128). More recent studies 
employing standardized questionnaires found just 18.6% to 25.5% of patients met 
consensus PA guidelines of 150 minutes of moderate to vigorous physical activity 
(MVPA) on most days of the week (Wong et al. 2011; Stringuetta-Belik et al. 2012).  
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Table 1.2 Physical activity level of m
aintenance haem
odialysis patients estim
ated via subjective and objective m
ethods. 
Study 
Sam
ple (n) 
M
/F %
 
Age 
PA m
easure 
Physical activity findings 
S
ridharan et al. 2013 
P
revalent H
D
 (n = 166)  
58/42 
62.0 ± 15.5 
S
tanford 7 day recall 
A
ctivity kcals/day: m
en 761 ± 315  w
om
en 588 ± 201 23%
↓(p < 0.001) 
Total kcals/day: m
en 2440 ± 590 w
om
en 1976 ± 452 (p < 0.001). 
M
atsuzaw
a et al. 2012 
P
revalent H
D
 (n = 202)  
48/52 
64 (57 - 42) 
Lifecorder uniaxial 
accelerom
eter (w
aist 
m
ounted) 
M
edian total P
A
 m
ins/day: 42.7 (22.8, 65.8),  
M
edian steps/day: 3925 (2287, 6284). 
A
vesani et al. 2012 
P
revalent H
D
 (n = 134) 
64/36 
54.9 ± 15.9  
S
enseW
ear™
 A
rm
band 
A
verage daily physical activity outcom
e values: Total kcal/day 1938 ± 
437; Activity related kcal/day 289 (0; 1793); S
teps 5660 (73; 16565), 
M
E
T/day 1.39 ± 0.2. 45%
 classed as sedentary (< 5000 steps/day) 
P
hysical activity outcom
e values: dialysis vs non-dialysis days 
Total kcals/day: 1864 ± 408 vs 1985 ± 484 ↓6%
  (p = 0.001)  
P
A
 related kcal/day: 202 (0, 1152) vs 303 (0, 2113) ↓33%
 (p = 0.001) 
S
teps/day: 4620 (77, 13 957) vs 5544 (72, 18 220) ↓17%
 (p = 0.001) 
M
E
T/day: 1.33 ± 0.2 vs 1.42 ± 0.3 ↓6%
  (p = 0.001). 
S
tringuetta-Belik et al. 
2012 
P
revalent H
D
 (n = 102) 
55/45 
58.7 ± 15.1 
International Physical Activity 
Q
uestionnaire 
P
articipants 
categorised: 
active 
(25.5%
), 
irregularly 
active 
(34.3%
), 
inactive/sedentary (40.2%
). 
W
ong et al. 2011 
P
revalent H
D
 (n = 70) 
59/41 
57.0 ± 12.5 
G
lobal physical activity 
questionnaire (W
H
O
 2009) 
81.4%
 of participants categorised as low
 active (18.6%
) m
oderately 
active. 
P
ainter et al. 2011 
P
revalent H
D
 (83%
), 
P
D
 (10.1%
), Transplant 
6.8%
 (n = 1323) 
56/44 
62.4 ± 15.2 
Q
uestionnaire on frequency, 
duration, intensity of habitual 
physical activity 
57%
 reported them
selves ‘regularly active’. 13.2%
 m
et P
A
 health 
guidelines for frequency, duration, intensity. 
D
iabetic participants least likely to m
eet P
A
 guidelines. 
B
aria et al. 2011 
P
revalent H
D
 (n = 32) 
H
ealthy sedentary 
controls (n = 22). 
 
63/37 
46.3 ± 12.2 
S
ensew
ear P
ro2 A
rm
band 
m
onitor biaxial accelerom
eter. 
          P
hysical activity scale for the 
elderly (P
A
S
E
) 
P
hysical activity outcom
e values: dialysis vs non-dialysis days  
S
teps/day: 7094 ± 2436 vs 8961 ± 3346, ↓21%
 (p < 0.01)  
Total kcal/day: (2096 ± 324 vs. 2265 ± 413, ↓7.5%
(p < 0.01) 
A
ctivity kcal/day: 278.7 (9.5, 1145) vs 364.5 (90, 1828), ↓24%
 (p < 0.01) 
P
A
 counts/day: 6599 ± 1503 vs. 7236 ± 1767, ↓9%
 (p = 0.05). 
M
E
T/day: 1.4 ± 0.3 vs. 1.5 ± 0.3, ↓7%
 ( p < 0.01)  
C
om
parison subgroup H
D
 patients vs sedentary controls (n = 22) 
H
D
 steps/day 7,425 ± 2,567 vs 10,427 ± 1,988 ↓29%
 (p < 0.01) 
P
A
 counts: 6,709 ± 1,179 vs 8,140 ± 679. ↓18%
 (p < 0.01) 
Total kcal/day: 2,111 ± 268 vs 2,514 6 307 ↓16%
 (p < 0.01) 
A
ctivity kcal/day: 303 (76 to 1,251) vs 565 (214 to 1,319) ↓46%
 (p<0.01) 
M
E
T/day: 1.38 ± 0.26 vs 1.52 ± 0.14 (p = 0.09) 
P
A
S
E
: 66 (3,181) vs 181 (3, 286), ↓74%
 (p < 0.01) 
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Study 
Sam
ple (n) 
M
/F %
 
Age 
PA m
easure 
Physical activity findings 
M
afra et al. 2011 
P
revalent H
D
 (n = 24) 
C
ontrols (n = 18)  
75/25 
67.0 ± 14.7 
62.3 ± 15.3 
S
ensew
ear P
ro2 A
rm
band 
biaxial accelerom
eter 
S
teps/day: controls 8104 ± 5419; H
D
 norm
al C
R
P
 6016 ± 3752; H
D
 w
ith 
increased C
R
P
 2801 ± 2754 (p = 0.001) 
Total kcal/kg/day: controls 31.8 ± 7.0, H
D
 norm
al C
R
P
 (32.0 ± 6.7; H
D
 
w
ith increased C
R
P
 25.5 ± 4.1 (p = 0.012).  
C
upisti et al. 2011 
P
revalent H
D
 (n = 50) 
C
ontrols (n = 33)  
64/36 
59.0 ± 13.0 
S
ensew
ear P
ro2 A
rm
band 
biaxial accelerom
eter. 
C
om
parison H
D
 vs controls  
M
ean daily M
E
Ts: 1.3 ± 0.3 vs. 1.5 ± 0.2 ↓13%
 (p < 0.01) 
M
ins/day in P
A
 >3 M
E
Ts: 89 ± 85 vs. 143 ± 104 ↓38%
 (p < 0.05) 
S
teps/day: 5584 ± 3734 vs. 11,735 ± 5,130 ↓52.5%
 (p < 0.001) Total 
kcals/day: 2190 ± 629 vs. 2462 ± 443 ↓11%
 (p < 0.05) 
62%
 defined as sedentary (< 1.4 M
E
Ts/day). 
A
garw
al and Light 
2011 
P
revalent H
D
 (n = 114) 
C
K
D
 2-4 (n = 148) 
C
ontrols (n = 19)  
63/37 
97/3 
89/11 
51.5 ± 11.4 
69.0 ± 10.6 
60.1 ± 10.0 
A
ctiw
atch 64 accelerom
eter 
(W
rist m
ounted) 
A
verage percentage of day spent sedentary : H
D
 71%
; C
K
D
 66%
; 
controls 56%
 (p < 0.0001). 
Li et al. 2010 
P
revalent H
D
 (n = 187)  
51/49 
59 
(IQ
 
not 
stated) 
International Physical Activity 
Q
uestionnaire 
M
edian  M
E
T m
inutes/w
eek 1743 (0 - 13482). Inactive 26.7%
, m
inim
ally 
active 73.3%
. 
Tentori et al. 2010 
D
O
P
P
S
 
P
revalent H
D
 &
 P
D
 
(n = 20920) 
58/42 
60.7 ± 14.8 
S
ingle question on exercise 
frequency 
S
evere difficulty w
ith: vigorous P
A
  = 69%
; m
oderate P
A
  = 38%
  
S
elf reported exercise frequency: daily 14.1%
, 4 - 5x/w
eek 5.7%
, 
3x/w
eek 17%
; 1x/w
eek 10.5%
; < 1x/w
eek 8.5%
; never 43.9%
. 
K
utsuna et al. 2010 
P
revalent H
D
 (n = 153) 
43/57 
64.0 ± 11.0 
Lifecorder uniaxial 
accelerom
eter  
A
verage daily P
A
 in activities > 1.8M
E
Ts = 43.1 ± 29 m
ins/day. 
M
asuda et al. 2009 
P
revalent H
D
 (n = 35) 
P
revalent P
D
 (n = 26)  
69/31 
58.3 ± 14.7  
47.5 ± 14.2 
O
m
ron pedom
eter 
A
verage steps/day: H
D
 3391 ± 2010 vs P
D
 6336 ± 4924.  
V
an den H
am
 et al. 
2005 
P
revalent H
D
 (n = 18) 
R
enal Transplant (n = 
35) 
C
ontrols (n = 21) 
63/37 
51/49 
52/48 
49.0 ± 11.9 
52.3 ± 10.4 
54.9 ± 10.8 
B
aecke A
ctivity questionnaire 
S
port activity  H
D
 1.8 ± 0.6  v Transplant 2.2 ± 0.8 v C
ontrols 2.5 ± 0.8  
Total activity H
D
 6.2 ± 1.5 v Transplant 7.2 ± 1.5 v C
ontrols 7.8 ± 1.4 
D
ifference betw
een H
D
 and controls: S
port ↓28%
 Total ↓21%
 (p < 0.05). 
Zam
ojska et al. 2006 
P
revalent H
D
 (n = 60) 
C
ontrols (n = 16) 
45/55 
36/64 
60 ± 13 
56 ± 6 
P
edom
eter (O
regon Scientific) 
A
verage steps/day 3500 
48 hour interdialytic stepcount: H
D
 6896 ±2357 vs controls 14181 ± 
5383 ↓51%
 (p < 0.001). 
M
ajchrzak et al. 2005 
P
revalent H
D
 (n = 20)  
 
50/50 
50.1 ± 9.9 
H
ip m
ounted R
T-3 triaxial 
accelerom
eter 
P
A
 counts/day: dialysis 128279 ± 74009; non-dialysis 168744 ± 95168  
(p = 0.025). 
dialysis day counts/day: diabetics 82397 ± 48,166; non-diabetic 152985 
± 74987 (p = 0.038);  
non-dialysis counts/day diabetics 85593 ± 40,054 versus 213,517 ± 
85,633 (p < 0.001).  
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Study 
Sam
ple (n) 
M
/F %
 
Age 
PA m
easure 
Physical activity findings 
S
tack et al. 2005 
O
’H
are et al. 2003 
D
M
M
S
 W
ave 2 
Incident H
D
 &
 P
D
 
(n = 2264) 
54/46 
58.0 ± 16 
S
ingle question on exercise 
frequency 
S
evere difficulty w
ith: vigorous P
A
  = 75%
; m
oderate P
A
  = 42%
  
S
elf reported exercise frequency: D
aily or alm
ost daily 19.8%
; 4 - 
5x/w
eek 5.5%
; 2 - 3x/w
eek 18.4%
, about 1x/w
eek 11.1%
, <1x/w
eek 
10.0%
; alm
ost never or never 35.1%
.  
S
akkas et al. 2004 
P
revalent H
D
 (n = 12) 
P
revalent C
A
P
D
  
(n = 12) 
83/17 
58/42 
61.7 ± 13.9  
55.2 ± 10.9 
S
tanford 7 D
ay recall 
Q
uestionnaire 
A
verage total kcals/day: H
D
 2750 ± 600; C
A
P
D
 2750 ± 610. 
Johansen et al. 2003a 
Incident H
D
 (n = 54)  
 
67/33 
51.7 ± 17 
TriTrac-R
3D
 triaxial 
accelerom
eter. 
H
um
an activity profile 
4 tim
e m
easurem
ent tim
e 
points over 12 m
onths 
Triaxial activity counts declined 3.4%
/m
onth from
 baseline (p = 0.01). 
 H
A
P
 m
axim
um
 activity score declined 6 points/m
onth (p = 0.025). 
Note: 31 participants with 12 m
onth follow up data.  
Longenecker et al. 
2002 
C
H
O
IC
E
 study 
Incident H
D
 (73%
) 
Incident P
D
 (27%
) 
(n = 1041) 
54/46 
57.8 ± 0.5 
Tw
o questions on exercise 
frequency long enough to elicit 
perspiration. 
14%
 reported P
A
 sufficient to elicit perspiration (≥ 5 M
E
Ts) ≥ 3 
tim
es/w
eek.  
W
inkler et al. 2002 
prevalent H
D
 (n = 44)  
0/100 
61.2 ± 10.3 
S
ingle yes/no P
A
 question. 
“D
o you exercise regularly” 
75%
 reported not doing regular P
A
. 
N
ielens et al. 2001 
P
revalent H
D
 (n = 32) 
38/62 
45.9 ± 13.1 
P
re-transplant P
A 
B
aecke A
ctivity questionnaire 
S
tanford 7-day recall  
 
C
om
parison w
ith norm
 values: 
S
core: 5.9 ± 2.39 ↓22%
 (p < 0.05), Fem
ales 4.1 ± 2.27 ↓35%
 (p < 0.01) 
Total kcals/day: M
ales 2367 ± 499 ↓26%
 (p < 0.05), Fem
ales 1869 ±367 
↓18%
 (p < 0.01). 
A
llen and G
appelm
aier 
2001 
P
revalent H
D
 (n = 135)  
58/42 
56.0 ± 17.0 
Three questions on exercise 
habits 
60%
 exercised > 1 x/w
eek.  
10.4%
 expended > 1000 kcal/w
eek in exercise.  
M
ales m
ore active. N
o fem
ales m
et exercise E
E
 requirem
ent 
Johansen et al. 2000 
P
revalent H
D
 (n = 34) 
S
edentary controls 
(n = 80) 
65/35 
51.5 ± 3.0 
TriTrac-R
3D
 triaxial 
accelerom
eter. 
 S
tanford 7 day recall  
P
A
 counts/day: H
D
 104,718 ± 9631 vs controls 161,255 ± 6792 controls. 
↓ 35%
 C
I: 20 to 50%
 (p < 0.0001) ↑difference w
ith advancing age (15%
 
at 30 yrs to 57%
 at 70 yrs). 
7D
R
 calculated kcal/kg/day: H
D
 33.6 ± 0.5 vs controls 36.2 ± 0.5 ↓7%
  
(p = 0.002). 
P
ainter et al. 2000 
P
revalent H
D
 (n = 286) 
43/57 
55.9 ± 15.2 
S
elf-report. P
A
 categorisation: 
1- A
D
Ls only; 2- stretches &
 
strengthening; 3-som
e 
exercise but less than 
recom
m
endations; 4- 
achieving exercise guidelines 
59%
 reported no P
A
 above basic A
D
Ls. 12 %
 reported exercising at 
recom
m
ended levels for m
aintaining C
V
 health. 
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A larger cohort study indicated that this could be as low as 13.2% (with diabetics 
even less active) despite 57% of respondents perceiving themselves to be regularly 
active (Painter et al. 2011). Similarly low levels of PA are reported in smaller studies 
employing objective measures. Average daily step counts, activity counts, minutes 
of MVPA, and activity related energy expenditure (EE) are 18% to 52.5% lower than 
those observed for age matched individuals without CKD (Johansen et al. 2000; 
Zamojska et al. 2006; Baria et al. 2011; Cupisti et al. 2011; Mafra et al. 2011). 
Notably, habitual PA of HD patients is even lower (18% to 46% depending on 
outcome) than sedentary non-uraemic peers (Johansen et al. 2000; Baria et al. 
2011). Furthermore, this disparity widens with advancing age (Johansen et al. 
2000), systemic inflammation and diabetes (Majchrzak et al. 2005; Mafra et al. 
2011). Notably, the average activity related EE among HD patients is just 15% of the 
total daily amount (similar to thermogenic effect of diet) compared to 24% for 
sedentary controls (Baria et al. 2011). Steps taken are often below 4000 per day 
(Masuda et al. 2009; Nowicki et al. 2010; Matsuzawa et al. 2012), which is 
consistent with other chronic conditions including: heart failure; peripheral arterial 
disease; chronic obstructive pulmonary disease; cerebrovascular accident (Tudor-
Locke et al. 2009b; Tudor-Locke et al. 2011a). 
1.2.1.2 Influence of haemodialysis on physical activity behaviour 
Low PA in the HD population is mediated at least in part by periods of enforced 
sitting while dialysis takes place. Objectively estimated indices of PA such as step 
count, activity related EE and activity counts are 17% to 37% lower on dialysis days 
compared to non-dialysis days (Majchrzak et al. 2005; Baria et al. 2011; Avesani et 
al. 2012). Behaviour is influenced beyond the HD period with PA in the two hours 
immediately after dialysis higher than the same epoch on non-dialysis days but 
significantly lower by hour four (Majchrzak et al. 2005). Worryingly, objectively 
estimated PA declines at a rate of 3.4% per month after initiation of HD therapy 
(Johansen et al. 2003a). Moreover, there are indications that HD negatively 
influences PA to a greater extent compared to other RRT modalities. Average daily 
stepcount for HD patients is almost half that of peritoneal (PD) dialysis patients 
(Masuda et al. 2009) while PA of transplant recipients is not significantly different to 
controls (van den Ham et al. 2005) or norm values (Nielens et al. 2001).  
Increased sedentary behaviour is precipitated by commencement of HD therapy but 
there is a paucity of data regarding this metric in stage 5 CKD. Wong et al. (2011) 
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reported seated time of their HD patients descriptively, but did not express this 
outcome as a percentage of waking hours. An accelerometry study revealed 
maintenance HD patients spent a significantly greater percentage of their day 
sedentary (71%) compared to people with stage 2 - 4 CKD (66%) (Agarwal and 
Light 2011). Moreover, HD patients in the cited study spent almost 30% more of 
their waking hours sedentary compared to asymptomatic participants of more 
advanced age in the 2003 - 2004 National Health and Nutrition Examination Survey 
(NHANES) (Matthews et al. 2008). This observation is particularly noteworthy in light 
of accumulating evidence linking seated time with health outcomes. 
Figure 1.4 ‘Couch potato’ / ‘hospital potato’. 
  
(Smith 2014, with permission (left); Huggins 2007 (right)) 
A preponderance of studies indicate that people undergoing maintenance HD for 
stage 5 CKD have lower levels of PA compared to the general population. 
Importantly however, findings from these studies are based on data from self 
selected volunteers. Large epidemiological studies such as the DMMS (O’Hare et al. 
2003) excluded a significant percentage (12.5%) of enrolled stage 5 CKD 
participants who were unable to transfer or ambulate and over a third more (37%) 
due to missing PA data. Latterly excluded participants were characterised by being 
slightly older, more likely to be malnourished and receiving HD therapy all factors 
associated with lower PA. Furthermore, other studies excluded potential candidates 
that required assistive aids for ambulation (Kutsuna et al. 2010; Matsuzawa et al. 
2012). Consequently, the actual prevalence of low PA in the wider stage 5 CKD 
population as reported in the current literature is likely under-represented.  
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1.2.1.3 Physical activity counselling practices in stage 5 CKD 
In light of the high prevalence of low PA and sedentary behaviour among 
maintenance HD patients, and well documented associations with a range of health 
outcomes there is a compelling case for routine monitoring of these behaviours. 
Importantly, section 14.2 of the KDOQI guidelines recommends “all dialysis patients 
should be counselled and regularly encouraged by nephrology and dialysis staff to 
increase their level of physical activity” (National Kidney Foundation 2005, p. S60). 
Despite this recommendation Painter et al. (2011) found that while 57% of people 
with stage 5 CKD had “been talked to about exercise” only 34% had received 
literature on initiating physical activity. Disturbingly, an earlier multi-centre survey 
found that over 60% of healthcare providers did not assess the exercise patterns or 
recommend appropriate exercise programmes for people with stage 5 CKD 
(Johansen et al. 2003b). 
Figure 1.5 Physical activity assessment methods - precision and ease of use. 
 
1.2.1.4 Overview of physical activity assessment  
A spectrum of methods is available to estimate habitual PA, which trade varying 
levels of measurement precision for expediency and cost (figure 1.5), with selection 
dependent on intended purpose. Subjective estimates of PA obtained via self-report 
questionnaires have been widely employed in health research due to expediency 
and low cost.  However, questionnaire responses may be influenced by education 
level, cognition, gender, social desirability, and are susceptible to measurement 
error such as misreporting of PA volume (Bonnefoy et al. 2001; Washburn et al. 
2003; Mahabir et al. 2006) and misclassification of PA intensity (Arroll and 
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Beaglehole 1991; Sallis and Saelens 2000). The most precise measures of PA are 
obtained via ‘gold standard’ techniques such as doubly labelled water and 
calorimetry but these methods carry significant burden of time, expense, and 
specialised personnel to administer. Devices such as heart rate (HR) monitors and 
participant mounted motion sensors are more feasible methods of objectively 
quantifying PA. Moreover, they can capture behaviour patterns as well as important 
PA parameters such as steps taken, time seated and epochs of PA at various levels 
of intensity, which ‘gold standard’ methods cannot. 
1.2.1.5 Objective estimation of habitual physical activity in stage 5 CKD 
In light of recognised limitations of PA questionnaires there has been a shift towards 
using objective PA assessment methods for CKD health research over the last 15 
years. A third of the 51 located PA studies undertaken in stage 5 CKD (up until 
2013) have used objective methods but HR monitoring has thus far not been 
employed as an activity proxy. Although HR can indicate PA intensity and patterns, 
this method is influenced by dietary thermogenesis, emotions, ambient temperature, 
variability of HR response and heart pacing medications/devices (Freedson and 
Miller 2000; Janz 2002). In addition, concordance studies with accelerometry 
conclude HR monitoring has lower utility in estimating light PA (MacFarlane et al. 
2006; Manohar et al. 2013). 
Pedometry, which has been frequently employed in epidemiological research 
(Tudor-Locke et al. 2009a) was used in four stage 5 CKD health studies (table 1.3). 
As well as being relatively cheap and expedient, pedometry has clinical utility with 
respect to PA stratification and health outcomes. Thresholds of <5000 steps/day 
and >8000 steps/day may be employed to classify individuals as sedentary (Le 
Masurier et al. 2003; Tudor-Locke et al. 2009a) and those likely to be achieving PA 
guidelines respectively (Tudor-Locke et al. 2009a). Notably, a cutpoint of <4040 
steps/day is associated with low serum concentration of high density lipoprotein 
(<1.03 mmol/L) among HD patients which is predictive of increased CV risk 
(Masuda et al. 2009). Moreover, incremental increases of 1000 steps/day are 
independently associated with statistically significant reductions in blood pressure of 
women with type 2 diabetes (Manjoo et al. 2010) and a 10% lower risk of metabolic 
syndrome among middle-aged adults (Sisson et al. 2010). 
A limitation of pedometers however is that they do not provide specific data 
regarding activity patterns, epochs at a given PA intensity or time spent inactive. 
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Moreover, although walking is the most common manifestation of daily PA, the 
metric of steps taken excludes other activity modalities such as swimming, cycling 
and resistance exercise. In addition there is general agreement from laboratory and 
free living studies that accuracy of pedometers declines markedly with slower gait 
(Tyo et al. 2011; Feito et al. 2012) and in overweight and obese individuals (Crouter 
et al. 2005). Importantly, gait speed declines with advancing age and reduced lower 
limb muscle strength (Bohannon 1997). Consequently, these devices may be 
inappropriate for use in stage 5 CKD, which is characterised by advanced average 
age and reduced physical function.  
1.2.1.6 Accelerometers and physical activity surveillance in stage 5 CKD  
Conceptually, motion sensors that convert body accelerations into activity counts 
are suggested to be better suited to estimating PA and are increasingly being 
employed. However, there is little uniformity regarding type of accelerometers 
employed for PA monitoring in the CKD literature. Five different accelerometers, 
which detect movement via uniaxial (Lifecorder, Actiwatch 64), biaxial (Sense Wear 
Pro2 Armband) and triaxial configurations (TriTrac-R3D, RT-3 Triaxial Research 
Tracker) have been employed in studies involving people with stage 5 CKD (table 
1.3). Multiaxial accelerometers capture movement in a greater number of planes 
compared to uniaxial devices, and are thus believed to offer greater sensitivity to 
detection of light activities. Accelerometers convert body accelerations into activity 
counts which can be categorised into categories of PA intensity by most of these 
devices, however only the SenseWear Armband offers a stepcount output. 
In addition to diversity of accelerometer methods used to monitor behaviour in the 
HD population the PA literature shows a remarkable lack of uniformity regarding 
data reduction methods (table 1.3). This further compounds the problems faced by 
investigators wishing to compare results and pool PA data for further analysis. 
Studies vary widely in the number and type of days monitored (ie: dialysis, non-
dialysis, and weekend), often with no stated rationale. Monitoring protocols for 
pedometry studies vary from seven days (Ota et al. 1997; Masuda et al. 2009), to 48 
hours during mid-week and a weekend (Nowicki et al. 2010), to just two inter-dialytic 
days (Zamojska et al. 2006). Accelerometer studies in stage 5 CKD tend to adopt a 
seven-day monitoring protocol (table 1.3), which is a commonly prescribed period in 
health studies (Kristensen et al. 2010; Colley et al. 2011; Feinglass et al. 2011; 
Tudor-Locke et al. 2011b; Esliger et al. 2012).  
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Table 1.3 Objective physical activity assessm
ent m
ethods em
ployed in stage 5 CKD. 
Study 
Sam
ple 
Age 
Objective m
easure 
M
onitoring period 
Data reduction criteria 
O
ta et al. 1997 
P
revalent fem
ale H
D
 
patients (n = 41) 
61 ± 16 
P
edom
eter/calorie 
counter 
(S
uzuken) 
7 days, w
aking hours. 
N
ot stated. 
Johansen et al. 2000 
P
revalent H
D
 (n = 34)  
S
ed’ controls (n = 80)  
51.5 ± 3.0 
TriTrac-R
3D
 accelerom
eter 
7 days, w
aking hours. 
5 days w
ear. V
alid w
ear day criterion not 
defined. 
Johansen et al. 2001a 
Johansen et al. 2001b 
P
revalent H
D
 (n = 39)  
 
52.0 ± 16.0 
TriTrac-R
3D
 accelerom
eter 
7 days, w
aking hours. 
5 days w
ear. V
alid w
ear day criterion not 
defined. 
H
ung et al. 2002 
P
revalent H
D
 (n = 47) 
50.3 ± 16.7 
TriTrac-R
3D
 accelerom
eter 
7 days, w
aking hours. 
5 days w
ear. V
alid w
ear day criterion not 
defined. 
Johansen et al. 2003a 
P
revalent H
D
 (n = 54)  
51.7 ± 17.0 
N
ot stated 
N
ot stated. 
N
ot stated. 
M
ajchrzak et al. 2005 
P
revalent H
D
 (n = 20)  
 
50.1 ± 9.9 
R
T-3 
Triaxial 
R
esearch 
Tracker (hip m
ounted) 
7 days, w
aking hours. 
5 days w
ear (2x dialysis &
 2x non-dialysis 
days m
inim
um
). Valid w
ear day criterion 
not defined. 
Zam
ojska et al. 2006 
P
revalent H
D
 (n = 60) 
60.0 ± 13.0 
P
edom
eter (O
regon Scientific) 
2 m
id-w
eek interdialytic days. 
N
ot stated. 
M
asuda et al. 2009 
P
revalent H
D
 (n = 35)  
58.3 ± 14.7 
O
m
ron pedom
eter 
7 days, w
aking hours. 
N
ot stated. 
K
utsuna et al. 2010 
P
revalent H
D
 (n = 153) 
64.0 ± 11.0 
Lifecorder accelerom
eter 
7 days, w
aking hours. 
N
ot stated. 
N
ow
icki et al. 2010 
P
revalent H
D
 (n = 33)  
 
58.3 ± 10.1 
D
T1845SW
 
P
edom
eter 
(S
henzhen) 
48 
hours 
betw
een 
m
id-w
eek 
dialysis 
sessions 
and 
inter-
dialytic w
eekend period. 
N
ot stated. 
G
ordon et al. 2011 
P
revalent H
D
 (n = 26)  
55 ± 13 
TriTrac-R
3D
 accelerom
eter 
1x dialysis and 1x non-dialysis 
day. 
N
ot stated. 
A
garw
al &
 Light 2011 
P
revalent H
D
 (n = 114)  
C
K
D
 2-4 (n = 148)  
C
ontrols (n = 19) 
51.5 ± 11.4 
69.0 ± 10.6 
60.1 ± 10.0 
A
ctiw
atch 64 (w
rist m
ounted) 
H
D
 2 interdialytic days. 
C
K
D
 7 days C
ontrols 7 days. 
N
ot stated. 
W
rist m
onitor reactivity. 
M
afra et al. 2011 
P
revalent H
D
 (n = 24)  
C
ontrols (n = 18)  
67 ± 14.7 
62.3 ± 15.3 
S
ense 
W
ear 
P
ro2 
A
rm
band 
accelerom
eter  
7 days, 24 hours continuous. 
M
inim
um
 w
ear tim
e of ≥95%
. 
B
aria et al. 2011 
P
revalent H
D
 (n = 32) 
46.3 ± 12.2 
S
ense 
W
ear 
P
ro2 
A
rm
band 
accelerom
eter 
7 days, 24 hours continuous. 
M
inim
um
 w
ear tim
e of >90%
 (2x dialysis, 
2x non-dialysis, 1x w
eekend day m
inim
um
)  
C
upisti et al. 2011 
P
revalent H
D
 (n = 50)  
C
ontrols (n = 33) 
59.0 ± 13.0 
S
ense 
W
ear 
P
ro2 
A
rm
band 
accelerom
eter 
48 hour m
id-w
eek interdialytic 
period. 
N
ot stated. 
M
atsuzaw
a et al. 2012 
P
revalent H
D
 (n = 202)  
64 
(57 
- 
72) 
Lifecorder accelerom
eter  
7 days, w
aking hours. 
4 
non-dialysis 
days. 
V
alid 
w
ear 
day 
criterion not defined. 
A
vesani et al. 2012 
P
revalent H
D
 (n = 134)  
54.9 ± 15.9 
S
ense 
W
ear 
P
ro2 
A
rm
band 
accelerom
eter 
7 day, 24 hours continuous. 
M
inim
um
 w
ear tim
e of >90%
 (1 dialysis &
 1 
non-dialysis day m
inim
um
). 
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There is less consistency across studies regarding minimum wear days for 
inclusion of participant PA data. Studies using triaxial accelerometers (TriTrac R3D, 
RT3 Research Tracker) show some agreement in stating a minimum of five wear 
days but only Majchrzak et al. (2005) specified how many dialysis days. Overall 
however, there is no adherence to a minimum standard for number and type of 
days required for participant PA data inclusion. The majority of protocols employed 
a waking hour monitoring period with the exception of those employing the 
Sensewear Armband, which was worn for 24 hours/day (Baria et al. 2011; Mafra et 
al. 2011; Avesani et al. 2012). Notably, only studies using the latter defined a valid 
wear day (>90 to ≥95% wear for the 24 hour wear period) in contrast to the 
remaining studies, which did not state this aspect of data reduction. Importantly, 
observations from PA studies indicate not all participants will wear their 
accelerometer for the prescribed period despite reminders and incentives 
(Baranowski et al. 2008; Rich et al. 2013). In addition, monitor wear time during the 
day is usually discretionary and thus subject to variation both within and between 
participants (Hinkley et al. 2012). A remarkable unifying aspect of all PA studies 
undertaken with motion sensors in stage 5 CKD is that not one participant was 
excluded from final analyses due to insufficient accelerometer wear. Worryingly, it 
appears that the majority of PA studies in stage 5 CKD have not explicitly at least, 
taken into account intra- and inter-individual differences in wear time and their 
potential impact on reported outcome variables.  
1.2.1.7 Reliability of objectively estimated physical activity outcomes 
Guidance regarding minimum accelerometer wear time is crucial to ensure PA data 
are sufficiently reliable for final analyses so that the ability to detect relationships 
with other variables is not diminished (Baranowski et al. 2008). Measurement error 
negatively impacts statistical power to investigate PA mediated mechanisms 
influencing health and determine dose-response relationships that potentially form 
the basis of health recommendations (Schatzkin et al. 2009). Appropriate 
comparison and synthesis of pooled data from different PA studies is also more 
easily facilitated if standardised wear time guidelines are adopted to ensure data 
are reliable. Physical activity assessment may become an adjunct to traditional 
clinical indices of health status in the future. Therefore, reliable characterisation of 
PA is necessary to identify individuals at risk of poor outcomes, as well as monitor 
change in behaviour. 
 19 
Investigators using accelerometers are faced with important methodological 
considerations regarding how many hours of wear constitute a ‘valid’ day and the 
number of days required to provide a reliable estimate of various PA indices (Masse 
et al. 2005; Troiano et al. 2008; Ojiambo et al. 2011). Given that PA patterns of HD 
patients vary according to the hour of day and day of the week (Majchrzak et al. 
2005) wear time guidelines are necessary to quality assure accelerometer data. 
However, in so doing there is a trade-off between application of wear time criteria 
that are stringent enough to ensure data integrity while at the same time allowing 
retention of a sample size that is sufficiently large and representative for 
subsequent analyses (Catellier et al. 2005; Hinkley et al. 2012). Importantly, even 
small increases in stringency of wear time criteria can adversely affect sample size 
(Masse et al. 2005; Chen et al. 2009; Miller et al. 2013), thereby increasing sample 
bias by reducing representativeness and adversely affecting group estimates of PA 
and sedentary behaviour (Masse et al. 2005; Tudor-Locke et al. 2012; Herrmann et 
al. 2013; Toftager et al. 2013). 
Statistically-based data imputation is one strategy that researchers may utilise to 
manage missing or incomplete PA data. Catellier et al. (2005) evaluated different 
algorithms according to type of ‘missingness’ for imputing incomplete PA data due 
to wear time inconsistencies. While it was observed that imputing data was never 
worse than deleting incomplete days, performance of the algorithms was adversely 
affected by a number of factors including larger proportion of missing data, lower 
correlation of PA across days of the week. Furthermore, the authors acknowledged 
there was no way of objectively determining whether data were ‘missing at random’, 
‘completely missing at random’ or ‘not missing at random’. This approach also 
assumes that episodes of missing data represent average PA. 
1.2.1.8 Minimum required accelerometer wear time 
An alternative to discarding incomplete participant PA data is to establish the 
minimum required accelerometer wear time that reliably reflects an individual’s 
habitual PA and sedentary behaviour. The first part of this process is to determine 
inter-day variability of PA and sedentary behaviour indices via intra-class correlation 
coefficient (ICC) calculations (Baranowski and de Moor 2000). An ICC value of 1.0 
for a given outcome indicates perfect reliability or repeatability with all variation 
observed to be between rather than within participants. Intuitively, the greater the 
variability of accelerometer estimated PA between days the higher the number of 
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monitor wear-days that will be required to reliably reflect an individual’s habitual PA 
patterns.  
Opinions vary regarding the reliability value that should be achieved in order to 
define a measurement as being reliable. Hicks (2005) argues that a clinically 
acceptable ICC should be higher than 0.60. In contrast a minimum ICC of 0.70 is 
recommended by Nunally (1978) to determine sufficient reliability of an outcome 
instrument while higher thresholds of 0.90 and 0.95 are recommended for groups 
and use at an individual level respectively. Vincent (2005) contends that values 
below a reliability level of 0.80 are questionable for physiological data and this 
threshold has been adopted as the standard in previous PA reliability studies (Trost 
et al. 2000; Penpraze et al. 2006). Accelerometer wear time recommendations for a 
chosen level of reliability are then calculated by applying the Spearman Brown 
Prophecy Formula (Stanley 1971) to the ICC.  
There is agreement in the general literature that a monitoring period of three to five 
days is sufficient to objectively estimate PA of adults via accelerometry with a 
reliability level of 0.80 (Trost et al. 2005; Ward et al. 2005). Wear time 
recommendations of three and three to four days for minutes of total PA were 
reported in studies involving elderly and middle aged adults (Hart et al. 2011c and 
Matthews et al. 2002 respectively). Interestingly these reliability studies employed 
the same monitoring protocols of 21 consecutive days and uniaxial Actigraphs but 
chose markedly different cutpoints of >50 (Hart et al. 2011c) and >500 cpm 
(Matthews et al. 2002) for total PA. That their recommendations agree so closely 
suggests reliability of this PA index is stable regardless of cutpoint used. In addition 
Matthews et al. (2002) specified a minimum of 12 hours wear for a valid data, while 
this criterion was not explicitly specified by Hart et al. (2011c). If the latter study 
used all 21 days irrespective of daily wear period length it might suggest outcome 
reliability is less susceptible to the effects of minimum daily wear time compared to 
wear days as observed in studies of children (Penpraze et al. 2006; Mattocks et al. 
2008).  
A more stringent requirement of four to five days was recommended by Cook and 
Lambert (2008) for estimation of total PA despite using the same uniaxial 
accelerometer and cutpoint as Matthews et al. (2002). Differing recommendations 
may be due to a combination of greater variability in daily PA associated with a 
much younger sample and the smaller sample size of the former study. Notably, all 
 21 
of these studies performed reliability analyses on minutes of PA and did not 
normalise outcome values to wear time, which takes into account the effects of 
variation in daily wear. Physical activity of maintenance HD patients is effectively 
clamped three days of the week due to a daily routine organised around therapy 
requirements and a compulsory period of inactivity. Reliability of accelerometer 
estimated PA and thus required wear time might therefore be different for dialysis 
days compared to non-dialysis days.  
Hart et al. (2011c) recommended five days of accelerometer wear to achieve a 
desired reliability level of 0.80 for estimated sedentary behaviour defined as <50 
cpm in a sample of older adults. Longer wear time requirements of one week and 
five to nine days are reported for middle-aged (Matthews et al. 2002) and young 
adults (Cook and Lambert 2008) respectively. Although similar uniaxial Actigraph 
accelometers were employed in all three studies, discrepant results may be the 
result of Matthews et al. (2002) and Cook and Lambert (2008) using an unorthodox 
cutpoint (<500 cpm) to determine sedentary behaviour. However, these results are 
consistent with the study of Ojiambo et al. (2011), which recommended eight days 
wear to estimate sedentary behaviour of children with the same level of reliability. It 
would appear sedentary behaviour is more variable on a day-to-day basis, and 
more susceptible to discretionary wear necessitating more monitoring days to 
estimate this behaviour with acceptable reliability. As with total PA, none of the 
cited studies calculated reliability for this sedentary behaviour on values adjusted 
for wear time.   
Recommended monitor wear time for moderate to vigorous PA (MVPA) appears to 
reduce with advancing age which is attributed to observations that PA of this 
intensity is often planned, and less variable in older adults (Rowe et al. 2007). Five 
to nine days wear is recommended for Actigraph derived estimates of MVPA 
among junior school age children and adolescents (Trost et al. 2000). Cook and 
Lambert (2008) observed four to five days were required for acceptable reliability of 
MVPA in their sample of young rural and urban adults while three to four days were 
recommended for asymptomatic middle aged men and women (Matthews et al. 
2002). In contrast, only two days of accelerometer wear were needed to reliably 
estimate MVPA of older adults (Hart et al. 2011c). Given the advanced average and 
weekly routine HD patients follow it is possible wear requirements for this 
population may fall somewhere between those of Hart et al. (2011c) and Matthews 
et al. (2002).  
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Several studies of people with stage 5 CKD have used activity counts obtained from 
triaxial accelerometers as a gross measure of habitual PA (table 1.3). Notably, only 
one PA reliability study was located that examined required accelerometer wear 
time using triaxial accelerometry in a sample of low-active young men (Coleman 
and Epstein 1998). The authors employed generalisability theory (signified by G*), a 
similar ANOVA based framework to the ICC in order to determine measurement 
reliability. The cited study indicated three to four days of monitor wear produced 
acceptable levels generalisability (G* >0.77 and G* >0.82 respectively) for triaxial 
activity counts obtained from a Tri-Trac-3D accelerometer. Earlier research by 
Gretebeck and Montoye (1992) using three Caltracs to simulate triaxial 
accelerometer output reported two days wear achieved a reliability level of 0.83 in a 
sample of 30 men (average age 36.9 years) using the Spearman Brown formula. 
Recommendations for uniaxial Actigraph accelerometers are not dissimilar with two 
to three days wear sufficient to provide a reliability level of at least 0.80 for healthy 
middle aged adults (Matthews et al. 2002; Cook and Lambert 2008) and older 
adults (Evenson et al. 2012). Large scale reliability studies undertaken with 
children, report wear time recommendations for uniaxial Actigraph accelerometers 
consistent with those for adults of two (Rich et al. 2013) or three days (Mattocks et 
al. 2008).  
The only data pertaining to wear time recommendations for objectively estimated 
step counts come from reliability studies employing pedometers. Studies with 
monitoring protocols ranging from seven to 21 days (Tudor-Locke et al. 2005; Rowe 
et al. 2007 and Hart et al. 2011c respectively) and up to one year (Kang et al. 2009) 
suggest a minimum of two to six days wear for a reliability level of 0.80. As with 
accelerometer estimated PA outcomes the recommended monitoring period for 
older adults appears to be slightly less at two to four days (Rowe et al. 2007; Hart et 
al. 2011c) compared to three to six for middle-aged adults (Kang et al. 2009; Tudor-
Locke et al. 2011c). Although step count is commonly used as a motivational 
outcome there is no literature regarding wear time requirements for accelerometer 
estimates of this index.  
Taken together the reviewed studies indicate that three to five wear days are 
recommended to obtain reliable estimates of PA from accelerometers, but this may 
vary according to participant age, and variable of interest. In addition PA reliability 
studies have only recently begun to take into account variations in discretionary 
wear, which will have a bearing on recommendations (Hinkley et al. 2012). Notably, 
 23 
PA reliability studies have almost exclusively relied on uniaxial Actigraph 
accelerometers and there is an absence of data regarding triaxial output from later 
models such as the GT3X. Furthermore there are no recommendations regarding 
other monitors employed in PA studies or novel devices such as the ActivPAL.  
Deciding whether to retain or exclude participants without weekend monitor wear is 
another methodological consideration. There is little consensus regarding whether a 
weekend day is mandatory to reflect habitual PA of adults. Studies by Gretebeck 
and Montoye (1992) and more recently by Ojiambo et al. (2011) have 
recommended monitoring at least one weekend day. Weekend days are observed 
to have less time spent inactive compared to week days (Matthews et al. 2002; 
Parry and Straker 2013) with Sunday being a less active day than Saturday 
(Matthews et al. 2002). Time in MVPA is reported to be greater during the week 
compared to weekend days (Matthews et al. 2002). However, a recent study of 
older adults in residential care showed no significant difference in daily PA (Reid et 
al. 2013). There is general agreement purposeful inclusion of weekend PA does not 
improve reliability of outcome estimates from a population-based study of adults 
(McClain et al. 2010) and large cohort studies of children (Penpraze et al. 2006; 
Rich et al. 2013). The issue of purposeful inclusion of weekend PA is more complex 
for the HD population as therapy schedules differ between individuals. For example 
some are required to undergo therapy on a day regarded as a ‘typical’ weekend 
day. It may be more appropriate to define the two day reprieve from HD as the ‘two 
day interdialytic period’ rather than the weekend. 
1.2.1.9 Defining a valid wear day 
A guideline regarding the number of hours an accelerometer has to be worn per 
day is crucial to determine which days are ruled in and thus whether a participant’s 
data meet the minimum requirement for acceptable reliability. For Actigraph 
monitors non-wear time determined by consecutive zero counts during data 
cleaning is an influential aspect of this guideline. Importantly, employing shorter 
periods of consecutive zero count minutes to identify monitor non-wear can reduce 
wear time (Evenson and Terry 2009) and the relative contribution of sedentary time 
in particular (Masse et al. 2005; Tudor-Locke et al. 2011d). It is argued that a 
proportion of what is categorised as non-wear time may in fact represent sedentary 
behaviour in less active, older or overweight populations (Masse et al. 2005; Tudor-
Locke et al. 2011d; Toftager et al. 2013).  
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Sedentary time erroneously categorised as non-wear not only impacts the 
proportional contribution of monitored variables but also adversely affects the 
number of participants retained for analysis due to insufficient monitor wear (Masse 
et al. 2005; Toftager et al. 2013). There is general agreement that epochs of 90 to 
180 consecutive zero count minutes provide similarly accurate and stable estimates 
of non-wear time for a range of adult populations (Troiano et al. 2008; Song et al. 
2010; Oliver et al. 2011; Hutto et al. 2013). Determination of ActivPAL wear time for 
waking hour protocols can be more easily identified using the first and last transfers 
between lying/sitting and standing postures to define ‘active’ monitoring periods 
assuming the device is not removed.  
A wear time criterion of ≥10 hours has been widely adopted to define a valid wear 
day (Trost et al. 2005; Troiano et al. 2008; Colley et al. 2010; Semanik et al. 2010; 
Tudor-Locke et al. 2011e). Interestingly, this standard was based on the research of 
Masse et al. (2005), which explored sample retention according to different non-
wear algorithms and not computed reliability analyses. The 10 hour threshold was 
further enshrined in accelerometer practice with subsequent application to 
accelerometry data from the NHANES project, and inclusion into the SAS syntax 
accompanying the NHANES PA data (Tudor-Locke et al. 2012). In contrast, recent 
analysis of NHANES data suggested 13 hours as the required minimum wear per 
day to provide a valid measure of PA when using 14 hours wear as a reference 
(Herrmann et al. 2013). However, recommendations from the latter study did not 
take into account intra and inter-individual variation in monitor wear times. It is 
argued that accelerometer outcome variables should be normalised against total 
wear time in order to reduce measurement bias due to wear time variation (Chen et 
al. 2009; Hinkley et al. 2012).  
An advantage of adopting the 10 hour wear threshold is that it allows direct 
comparison of findings with previous PA health research, but it is important to 
consider the unique characteristics of the HD population. These include high 
average age, high prevalence of multi-morbidity and debilitating symptoms. 
Therefore it may be impractical to expect every individual in this population to 
achieve the 10 hour benchmark. More recently, shorter wear time criteria of six to 
eight hours have been recommended for preadolescent participants (Steele et al. 
2009; Jago et al. 2010; Ojiambo et al. 2011). Notably, a wear time threshold of eight 
hours is reported to provide similar levels of reliability to 10 and 12 hour thresholds 
when estimating habitual PA of populations that are typically sedentary (Chen et al. 
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2009; Miller et al. 2013). Another suggested wear day criterion is the 80/70 rule, 
which is derived using a study-specific ratio. A valid day is calculated as 80% of a 
‘standard day’ with a standard day defined as the length of time 70% of the sample 
wore their monitor (Catellier et al. 2005; Masse et al. 2005). 
1.2.1.10 Summary and research questions 
Accelerometers are increasingly being employed to characterise behaviour of 
people with stage CKD, however, there appears to be low awareness of the 
importance of data quality assurance. Accelerometer wear time guidance exists for 
other populations but there are presently no recommendations regarding their 
implementation in stage 5 CKD. There is an urgent need for PA data reduction and 
processing guidelines to ensure accelerometer derived outcomes are reliable.  
What is the minimum number of wear days required for ActivPAL and 
Actigraph accelerometers to obtain reliable estimates of habitual PA and 
sedentary behaviour of people receiving maintenance HD? 
What is the recommended minimum number of accelerometer wear hours 
required to define a ‘valid’ wear day for people receiving maintenance HD?  
How do different accelerometer wear criteria affect participant retention for 
final analysis in a sample of people undergoing maintenance HD? 
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1.2.1.11 Concordance of accelerometer estimates of activity behaviours 
Interestingly, none of the CKD studies reviewed used accelerometers from the 
Actigraph family, despite their extensive use in large-scale epidemiological studies 
such as NHANES. In addition, much of the research regarding the deleterious 
effects of sedentary behaviour on metabolic health has been undertaken using 
Actigraphs. Only the Actiwatch 64, which was originally designed for sleep research 
has been employed to derive an estimate of sedentary behaviour of people with 
CKD. Importantly, characterising habitual PA and sedentary behaviour in stage 5 
CKD using an Actigraph accelerometer would allow contextualisation with a large 
amount of existing research.  
The GT3X (Actigraph Corp, Pensacola, Florida) is the latest Actigraph model, and 
can estimate activity from triaxial and uniaxial configurations. In contrast to uniaxial 
accelerometers, which only detect movement in the vertical axis, triaxial 
accelerometers measure accelerations in three orthogonal planes and should 
theoretically be more accurate. Output from the GT3X includes steps taken and 
energy expenditure (EE). In addition acceleration output can be categorised 
according to cutpoints to derive time spent at different levels of PA intensity that 
relate to health guidelines. However, monitoring only these outcomes may be 
inappropriate in the HD population, which is characterised by advanced average 
age, enforced sitting, and high prevalence of multi-morbidity and debilitating 
condition-related symptoms. Light intensity PA, represents the domain in which 
many routine ADLs are performed and constitutes around 20% of all daily activity 
(Levine et al. 2005). Moreover, accelerometer studies indicate all PA including light 
intensity is associated with longevity and physical function of maintenance HD 
patients (Johansen et al. 2001a; Kutsuna et al. 2010; Matsuzawa et al. 2012). An 
advantage of accelerometers like the Actigraph is that they are able to estimate 
behaviour at the lower end of the PA spectrum and differentiate this from sedentary 
time. Accumulating evidence linking sitting time with health outcomes (Owen et al. 
2010, Thorp et al. 2011) and higher levels of sedentary behaviour in the HD 
population (Agarwal and Light 2011) provide a compelling argument for monitoring 
of this outcome.  
As with PA categorisation, Actigraph estimates of sedentary time are determined by 
application of a specific cutpoint (<100 cpm) to activity data (Evenson et al. 2008). 
The ActivPAL (PAL Technologies Ltd, Glasgow) is a more recently developed 
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accelerometer which employs inclinometry to monitor sitting and standing 
behaviours and detect changes between these postures. Although Actigraphs have 
been widely adopted to characterise behaviour of populations and in studies 
exploring metabolic effects of sedentary time some doubts have surfaced regarding 
their ability to accurately estimate this outcome.  
Concordance studies of Actigraph and ActivPAL estimates of sedentary behaviour 
report moderate to strong correlations (range r = 0.68 to 0.81) during free-living 
situations in pre-school age children (Martin et al. 2011) and adults (Clemes et al. 
2012; Matthews et al. 2013). However, when level of agreement between these two 
devices is inspected the Actigraph is frequently found to estimate significantly 
higher amounts of sedentary time (mean systematic bias range: +44 to +132 
mins/day) compared to ActivPAL (Hart et al. 2011a; Hart et al. 2011b; Clemes et al. 
2012). The largest bias was observed with a 15 second data-sampling epoch (Hart 
et al. 2011a) suggesting epochs shorter than one minute exacerbate estimation 
discrepancies. 
Matthews et al. (2013) and Ridgers et al. (2012) reported lower non-significant 
mean differences (+13.2 to +19.2 and +5.2 mins/day respectively), which may be 
attributed to use of later model Actigraphs (GT1M, GT3x) known to have reduced 
sensitivity to lower frequency movements. In addition, the monitoring period (390 
minutes) in the latter study was comparatively short which likely reduced 
subsequent bias magnitude. In contrast Martin et al. (2011) found Actigraph 
estimated sedentary behaviour (expressed as a percentage of wear time) for pre-
school children was lower than ActivPAL (-4.3% and -2.1% corrected/uncorrected 
estimates). Differing findings are likely due to a higher cutpoint (<1100 cpm) and 
inclusion of periods of ‘quiet standing’ in addition to lying/sitting time, which differs 
from the current consensus definition. 
Actigraph cutpoint selection for determination of sedentary behaviour also appears 
to influence concordance with ActivPAL estimates. The widely adopted cutpoint of 
<100 cpm was originally calibrated with a sample of children aged five to eight 
years (Evenson et al. 2008). Validity of this threshold for adults has been evaluated 
more recently and there are indications that a <50 cpm cutpoint initially suggested 
by Crouter et al. (2006) may better reflect sedentary behaviour in free-living 
conditions. Application of this threshold is observed to produce lower mean 
systematic bias between ActivPAL and Actigraph monitors regardless of model 
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generation to a level, which is not statistically significant (Hart et al. 2011b; Clemes 
et al. 2012). Moreover Clemes et al. (2012) concluded a cutpoint of <50 cpm 
offered more favourable specificity and sensitivity for detecting sitting/lying 
compared to <100 cpm. In contrast Kozey-Keadle et al. (2011) found <150 cpm 
produced the lowest bias (compared to <50cpm and <100cpm) during a six hour 
direct observation protocol, but this result pertains only to later Actigraphs 
employing a low frequency filter extension.  
Regardless of cutpoint choice, size and direction of measurement bias, there is 
general agreement that Actigraph and ActivPAL limits of agreement (LOA) are 
wide. Random error for a cutpoint of <100 cpm ranges from 143 to 570 mins/day 
around the mean bias (Hart et al. 2011b; Ridgers et al. 2012; Matthews et al. 2013) 
and 18.6% to 19.4% when normalised to monitor wear time (Martin et al. 2011). 
Moreover LOA observed with a lower Actigraph cutpoint of <50 cpm remain wide at 
over two hours either side of the mean bias (Hart et al. 2011b; Clemes et al. 2012). 
Notably, studies employing direct observation as a criterion measure during 
controlled and free living conditions indicate that classification of sedentary 
behaviour by ActivPAL is more precise compared to Actigraph regardless of 
cutpoint applied and manipulation of monitor sensitivity (Hart et al. 2011b; Kozey-
Keadle et al. 2011; Lyden et al. 2012). Moreover, Actigraph output for standing still 
and washing dishes is below 100 cpm (Kozey et al. 2010), consequently this 
monitor may erroneously misclassify some routine light activities as sedentary 
behaviour. Taken together it would appear that ActivPAL provides a more precise 
proxy measure of sedentary behaviour compared to Actigraph. 
An important research consideration of cited concordance studies is that few 
explicitly state whether wear epochs for ActivPAL and Actigraph were 
synchronised, which may have contributed to estimation discrepancies. Smaller 
bias between the devices was observed in studies where this aspect of data 
reduction was stated (Ridgers et al. 2012; Matthews et al. 2013). In addition, 
concordance studies for these monitors have been undertaken with younger, 
asymptomatic participants. In light of growing interest in the health consequences of 
sedentary behaviour and its particular relevance to stage 5 CKD, concordance of 
the Actigraph and ActivPAL monitors should be examined in a clinical population. 
Although several cutpoints exist to determine sedentary time from the Actigraph it 
would be prudent to evaluate concordance using the <100 cpm threshold to enable 
contextualisation of results with previous research. 
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Output from both ActivPAL and Actigraph accelerometers include activity counts 
and EE. While the Actigraph calculates EE from activity counts the ActivPAL 
estimates this outcome from an algorithm based on step rate. Harrington et al. 
(2011) found ActivPAL significantly underestimated EE compared to indirect 
calorimetry at all walking speeds (from 3.2 to 7.0 km/h) during a treadmill protocol in 
a sample of 62 young (15 - 25 years) women. The authors concluded a prediction 
equation based on activity counts as opposed to step rate would be more valid as 
the former was more strongly associated with indirect calorimetry (r = 0.75 vs 0.59, 
p < 0.001 respectively). However, this approach may not necessarily ameliorate 
estimation error as there is general agreement that Actigraph prediction equations 
based on activity counts underestimate EE irrespective of prediction equation 
employed (Welk et al. 2000; Leenders et al. 2001; Slootmaker et al. 2009; Albinali 
et al. 2010; Lyden et al. 2011). Taken together it appears both Actigraph and 
ActivPAL underestimate EE compared to criterion measures. No previous studies 
have evaluated concordance of EE estimates obtained from these devices.  
Interestingly, although ActivPAL records activity counts the proprietary software 
does not currently convert this output into outcomes that are meaningful and 
interpretable such as PA intensity. Dowd et al. (2012) found activity count output 
from the two monitors correlated strongly (rho = 0.96, p < 0.01), however level of 
agreement has not been fully evaluated via Bland Altman analysis. Interestingly, the 
cited study indicated ActivPAL activity counts could be categorised, however the 
calibration was undertaken in a modest sample of 30 adolescent females limiting 
cutpoint generalisability. Cutpoints for categorising PA and EE already calibrated for 
the Actigraph could conceivably be generalised to the ActivPAL if agreement for 
this output was within acceptable limits. 
Output from these monitors also includes the number of steps taken, a commonly 
employed motivational outcome. Notably, the stepcount capability of the Actigraphs 
has been employed to help characterise PA of the North American population in 
NHANES (Matthews et al. 2008). Studies employing direct observation concur that 
at moderate to brisk walking speeds ActivPAL and Actigraph estimated stepcounts 
do not differ significantly from each other (Harrington et al. 2011) or direct 
observation (Ryan et al. 2006; Sorti et al. 2008; Harrington 2011; Feito et al. 2012). 
However, there is general agreement from several criterion validity studies that later 
model Actigraphs (GT1M, GT3x) show a propensity to underestimate steps taken 
as gait decreases below 1.0 m/s (Sorti et al. 2008; Harrington 2011; Feito et al. 
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2012). Moreover studies employing 100-step treadmill and overground walking 
protocols agree magnitude of underestimation by Actigraph monitors increases to a 
startling 19% to 40% when ambulation speed drops under 0.80 m/s (Sorti et al. 
2008; Feito et al. 2012). Although ActivPAL also underestimated steps at this speed 
the device still recorded 98% (± 3%) of directly observed steps (Feito et al. 2012). 
Similarly, Ryan et al. (2006) reported excellent criterion validity for ActivPAL at low 
gait speed with less than 1% error observed at 0.9 m/s. It is believed slower 
ambulation speeds affect accuracy of hip mounted accelerometers in a similar 
manner to pedometers by reducing the magnitude of vertical accelerations (Feito et 
al. 2012). 
Notably ActivPAL step count accuracy evaluated by direct observation was lower 
for indoor compared to outdoor mobility (96.1% and 99.6% respectively) in a 
sample of 18 healthy adults (Busse et al. 2009). Indoor PA such as ADLs tend to be 
of lower intensity (Ainsworth et al. 2000) and more intermittent (Orendurff et al. 
2008) with cadence that is unlikely to be continuous as in treadmill validation 
protocols. The consequences of gait speed on accuracy of step count estimation 
may be more profound in the HD population, which is characterised by slow gait 
(Painter et al. 2000) and advanced average age, which is also a determinant of 
walking speed (Bohannon 1997). Slow cadence appears to interact with stepcount 
estimates from both Actigraph and ActivPAL, however there are no studies 
evaluating concordance of this outcome in a clinical population like stage 5 CKD. 
1.2.1.12 Summary and research question 
Accelerometers such as the Actigraph and ActivPAL are increasingly being adopted 
in health research to obtain objective estimates of PA and sedentary behaviour. 
However, there is a paucity of information on concordance of similar outcomes 
obtained from these monitors in clinical populations. Research in this area is 
needed to support investigators and clinicians making an informed choice as to the 
most suitable device to assess a given behavioural outcome.  
What is the level of agreement for shared physical activity outcomes obtained 
from Actigraph GT3x and ActivPAL accelerometers?  
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1.2.1.13 Questionnaire assessment of physical activity in stage 5 CKD 
The majority (66%) of studies characterising PA of HD patients have employed self-
report questionnaires exclusively, while a further 10% used a combination of 
subjective and objective methods. Up until 10 years ago self-reported exercise 
frequency was predominantly employed as a pragmatic PA metric. Subsequent 
studies with the exception of DOPPS (Tentori et al. 2010) have adopted 
questionnaires, which record different dimensions of habitual PA (mode, frequency, 
duration, intensity) to derive outcomes that translate to contemporary PA guidelines 
(table 1.4).  
Table 1.4 Frequency of different PA questionnaires employed in stage 5 CKD. 
Physical activity 
assessment tool 
n  Studies 
Question/s on 
exercise habits 
9 Painter et al. 2000 Allen & Gappelmaier 2001 Longenecker et al. 2002 
Painter et al. 2002 Winkler et al. 2002 O’Hare et al. 2003 
Stack et al. 2005 Tentori et al. 2010 Byrne & Russell 2011 
Questions on habitual 
PA  
1 Painter et al. 2011   
Human Activity Profile 13 Johansen et al. 2001b Johansen et al. 2003a Wellard 2003 
Bonner et al. 2009 Bonner et al. 2010  
Comprehensive Dialysis Study  
Johansen et al. 2010b; Kutner et al. 2010; Anand et al. 2011a; Anand et al. 2011b; 
Gordon et al. 2011; Johansen et al. 2013; Wasse et al. 2013; Anand et al. 2013 
Baecke Activity 
questionnaire 
2 Nielens et al. 2001 van de Ham et al. 2006  
Stanford 7 Day Recall 5 Johansen et al. 2000 Johansen et al. 2001b Nielens et al. 2001 
Sakkas et al. 2004 Sridharan et al. 2013  
Physical Activity 
Scale for the Elderly 
3 Johansen et al. 2001b Baria et al. 2011 Rosas et al. 2012 
International Physical 
Activity Questionnaire  
3 Li et al. 2010 Stringuetta-Belik et al. 
2011 
Leng et al. 2012 
Global Physical 
Activity Questionnaire  
1 Wong et al. 2011   
EPIC-Norfolk activity 
Questionnaire  
1 Brenner & Brohart 2008   
KDQOL-SF ‘activity 
questions’  
1 Hicks et al. 2004   
Of the eight different questionnaires employed in stage 5 CKD research the Human 
Activity Profile (HAP) is the most frequently cited instrument due to publications 
arising from the Comprehensive Dialysis Study (table 1.4). However, responses in 
the HAP are reduced to a linear score derived from the number of different activities 
able to be performed while other PA dimensions are not quantified. Although the 
HAP is strongly correlated with accelerometer estimated PA (Johansen et al. 
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2001b) it is not an appropriate surrogate measure of habitual activity and is more 
indicative of functional status.  
Other questionnaires such as the Baecke Activity Questionnaire (Baecke et al. 
1982) and Physical Activity Scale for the Elderly (PASE) derive a linear score from 
responses relating to PA frequency, duration and intensity based on predefined 
descriptors and epochs. However, outcomes obtained from these questionnaires do 
not readily translate to PA guidelines. Of the questionnaires quantifying PA 
according to its different dimensions the Stanford 7 Day Recall (7DR) (Sallis et al. 
1985) has been used the most frequently, while the international physical activity 
questionnaire (IPAQ) has been employed more recently (Li et al. 2010; Stringuetta-
Belik et al. 2011; Leng et al. 2012). Although it is an older questionnaire there are 
indications the 7DR may be a better instrument for estimating PA associated with a 
health protective effect in stage 5 CKD. Higher systematic and random error relative 
to accelerometry is reported for the IPAQ compared to the 7DR in a cohort of 
women with breast cancer (Johnson-Kozlow et al. 2006). Moreover, the same study 
observed superior sensitivity and specificity for the 7DR in classifying individuals 
according to PA guidelines.  
Despite the number of studies employing PA questionnaires in CKD research, there 
is a paucity of studies evaluating concordance of these instruments with objective 
measures, which are increasingly being used. To date the 7DR is the only 
questionnaire assessing different dimensions of habitual PA that has been 
evaluated for concordance with an objective measure in the HD population. 
Johansen et al. (2001b) found a moderate association between 7DR derived total 
EE (kcals/kg/day) and triaxial (Tri-Trac R3D) activity counts/day (r = 0.59, p = 
0.0005) in a sample of 31 HD participants. However, activity counts are not readily 
interpretable or meaningful as a PA outcome making these findings of limited value 
in determining whether 7DR outcomes may be used interchangeably with objective 
measures or whether data may be directly compared or pooled.  
Importantly, large epidemiological studies undertaken in the general population 
indicate a mismatch between what people report they do and their PA level as 
estimated by accelerometers. Participants in NHANES reporting >150 minutes of 
MVPA/week accumulated an average of just 57 minutes/week according to 
accelerometry (Schuna et al. 2013). The Canadian Health Measures Study found 
that although over half of Canadian adults reported being at least ‘moderately 
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active’, accelerometer estimates indicated just 15% met PA guidelines (Colley et al. 
2011). Results from the Health Survey for England indicate an even wider disparity 
in the UK (Townsend et al. 2012). There is general agreement from systematic 
reviews that the relationship between self-reported and objectively estimated PA 
outcomes is weak to moderate (van Poppel et al. 2010; Helmerhorst et al. 2012) 
averaging a relatively modest r = 0.37 overall (Prince et al. 2008). Moreover few PA 
questionnaires demonstrate acceptable levels of reliability across different age 
groups, a property which is often poorly assessed (Helmerhorst et al. 2012; van 
Poppel et al. 2010).  
The majority of studies evaluating concordance of 7DR-derived PA estimates with 
accelerometry have observed weak to moderate associations for shared estimated 
outcomes (table 1.5). However, correlational analysis only tests strength of 
association between two assessment techniques and does not evaluate systematic 
bias or level of agreement (Bland and Altman 1986), and thus whether instruments 
may be used interchangeably. On the whole, level of agreement between the 7DR 
and accelerometer estimated PA outcomes is infrequently examined. Three studies 
from which level of agreement results could be extracted indicated a systematic 
bias with 7DR MVPA estimates higher than those derived via accelerometry 
(Timperio et al. 2003; Johnson-Koslow et al. 2006; Soundy et al. 2007). Although 
the bias observed by Johnson-Koslow et al. (2006) was not statistically significant, 
all cited studies demonstrated wide limits of agreement (LOA) and thus a large 
amount of random error/biological variation. Moreover, amount of random error 
observed for average daily MVPA by Timperio et al. (2003) was greater than weekly 
PA recommendations. In addition, correlations between the 7DR and accelerometry 
were not only lower for women (Richardson et al. 2000; Timperio et al. 2003) as 
observed in the wider PA literature (Prince et al. 2008) but random error was also 
comparatively greater (Timperio et al. 2003). 
Moderate to strong associations are observed for EE outcomes derived from 7DR 
and objective measures (table 1.6). Stronger correlations are generally found for 
total EE, which may be due to a data smoothing effect of whole day estimates as 
associations between PA related EE are generally lower (Matthews and Freedson 
1995; Richardson et al. 2001). Although correlations for total EE are stronger, 
current consensus guidelines emphasise the importance of EE accumulated during 
time in MVPA for a health-protective effect.  
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Table 1.5 Concordance of 7DR questionnaire M
VPA outcom
es with objective m
easures. 
Study 
Sam
ple 
Age 
Objective 
m
easure 
Correlation 
Sig difference 
Bland and Altm
an analysis 
G
arfield 
et 
al. 
2012 
C
O
P
D
 n = 43 
68.0 ± 9.0 
S
ensew
ear 
A
rm
band 
M
V
P
A
 
r 
= 
0.54 
(p 
< 
0.001) 
N
ot tested 
N
ot done 
S
oundy 
et 
al. 
2007 
S
evere m
ental illness 
n = 14 
52.9 ± 9.0 
TriTrac-R
3D
 
M
V
P
A
 
N
o 
correlation 
p 
value (not stated) 
N
ot tested 
7D
R
 m
oderate P
A
 m
ean bias: +16.9 m
ins/day 
(calculated LO
A
 -87.5 to 121.3 m
ins/day) 
7D
R
 
vigorous 
P
A
 
m
ean 
bias 
-10.4 
m
ins/day 
(calculated LO
A
-58.0 to +37.3 m
ins/day. 
Johnson-Kozlow
 
et al. 2006 
W
om
en 
w
ith 
breast 
cancer n = 159 
56.6 
S
D
 
not stated 
A
ctigraph 
(C
S
A
 7164) 
M
V
P
A
 m
ins rho = 0.73 (p 
<0.001) 
N
o sig’ difference (p 
value not stated) 
M
ean bias 7D
R
 M
V
P
A
 +22 m
ins/w
eek (LO
A
 +226 
to -182 m
inutes/w
eek. 
H
ayden-W
ade 
et al. 2003 
A
sym
ptom
atic 
adults 
n = 69 
33.8 ± 11.2  
TriTrac-R
3D
 
M
V
P
A
 m
ins r = 0.41  
M
oderate P
A
 r = 0.34 
H
ard P
A
 r = 0.43 
V
. H
ard P
A
 r = 0.71  
(p values not stated) 
N
ot tested 
7D
R
 estim
ates of all P
A
 intensities higher but LO
A 
and bias not stated. 
Tim
perio 
et 
al. 
2003 
A
sym
ptom
atic 
adults 
n = 59 
39.0 ± 15.0 
A
ctigraph 
(C
S
A
 7164) 
M
en M
V
P
A
 m
ins  rho = 
0.29 (p < 0.05) 
 W
om
en M
V
P
A
 m
ins rho 
= 0.25, (p < 0.05) 
Yes (p < 0.001)  
Z value not stated   
M
en 7D
R
 M
V
P
A
 m
ins: +35.3 ± 71.2 m
ins/day 
(calculated LO
A
: -104.3 to +174.9 m
ins/day) 
W
om
en 7D
R
 M
V
P
A
 m
ins: +69.0 ± 127.8 m
ins/day 
(calculated LO
A
: -122.7 to +319.5. 
Leenders 
et 
al. 
2000 
A
sym
ptom
atic w
om
en 
n = 11 
26.0 ± 6.0 
A
ctigraph 
(C
S
A
 7164) 
M
V
P
A
 m
ins not tested 
 
N
o sig’ difference (p 
value not stated) 
N
ot done 
 
A
insw
orth et al. 
2000 
A
sym
ptom
atic 
adults 
n = 83 
46.2 ± 15.4 
A
ctigraph 
(C
S
A
 7164) 
M
oderate P
A
 rho = 0.26, 
H
ard P
A
 rho = 0.32  
N
ot tested 
7D
R
 estim
ates of all P
A
 intensities higher but LO
A 
and bias not stated. 
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Table 1.6 Concordance of 7DR questionnaire energy expenditure outcom
es with objective m
easures. 
Study 
Sam
ple 
Age 
Objective m
easure 
Correlation 
S
ig’ difference 
Bland and Altm
an analysis 
G
arfield et al. 2012 
C
O
P
D
 n = 43 
68.0 ± 9.0 
S
ensew
ear 
A
rm
band 
(Total kcals/day) 
r = 0.83 (p < 0.001) 
N
ot tested 
M
ean bias 7D
R
 total E
E
: +410 
kcals/day. (LO
A
 -262 to 1082 
kcals/day). 
S
oundy et al. 2007 
S
evere 
m
ental 
illness n = 14 
52.9 ± 9.0 
TriTrac-R
3D
 
(Total kcals/day) 
r = 0.43 (p = not stated) 
N
ot tested 
M
ean 
bias 
7D
R
 
total 
E
E: 
+606.5 
kcals/day (S
D
 and LO
A
 not stated). 
M
ahabir et al. 2006 
P
ost-m
enopausal 
w
om
en n = 65 
59.9 ± 7.5 
D
oubly Labelled W
ater 
(Total kcals/day) 
rho = 0.47 (p < 0.05) 
Yes (p < 0.05) 
M
ean 
bias 
7D
R
 
total 
EE
: 
+732 
kcals/day (16%
) (LO
A
 +2860 to 1394). 
R
ichardson et al. 
2001 
A
sym
ptom
atic 
adults n = 77 
37.5 ± 10  
C
altrac (M
E
Tm
ins/day) 
Total P
A
 
V
ery H
ard P
A
 
 M
oderate P
A
 
 M
en rho = 0.60 (p < 0.01) 
W
om
en rho =0.36 (p < 0.01) 
M
en rho = 0.49 (p < 0.05) 
W
om
en rho = 0.57 (p < 0.01) 
M
en rho = 0.52 (p < 0.01) 
W
om
en rho = 0.17 (p > 0.05) 
 N
ot tested 
 N
ot evaluated 
A
llor &
 Pivarnik 
2001 
A
dolescent 
fem
ales n = 46 
12.0 ± 0.6  
C
altrac (kcals/hr) 
H
eart rate (kcals/hr) 
r = 0.76 (p < 0.01) 
r = 0.50 (p < 0.01) 
Yes (p < 0.01) 
7D
R
 kcals/hr 146 ± 43 vs C
altrac 100 ± 
26 vs H
eart rate 166 ± 41. LO
A
 not 
stated. 
Leenders et al. 
2001 
A
sym
ptom
atic 
w
om
en n = 30 
25.8 ± 1.6 
D
oubly Labelled W
ater 
(P
A
 kcals/day) 
N
ot stated (betw
een 0.42 
and 0.55, p < 0.05) 
N
o (p > 0.05) 
7D
R
 P
A
 m
ean bias: not stated (LO
A
 -
633 to +280 kcals/day). 
B
onnefoy et al. 
2001 
A
sym
ptom
atic 
older 
adults 
n 
= 
19 
73.4 ± 4.1 
D
oubly Labelled W
ater 
(Total kcals/day) 
rho = 0.51 (p < 0.05) 
N
o (p = 0.09) 
7D
R
 total E
E
 bias: +276 kcal/d or 
10.8%
 (LO
A
 -1075 to +1625 kcals/day) 
M
cD
erm
ott et al. 
2000 
P
eripheral arterial 
disease &
 controls 
n = 41 
67.2 ± 7.0 
66.1 ± 5.4  
C
altrac 
(kcals/w
eek) 
v 
7D
R
 M
E
T hours 
rho = 0.60 (p < 0.001) 
N
ot tested 
N
ot evaluated 
Leenders et al. 
2000 
A
sym
ptom
atic 
w
om
en n = 11 
26.0 ± 6.0 
A
ctigraph C
S
A
 7164 
(P
A
 kcals/kg/day) 
r = 0.82 (p < 0.001) 
Yes (p < 0.05) 
7D
R
 
P
A
 
E
E
: 
9.7 
kcal/kg/day 
vs 
A
ctigraph 5.4 7 kcal/kg/day. LO
A
 not 
stated.  
M
atthew
s &
 
Freedson 1995 
A
sym
ptom
atic 
adults n = 25 
26.7 
TriTrac R
-3D
  
(kcals/day)  
Total r = 0.77 (p < 0.001) 
M
V
P
A
 r = 0.51 (p < 0.01) 
Yes (p < 0.001) 
N
ot tested 
7D
R
 total E
E
 bias: 
+310.3 kcals/day 
LO
A
 not stated 
M
iller et al. 1994 
P
hysiotherapists 
n = 33 
28.0  ± 5.5 
C
altrac 
Total E
E
 r = 0.79 (p < 0.01) 
N
ot tested 
N
ot evaluated. 
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Several studies agree 7DR estimated EE is significantly higher than values obtained 
from three different accelerometers (Miller et al. 1994; Matthews and Freedson et al. 
1995; Leenders et al. 2000; Allor and Pivarnik 2001). However, heterogeneity of 
accelerometers and inconsistent standardisation of EE outcome hamper the 
synthesis of results to ascertain overall degree of bias. In contrast only one of three 
criterion validity studies employing doubly labelled water (DLW) found the 7DR 
significantly overestimated EE (Mahabir et al. 2006). Nevertheless, wide LOA were 
observed by all studies (table 1.6) indicating that utility of the 7DR as a proxy 
measure of EE at an individual level was limited. Moreover, Leenders et al. (2001) 
found differences in activity derived EE were related to PA level (overestimation with 
lower PA, underestimation with higher PA). Agreement analysis with accelerometry 
derived EE outcomes is scant with only bias level data reported (Matthews and 
Freedson 1995) or Bland-Altman plot LOA not stated (Allor and Pivarnik 2001).   
Overall concordance studies show broad agreement between the 7DR and objective 
measures, but indicate questionnaire utility is limited at an individual level. Modest 
concordance between 7DR and accelerometry is largely attributed to reporting error, 
which increases with greater contribution of lower intensity PA to the total amount of 
habitual activity (Durante and Ainsworth 1996; Duncan et al. 2001). In contrast self-
reported vigorous PA is more strongly associated with accelerometery, due to being 
well defined, often scheduled and thus easier to recall (Durante and Ainsworth 1996; 
Richardson et al. 2001; Timperio et al. 2003). Nonetheless, Buchowski et al. 1999 
observed PA above 4.5 METs was oversestimated during two days of room 
calorimetry monitored living. Differential effect of activity intensity on PA recall may 
exacerbate questionnaire error in stage 5 CKD, which is characterized by high 
prevalence of difficulty with moderate to vigorous PA (Stack and Murthy 2008). 
Limitations of accelerometry may also contribute to modest concordance with 7DR 
outcomes. Accelerometers are unable to detect increased work from gradient 
change during walking (Melanson and Freedson 1995), cycling, and load bearing 
activities (Westerterp 1999; Welk 2002) and cannot be worn swimming. In addition, 
they rely on calibrated cutpoints to categorise PA and calculate EE. Cutpoints and 
EE prediction equations are developed from calibration studies employing indirect 
calorimetry during treadmill walking or ADL protocols (Freedson et al. 1998; Swartz 
et al. 2000; Crouter et al. 2006). However, aerobic fitness, biomechanical efficiency, 
and resting metabolic rate decline with advancing age (Fitzgerald et al. 1997, Byrne 
et al. 2005; Kozey et al. 2010) and sedentary behaviour (Duncan et al. 2001). 
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Consequently, an activity at a given ‘absolute intensity’ will require a greater 
‘relative’ percentage of VO2max in older and/or more sedentary individuals.  
Five previous studies have evaluated concordance of similar 7DR and Actigraph 
outcomes (tables 1.5 and 1.6). The prediction equation and cutpoints employed by 
the Actigraph software to calculate EE and categorise PA were developed from a 
calibration study employing a treadmill protocol of ‘slow walking’, ‘brisk walking’ and 
‘jogging’ (Freedson et al. 1998). Notably, the ‘slow walking’ component was a speed 
of 4.8 km/hr (1.3 m/s), which is still higher than the average gait speed of most HD 
patients. Recent research supports the validity of the widely used Freedson et al. 
(1998) cutpoints for ‘absolute’ measures of MVPA in 20 to 69 year olds (Miller et al. 
2010). However, the same study suggested application in older adults may be 
limited as MVPA cutpoints for the Actigraph were significantly different when 
expressed relative to an individual’s maximum aerobic power and age. Notably, 
Timperio et al. (2003) observed stronger associations between 7DR and 
accelerometer estimates of moderate PA when the threshold was lowered from 3.0 
METs (≥1952 cpm) to 2.5 METs (≥1334 cpm) for overweight men (rho = 0.39 and 
0.46 respectively, p < 0.01) and women (rho = 0.21 to 0.40 respectively, p < 0.05).  
There is general agreement that accelerometry underestimates EE during controlled 
walking and ADL protocols as well as free living situations when compared to direct 
calorimetry and doubly labelled water respectively (Welk et al. 2000; Slootmaker et 
al. 2009; Albinali et al. 2010). Moreover, underestimation occurs whether the EE 
equation is based on single linear (Freedson et al. 1998; Hendelman et al. 2000; 
Swartz et al. 2000) or dual regression models (Crouter et al. 2006). It is also 
suggested accuracy of accelerometry derived PA outcomes may depend on type of 
typical activity and population the prediction equations were originally calibrated for.  
1.2.1.14 Summary and research question 
Concordance studies for the 7DR in the general literature are predominantly drawn 
from samples of younger participants limiting generalisability to the stage 5 CKD 
population. Given the number of CKD studies with 7DR data it would be 
advantageous to evaluate concordance of this instrument with an objective measure 
to facilitate data pooling and synthesis of results.  
What is the level of agreement between subjective and objectively estimated 
PA outcomes in stage 5 CKD? 
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1.2.1.15 Physical activity and mortality in stage 5 CKD. 
It is important to address issues regarding PA surveillance in the stage 5 CKD 
population as large-scale epidemiological studies demonstrate PA level is inversely 
related to CV and all-cause mortality of people with stage 5 CKD (table 1.7) as it is 
in the general population (Blair et al. 2001; Lee and Skerrett 2001; Warburton et al. 
2006; Beddhu et al. 2009). Sedentary incident HD patients in the Dialysis Morbidity 
and Mortality Study (DMMS) were 62% more likely to die during their first year 
(figure 1.6) compared to non-sedentary individuals (O’Hare et al. 2003).  
Figure 1.6 Sedentary behaviour and first year mortality. (O’Hare et al. 2003, p. 
451). 
 
Importantly, exercise frequency was independently associated with survival in both 
the DMMS and larger Dialysis Outcomes and Practice Patterns Study (DOPPS) 
(Tentori et al. 2010). Illustratively, mortality risk for dialysis patients who exercised 
more than twice a week was 26 - 31% lower than sedentary individuals (Stack et al. 
2005; Tentori et al. 2010), comparable to observations in the general population 
(Nocon et al. 2008). Not only did survival improve progressively with exercise 
frequency, mortality risk declined by 9% for every 10% increase in regular 
exercisers at a renal unit (Tentori et al. 2010). Self-reported PA is also 
independently predictive of all cause and CV mortality among kidney transplant 
recipients (Rosas et al. 2012 and Zelle et al. 2011). Although a single question 
regarding exercise frequency has been shown to be predictive of survival, this 
behavioural metric excludes other beneficial habitual PA. Exercise forms a sub-
domain of PA, which is defined as: “any bodily movement produced by skeletal 
muscles that results in energy expenditure” (Caspersen et al. 1985, p. 126).  
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 Table 1.7 Epidem
iological studies of physical activity and survival in stage 5 CKD. 
Study 
Sam
ple (n) 
M
/F %
 
Age 
PA m
easure 
Design 
Outcom
e 
Johansen et al. 2013 
C
om
prehensive 
D
ialysis S
tudy 
Incident H
D
 & 
P
D
, (n = 1554) 
55/45 
59.8 ± 14.2 
H
um
an activity profile 
M
ulti-centre, prospective 
study. M
edian follow
 up 
2.6 years (2.2 - 3.1). 
Increased m
ortality risk per 10 point reduction of H
A
P 
adjusted activity score H
R
 = 1.30 (C
I: 1.23 - 1.39). 
M
atsuzaw
a 
et 
al. 
2012 
P
revalent H
D
 
(n = 202)  
48/52 
64 (57 - 42) 
Lifecorder 
uniaxial 
accelerom
eter 
P
rospective 
single 
centre. 
M
ean 
follow
 
up 
45 
m
onths 
(range 
2 
- 
84). 
≥ 50 m
ins of total P
A
 per day significantly associated 
w
ith better survival (Log rank p = 0.001).  
A
djusted m
ortality risk per 10 m
inute increase of total 
daily P
A
: H
R
 = 0.78 (C
I: 0.66 - 0.92, p = 0.002). 
R
osas et al. 2012 
Transplant 
recipients, (n = 
507) 
61/39 
51.4 ± 13.1 
(inactive) 
47.3 ± 12.7 
(m
oderate) 
44.8 ± 11.6 
(active) 
P
hysical A
ctivity S
cale 
for the E
lderly 
M
ulti-centre, prospective 
study. M
edian follow
 up 
8.4 yrs (7.2 - 9.6). 
A
ll cause m
ortality according to tertiles of increasing P
A
: 
inactive 36.3%
; m
oderately active 23.3%
; active 16.3%
  
(p = 0.01). 
P
A
 level inversely associated w
ith all cause m
ortality. 
M
ost active vs inactive tertile: H
R
 = 0.52 (C
I: 0.31 - 
0.87; p = 0.01). 
Zelle et al. 2011 
Transplant 
recipients 
> 
1 
yr, (n = 540) 
54/46 
51 ± 12  
Tecum
seh 
O
ccupational 
A
ctivity 
Q
uestionnaire, 
M
innesota 
Leisure 
Tim
e 
P
hysical 
A
ctivity 
Q
uestionnaire  
S
ingle-centre 
prospective 
study 
w
ith 
retrospective 
12 
m
onth 
P
A
. M
edian follow
 up 5.3 
yrs (4.7 - 5.7). 
A
ll cause m
ortality according to tertiles of P
A
: inactive 
24.4%
, 
m
oderately 
active 15.0%
, 
active 5.6%
 
(p 
= 
0.001). C
V
 m
ortality: 11.7%
, 7.1%
, 1.7%
 (p < 0.001) 
C
V
 m
ortality risk w
ith increasing P
A
: H
R
 0.62 (C
I: 0.45 - 
0.86, p = 0.004) adjusted for age, gender, C
V
D
 history, 
Fram
ingham
 risk score, B
P
, w
aist size, sm
oking. 
Tentori et al. 2010 
D
ialysis O
utcom
es & 
P
ractice 
P
atterns 
S
tudy 
P
revalent 
H
D
 
(n = 20912) 
N
ot 
stated 
N
ot stated 
S
ingle 
question 
on 
exercise frequency 
M
ulti-centre 
prospective 
study. 
M
ean 
follow
 
up 
3.6 ± 1.9 yrs. 
E
xercise frequency and survival advantage (adjusted): 
≥ 1x/w
eek R
R
 0.73 (C
I: 0.69 - 0.78, p < 0.0001) 
2 - 3x/w
k R
R
 0.72 (C
I:0.66 - 0.79, p < 0.0001) 
4 - 5x/w
k R
R
 0.73 (C
I:0.62 - 0.86, p ≤ 0.0002) 
6 - 7x/w
k R
R
 0.69 (C
I:0.63 - 0.76, p < 0.0001) 
10%
 increase in facility regular exercisers associated 
w
ith 9%
 low
er m
ortality risk (C
I 0.89 - 0.94, p < 0.0001). 
S
tack et al. 2005 
D
ialysis 
M
ortality 
&
 
M
orbidity S
tudy  
Incident H
D
 & 
P
D
 (n = 2064) 
54/46 
58.0 ± 16 
S
ingle 
question 
on 
exercise frequency 
M
ulti-centre 
prospective 
study. 
M
ean 
follow
 
up 
3.6 ± 1.9 yrs. 
E
xercise frequency and survival advantage (adjusted): 
2 - 3x/w
k R
R
 0.74  (C
I: 0.58 - 0.95, p < 0.05) 
4 - 5x/w
k R
R
 0.70 (C
I: 0.47 - 1.04, p = 0.07) 
D
aily R
R
 1.06 (C
I: 0.86 to 1.30, p > 0.05). 
O
’H
are et al. 2003 
D
ialysis 
M
ortality 
&
 
M
orbidity S
tudy 
Incident H
D
 & 
P
D
 (n = 2264) 
54/46 
58.0 ± 16 
S
ingle 
question 
on 
exercise frequency 
O
ne year follow
-up 
First year m
ortality - S
edentary 11%
 vs non-sedentary 
5%
. 
S
edentary m
ortality risk H
R
 1.62 C
I:1.16 - 2.27 ( p = 
0.005). 
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Matsuzawa et al. (2012) found that 50 mins/day of all PA (>1.8 METs) estimated via 
accelerometry was independently associated with lower all-cause mortality over four 
years (figure 1.7). Moreover, each 10 minute increment of accumulated PA equated 
to a 22% reduction in all-cause mortality. Interestingly, this study did not differentiate 
between PA attributed to daily ADLs and PA associated with a cardio-protective 
effect. Nonetheless, the results are consistent with evidence that as little as 10 - 15 
minutes PA is also beneficial to health outcomes (Samitz et al. 2011; Sattlmair et al. 
2011; Wen et al. 2011).  
Figure 1.7 Objectively estimated PA and survival of HD patients (Matsuzawa et 
al. 2012, p. 4). 
 
1.2.1.16 Physical activity and intermediate health outcomes in stage 5 CKD 
Deranged bone metabolism, and subsequent bone dystrophy is one of the sequelae 
of CKD and highly prevalent among HD patients (Ambrus et al. 2010). Secondary 
hyperparathyroidism is believed to be an important mediating factor in bone 
demineralisation (Taal et al. 1999) but PA level may also play a role. Pedometry 
derived daily energy expenditure (EE) is independently associated with dual energy 
x-ray absorptiometry measured bone mineral density of women receiving 
maintenance HD (Ota et al. 1997). As well as having clear implications for higher 
fracture risk among HD patients (Chang et al. 2013), bone demineralisation has 
been linked to CV morbidity and mortality in the general population (Farhat and 
Cauley 2008). 
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Decreased concentration of high-density lipoprotein (HDL) often associated with 
elevated levels of harmful triglycerides, is a common feature of uraemia (Imamura et 
al. 2012). Average daily pedometer steps of HD patients is independently 
associated with an HDL subfraction and significantly associated with apolipoprotein 
(Apo) A-I (Masuda et al. 2009). Importantly the latter is responsible for modulating 
lipid metabolism and predictive of myocardial infarction (McQueen et al. 2008). In 
addition, moderate inverse associations with pedometry have been observed for 
serum cholesterol and triglyceride levels of HD patients (Nowicki et al. 2010).  
Systemic inflammation is also implicated in CVD genesis, however triaxial 
accelerometry PA studies either observe no correlation with pro-inflammatory 
cytokines (Hung et al. 2002) or report an inverse association without detailing the 
strength and significance of observed relationships (Johansen et al. 2003a). Mafra 
et al. (2011) found moderate to strong associations between C-reactive protein 
(CRP) and total EE as well as steps estimated by the Sensewear Armband. 
However, other studies employing the same device observed either only a trend 
(Avesani et al. 2012) or no association with any PA parameter (Baria et al. 2011; 
Cupisti et al. 2011). Pedometer studies also report contrasting results with high 
sensitivity CRP (Zamojska et al. 2006; Nowicki et al. 2010). Inconsistent findings are 
possibly due to some studies being statistically underpowered (<30 participants), 
high inter-individual differences in inflammatory markers and condition variability. 
Increased visceral adiposity is a putative CV risk factor and indices of objectively 
estimated PA are inversely associated with BMI in stage 5 CKD (Mafra et al. 2011; 
Avesani et al. 2012), which is consistent with findings in the general population. 
Moreover, serum concentration of Leptin the satiety hormone produced by adipose 
tissue is inversely associated with objectively estimated PA of HD patients 
(Johansen et al. 2003a). It is speculated studies reporting no relationship between 
objectively estimated PA and BMI (Johansen et al. 2000) or reverse epidemiology 
(Zamojska et al. 2006; Cupisti et al. 2011) may in fact reflect better nutritional status 
of participants. A growing body of literature (table 1.8) indicates PA is linked to 
traditional CV risk factors and some of the criteria for metabolic syndrome 
(dyslipidaemia; hypertriglyceridaemia; central obesity; glucose intolerance; 
hypertension), which affects around two thirds of HD patients (Young et al. 2007; 
Shahrokh et al. 2012; Tu et al. 2012). Overall, stronger correlations with markers of 
health status are observed for objectively estimated PA compared to self-report 
which is consistent with findings from NHANES data (Atienza et al. 2011).                                       
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 Table 1.8 Physical activity and clinical indices of health status in stage 5 CKD. 
Study 
Sam
ple (n) 
M
/F %
 
Age 
PA m
easure 
Associations with anthropom
etric and physiological variables 
A
vesani et al. 
2012 
P
revalent H
D
  
(n = 134) 
64/36 
54.9 ± 15.9  
S
ensew
ear P
ro2 
A
rm
band  
 
Age:  total E
E
 r = 0.51; P
A
 E
E r = 0.34; steps r  = 0.49; P
A
 level r = 0.27 (p < 0.001). 
BM
I: total E
E
 r = -0.20; steps r = -0.21; P
A
 level r = -0.28 (p < 0.001); P
A
 E
E
 r = 0.20 
(p < 0.05) . 
Serum
 creatinine: total E
E
 r = 0.37; steps r = 0.30 (p < 0.001). 
CRP: steps r = -0.16 (p = 0.06). 
A
ge and diabetic status m
ain determ
inants of steps/day (r 2 = 0.30). D
iabetes and 
B
M
I determ
inants of P
A
 level (r 2 = 0.12). 
S
tringuetta-Belik 
et al. 2012 
P
revalent H
D
  
(n = 102) 
55/45 
58.7 ± 15.1 
IP
A
Q
 
 
R
isk of cognitive dysfunction (M
ini M
ental S
tate E
xam
ination) low
est for active 
com
pared to sedentary: R
R
 0.06, (C
I 0.01 - 0.76, p = 0.03). 
W
ong et al. 2011 
P
revalent H
D
 (n = 70) 
59/41 
57.0 ± 12.5 
G
lobal physical 
activity questionnaire  
Serum
 creatinine: r = 0.34 (p = 0.004), education level: r = 0.36 (p = 0.002), 
incom
e: r = 0.33 (p = 0.006), potassium
 knowledge: r = 0.26 (p = 0.029) 
C
upisti et al. 2011 
P
revalent H
D
 (n = 50) 
C
ontrols (n = 33)  
64/36 
59.0 ± 13.0 
S
ensew
ear P
ro2 
A
rm
band  
 
Total E
E
: BM
I r = 0.51 (p < 0.001), phase angle r = 0.40 (p < 0.01), serum
 
phosphate r = 0.49 (p < 0.001) album
in r = 0.41 (p < 0.01). 
M
ean daily M
E
Ts: norm
alized energy intake r = 0.47 (p < 0.001); protein intake r 
= 0.33 (p < 0.05); phase angle r = 0.38 (p < 0.01). 
M
inutes of P
A
 >3M
E
Ts: phase angle r = 0.36 (p < 0.01); body cell m
ass index r = 
0.41 (p < 0.01); norm
alized energy intake r = 0.51 (p <0.001); dietary protein 
intake r = 0.37 (p < 0.01). 
N
o relationship betw
een P
A
 param
eters and C
R
P
,K
t/V
, H
b or H
ct. 
B
aria et al. 2011 
P
revalent H
D
 (n = 32) 
S
ed’controls (n = 22). 
63/37 
46.3 ± 12.2 
S
ensew
ear P
ro2 
A
rm
band  
A
ctivity related E
E associated w
ith: lean body m
ass%
 r = 0.42 (p = 0.02), body cell 
m
ass %
 r = 0.35 (p =0.047). N
ot associated w
ith C
R
P
, H
b, H
ct, creatinine, album
in. 
M
afra et al. 2011 
P
revalent H
D
 (n = 24) 
C
ontrols (n = 18)  
75/25 
67.0 ± 14.7 
62.3 ± 15.3 
S
ensew
ear P
ro2 
A
rm
band  
Total E
E
 and CRP
 r = -0.70 (p = 0.0001); step counts and CRP
 r = -0.62 (p = 0.001). 
G
ordon et al. 
2011 
P
revalent H
D
 (n = 58)  
 
70/30 
55 ± 13 
TriTrac-R
3D
 triaxial 
accelerom
eter n = 26 
H
um
an activity 
profile (H
A
P
) 
Post-dialysis fatigue index score and activity counts r = -0.45 (p = 0.02); H
A
P
 
adjusted activity score (r = -0.32, p = 0.02) 
A
ctivity counts largest contributor to post dialysis fatigue after adjustm
ent for K
t/V
 
and dialysis vintage r 2 = 0.40 (p = 0.009). Self-reported P
A
 not retained in m
ultiple 
regression m
odel.  
Li et al. 2010 
P
revalent H
D
  
(n = 187)  
51/49 
59.0 
(IQ
 
not stated) 
International Physical 
A
ctivity 
Q
uestionnaire 
A
ctivity related E
E associated w
ith: serum
 album
in concentration (r = 0.16, p < 0.05), 
physical function (r = 0.47, p < 0.001) and S
F-36 physical com
ponent sum
m
ary 
scores (r = 0.32, p < 0.001). 
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 Study 
Sam
ple (n) 
M
/F %
 
Age 
PA m
easure 
Associations with anthropom
etric and physiological variables 
B
onner et al. 2010 
P
revalent H
D
, P
D
, 
P
redialysis, K
T  
(n = 112) 
60/40 
55.0 (S
D
 
not stated) 
H
um
an Activity 
P
rofile 
Fatigue severity scale r = 0.49 (p < 0.01). 
N
ow
icki et al. 
2010 
P
revalent H
D
 (n = 33) 
52/48 
58.3 ± 10.1 
S
tep count 
P
edom
eter 
Cholesterol r = 0.35 (p = 0.04); triglycerides r = 0.45 (p = 0.008); album
in r = 0.43 
(p = 0.012); haem
oglobin r = 0.37 (p = 0.033); haem
atocrit r = 0.36 (p = 0.04); C-
reactive protein r = -0.39 (p = 0.023). 
K
utsuna et al. 
2010 
P
revalent H
D
 
(n = 153) 
42/58 
64.0 ± 11.0 
Lifecorder uniaxial 
accelerom
eter 
50 m
inutes of all P
A
 per day (> 1.8 M
E
Ts) required to prevent deterioration in norm
al 
and m
axim
um
 w
alking speed. A
rea under curve = 0.78. 
M
asuda et al. 
2009 
P
revalent H
D
 (n = 35) 
P
revalent P
D
 (n = 26)  
69/31 
58.3 ± 14.7  
47.5 ± 14.2 
O
m
ron pedom
eter. 
S
teps/day independently associated w
ith HDL2-C r = 0.38 (p < 0.05) and 
apolipoprotein (Apo) A-I r = 0.37 (p < 0.01).  
Trends for    HDLC
 r = 0.38 (p = 0.051)     HDL 3 -C
 r = 0.32 (p = 0.062) 
H
ighest tertile of steps/day (4,060–8,410) had significantly higher H
D
L 2-C
 and Apo 
A
-I com
pared to low
est (50–2,530 steps/day). 
Zam
ojska et al. 
2006 
P
revalent H
D
 (n = 60) 
C
ontrols (n = 16) 
45/55 
36/64 
60.0 ± 13.0 
56.0 ± 6.0 
P
edom
eter (O
regon 
S
cientific) 
S
tep count and Hb r = 0.42 p = 0.001) Hct (r = 0.46, p = 0.001); serum
 album
in r = 
0.32 p < 0.01); phase angle r = 0.46 p = 0.002). 
M
ajchrzak et al. 
2005 
P
revalent H
D
 (n = 20)  
50/50 
50.1 ± 9.9 
H
ip m
ounted R
T-3 
triaxial accelerom
eter 
N
on-dialysis activity counts and prealbum
in (r = 0.52 p = .019),  
Trends for cholesterol r = -0.43 (p = 0 .058), CRP
 r = -0.41 (p = 0.073). 
Johansen et al. 
2003a 
Incident H
D
 (n = 54)  
 
67/33 
51.7 ± 17 
TriTrac-R
3D
 triaxial 
accelerom
eter. 
H
um
an activity 
profile 
4 tim
e points over 12 
m
onths 
A
ctivity counts and serum
 IL-1β (correlation and p value not stated) 
A
ctivity counts declined by 17000 w
ith each log increase in leptin concentration (p = 
0.0015). 
H
ung et al. 2002 
P
revalent H
D
 (n = 47)  
66/34 
50.3 ± 16.7 
TriTrac-R
3D
 
triaxial 
accelerom
eter 
A
ge adjusted associations w
ith protein intake r 2=0.42 (p = 0.004); caloric intake r 2 
= 0.34 (p = 0.03). Inflam
m
ation not associated w
ith P
A
. 
Johansen 
et 
al. 
2000 
P
revalent H
D
 (n = 34)  
S
ed’ controls (n = 80). 
65/35 
51.5 ± 3.0 
TriTrac-R
3D
 
triaxial 
accelerom
eter 
A
ctivity counts and album
in r = 0.57 (p = 0.003); phase angle r = 0.40 (p = 0.02); 
creatinine r=0.37 (p = 0.03). 
O
ta et al. 1997 
P
revalent H
D
 patients 
n = 41 
0/100 
61.0 ± 16.0 
P
edom
eter 
calorie 
counter (S
uzuken) 
E
nergy expenditure independently associated w
ith total bone m
ineral density 
m
easured by D
E
XA
 (p < 0.0001) after adjustm
ent for age, dry body w
eight, H
D
 
vintage, serum
 protein. 
K
T = K
idney transplant recipients 
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While data regarding the relationship between PA and metabolic syndrome among 
maintenance HD patients is scant, it likely mirrors the positive relationship observed 
for kidney transplant (KT) recipients (Zelle et al. 2011). Metabolic syndrome is 
suggested to be a pre-disease state that not only foreshadows CVD and predicts 
CV events in stage 5 CKD (Wu et al. 2011) but also increases the risk of new onset 
diabetes almost threefold (Bonet et al. 2013). Worryingly, not only were HD patients 
with diabetes in the study of Majchrzak et al. (2005) significantly less active than 
non-diabetics, the disparity widened from 46% to 60% on dialysis days and non-
dialysis days respectively. 
There is general agreement that indices of objectively estimated PA obtained via 
accelerometry are associated with biochemical and anthropometric indicators of 
nutritional status (table 1.8). Average daily stepcount, MVPA, daily EE and activity 
counts are moderately correlated with serum albumin, phase angle and body cell 
mass index (Johansen et al. 2000; Zamojska et al. 2006; Nowicki et al. 2010; 
Cupisti et al. 2011). Self reported PA is also correlated with serum albumin (Li et al. 
2010) but more modestly than objective PA measures. In addition, accelerometer 
estimated minutes of MVPA and average PA intensity are moderately correlated 
with energy and protein intake of HD patients (Cupisti et al. 2011). Serum creatinine 
(a gross marker of muscle mass) is positively associated with self-reported PA 
(Wong et al. 2011) and indices of objectively estimated PA including steps taken, 
total EE (Avesani et al. 2012) and activity counts (Johansen et al. 2000; Johansen 
et al. 2001a; Hung et al. 2002). Importantly, protein energy wasting is reported to 
interact with inflammation and increase CV mortality risk threefold among 
maintenance HD patients (de Mutsert et al. 2008). 
Although relationships with risk factors are based on cross-sectional data there is 
overwhelming evidence that many of these are amenable to behavioural 
intervention in the general population. Meta-analytical reviews show structured or 
habitual PA reduces visceral adiposity (Ismail et al. 2012), improves lipid profile and 
lowers triglycerides (Monda et al. 2009), decreases risk of developing diabetes 
(Gillies et al. 2007), and lowers blood pressure (Whelton et al. 2002). Moreover, a 
Cochrane review of PA interventions indicates similar improvement in some of these 
health status indices for the stage 5 CKD population (Heiwe and Jacobsen 2011). 
There is general agreement that self-reported PA correlates with quality of life 
indicated by Medical Outcomes Short-Form 36 (MOS SF-36) and SF-12 scores from 
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single-centre (Brenner and Brohart 2008; Li et al. 2010) and large multi-centre 
(Johansen et al. 2010b) studies involving HD patients. Habitual PA is also inversely 
associated with fatigue among maintenance HD patients (Bonner et al. 2010; 
Gordon et al. 2011). Moreover, multivariable analysis by Gordon et al. (2011) 
suggested that objectively estimated PA explained the greatest proportion of shared 
variance in post-dialysis fatigue while self-reported PA was not independently 
associated. Anaemia status is also a contributor to fatigue and there is agreement 
that the former is independently predictive of PA level derived via objective 
(Johansen et al. 2000; Zamojska et al. 2006) but not subjective measures 
(Johansen et al. 2010b; Wong et al. 2011). In addition, maintenance HD patients 
who achieve consensus PA guidelines are 94% less likely to have cognitive 
dysfunction compared to sedentary patients (Stringuetta-Belik et al. 2012).  
1.2.1.17 Sedentary behaviour and health outcomes 
While the importance of PA is well documented, accumulating evidence indicates 
sedentary behaviour is not simply the flipside of the same coin. In the general 
population, clear dose-response relationships between self-reported sitting time and 
increased mortality risk have been documented in large epidemiological studies with 
follow up periods of 6.6 to 21 years (Inoue et al. 2008; Katzmarzyk et al. 2009; 
Dunstan et al. 2010, Wijndaele et al. 2010; Warren et al. 2010). Notably, the 
Canada Fitness Survey found the association between sedentary time and CV and 
all-cause mortality remained significant regardless of whether participants were 
classified as active or inactive (Katzmarzyk et al. 2009). Self-reported time spent 
seated is independently associated with subclinical CVD (Kozàkovà et al. 2010) and 
health biomarkers (Celis-Morales et al. 2012). Moreover, the latter were more 
strongly correlated with accelerometer estimated sitting time (Celis-Morales et al. 
2012). Sedentary time, as well as breaks in sedentary time, estimated via Actigraph 
accelerometers are significantly correlated with markers of metabolic risk (Healy et 
al. 2007; Healy et al. 2008b; Gaya et al. 2009; Helmerhorst et al. 2009) independent 
of PA level. Studies of enforced curtailment of PA with active (non-exercising) men 
over two weeks (Olsen et al. 2008; Krogh-Madsen et al. 2010), and 3 days of 
bedrest (Smorawiński et al. 2000) show significant adverse effects on metabolic 
indices and visceral fat. Although protocols in these studies are imperfect models of 
sedentary behaviour they demonstrate the deleterious effects that even short-term 
increases in this metric can exert.  
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Clearly, people with stage 5 CKD at greatest risk of premature mortality are those 
categorised as sedentary defined as one or fewer exercise bouts/week (O’Hare et 
al. 2003; Tentori et al. 2010), or inactive defined as the lowest tertile of PA (Zelle al. 
2011; Rosas et al. 2012). However, such categorisations are not completely 
congruent with the currently agreed working definition of sedentary behaviour as:  
‘‘Any waking behaviour characterized by an energy expenditure of ≤1.5 metabolic 
equivalents (METs) while in a sitting or reclining posture’’  
(Sedentary Behaviour Research Network 2012, p. 540). 
Review of the current literature reveals a remarkable absence of data exploring 
sedentary time and its relationship with health outcomes in stage 5 CKD.  
1.2.1.18 Summary 
There is overwhelming evidence that PA is implicated in survival and important 
health outcomes of people with stage 5 CKD. Large-scale epidemiological studies 
attest to the prognostic utility of self-reported PA in this population. However, 
smaller studies employing objective PA measures show comparatively stronger 
associations with numerous putative risk factors for morbidity and mortality. As well 
as helping elucidate why PA is prognostic of outcomes, activity monitors have 
provided comparatively greater insight into activity patterns of maintenance HD 
patients. Maintenance HD patients are beset by lower levels of PA but the true scale 
of low PA in this population is likely greater than has been reported. Physical activity 
counselling is recommended as part of health management for this population, 
however there is little guidance to support renal healthcare providers in 
implementing this recommendation.  
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1.2.2 Epidemiology of physical function in stage 5 CKD 
The International Classification of Functioning, Disability and Health (ICF) model 
was developed by the World Health Organisation (WHO 2001) to clarify confusion of 
terms and concepts related to physical functioning (Freedman 2009). Figure 1.8 
describes the ICF framework in which physical function is an umbrella term 
composed of three levels of increasing complexity. Physical function refers to an 
individual’s physiological status, ability to perform activities of daily life and more 
complex leisure time pursuits and roles that include social integration. There is 
considerable evidence that stage 5 CKD is characterised by severely reduced PF 
across all three levels of the ICF model and that this is closely linked to health 
outcomes and quality of life. 
Figure 1.8 International classification of functioning, disability and health 
(WHO 2001) adapted for stage 5 CKD. 
 
1.2.2.1 Impaired physical function status in stage 5 CKD 
Several reviews concur that cardiorespiratory fitness (CRF) of haemodialysis (HD) 
participants is on average 60 to 70% of age predicted VO2peak values (Cheema and 
Singh 2005; Johansen 2007; Parsons and King-Van Vlack 2009; Segura-Orti 2010; 
Smart and Steele 2011). Dynamometry measures of lower limb muscle strength 
(table 1.9) are 22 to 45% lower than asymptomatic controls (Johansen et al. 2003a; 
Blake and O’Meara 2004) and age-predicted values (Bohannon et al. 1995; 
Boudeville et al. 2010). In addition hand-grip strength (HGS) of maintenance HD 
patients is 20 to 76% lower compared to age-equivalent norm values (Qureshi et al. 
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1998; Stenvinkel et al. 2002; Nascimento et al. 2004; Silva et al. 2011), peritoneal 
dialysis  (Wang et al. 2005) and predialysis patients (Pagels et al. 2008) (table 1.9). 
Estimates of functional capacity obtained via physical performance tests also 
indicate profound impairment (table 1.10). Proxy measures of CRF for middle-aged 
HD patients (Greenwood et al. 2012; Lane et al. 2013) are a staggering 61% 
reference values for adults aged over 70 years (Harrison et al. 2013) and 41% lower 
than people with chronic heart failure (Pulz et al. 2008). Walk test estimates of 
endurance (Painter et al. 2000; Ling et al. 2003; Bullani et al. 2011; Ragnarsdottir et 
al. 2012) are 10 to 32 % lower than norm values for adults 10 - 25 years older 
(Steffen and Seney 2002) with an even greater disparity observed for senior adults 
(Jamal et al. 2006). Gait speed of HD patients is 18 to 34% slower than healthy 
controls (Johansen et al. 2003a; Blake and O’Meara 2004) and norm values 
(Bohannon et al. 1995; Painter et al. 2000; Johansen et al. 2001a; Johansen et al. 
2003a). Worryingly, 65% of participants in the study of Painter et al. (2000) were 
slower than a key prognostic threshold of 1.0 m/s. Surrogate measures of lower limb 
neuromuscular function also reflect values of more aged individuals (table 1.10). 
Chair stand performances of younger HD patients (Blake and O’Meara 2004) are 
closer to norm values for adults over 60 (Bohannon et al. 2006a), while middle-aged 
individuals (Johansen et al. 2001a; Johansen et al. 2003a) are still 10 to 12% slower 
than healthy octogenarians (Bohannon 2006a). Similarly, functional mobility is 4 to 
18% slower than asymptomatic adults 10 – 20 years more senior (Jamal et al. 2006; 
Bullani et al. 2011; Greenwood et al. 2012; Ragnarsdottir et al. 2012). Moreover, 
prevalence of poor functional mobility among older HD patients is reported to be an 
alarming 80% (Cook and Jassal 2010). 
Significant deficits are also apparent at the participation level of the ICF model. The 
Dialysis Mortality and Morbidity Study (DMMS) revealed 42% of North American 
dialysis patients reported severe limitations with activities of moderate intensity 
(Stack and Murthy 2008). There is overwhelming agreement from large-scale 
studies that regardless of whether functional status is characterised by subscales 
from quality of life questionnaires or dedicated instruments, outcome values are well 
below age expected norms (DeOreo 1997; Painter et al. 2000; Tawney et al. 2000; 
Mapes et al. 2003; Johansen et al 2010b). Moreover, functional status of all 1547 
participants in the Comprehensive Dialysis Study (CDC) was at or below the 50th 
percentile for healthy adults aged over 70, while almost 95% had transformed 
scores that equated to low aerobic fitness (Johansen et al. 2010b).  
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  Table 1.9 Severity of im
paired m
uscle fitness in stage 5 CKD (body structure and function level of ICF). 
Study 
Sam
ple (n) 
Age 
M
/F 
Tests 
M
ean values 
Norm
 or control value com
parison 
S
u et al. 2012 
P
revalent H
D
 (274) 
60.7 ± 11.7 
36/64 
H
G
S
 (K
g) 
A
ll          20.9 ± 9.6 
N
o values by gender 
S
ilva et al. 2011 
P
revalent H
D
 (436) 
47.3 ±14.2 
63/37 
H
G
S
 (K
g) 
M
en       29.1 ± 8.7  
W
om
en 19.4 ± 6.5  
↓47%
  
↓43%
  
B
oudeville et al. 2010 
P
revalent H
D
 (25) 
69.8 ± 12.1 
80/20 
K
nee extensor force 
19 kg (5 - 46 kg) 
N
on-uraem
ic participants 35 - 58 kg 
P
agels et al. 2008 
P
re-dialysis (116) 
63.0 ± 15.0 
68/32 
H
G
S
 (K
g) 
M
en      37.1 ± 10.2 
W
om
en 20.4 ± 6.6  
↓11%
 
↓21%
 
Jam
al et al. 2006 
P
revalent H
D
 (52) 
66.0 ± 9.0 
71/29 
H
G
S
 (K
g) 
A
ll          21.5 ± 9.3  
N
o values by gender 
W
ang et al. 2005 
P
revalent P
D
 (233) 
55.0 ± 12.0 
51/49 
H
G
S
 (K
g) 
A
ll         19.9 ± 10.6 
M
en      24.8 ± 10.3 
W
om
en 14.7 ± 8.1 
 ↓44%
 
↓51%
 
B
lake and O
’M
eara 
2004 
P
revalent H
D
 (12) 
 
42.0 ± 8.5 
58/42 
K
nee extensor 
Isom
etric P
eak torque (N
) 
K
nee extensor 
Isokinetic peak torque (N
) 
Tim
e to peak (s) 
 134.3 ± 62.8 
 61.8 ± 33.3 
6.8 ± 2.7 
C
om
pared to 12 controls 
203 ± 59.8, 34%
 low
er (p < 0.05)  
 111.8 ± 43.3, 45%
 low
er (p < 0.005)  
5.0 ± 2.8 (p = 0.10) 
N
ascim
ento et al. 2004 
P
revalent H
D
 (109) 
53.0 ± 12.0 
62/38 
H
G
S
 (K
g) 
N
ot stated 
 
A
ll ↓25%
, M
en ↓29%
, W
om
en ↓19%
 
W
ell nourished ↓17%
,  
M
alnourished ↓38%
 
Johansen et al. 2003a 
P
revalent H
D
 (22) 
55.0 ± 15.0 
53/47 
Leg D
orsiflexors  
Isom
etric peak M
V
C
 (N
) 
 169.6 ± 65.5 
 ↓22%
 com
pared to 17 controls (p = 0.03) 
S
tenvinkel et al. 2002 
P
revalent H
D
 (206) 
52.0 ± 10.0 
61/39 
H
G
S
 (K
g) 
M
en      37 ± 1 
W
om
en 23 ± 1 
↓27%
 
↓26%
 
Q
ureshi et al. 1998 
P
revalent H
D
 (128) 
57 (26-79) 
 
68 (32-85) 
 
64 (33-83) 
59/41 
H
G
S
 (K
g) w
ell nourished 
          
m
ildly m
alnourished 
          
m
od-severe m
alnourished 
M
en      34 ± 12 
W
om
en 22 ± 9 
M
en      24 ± 9 
W
om
en 13 ± 7 
M
en      12 ± 11 
W
om
en 11 ± 6 
↓31%
 C
om
pared to 44 controls 
↓19%
 
↓51%
 
↓52%
 
↓76%
 
↓59%
 
B
ohannon et al. 1995 
P
revalent H
D
/P
D
 (110)   
45.1 ± 11.6 
69/31 
N
on-dom
inant knee 
extensor force (N
) 
D
om
inant knee extensor 
force (N
) 
 309.3 ± 120.5 
 317.0 ± 119.6 
 33.2%
 low
er than controls (472.6 ± 89.8) 
 34.6%
 low
er than controls (474.8 ± 88.2) 
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  Table 1.10 Im
paired functional capacity in stage 5 CKD (activity level of ICF). 
Study 
Sam
ple (n) 
Age (yrs) 
M
/F %
 
Tests 
M
ean values 
Norm
 or control values 
Lane et al. 2013 
P
revalent H
D
 (42) 
44 ± 5 
62/38 
ISW
T (m
) 
251 ± 120 
↓61%
 (>70 yrs, H
arrison et al. 2013) 
G
reenw
ood et al. 2012 
P
revalent H
D
 (128) 
56.6 ± 12.2 
48/52 
ISW
T (m
) 
TU
A
G
 (s) 
S
TS 60 (reps) 
S
tair clim
b &
 descend (s) 
247.7 ± 137.1 
10.2 ± 11.0 
19.3 ± 7.1 
29.9 ± 21.0 
↓61%
 (>70 yrs, H
arrison et al 2013)  
↑11%
 (> 70-79yrs, B
ohannon 2006b) 
N
o norm
ative data 
N
o norm
ative data 
R
agnarsdottir et al. 2012 
P
revalent H
D
 (21) 
69 (37-88) 
N
ot 
stated 
6M
W
T (m
) 
TU
A
G
 (s) 
S
TS
10 (s) 
275 (90-452) 
13 (5.4-33) 
44 (22.9-58.4) 
↓32%
 (>80 yrs, S
teffen et al. 2002) 
↑41%
 (70-79yrs, B
ohannon 2006b) 
↑128%
 (C
suka and M
cC
arty 1985) 
B
ullani et al. 2011 
P
revalent H
D
 (11) 
70 ± 10.7 
73/27 
6M
W
T (m
) 
TU
A
G
 (s) 
307 ± 155 
12.1 ± 6.6 
↓24%
 (>80 yrs, S
teffen et al. 2002) 
↑7%
 (>80 yrs, B
ohannon 2006b) 
C
ook and Jassal 2010 
P
revalent H
D
 (130) 
74.8 ± 5.9 
57/43 
TU
A
G
 (s) 
N
ot stated 
80%
 >10 sec 
N
onoyam
a et al. 2010 
P
revalent H
D
 (10)  
68.1 ± 7.1 
78/22 
2M
W
T (m
) 
TU
A
G
 (s) 
96.8 ± 44.2 
14.2 ± 7.1 
↓36%
 (C
onnelly and Thom
as 2009) 
↑46%
 (70-79yrs, B
ohannon 2006b) 
Jam
al et al. 2006 
P
revalent H
D
 (52) 
66.0 ± 9.0 
71/29 
6 M
W
T (m
) 
TU
A
G
 (s) 
109m
 ± 58 
13.6 (9.9-17.4) 
↓73%
 (>80 yrs, S
teffen et al. 2002) 
↑48%
 (70-79yrs, B
ohannon 2006b) 
S
terky and Stegm
ayr 2005 
P
revalent H
D
 (11) 
 
75 (60-82) 
91/9 
S
TS
10 seconds (reps) 
S
tair clim
b/descend (reps) 
3.4 
4 
↓50%
 com
pared to 22 controls 
↓54%
 com
pared to 22 controls 
B
lake and O
’M
eara 2004 
P
revalent H
D
 (12) 
 
42.0 ± 8.5 
58/42 
A
verage gait speed (m
/s) 
M
ax w
alk speed (m
/s) 
S
TS
5 (reps) 
1.31 ± 0.12 
1.74 ± 0.18 
10.1 ± 0.16 
↓18%
 (p < 0.005) com
pared to 12 controls 
↓15%
 (p = 0.01) com
pared to 12 controls 
↑38%
 (p < 0.001) com
pared to 12 controls 
Johansen et al. 2003a 
P
revalent H
D
 (38) 
55 ± 15 
53/47 
A
verage gait speed (cm
/s) 
100.2 ± 33.2 
↓33%
 (p < 0.001) com
pared to 19 controls 
Johansen et al. 2003c 
Incident H
D
 (54) 
51.5 ± 17 
67/33 
A
verage gait speed (cm
/s) 
S
TS 5 (s) 
S
tair C
lim
b (s) 
112.8 ± 34.5 
16.3 ± 9.3 
10.0 ± 7.5 
↓21%
 (50-59 yrs, B
ohannon 2011) 
↑10%
 (>80 years, B
ohannon 2006a) 
N
o norm
ative data  
Ling et al. 2003 
P
revalent H
D
 &
 P
D
 (72)  
52.8 ± 9.8 
N
ot 
stated 
TU
A
G
 (s) 
6M
W
T (m
) 
9.6 ± 3.7 
368.8 ± 97 
↑4%
 (B
ohannon 2006b) 
↓10%
 (80-89yrs, S
teffen et al. 2002) 
Johansen et al. 2001a 
Incident H
D
 (46) 
52 ± 17 
67/33 
A
verage gait speed (cm
/s) 
S
TS 5 (s) 
S
tair C
lim
b (s) 
113.1 ± 34.5 
16.6 ± 9.5 
10.3 ± 7.7 
↓19%
  slow
er than predicted 139.3 ± 4.7  
↑12%
  (>80 years, B
ohannon 2006a)  
N
o norm
ative data 
P
ainter et al. 2000 
P
revalent H
D
 (205) 
56.6 ± 15.6 
44/57 
G
ait speed (cm
/s) 
S
TS
10 (s) 
6M
W
T (m
) 
90.5 ± 25.6 
29.3 ± 12.5 
347.0 ± 127.1 
34%
 slow
er than predicted norm
 
75%
 slow
er than predicted norm
 
↓14%
 (80-89 yrs, Steffen et al. 2002) 
B
ohannon et al. 1995 
P
revalent H
D
 &
 P
D
 (110) 
45.1 ± 11.6 
69/31 
A
verage gait speed (cm
/s) 
M
ax gait speed (cm
/s) 
S
TS 10 seconds (reps) 
109.1 ± 21 
176 ± 45.6 
5.8 ± 2.0 
↓23%
 com
pared to predicted (141.1 ± 5.1) 
↓20%
 com
pared to predicted (221.3 ± 17.3)  
N
o norm
ative data 
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Impaired PF ultimately manifests itself in reduced participation and disability, the 
scale of which was first revealed by Gutman et al. (1981), who found just 23 to 60% 
of HD patients (diabetic and non-diabetic respectively) engaged in activities more 
strenuous than basic self-care. Worryingly, these findings are just as relevant today 
as prevalence of disability with one or more basic activities of daily living (feeding, 
dressing, grooming, ambulation, toileting and bathing) is still 41% among HD 
patients of all ages (McAdams-Demarco et al. 2012) compared to 5.0 to 8.1% for 
community dwelling older adults (Wiener et al. 1990).  
1.2.2.2 Assessment of physical function in stage 5 CKD 
In light of the high prevalence of PF impairment in stage 5 CKD routine monitoring of 
physical function is recommended in section 14.3 of the National Kidney Foundation 
(NKF) Kidney Disease Outcomes Quality Initiative (KDOQI) as part of health 
management (NKF 2005). Regular PF assessment is compatible with the shift 
towards ‘person-focused’ care, which implies more comprehensive recognition, 
knowledge and care of the individual’s problems as well as their primary diagnosis 
(Starfield 2011). The value of PF assessment lies in being able to: identify 
individuals at risk of poor outcomes who may benefit from further medical evaluation 
or preventive interventions by monitoring over time; stratifying risk for surgery or 
other interventions; evaluating the effectiveness of interventions or clinical trials 
(Koufaki and Kouidi 2010). In addition, there is growing recognition of the 
deleterious effects of frailty on health outcomes in this population a condition that is 
not exclusive to gerontology but also highly prevalent in stage 5 CKD (Johansen et 
al. 2007; Bao et al. 2012; McAdams-Demarco et al 2013; Painter et al. 2013). 
Furthermore, it is argued that consistent use of physical function outcomes for 
kidney transplant candidates could yield improved post-transplant outcomes (Kutner 
et al. 2006) and use of healthcare resources (Houle et al. 2002).  
Although routine PF assessment is strongly indicated there is little to support renal 
healthcare providers in operationalising KDOQI recommendations except for a 
broad statement suggesting use of physical performance testing or questionnaires. 
Importantly, if PF assessment is to be adopted as part of standard clinical practice 
or employed in research it must meet certain scientific criteria outlined by Lohr et al. 
(1996): validity (does it measure what it claims to measure?); utility (does the 
measure have prognostic and discriminatory usefulness in the clinical setting?); 
reproducibility (are repeat measures similar enough to be consistent?); 
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responsiveness (is the measure sensitive enough to track changes over time?). 
Fulfilment of these criteria is crucial in order that healthcare providers can invest in 
outcomes that will benefit their patients. The following section will review PF 
assessment methods employed in stage 5 CKD according to the ICF framework. 
Gold standard cardiopulmonary exercise tests (CPET) have often been used to 
measure exercise tolerance for exercise intervention programmes in stage 5 CKD 
(Johansen 2007; Parsons and King-van Vlack 2009; Smart and Steele 2011). The 
seminal paper of Sietsema et al. (2004) is frequently cited as an example of the 
prognostic utility of CRF in this population. A VO2peak value above 17.5 ml/kg/min (5 
METs) obtained via cardiopulmonary exercise test (CPET) was independently 
associated with improved survival in a cohort of 175 prevalent HD patients over a 
mean follow up of 3.5 years. Participants below this threshold had significantly 
greater mortality compared to those above it (22% and 5% respectively). 
Figure 1.9 Survival of maintenance HD patients as a function of baseline 
VO2peak (Sietsema et al. 2004, p. 721). 
 
Although these findings were derived from relatively young and healthy HD patients 
(46 ± 13 years) with a comparatively low overall mortality rate (13%) this threshold 
appears to be robust for different levels of renal impairment. A study of 5716 middle-
aged women (52.5 years ± 10.8) found a CRF below 5 METs was independently 
associated with the highest mortality risk at every level of estimated GFR over a 16 
year follow up period (Gulati et al. 2012). Moreover, even though all-cause mortality 
increased with declining GFR in the cited study, CRF continued to significantly 
modify the relationship between renal function and mortality. In addition, peak 
aerobic power also shows moderate to strong inverse associations with depression 
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scores of HD patients (r = -0.53 to -0.64, p < 0.01) (Carney et al. 1986), which 
affects 20 - 26% of this population (Hedayati et al. 2009; Fischer et al. 2010).  
Figure 1.10 Mortality rates stratified by eGFR and cardiorespiratory fitness 
level (Gulati et al. 2012, p. 922). 
 
Upper limb muscle fitness is commonly measured via hand grip dynamometry, while 
lower limb measures are less common (table 1.9), likely due to the former being 
easier to obtain. Three-year survival among 126 middle aged (52 ± 1.0 years) 
incident male HD patients was higher for participants whose isometric HGS was 
above the median value (Stenvinkel et al. 2002), however the precise value was not 
reported. Notably, this outcome measure is also predictive of disability, as well as 
CV and all-cause mortality among older adults and people with less severe CKD (Al 
Snih et al. 2002; Qureshi et al. 2002; Rantanen et al. 2003). Hand-grip strength is 
also prognostic of nutritional status (indicated by lean body mass) in HD (Stenvinkel 
et al. 2002) and PD cohorts (Wang et al. 2005; Dong et al. 2008) and is 
independently predictive of malnutrition among predialysis patients (Heimburger et 
al. 2000). Moreover, declining HGS of HD patients relative to predicted values 
(Nascimento et al. 2004) and controls (Qureshi et al. 1998) (table 1.9) was 
associated with level of malnutrition indicated by subjective global assessment. 
Hand-grip strength was also independently and inversely associated with 
malnutrition and inflammation score in a large cohort of 436 maintenance HD 
patients (Silva et al. 2011). 
Maximum aerobic power (VO2peak) determined by CPET is considered to provide the 
most valid measure of CRF. However, reproducibility of this outcome shows 
appreciable intra-individual variability in older adults (Greig et al. 1994) and clinical 
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populations such as CHF (Bensimhon et al. 2008) and stage 5 CKD (Koufaki et al. 
2001). Furthermore, although it is predictive of mortality risk, CPET measured CRF 
may not necessarily indicate ability to perform essential ADLs requiring lower effort 
for longer periods (Koufaki and Mercer 2006; Johansen 2007). In addition, although 
physiological indices may provide invaluable data regarding the mechanisms of 
functional impairment, their relationship with meaningful person-centred outcomes 
such as functional status and falls is not well defined. Furthermore, laboratory tests 
carry significant burden in terms of equipment, time, specialised personnel, expense 
and space, and do not lend themselves well to routine clinical use.  
1.2.2.3 Physical performance tests  
Feasible proxy measures of cardiorespiratory and neuromuscular fitness are 
obtained via physical performance tests, which are more cost effective, require less 
equipment and are easily administered. Tests of functional capacity where 
individuals determine their exertion level correspond to the activity level of the ICF 
framework. Tasks are designed to approximate activities commonly encountered 
during daily life and arguably have greater construct validity in capturing activity 
impairment. Moreover they are an important determinant of functional status and 
disability in stage 5 CKD (Cook and Jassal 2008).  
Chair stand tests that replicate the ability to transfer have frequently been employed 
in HD studies as surrogate measures of lower limb neuromuscular function (table 
1.10). The sit-to-stand 5 (STS5) test (Guralnik et al. 1994) which records the time 
taken to complete five transfers from a standardised chair height has well 
documented psychometric properties (table 1.11) and is increasingly being used in 
CKD research. Good to excellent reproducibility has been observed among 
community dwelling elderly (Schaubert and Bohannon 2005; Bohannon et al. 2007; 
Tiedeman et al. 2008) and people with stage 5 CKD (Koufaki et al. 2002). Test 
performance is moderately correlated with lower limb muscle strength of elderly 
asymptomatic individuals (Lord et al. 2002; McCarthy et al 2004) and people with 
stage 5 CKD (Bohannon et al. 1995). In addition strong correlations have been 
observed with other prognostic physical performance measures including average 
gait speed and the timed up-and-go test (Merretta et al. 2006; Schaubert and 
Bohannon 2007). Importantly the STS5 has clinical utility with a cutpoint range of 10 
and 15 seconds predicative of falls risk (Tiedeman et al. 2008; Buatois et al. 2010) 
and balance dysfunction (Whitney et al. 2005).  
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  Table 1.11 Psychom
etric properties of sit-to-stand 5 test. 
Psychom
etric Property 
Value 
Population 
Author 
M
inim
um
 detectable difference 
4.2 seconds 
H
ealthy com
m
unity dw
elling elderly 
n = 10, age 75.5 ± 5.8 years 
S
chaubert and Bohannon 2005 
M
inim
um
 
clinically 
im
portant 
difference  
2.3 
seconds 
for 
im
proved 
D
izziness 
H
andicap 
Inventory score 
B
alance disorders  
n = 117, age 62.7 years 
M
eretta et al. 2006 
P
rognostic utility 
>12 seconds 
Further falls risk assessm
ent indicated 
C
om
m
unity dw
elling elderly,  
n = 362, age 74-98 years 
Tiedem
ann et al. 2008 
>15 seconds. Falls risk ratio = 1.74, C
I: 1.24– 2.45 
(p<0.001). Follow
 up 1.5 to 3 years 
C
om
m
unity dw
elling elderly,  
n = 1958, age 70 ± 4 years.  
B
uatois et al. 2010 
>10 seconds. B
alance dysfunction (<60 yrs)  
>14.2 seconds. Balance dysfunction (>60 yrs) 
B
alance disorders n = 93.  
A
ge m
atched controls n = 81 
W
hitney et al. 2005 
Test –retest reliability 
IC
C
 = 0.81, C
I not stated. C
V
 = 16.85%
 Interval 0, 6, 
12 w
eeks 
C
om
m
unity dw
elling elderly. n = 10, 
age 75.5 ± 5.8 yrs.  
S
chaubert and Bohannon 2005 
 
IC
C
 = 0.89, 95%
 C
I = 0.79, 0.95. Interval 12 m
onths  
C
om
m
unity dw
elling elderly.  
n = 362, age 80.4 ± 4.5 yrs 
Tiedem
ann et al. 2008 
IC
C
 = 0.96, C
I not stated 
A
sym
ptom
atic adults. n=94 
B
ohannon et al.  2007 
Intra-session C
V
 = 15.1%
 
S
tage 5 C
K
D
 5, n = 33  
K
oufaki et al. 2002 
C
onstruct V
alidity 
C
orrelation w
ith isokinetic strength of hip flexors, knee 
extensors, ankle plantarflexors, r = -0.58, -0.46, -0.58 
respectively, (p < 0.01) 
W
om
en. n = 46, 64.5 ± 3.1  
M
cC
arthy et al. 2004 
C
orrelation w
ith knee flexion and extension isom
etric 
force r = -0.43 (p < 0.01) 
C
om
m
unity dw
elling elderly.  
n = 669, 78.9 ± 4.1 years 
Lord et al. 2002 
K
nee extension isom
etric force:   dom
inant  r = 0.59, 
non-dom
inant  r = -0.64 (p < 0.001) 
S
tage 5 C
K
D
. n = 110, age 45.1 ± 
11.6 years. 
B
ohannon et al. 1995 
C
onvergent Validity 
C
orrelation w
ith TU
A
G
 r = 0.59 (p < 0.01) 
C
orrelation w
ith gait speed r = 0.53 (p < 0.01) 
B
alance disorders  
n = 117, age 62.7 years 
M
eretta 2006 
C
orrelation w
ith TU
A
G
 r = 0.92 (p < 0.05) 
C
orrelation w
ith gait speed r = 0.94 (p < 0.01) 
H
ealthy com
m
unity dw
elling elderly 
n = 10, age 75.5 ± 5.8 years 
S
chaubert and Bohannon 2005 
R
esponsiveness 
R
esponsiveness-treatm
ent coefficient = 0.58 
B
alance disorders. n = 117 
M
eretta et al. 2006 
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  Table 1.12 Psychom
etric properties of Tim
ed up-and-go test. 
Psychom
etric Property 
Value 
Population 
Author 
R
eliability 
Intra session test-retest reliability IC
C
 = 0.97 (C
I not stated). 
C
om
m
unity dw
elling elderly.  
n = 96, age 73 ± 8 years 
S
teffen et al. 2002 
Test-retest reliability IC
C
 = 0.97, follow
 up 2 m
onths  
Interrater reliability IC
C
 0.99 (C
I not stated)  
O
lder adults. n = 20 79.5 years 
O
lder adults. N
 = 22  
P
odsiadlo and R
ichardson 1991 
Intrarater R
eliability IC
C
 = 0.92 (C
I = 0.86 - 0.95)  
Interrater R
eliability IC
C
 = 0.91 (C
I = 0.86 - 0.94) 
E
lderly in residential care. n = 78, 
age 84.8 ± 5.7 years 
N
ordin et al. 2006, 
P
rognostic utility 
>12.3 secs. Falls. Sensitivity 83%
, specificity 97%
  
C
om
m
unity dw
elling older adults,  
n = 35. 72.9 ± 7.8 yrs. 
W
risley and Kum
ar 2010 
>13.5 secs. Falls, sensitivity 87%
, specificity 87%
. 
N
on-fallers, n = 15, age 78 ± 6 yrs. 
Fallers, n = 15, age 86 ± 6 yrs.  
S
hum
w
ay-C
ook et al. 2000 
>10 
secs 
independently 
associated 
w
ith 
6.64 
(C
I 
2.24-19.71) 
higher odds ratio of dependency w
ith one or m
ore core A
D
Ls.  
M
aintenance H
D
 patients. n = 162, 
age 74.8 ± 5.9 yrs  
C
ook and Jassal 2008 
1 second increm
ents = 8%
 increase in m
ortality risk over m
edian 3 
year follow
 up. 
C
K
D
 stage 2 to 4. n = 385, age 61 ± 
13 years. 
R
oshanraven et al. 2013 
C
onstruct validity 
B
E
R
G
 balance scale r = -0.81, gait speed r = -0.61, (p value not 
stated). 
C
om
m
unity dw
elling older adults.  
n = 60, age 79.5 years 
P
odsiadlo and R
ichardson 1991 
Functional gait assessm
ent , r = 0.84, (p < 0.001) 
C
om
m
unity dw
elling older adults,  
n = 35. 72.9 ± 7.8 yrs. 
W
risley and Kum
ar 2010 
C
orrelation w
ith Tinetti B
alance, Tinetti G
ait, w
alking speed  
r = -0.55, -0.53, 0.66 respectively (p value not stated). 
C
om
m
unity dw
elling older adults,  
n = 1200, m
ean age 73.4 years  
Lin et al. 2004 
C
onvergent validity 
Tw
o m
inute w
alk test r = -0.68, Functional Independence M
easure 
r = -0.59 (p < 0.001), Functional reach r = -0.36 (p = 0.02) 
S
enior adults inpatient rehab,  
n = 52, age 80 ± 8 years. 
B
rooks et al. 2006 
B
arthel index r = -0.78 (p value not stated) 
C
om
m
unity dw
elling older adults.  
n = 60, age 79.5 years 
P
odsiadlo and R
ichardson 1991 
C
orrelation w
ith O
lder A
dults R
esources and S
ervices A
D
L scale  
r  = -0.45 (p value not stated)   
C
om
m
unity dw
elling older adults,  
n = 1200, age 73.4 years 
Lin et al. 2004 
R
esponsiveness 
M
oderate effect for A
D
L decline (E
S
 = 0.42)  
S
m
all effect for A
D
L im
provem
ents (E
S = 0.05) 
S
m
all effect for falls (E
S
 = 0.12)  
C
om
m
unity dw
elling older adults,  
n = 1200, age 73.4 years 
Lin et al. 2004 
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The STS5 is also a component of the short physical performance battery commonly 
used to evaluate lower limb function in the elderly (Guralnik et al. 1994) and has well 
established age-equivalent norm values (Bohannon 2006a). Other variations of this 
test exist such as the sit-to-stand 10 and longer 30 and 60 second protocols in 
which the number of transfers is counted. Longer duration tests such as the sit-to-
stand 60 are proposed as indicators of lower limb muscle endurance and fatigability 
(McCarthy et al. 2004) and the latter has been used in a number of exercise studies 
involving HD patients (Cappy et al. 1999; Koufaki et al. 2002; Majchrzak et al. 2005; 
McIntyre et al. 2006; Cook et al. 2008). Test performance is strongly correlated with 
self-reported nutritional status (Mercer et al. 2004) and thigh muscle cross-sectional 
area of people with stage 5 CKD (McIntyre et al. 2006). The STS60 demonstrates 
clinically acceptable reliability in this population (Koufaki et al. 2002; Segura-Orti and 
Martinez-Olmos 2011). However, as with the STS10 and STS30, there is no data 
regarding prognostic utility or agreed norm values for any of these test variations.  
The timed up-and-go (TUAG), which measures the time taken to stand up from a 
chair, walk out three metres, return and sit (Podsiadlo and Richardson 1991) is a 
physical performance test commonly used in clinical practice. The TUAG is 
proposed as a composite measure of lower limb strength, balance and gait (Bischoff 
et al. 2003). Generally regarded as an indicator of functional mobility the test 
sequentially simulates demands on the neuromuscular and balance systems 
commonly encountered during daily activities (Bischoff et al. 2003; Podsiadlo and 
Richardson 1991). 
Psychometric properties of the TUAG are also well documented (table 1.12). 
Intraclass correlation coefficients are excellent for test reproducibility (Podsiadlo and 
Richardson 1991; Steffen et al. 2002) and inter-rater reliability (Shumway-Cook et 
al. 2000; Nordin et al. 2006) in asymptomatic adults. Convergent validity has been 
observed with other physical performance measures of endurance (Brooks et al. 
2006), lower limb strength (Meretta et al. 2006), balance and gait speed as well as 
functional status (Podsiadlo and Richardson 1991; Lin et al. 2001). The TUAG is 
also well supported with age-equivalent norm values established by a meta-
analytical review (Bohannon 2006b).  
Notably, a TUAG time over 10 seconds is independently associated with an almost 
sevenfold risk of dependency with one or more basic activities of daily living (ADL) 
among senior HD patients (Cook and Jassal 2008).  Moreover, test duration above 
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this threshold is predictive of future placement in long term care for older adults 
(Nikolaus et al. 1996). This may be especially salient in light of prevalence of slow 
TUAG times being as high as 80% among older HD patients (Cook and Jassal 
2010). Importantly, there is agreement that a test time above 12 seconds is highly 
accurate in identifying community dwelling older adults with a history of falls 
(Shumway-Cook et al. 2000; Wrisley and Kumar 2010). Such prognostic utility might 
be considered invaluable in a population beset by higher incidence of falls among 
older adults compared to the general population (12.7% versus 4% respectively) 
(Desmet et al. 2004; Hestekin et al. 2013). In addition, it may also explain in part 
why the TUAG has greater discriminative ability than bone mineral density testing in 
detecting bone fractures among older adults receiving HD therapy (Jamal et al. 
2006). Importantly, increments of 1 second are independently associated with an 
attendant 8% increased risk of mortality over 3 years among people with less severe 
CKD (Roshanraven et al. 2013).  
Various walking tests have been employed to assess exercise tolerance in stage 5 
CKD without the need for expensive equipment and specialised personnel. These 
physical performance tests are relevant for people with low functional capacity as 
they replicate the most common form of daily activity. The six-minute walk test 
(6MWT) has been employed in several stage 5 CKD studies, and the 2 minute walk 
test less frequently (table 1.10). Psychometric properties are well supported and 
there are indications the 6MWT is at least as prognostic of health outcomes in CKD 
as the TUAG (Jamal et al. 2006; Roshanraven et al. 2013). Other walk tests 
employing stair climb and/or descent such as the North Staffordshire Royal Infirmary 
walk test (Mercer et al. 1998) have also shown clinically acceptable psychometric 
properties for people with stage 5 CKD. However, low use stairs and space required 
for the 6MWT may not always be available in a hospital environment potentially 
limiting feasibility of these tests. In addition, walk tests requiring a self-selected gait 
speed for a pre-specified time or distance are susceptible to variations in pacing 
judgement, mood and motivation.  
More recently the incremental shuttle walk test (ISWT) (Singh et al. 1992), which is 
an externally paced, symptom limited walking test has been increasingly adopted as 
a functional capacity outcome in stage 5 CKD (Wilund et al. 2010; Greenwood et al. 
2012; Lane et al. 2013). The test requires limited space (10 metres) and equipment 
(CD player and two marker cones), and elicits a graded cardiovascular response 
(unlike the 6MWT) with incrementally quicker walking speeds. In addition, theoretical 
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  Table 1.13 Psychom
etric qualities of the increm
ental shuttle walk test. 
Psychom
etric 
Property 
Value 
Population 
Author 
M
inim
um
 
clinically 
im
portant difference 
47.5 m
etres, C
I: 38.6 to 56.5 m
etres 
C
hronic 
obstructive 
pulm
onary 
disease 
(C
O
PD
), n = 372, age 69.4 ± 8.4 years. 
Singh et al. 2008 
Prognostic utility 
<450 m
: tertile w
ith low
est 12 m
onth event-free survival 
(36%
) (p < 0.01) 
C
lass 2-4 H
eart failure, n = 53, age 53 ± 10 
years 
M
orales et al.1999 
R
eliability 
Test-retest IC
C
 = 0.80 C
I: 0.62 to 0.90 (8 w
eek interval) 
Stable C
VD
 patients, n = 30, age 67 ± 8 
years. 
Pepera et al. 2010 
Intra-session test-retest difference 29.5 m
, C
I: 23.0 to 
36.0 (p < 0.001). IC
C
 = 0.94, C
I not stated.  
C
ardiac rehabilitation, n = 353, age 61.6 ± 
10.2 years 
Jolly et al. 2008 
Intra-session test-retest difference 7.0 m
 , C
I: -33.0 to 
47.0 (p > 0.05) 
C
hronic heart failure (C
H
F) grade 2-4, n = 
63, age 51.3 ± 10.2 years 
Pulz et al. 2008 
P
earson’s r = 0.90, p < 0.001 
H
eart transplant candidates, n = 25, age 53 
± 8 years 
Lew
is et al. 2001 
Intra-session P
earson’s r = 0.98, p < 0.01 
C
H
F grade 2 - 4, n = 7, 52.4 ± 3.2 years. 
G
reen et al. 2001 
IC
C
 = 0.87 C
I not stated, C
V 15.9%
 
Interm
ittant claudication, n = 55, age 68 
(52–80) years 
Zw
ierska et al. 2004 
Validity 
VO
2peak  r = 0.93, S
EE 2.8m
L/kg/m
in  (p < 0.01) 
C
KD
 5, n = 22, age 57 ± 17.4 years 
M
ercer et al. 2011 
Treadm
ill VO
2peak   r = 0.83,  Am
bulatory VO
2peak during 
ISW
T r = 0.78 (p < 0.05) 
C
H
F grade 2 - 4, n = 7, 56.7 ± 1.5 years. 
G
reen et al. 2001 
VO
2m
ax r = 0.81 to 0.88, (p value not stated
 
C
O
PD
 2 sam
ples, n = 19 age 61 ± 7 years, 
and n = 10, age 64 ± 7 years. 
Singh et al. 1994 
VO
2peak r = 0.73, p < 0.001). D
iscrim
inatory pow
er >360-
430m
 predicts VO
2peak  >14 m
l O
2 /kg/m
in. Sensitivity 
75%
, specificity 77%
 
H
eart transplant candidates, n = 25, age 53 
± 8 years 
Lew
is et al. 2001 
VO
2m
ax  r = 0.83, (p < 0.001). >450 m
 predicts VO
2m
ax  > 
14 m
l O
2 /kg/m
in, sensitivity and specificity not stated. 
C
H
F grade 2 - 4, n = 46, age 53 ± 10 years 
M
orales et al. 1999 
R
esponsiveness 
Standardised response m
ean: 1.18 for antibiotics 
C
ystic Fibrosis, n = 24, 30.3 ± 15.3 years. 
Bradley et al. 2000 
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peak oxygen consumption can be calculated from terminal walking speed using a 
formula developed by the American College of Sports Medicine (ACSM 2010). The 
ISWT is considered a feasible proxy measure of CRF compared to CPET measured 
VO2peak. Although originally developed for people with chronic obstructive airways 
disease the ISWT has been employed in other clinical populations. It exhibits 
clinically acceptable psychometric qualities and has been validated in stage 5 CKD 
(table 1.13). Moreover, the ISWT is supported by comprehensive age-stratified 
normative values for the UK population (Harrison et al. 2013). Data regarding 
prognostic utility of the ISWT are limited to individuals with chronic heart failure (Pulz 
et al. 2008). However, there are indications that test performance may be linked to 
mortality risk via intermediate CV vectors. Wilund et al. (2010) found change in 
ISWT performance was inversely associated with epicardial fat (r = −0.66, P = 0.01) 
a marker of CVD presence and severity in a small study of 15 HD patients. 
Moreover, moderate inverse associations have been observed between the ISWT 
and indices of central arterial stiffness of maintenance HD patients (Lane et al. 
2013), which is strongly predictive of CV and all-cause mortality in this population 
(Blacher et al. 2003; Verbeke et al. 2011).  
Lastly, high prevalence of slow self-selected gait speed is also well documented in 
stage 5 CKD (Bohannon et al. 1997; Painter et al. 2000; Johansen et al. 2001a; 
Johansen et al. 2003b; Blake and O’Meara 2004). Not only is an ambulation speed 
of 1.2 m/s required to cross a pedestrian crossing safely (Asher et al. 2012), a gait 
below 1.0 m/s is significantly associated with reduced survival among community 
dwelling older adults (Abellan van Kan et al. 2009; Afilalo et al. 2010). Moreover, a 
0.1 m/s reduction in gait speed is associated with an incremental 26% increase in 
adjusted mortality risk over three years in stage 2 - 4 CKD (Roshanraven et al. 
2013). 
1.2.2.4 Self-reported physical function in stage 5 CKD 
Impact of reduced physical performance ultimately manifests itself in reduced 
participation in social activities and functional disability, which is associated with the 
third level of physical function of the ICF framework. Large-scale studies attest to 
the predictive utility of patient reported functional status in the dialysis population. 
The Dialysis Morbidity and Mortality Wave 2 study (DMMS) revealed mortality risk 
was 75% higher over 3.6 years for incident HD patients reporting severe limitations 
with moderate intensity activities (Stack et al. 2005). McClellan et al. (1991) were 
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  Table 1.14 Functional status and health outcom
es in stage 5 CKD. 
Study / outcom
e 
Sam
ple (n) 
Age ± SD 
M
/F %
 
Period 
M
ean score ± SD 
Findings (adjusted or stated if not) 
M
cC
lellan et al. 1991 
K
arnofsky 
P
erform
ance scale 
Incident H
D
 
&
 P
D
 (294 ) 
56.6 ± 15.1 
51.2/48.8 
1.3 yrs 
7.06 ± 0.11 
First year survival: Low
est quartile 55.7%
 highest quartile 94.5%
 (p < 0.001).M
ortality 
risk relative to no im
pairm
ent: m
ild (2.4, C
I 0.66-3.64), m
oderate (6.1, C
I: 1.78-20.74), 
severe (14.5, C
I: 4.7 – 41.3) (p < 0.001). 1 unit = 28%
 change m
ortality risk (0.61-2.01) 
D
eO
reo 1997 
M
O
S
 S
F-36 
Incident H
D
 
(1000) 
58.2 ± 15.4 
50/50 
1.5 yrs 
P
C
S
1 44.3 ± 27.8 
M
C
S
2 47.9 ± 11.6 
P
C
S
 < 34.6, relative risk m
ortality = 2.03 (1.44-2.85, p < 0.001), hospitalisation = 1.67 
(1.43-1.95, p < 0.001). 
 5 point P
C
S
 change = 10.4%
 change in survival (0.6 – 19.0, p = 0.04)  
Ifudu et al. 1998 
M
odified K
arnofsky  
P
revalent 
H
D
 (522) 
59.0 ± 15.0 
48.3/51.7 
3 yrs 
N
ot stated 
S
core <70, unadjusted relative risk of m
ortality 44%
 (1.24 – 1.68, p < 0.001)  
K
alantar-Zadeh et al. 
2001 
M
O
S
 S
F-36 
P
revalent 
H
D
 (65) 
54.5 ± 15.8 
53.8/46.2 
1 yr 
P
C
S
 48.8 ± 18.8 
M
C
S
 55.7 ± 18.4 
10 point decrease total S
F-36 score = hazard ratio 2.03 (1.08 – 3.98, p = 0.024). P
C
S
 
not independently predictive of m
ortality (p = 0.14)  
10 point P
C
S
 decrease: relative risk first hospitalisation 23%
 (1.01 to 1.51, p = 0.048). 
P
C
S
 correlated w
ith hospitalisation days (r = -0.28) and frequency (r = -0.40), nutrition 
(r = -0.10), B
M
I (r = -0.35), album
in (r = -0.29), haem
oglobin (r = -0.27), (p < 0.01).  
Low
rie et al. 2003 
M
O
S
 S
F-36 
P
revalent 
H
D
 (13952) 
59.0 ± 15.4 
51.4/48.6 
6 m
ths 
P
C
S
 33.3 ± 10.5 
M
C
S
 47.5 ± 11.7 
1 point P
C
S
 reduction = 2%
 higher m
ortality risk (C
I 0.969-0.982, p < 0.001) 
1 point P
C
S
 increase = 2%
 low
er hospitalisation risk (C
I and p value not stated) 
M
apes et al. 2003 
K
D
Q
O
L-S
F 
Incident H
D
 
(10030) 
 
58.9 ± 14.9 
57.4/42.6 
3.4 yrs 
P
C
S
 35.3 ± 10.8 
M
C
S
 44.9 ± 11.9 
Low
est P
C
S
 quintile (S
core < 25) relative m
ortality risk = 1.93 (C
I not stated, p< 0.001), 
hospitalisation 1.53 (C
I not stated, p < 0.001)  
10 point change P
C
S
 = 29%
 higher m
ortality risk (1.23-1.35, p < 0.001), 15%
 relative 
risk hospitalisation (1.11-1.18, p < 0.001). 
K
night et al. 2003 
M
O
S
 S
F-36 
Incident H
D
 
(5773) 
61.0 ± 15.4 
54/46 
2 yrs 
P
C
S
 31.6 ± 9.8 
M
C
S
 46.0 ± 11.3 
10 point decline in P
C
S
 = 25%
 higher m
ortality risk at 1 year (1.18 – 1.33, p value not 
stated)  
Feroze et al. 2011 
M
O
S
-S
F36 
P
revalent 
H
D
 (705) 
53.5 ± 14.7 
53/47 
6 yrs 
N
ot stated 
Low
est P
C
S
 quartile (S
core < 37.2) hazard ratio = 1.45 (1.0-2.1, p < 0.05).  
10 point PCS change = 8%
 change in relative m
ortality risk (1.02-1.15, p < 0.05). 
P
C
S
 correlated w
ith B
M
I (r = -0.10), album
in (r = 0.21), creatinine (r = 0.25), C
R
P
 (r = -
0.13), H
D
 vintage (r = 0.08) 
                                                
1 P
C
S
 physical com
ponent sum
m
ary score 
2 M
C
S
 m
ental com
ponent sum
m
ary score 
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the first to explore the relationship between functional status and survival in stage 5 
CKD using the Karnofsky Performance Status (KPS) scale (Karnofsky et al. 1948). 
The study found mortality risk at one year more than doubled for each level of 
progressively greater functional impairment. However, the KPS questionnaire was 
designed for oncology palliative care, and there are no data regarding its 
psychometric properties in the CKD population. The scale is completed by a health 
professional, and therefore it may not actually capture the individual’s perceived 
level of physical function.  
The physical component summary score (PCS) derived from the Medical Outcomes 
Study Short Form-36 (MOS SF-36) (Ware and Sherbourne 1992) or the Kidney 
Disease Quality of Life Short Form (KDQOL-SF) (Hays et al. 1994) which has the 
SF-36 at its core, is commonly used to indicate functional status (table 1.14). As 
with the SF-36, KDQOL-SF item scores are aggregated without weighting and 
transformed linearly to a 0-100 range from which the PCS is derived. Higher scores 
indicate better functional status. Psychometric properties are well documented in the 
dialysis population with clinically acceptable levels of reliability, responsiveness, 
content and construct validity for both the SF-36 (Mingardi et al. 1999; Gomez-
Besteiro et al. 2004) and KDQOL-SF (Hays et al. 1994; Korevaar et al. 2002; Park 
et al 2007; Bataclan and Dial 2009).  
Since the study of McClellan et al. (1991) functional status and mortality has been 
explored several times using the PCS from the MOS SF-36 questionnaire (table 
1.14). Participants with a PCS less than the median score (34.6) were twice as likely 
to die and 1.5 times more likely to be hospitalised compared to those at or above 
the median score over 1.5 years (DeOreo 1997). Similar findings were reported for 
the lowest quintile of PCS scores obtained via the KDQOL-SF in the much larger 
international Dialysis Outcomes and Practice Pattern Study (Mapes et al. 2003). 
Notably the study of Knight et al. (2003) found a 10 point reduction in PCS over 6 
months after HD initiation was independently associated with a 25% higher risk of 
death at one year (Knight et al. 2003). 
In general 5 point increments in PCS score are consistently associated with 
increases in adjusted mortality risk of 10-15% (table 1.14) among incident (DeOreo 
et al 1997; Mapes et al. 2003) and prevalent dialysis patients (Lowrie et al. 2003). 
Risk of hospitalisation for the same change in outcome score is broadly similar 
(Kalentar-Zadeh et al. 2001; Lowrie et al. 2003; Mapes et al. 2003). Notably, 
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functional status is reported to be as significant a predictor of mortality risk as 
clinical indices of health status such as dialysis adequacy (Kt/V), normalised protein 
catabolic rate, and albumin (DeOreo 1997; Mapes et al. 2003; Feroze et al. 2011). 
Moreover, PCS scores in the DOPPS study were independently associated with 
greater risk of hospitalisation while important clinical markers such as albumin were 
not (Mapes et al. 2003). Self-reported function is also correlated albeit modestly with 
clinical markers of health status including BMI, haemoglobin, nutritional status, and 
CRP (Kalantar-Zadeh et al. 2001; Lowrie et al. 2003; Feroze et al. 2011). 
Perhaps a disadvantage of the SF-36 and KDQOL-SF is the completion time 
required. The Duke Activity Status Index (DASI) (Hlatky et al. 1989), a short 
questionnaire comprising 12 activity items weighted according to their physiological 
cost has also been employed to monitor functional status in stage 5 CKD (Cook et al 
2008; Nonoyama et al. 2010; Greenwood et al. 2012). The Duke was initially 
validated in cardiac patients using CPET obtained VO2max (Pearson’s r = 0.58 to 
0.81, p < 0.001) by Hlatky et al. (1989). Subsequent studies have demonstrated fair 
to moderate criterion validity (Pearson’s r = 0.31 to 0.65) in a number of clinical 
populations (Merz et al. 2000; Carter et al. 2002; Struthers et al. 2008) including 
CKD (Ravani et al. 2012). Internal consistency is high (Cronbachs alpha = 0.86, Von 
Dras et al. 1997) and the Duke has shown clinically acceptable reproducibility in 
CKD (Ravani et al. 2012). Notably CRF scores derived from the Duke are 
independently predictive of fatal and non-fatal cardiac events in women with 
symptomatic coronary artery disease over 5 years (Shaw et al. 2006). Prognostic 
utility observed in a cardiac population and expediency could conceivably lend the 
DASI to CV risk stratification in stage 5 CKD. 
Independent associations between functional status and survival have not been 
observed in every study and this may be due to their smaller size (Kalantar-Zadeh 
et al. 2001) and modification of the functional status outcome (Ifudu et al. 1998). 
However, the weight of evidence from studies adjusted for multiple demographic 
and clinical variables supports the prognostic utility of self-reported functional status 
in stage 5 CKD. A limitation of these observational studies is their inability to 
determine causation. Low functional status may therefore be a marker of disease 
severity or comorbidity burden, and reflect those who are destined to have higher 
mortality rates. This relationship could be bi-directional with functional disability 
impacting important aspects of health like nutritional status. For example HD 
patients unable to undertake shopping and cooking independently are more than 
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two and a half times more likely to be malnourished than those able to perform 
these activities (Sehgal et al. 1998).  
An advantage of functional status measures is their ability to capture individuals’ 
perceptions of their capability to perform activities of daily living (ADLs) or engage in 
leisure pursuits in a way that objective methods cannot. Moreover, they are cost 
effective, expedient and can be administered to people unable to undertake physical 
performance tests. There is increasing recognition of person-centred outcomes to 
complement traditional clinical outcomes such as mortality, non-fatal events, 
hospital admissions, and healthcare cost (Liem et al. 2007; Valderas et al. 2008). 
However, by virtue of their subjective nature questionnaire responses are 
susceptible to influences such as temporal variations in symptoms (Lyons et al. 
1999; Nelson-Danquah et al. 2010), cognitive impairment (Guralnik et al. 2001), and 
education level (Koufaki and Koudi 2010). Psychosocial factors influence both 
physical performance and self reported function but there are indications their 
relative contribution to the latter is greater (Carmichael et al. 2000; Lord et al. 2002; 
Bean et al. 2011). Moreover, reliability of self-reported physical function is 
comparatively lower than physical performance measures (Davey et al. 2003; 
Overend et al. 2010).  
1.2.2.5 Physical function, disability and frailty in stage 5 CKD 
Importantly, declining PF is part of a process leading to functional disability, 
increased healthcare burden and also ADL dependency (Cook and Jassal 2008), 
placement in private care and in-hospital mortality (Sood et al. 2011). Worryingly, 
disability with one or more basic ADLs in the study of McAdams-Demarco et al. 
(2012) was associated with a more than threefold higher adjusted risk of premature 
mortality compared to HD patients without disability. There is growing recognition of 
the importance of undiagnosed frailty on health outcomes of HD patients (Painter et 
al 2013). Frailty among incident HD patients is independently associated with a 50% 
higher risk of hospitalisations and a two to threefold increased risk of mortality 
among incident and prevalent HD patients over one and three years respectively 
(Johansen et al. 2007; McAdams-Demarco et al 2013). Importantly three of the five 
core components of Fried’s frailty phenotype (Fried et al. 2001) may be obtained 
from measures of physical performance (muscle weakness, slow gait) and 
functional status (exhaustion) measures. Early identification of frailty facilitated by 
routine PF monitoring may therefore play an important role in early identification of 
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at risk individuals. Timely interventions could then be targeted to ameliorate 
functional decline and reduce risk of hospitalisations and mortality in the HD 
population. 
This review shows there is overwhelming evidence of high prevalence of severe PF 
impairment in stage 5 CKD. Not only is the disparity between maintenance HD 
patients and age-matched peers (or reference values) alarming in magnitude, in 
many cases reported physical function is even lower than non-uraemic individuals 
two decades more senior. Physical function assessment in this population shows 
little standardisation with numerous subjective and objective measures employed 
(summarised in table 1.15). Importantly, there is general agreement that 
physiological indicators of function and self-reported functional status are predictive 
of numerous health outcomes in this population. Prognostic utility of physical 
performance tests is largely inferred from findings in the general population and is 
an area that requires further exploration in people with stage 5 CKD. Importantly 
there is an absence of research regarding the responsiveness of PF outcome 
measures to PA change in stage 5 CKD.  
Table 1.15 Measurement of physical function in stage 5 CKD. 
 
1.2.2.6 Physical function and physical activity in stage 5 CKD  
It has been suggested that the reason why physical function is predictive of health 
outcomes in stage 5 CKD is because it is likely to be associated with physical 
activity/exercise behaviour (Kutner et al. 2000; Johansen et al. 2001a). Worryingly, 
low levels of PA are highly prevalent in stage 5 CKD (Johansen et al. 2001b; Stack 
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and Murthy 2008; Tentori et al. 2010) with only a small percentage (13%) achieving 
recommended PA levels (Painter et al. 2011). This is due in part to HD patients 
enduring extended periods of enforced sitting during dialysis, accumulating an 
additional 12 to 15 hours per week. Moreover, fatigue associated with uraemia and 
the HD procedure and multi-morbidity add up to form a potent triad, which contribute 
to high prevalence of sedentary behaviour. The deleterious effects of inactivity on 
muscle mass and strength on healthy individuals are well documented in bedrest 
studies (Kortebein et al. 2007; Ikezoe et al. 2011). Furthermore, inactivity per se is a 
low-grade inflammatory state, which inhibits muscle protein synthesis, a key 
mechanism, which leads to muscle atrophy (Guadagni and Biolo 2009).   
Aerobic activities which comprise most habitual daily PA may not offer the same 
level of hypertrophy that resistance exercise does but there is evidence that the 
former do stimulate muscle protein synthesis (Sheffield-Moore et al. 2004; 
Bechshoeft et al. 2012). In addition, although genetic heritability is reported to 
explain around 55% of the variance in CRF, recent PA is the largest modifiable 
enviromental determinant (Bouchard and Perusse 2005). High prevalence of 
sedentary behaviour in stage 5 CKD likely explains in part the severity and scale of 
PF impairment observed. Encouragement of PA by renal staff forms part of KDOQI 
recommendations (NKF 2005) presumably based on the premise that this form of 
lifestyle intervention will improve physical function. Candidate assessment methods 
for routine monitoring of physical function should therefore be sensitive to change in 
PA as well as having prognostic utility. Although PA is believed to underpin aspects 
of physical function there is a paucity of information regarding which measures may 
adequately reflect behavioural change in stage 5 CKD.  
To date, just two studies have explored the association between PA and physical 
function in stage 5 CKD (Johansen et al. 2001a; Kutsuna et al. 2010). In both 
studies habitual PA determined objectively by accelerometry was independently 
associated with average gait speed. Notably, Kutsuna et al. (2010) found that a 
minimum of 50 minutes of total PA per day above 1.8 METs was sufficient to 
prevent deterioration of gait speed in a sample of 157 maintenance HD patients. 
Johansen et al. (2001a) observed that HD dosage indicated by Kt/V was also an 
independent predictor of average gait speed, chair rise and stair climb performance. 
The inference being that greater dialysis dosage may improve functional capacity. 
However, a more recent study did not find physical performance measured by short 
physical performance battery was improved with greater nocturnal dialysis 
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frequency (Hall et al. 2012). Importantly, the modest sample size (n = 39) in the 
study of Johansen et al. (2001a) did not meet the minimum requirement for multiple 
regression analysis (n = 50 + number of candidate variables) outlined by Harris 
(1985) increasing the risk of a type II error.  Moreover accelerometer data reduction 
criteria were not explicitly stated, which may have adversely affected integrity of the 
PA data and attenuated associations with the physical performance outcomes.  
Implications of such research considerations are important as findings may 
inadvertently dissuade healthcare providers from seeing PA recommendations as 
complementary to medical management of health in stage 5 CKD. Re-visiting 
clinical, demographic and behavioural correlates of PF across a wider spectrum of 
physical performance tests in a larger cohort of maintenance HD patients is 
therefore warranted. Lastly, prognostic utility of self reported physical function in 
stage 5 CKD is well documented, however as with physical performance there is 
limited research exploring the correlates functional status questionnaires in this 
population. Gender, comorbidity status, albumin and age were independently 
associated with PCS scores from the KDQOL-SF in the international DOPPS project 
(Lopes et al. 2007). However, the relative contribution of PA to functional status of 
maintenance HD patients has thus far not been explored. 
1.2.2.7 Summary and research questions 
There is overwhelming evidence that low physical function is highly prevalent in 
stage 5 CKD and that it is associated with health outcomes across all three levels of 
the ICF framework. Routine monitoring of physical function is recommended in 
addition to traditional clinical indicators to augment health management of this 
population. However there is little in the way of constructive guidelines to support 
health professionals with selection of suitable physical function outcomes that have 
clinical utility and are sensitive to behavioural change. Research in this area is 
strongly indicated in order that routine monitoring of functional level may be feasibly 
implemented in stage 5 CKD and outcomes standardised.     
What are the correlates of physical performance measures of physical 
function in stage 5 CKD? 
What are the correlates of self-reported physical function in stage 5 CKD? 
What is the relative contribution of physical activity to physical performance 
and self-reported measures of physical function in stage 5 CKD? 
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1.2.3 Epidemiology of arterial stiffness in stage 5 CKD 
There is overwhelming agreement from renal registry data in different countries that 
high mortality and morbidity in the haemodialysis (HD) population is driven by 
cardiovascular (CV) causes (UKRR 2012; USRDS 2011, SRRR 2013). Depending 
on country CV disease accounts for 33-52% of all mortality among people receiving 
maintenance HD (Uchida et al. 2007; Breidthardt et al. 2011; USRDS 2012; UKRR 
2012; SRRR 2013), with sudden cardiac death accounting for almost 30% (Herzog 
et al. 2008a). Alarmingly, incidence of myocardial infarction and stroke is three to 
fifteen times higher in stage 5 CKD compared to the general population (Parfrey et 
al. 1996, Go et al 2004, Tonelli et al 2006). Moreover, CKD is an established CV risk 
factor (Sarnak et al. 2003) with a graded inverse association between glomerular 
filtration rate, and risk of CV events and hospitalisations (figure 1.11) (Zoccali et al. 
2011; Briet et al. 2006; Go et al. 2004). 
Figure 1.11 Relationship between renal function and risk of CV events (Zoccali 
et al. 2011, p. 3). 
 
Increased presence of focal plaques and occlusive lesions (atherosclerosis) of the 
intima (surface) layer of the arteries may mediate higher CV risk in stage 5 CKD. 
Autopsy findings show atherosclerotic changes in the aortae of HD patients are 
more severe compared to age and gender matched individuals with CVD with an 
eGFR of >60 mL/min/1.73m2 (Suzuki et al. 2011). Moreover, a large ultrasound 
study demonstrated prevalence and severity of carotid artery plaques was highest 
among individuals on dialysis compared to people with stages 1 to 3 CKD and 
normal renal function (78%, 56% and 43% respectively) (Coll et al. 2010). 
Interestingly, multivariable modeling in the latter study confirmed traditional risk 
factors rather than CKD related variables were predictors of aortic atherosclerosis.  
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However, disproportionately high CV mortality and morbidity in the stage 5 CKD 
population is not explained by the presence of traditional CV risk factors such as 
diabetes, smoking, BMI and elevated serum cholesterol (Zoccali 2000; Longenecker 
et al. 2002). Moreover a “U” shaped relationship exists between blood pressure and 
mortality risk in this population (Zager et al. 1998). Aggressive pharmacotherapy of 
traditional risk factors is a cornerstone of CV health management in the general 
population but it does not appear to have the same efficacy in ameliorating CVD 
burden in stage 5 CKD. Large-scale randomized control trials have found no 
significant difference in mortality and CV events for HD patients receiving statin 
therapy compared to those who did not (Kalantar-Zadeh et al. 2003; Wanner et al 
2005). Moreover, long-term prognosis remains poor even after myocardial 
revascularization via percutaneous stenting or bypass graft (Herzog et al. 2008b). 
Consequently atherosclerosis, is believed to be only partially responsible for high 
CVD morbidity and mortality in stage 5 CKD (London et al 2002). 
1.2.3.1 Haemodynamic consequences of arterial stiffness 
Attention has increasingly focused on the deleterious haemodynamic implications of 
reduced compliance of large capacitive arteries. Increased arterial stiffness is 
believed to be the principal mechanism for isolated systolic hypertension whereby 
reduced compliance results in early wave reflections, augmenting systolic afterload 
and a widening of pulse pressure (O’Rourke & Hashimoto 2007; London et al. 
1996). The other outcome of increased arterial stiffness is impaired coronary 
perfusion during diastole leading to subendocardial ischaemia (O’Rourke & 
Hashimoto 2007; Wang et al. 2007). Although the relationship between blood 
pressure and mortality in stage 5 CKD differs to non-uraemic individuals, large-scale 
studies concur severely abberant systolic and diastolic blood pressure is 
independently predictive of survival over four years (Iseki et al. 1997; Zager et al. 
1998)  
The pulsatile work of the heart is consequently increased and it is believed 
chronically elevated systolic pressure mediates pathological concentric hypertrophy 
of the left ventricle. There is consensus that indices of central arterial stiffness are 
independently associated with left ventricular mass and cardiac wall thickness of 
adolescents and young adults (Toprak et al 2009; Urbina et al. 2011), diabetics 
(Henry et al 2004), maintenance HD patients (Marchais et al 1993; Nitta et al. 2004) 
and people with less severe CKD (Wang et al. 2007). Although the cited studies are 
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cross-sectional further support for role of arterial stiffness in deleterious cardiac 
remodeling comes from aggressive blood pressure management studies. 
Concomitant decreases in left ventricular mass have been observed with reductions 
in central arterial stiffness during year-long interventions in essential hypertension 
(Shimamoto and Shimamoto 1996) and stage 5 CKD (London et al. 1994; Suzuki et 
al 2003).   
Worryingly, left ventricular hypertrophy (LVH) is present in 75% of people with CKD 
by the time HD is initiated (Foley et al. 1995), and prevalence reportedly increases 
to 90% thereafter (London et al. 2001b). Moreover, increasing severity of LVH, and 
in particular, ventricular dilation is greatest over the first year of dialysis (Foley et al. 
1998). Abnormal LV dilation and systolic dysfunction are independently associated 
with the development of ischaemic heart disease subsequent to initiation of HD as 
well as a threefold higher risk of heart failure (Parfrey et al. 1996). In addition, LVH 
in patients with hypertension is associated with features that promote myocardial 
conduction instability and ventricular arrhythmias (Zoccali 2010) and sudden cardiac 
death. The presence of LVH is independently predictive of CV and all-cause 
mortality of HD patients over three years (Silberberg et al. 1989; Zoccali et al. 2001; 
London et al. 2001b).  
1.2.3.2 Measurement of arterial stiffness 
Non-invasive measurement of central arterial stiffness is increasingly being 
employed as part of health research targeting CV health. An expert consensus 
document recommends carotid-femoral (aortic) pulse wave velocity (PWV) as the 
‘gold standard’ for measurement of central arterial stiffness (Laurent et al. 2006).  
Pulse wave velocity is calculated by measuring the time taken for the pressure wave 
to travel between two selected sites after ventricular ejection (arterial path length 
divided by transit time). Pulse wave velocity is calculated via the Moens-Korteweg 
equation (equation 2.1), where k is a constant, E is the vessel wall elastic modulus, 
h is wall thickness and R is lumen diameter. Higher velocities indicate greater aortic 
stiffness.  
Equation 2.1 Moens-Korteweg equation for pulse wave velocity. 
PWV = k(Eh/R)1/2                                     (Safar and Frohlich 2007) 
Augmentation index is another vascular stiffness measure, which represents the 
impact of waves reflected from the periphery mainly at branch points (or sites of 
impedance mismatch) on the ascending aortic pressure waveform (O’Rourke and 
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Kelly 1993). The difference between the early and late systolic peaks of the systolic 
pulse wave contour, known as augmentation pressure (AP) is divided by the pulse 
pressure (difference between systolic and diastolic pressure) in order to derive a 
percentage increase value (O’Rourke and Kelly 1993). Considered a composite 
measure of central arterial stiffness and peripheral pulse wave reflections (Safar et 
al. 2003), higher values also indicate stiffer vessels.  
Figure 1.12 Components of pressure wave analysis for calculation of AI 
(adapted from Stoner et al. 2014).  
 
Techniques for measuring arterial stiffness in stage 5 CKD vary. Doppler probes 
were initially used (tables 1.16 and 1.17), while later studies have employed devices 
utilising applanation tonometry (SphygmoCor®, AtCor Medical, Victoria, Australia) 
or mechano-transducers (Complior SP®, Artech medical, Pantin, France), which 
have been validated invasively (Laurent et al. 2006). Arterial stiffness outcomes 
from these machines are highly reproducible in CKD (Shoji et al. 2001; Sigrist et al. 
2010; Avramovski et al. 2013) and asymptomatic populations (Papaioannou et al. 
2007), however, they are expensive and require specialised training. The Vicorder® 
(Skidmore Medical Ltd, Bristol, UK) is a more recent device that employs 
oscillometry to measure arterial stiffness with similar reliability (Hickson et al. 2009; 
Kis et al. 2011). There is general agreement that Vicorder underestimates PWV 
relative to SphygmoCor at higher arterial stiffness values (Hickson et al. 2009; van 
Leeuwen-Segarceanu et al 2010; Kis et al. 2011; Shahin et al 2013) but agreement 
can be improved with a correction equation (Hickson et al. 2009). Additional 
advantages of the Vicorder system are that it is automated and thus largely operator 
independent, as well as being comparatively more portable and lower cost.  
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1.2.3.3 Prognostic utility of arterial stiffness in stage 5 CKD 
Prospective observational studies agree that regardless of measurement device 
employed higher aortic PWV is predictive of premature mortality among people 
receiving dialysis after adjustment for traditional CV risk factors (table 1.16).  
Moreover, there is consensus that risk of all-cause mortality, as well as fatal and 
non-fatal CV events is 15% higher for every 1 m/s increment in PWV (Shoji et al. 
2001; London et al. 2001a; Blacher et al. 2003, Pannier et al. 2005; Verbeke et al. 
2011). This is in agreement with a meta-analytic review, which found that risk of all-
cause mortality and CV events was 14 to 15% higher for the same increment across 
15,877 participants followed up over an average of 7.7 years (Vlachopoulos et al. 
2010). In contrast, Blacher et al (1999) reported a markedly higher risk of 39% but it 
is possible the authors may have reported the risk associated with one standard 
deviation of the mean PWV as opposed to 1 m/s.  
Individuals receiving HD who are in the highest tertile of PWV experience the 
greatest mortality burden (Blacher et al. 1999; London et al. 2001a; Verbeke et al. 
2011), and a PWV value equal to or exceeding 11 m/s appears to be a crucial 
threshold (London et al. 2001a; Pannier et al. 2005). While PWV may also be 
obtained from the femoral and brachial arteries it appears only aortic values have 
prognostic utility in this population (Pannier et al. 2005). Augmentation index, is also 
predictive of outcomes but this has only been demonstrated in the study of London 
et al. (2001a). Cox’s proportional hazard models from these studies also indicated 
age, gender, diabetes and dialysis vintage were predictive of CV outcomes with the 
notable exception of blood pressure indices (Blacher et al. 1999; Shoji et al. 2001; 
Blacher et al. 2003; Pannier et al. 2005; Verbeke et al. 2011).  
Arterial stiffness may simply be a marker of established CVD and reflect the higher 
disease burden of people ‘destined’ for premature death. However, associations 
with adverse changes in cardiac morphology (Marchais et al. 1993; London et al 
1996; Nitta et al. 2004) suggest that changes in aortic structural properties likely 
pre-figure the development of clinically overt CVD. Consequently, arterial stiffness 
indices offer a novel means by which CVD risk may be monitored. Although AI and 
aortic PWV are both proposed as arterial stiffness outcomes they may not be used 
interchangeably (Laurent et al. 2006). Importantly, intervention studies for targeting 
vascular health in CKD are increasingly using one or both of these outcomes 
(Mustata et al. 2004; Toussaint et al. 2008a; Koh et al. 2010; Mustata et al. 2011).
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Table 1.16 Prognostic utility of indices of arterial stiffness in stage 5 CKD. 
Study 
Study 
Sam
ple (n) 
Age 
M
/F 
(%
) 
DM
 
(%
) 
HD 
vintage 
Index & 
Device 
Value 
Period 
(m
ths) 
Findings 
V
erbeke 
2011 
H
D
 &
 P
D
 
(1076) 
E
vent 
N
o event 
  59.2 
68.1 
  59/41 
62/38 
  17 
29 
  28 
30 
 A
ortic PW
V  
S
phygm
oC
or 
 
  9.5 
11.8 
  
24 
 PW
V 1 m
/s: A
ll cause m
ortality and non-fatal C
V
 events RR = 1.15 (C
I 1.08 to 1.23, p < 
0.001) 
PW
V > 12 m
/s vs < 8.8 m
/s HR 1.94 (C
I 1.38 – 2.73, p value not stated) 
P
annier 
2005 
H
D
 (305) 
53 ±16 
 
N
ot 
stated 
10 
N
ot 
stated 
A
ortic PW
V 
D
oppler 
 
11.1 ±3.1 
 
70 ± 49 
 
1 m
/s increase in PW
V CV m
ortality adjusted RR 1.12 (C
I 1.03–1.25, p not stated) 
PW
V cutoff for increased CV m
ortality 10.75 m
/s, (84%
 sensitivity, 73%
 specificity, 
87%
 negative predictive value, 72%
 positive predictive value. 
B
lacher 
2003 
H
D
 (242) 
no previous 
C
V
D
 
52 ±16 
 
61/39 
7 
49 ±54 
A
ortic PW
V 
D
oppler 
 
N
ot 
stated 
78 ± 46 
 
PW
V 1 m
/s: All cause m
ortality: crude R
R
 = 1.34 (1.23–1.47); adjusted RR 1.14 (C
I 
1.03–1.26) (p = 0.02) 
CV m
ortality: crude R
R
 1.34 (1.24–1.44); adjusted RR 1.14 (1.05–1.24) (p = 0.02) 
London 
2001a 
H
D
 (180) 
54 ±16 
 
60/40 
10 
59 ±64 
 
A
I (%
) 
A
ortic PW
V  
D
oppler 
 
26.0 ±15 
11.7 ±3.0 
 
52 ± 36 
 
Augm
entation Index 10%
: A
ll cause m
ortality adjusted RR = 1.51 (C
I 1.23 - 1.86, p = 
0.0001); C
V
 m
ortality RR = 1.48 (C
I 1.16 - 1.90; p = 0.002). 
AI cut-off for increased all cause m
ortality 24.5%
 (sensitivity 83%
, specificity 67%
, 
A
U
C
 0.74 ± 0.04) 
AI cut-off for increased CV m
ortality 25%
 (sensitivity 80%
, specificity 70%
, A
U
C
 0.82 
± 0.05) 
PW
V 1 m
/s: All cause m
ortality adjusted RR = 1.16 (C
I 1.06 - 1.28, p = 0.001); CV 
m
ortality adjusted RR = 1.14 (95%
 C
I 1.02 to 1.26; P = 0.02). 
PW
V cutoff all-cause m
ortality 11.5 m
/s (specificity 80%
; sensitivity 74%
; A
U
C
, 0.82 
± 0.03) CV m
ortality 11.3 m
/s (specificity 79%
; sensitivity 64%
; A
U
C
 0.76 p = 0.04) 
S
hoji 
2001 
H
D
 (265) 
55 ±11 
 
41/69 
19 
83 ±62 
A
ortic PW
V 
PW
V
-200 
D
enshi 
8.6 ±2.2 
 
63 ± 23 
 
PW
V 1 m
/s: adjusted CV m
ortality OR 1.18  (C
I 0.98 -1.36, p = 0.079) 
PW
V 1 m
/s: adjusted all-cause m
ortality OR 1.16 (C
I 1.03 – 1.30, p < 0.01) 
B
lacher 
1999 
H
D
 (241) 
52 ±16 
 
61/39 
7 
48 ±51 
A
ortic PW
V 
D
oppler 
 
11.1 ±3.1 
 
72 ± 41 
 
PW
V 1 m
/s adjusted all-cause m
ortality OR 1.39 (C
I 1.19 - 1.62, p < 0.0001). 
PW
V
 tertile adjusted all-cause m
ortality O
R
: > 12.0 vs < 9.4 m
/s w
as 5.4 (C
I 2.4 - 11.9) 
A
djusted C
V
 m
ortality O
R
:  PW
V > 12.0 vs < 9.4 m
/s w
as 5.9 (C
I, 2.3 - 5.5). 
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Lack of uniformity in arterial stiffness outcome may hinder meta-analytic evaluation 
of interventions targeting CV morbidity and mortality in the future. There is now a 
growing need for recommendations regarding which outcome may be the most 
appropriate for monitoring vascular health and effectiveness of interventions in 
stage 5 CKD. 
1.2.3.4 Aetiology of accelerated arterial stiffness and uraemia 
Aortic PWV for people with stage 5 CKD averages over 11 m/s (Blacher et al. 1999; 
London et al. 2001a; Pannier et al. 2005; Verbeke et al. 2011; Avramovski et al. 
2013). Not only is this around 37% higher than values for middle-aged non-uraemic 
individuals, a PWV this high is closer to normative values observed for hypertensive 
seniors aged over 70 years (Mattace-Raso et al. 2010; Elias et al. 2011). Values 
approaching those of non-uraemic individuals have been observed, but only in a 
predominantly female sample (Shoji et al. 2001). Studies including a comparator 
group of age-matched controls confirm PWV of people with stage 5 CKD is at least 
27% higher (Temmar et al. 2010; Lilitkarntakul et al. 2011; Avramovski et al 2013). 
In addition, cross-sectional studies indicate arterial stiffening occurs early in the 
disease process (Wang et al. 2005) with two thirds of people with stage 2 to 3 CKD 
demonstrating elevated PWV compared to controls even after adjustment for age, 
gender, BP, heart rate and BMI (Lilitkarntakul et al. 2011). Moreover, compared to 
age matched hypertensives and normotensives aortic PWV values for people with 
CKD are 7% and 19% higher respectively (Briet et al. 2006). Taken together there is 
substantial evidence that increased central arterial stiffness is a phenotype of CKD. 
There is overwhelming agreement that age and blood pressure are the principal 
determinants of increased arterial stiffness in stage 5 CKD (table 1.17), which is in 
agreement with 90% of similar studies involving non-uraemic individuals (Cecilja 
and Chowienczyk 2009). Age-related changes in the central and conduit arteries are 
characterised by increases in lumen diameter and vessel wall thickness and an 
attendant increase in stiffness (O’Rourke and Hashimoto 2007; London et al. 2011). 
In addition, advancing age exerts a differential effect on the vascular system by 
preferentially altering the structural properties of the aorta, while distal muscular 
arteries are less affected (Benetos et al. 1993; Safar et al. 2005, Nichols and 
O’Rourke 2005). Notably, chronological age increments of 10 to 13 years are 
independently associated with a 1 m/s increase in aortic PWV (Avolio et al. 1983; 
McEniery et al. 2005).  
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The physiological basis for age attendant increases in arterial stiffness is mediated 
in part by changes in the extracellular matrix (ECM) of vessels, which consists of 
collagen, elastin, glycoproteins and proteoglycans (Zieman et al. 2003). Elastin cells 
are gradually lost or become calcified (Yu & Blumentahl 1963) and there is an 
overproduction of abnormal collagen cells which start to form cross-links 
(Greenwald 2007). In addition, degradation and fragmentation of the elastin lamellae 
from repetitive stress cycles subsequently places greater load on stiffer collagen 
fibres and changes arterial diameter (Watanabe et al. 1996; Benetos et al. 2002). 
Age perhaps represents the least modifiable risk factor for increased arterial 
stiffness. However, whether ECM changes in the arterial wall are due to the aging 
process per se or associated with long-term exposure to other risk factors for 
vascular aging such as diabetes, elevated blood pressure, and systemic 
inflammation is not yet certain (Chue et al. 2010).  
The role of hypertension in hypertrophy of the arterial media to maintain tensile 
stress within physiological limits (Laplace’s law) is well documented (equation 2.2). 
Animal models of induced hypertension demonstrate thickening of the media layer 
of the artery occurs in response to increased circumferential deformation (Dobrin 
1995; Xu et al. 2000). Histological findings from autopsy studies indicate the 
diameter of the ascending aorta increases at a rate of 9% per decade (Watanabe et 
al. 1996), with an attendant doubling or tripling of the carotid artery tunica media 
between the ages of 20 to 90 years (Nagai et al. 1999; O’Leary et al. 1999).  
Equation 2.2 Laplace’s Law. 
Wall stress = mean arterial pressure x arterial diameter / wall thickness 
(Nichols and O’Rourke 1998) 
Qualitative changes also occur in the ECM as collagen production is up-regulated at 
the expense of elastin, further altering the structural properties of the vessel wall (Xu 
et al.  2000). In addition, according to the Maxwell model, as transmural pressure 
rises and distends the artery there is progressively greater recruitment of collagen 
fibres, and a concomitant reduction in elasticity (Bank et al 1996). Furthermore, 
elevated blood pressure is inversely associated with endothelial function (Nigam et 
al. 2003), which provides functional regulation of aortic stiffness via vasomotor 
control (Bruno et al. 2012, McEniery et al. 2006).  
Temmar et al. (2010) found diabetes was a predictor of aortic stiffness across the 
CKD trajectory, while plasma glucose was also associated with PWV in the 
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composite CKD sample of Lilitkarntakul et al. (2011). Similarly, diabetes is 
independently associated with arterial stiffness in just over half of published studies, 
explaining on average 5% of the variance (Cecilja and Chowienczyk 2009). A 
comprehensive review by Stehouwer et al. (2008) indicates increased arterial 
stiffness is a phenotype of diabetes, which is of particular importance in CKD as this 
is the primary renal diagnosis of at least a quarter of people starting dialysis (UKRR 
2012; SRRR 2012). The role of diabetes in arterial stiffness aetiology is incompletely 
understood but there are several mechanisms by which insulin resistance and 
hyperglycaemia may directly and indirectly influence vessel properties. 
Hyperglycaemia mediates non-enzymatic glycation of ECM proteins forming 
advanced glycation end products (AGE), which subsequently increase collagen 
crosslinking (Lakatta 2003; Konova et al. 2004), thereby reducing elasticity and 
promoting vessel rigidity.  
The arterial endothelium expresses a receptor for AGE (RAGE), and interaction 
between the two produces reactive oxygen species (Yan et al. 1994), which quench 
endogenous nitric oxide a potent vasorelaxant. In addition RAGE provokes 
increased endothelial permeability (Basta et al. 2004) and an immunological 
response resulting in endothelial expression of adhesion molecules and 
inflammatory cytokines (Basta 2008; Zhang 2008). Histological studies indicate stiff 
vessels are immunologically stressed showing elevated levels of cytokines, 
intercellular adhesion molecules, transforming growth factor-β and evidence of 
smooth muscle proliferation, as well as infiltration of macrophages and mono-
nuclear cells (Lakatta 2003; Zieman et al 2005; Park and Lakatta 2012). Also 
present, are elevated levels of matrix metalloprotease and elastase enzymes 
associated with inflammatory regulation, which degrade the strength and elasticity of 
the vessel wall by fraying elastin and eliciting production of weaker collagen fibres 
(Wang and Lakkata 2002; McNulty et al. 2006). 
The immunological response elicited by AGEs contributes to persistent low-grade 
inflammation that characterises stage 5 CKD, which is also implicated in endothelial 
dysfunction (Gunnett et al. 2005). There is agreement that impairment of this organ, 
which regulates vascular tone and thus the functional component of arterial stiffness 
is also a phenotype of diabetes (Naka et al. 2012; Tan et al. 2002; Ravikumar et al. 
2002) and stage 5 CKD (van Guldener et al. 1998; Bolton et al. 2001).   
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Table 1.17 Variables independently associated with aortic pulse wave velocity and augm
entation index in stage 5 CKD. 
Study 
Sam
ple (n) 
Age 
M
/F 
Index 
Independent variables 
Variance explained 
Lilitkarntakul 
et 
al. 
2011 
C
KD
 1-5 
(C
KD
 5 n = 7) 
48  ± 8 
 
68/32 
Aortic PW
V 
(Sphygm
ocor
) 
Age, m
ean arterial pressure, high 
sensitivity 
C
R
P, 
asym
m
etric 
dim
ethyl arginine. 
r 2 = 0.46 (p < 0.05) 
Tem
m
ar et al. 2010 
H
D
 (47) 
C
KD
 4-5 (51) 
C
KD
 2-3 (52) 
65  ± 13 
70  ± 13 
65  ± 11 
60/40 
63/37 
58/42 
Aortic PW
V 
(Sphygm
ocor) 
H
D
: Age, M
AP
, D
iabetes, Aortic 
calcification score 
Stage 
2-5 
C
K
D
: 
Age, 
M
A
P, 
D
iabetes 
r 2 = 0.49 (p < 0.01) 
Blacher et al. 2003 
H
D
 (242) 
 
52  ± 16 
 
61/39 
 
Aortic PW
V 
(D
oppler 
ultrasound) 
Age, 
m
ean 
arterial 
pressure, 
heart period, gender 
r 2 = 0.57 (p < 0.001) 
 
C
ontrols (469) 
not stated 
 
not stated 
 
Age, 
m
ean 
arterial 
pressure, 
heart period, gender 
r 2 = 0.65 (p < 0.001) 
 
All (711) 
not stated 
 
not stated 
 
 
Age, 
m
ean 
arterial 
pressure, 
heart period, gender, presence of 
stage 5 C
KD
 
r 2 = 0.62 (p < 0.001) 
 
London et al. 2001a 
H
D
 (180) 
54 ± 16 
 
not stated 
AI 
(Applanation 
tonom
etry) 
G
ender, age, height, aortic PW
V, 
left 
ventricular 
ejection 
tim
e, 
m
ean blood pressure. 
r 2 = 0.49 (p value not stated) 
London et al. 1992 
H
D
 (79) 
C
ontrols (73) 
51.8 ± 18.6 
52.7 ± 15.8 
59/41 
56/44 
AI 
(Applanation 
tonom
etry) 
H
eight, 
aortic 
PW
V, 
left 
ventricular 
ejection 
tim
e, 
presence of stage 5 C
KD
. 
r 2 = 0.58 (p < 0.0001) 
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1.2.3.5 Vascular calcification in stage 5 CKD 
A large body of evidence indicates accelerated vascular calcification (VC) plays a 
pivotal role in arterial stiffness of HD patients. Calcification can take place in the 
intima (atherosclerosis) and the tunica media of arterial walls (arteriosclerosis). 
Arteriosclerosis (Mönckeberg’s sclerosis) is characterized by diffuse mineral 
deposition within the elastic lamellae of the arterial media and is distinct from intimal 
calcification, which is patchy, irregular and restricted to areas of atherosclerotic 
plaques (London et al. 2005; Mizobuchi et al 2009). Calcified atherosclerotic 
plaques and medial calcification of the epicardial coronary arteries are highly 
prevalent in adults with stage 5 CKD (Braun et al 1996; Block et al 2005). However, 
arteriosclerosis is a non-occlusive pathology and affects haemodynamics differently 
to intimal calcification by altering structural properties of the vessel walls (London et 
al. 2003).  
Although there is a degree of heterogeneity in methods of calcification assessment 
and vascular section examined, commonly observed determinants of greater VC 
are: age, male gender, diabetes, dialysis vintage and calcium phosphate product 
(Taniwaki et al. 2005; Sigrist et al. 2006; Sigrist et al. 2007). Of these risk factors, 
considerable attention has been devoted to abnormalities of calcium and phosphate 
metabolism. Moreover, biochemical parameters implicated in calcification are also 
associated with mortality risk. High calcium, phosphorous and either high or low 
parathyroid hormone are independently associated with the highest mortality risk 
among maintenance HD patients in large retrospective Canadian studies (Block et 
al. 1998; Stevens et al. 2004) and the more recent DOPPS (Tentori et al. 2008). 
Moreover, time dependent Cox models indicate hyperphosphataemia has the 
greatest influence on all-cause and CV mortality (Kalantar-Zadeh et al. 2006; 
Noordzik et al. 2005).  
There is consensus that rather than being a passive process whereby calcium-
phosphate product simply exceeds solubility and precipitates, arteriosclerosis is the 
culmination of multiple metabolic stressors. Low-density lipid oxidation, uraemia and 
elevated serum phosphate precipitate the differentiation of vascular smooth muscle 
cells (VSMCs) into osteoblast like cells in the vessel wall (London et al. 2005; 
Mizobuchi et al. 2009; Nemcsik et al. 2012). Endogenous calcification inhibitors 
such as osteoprotegerin, matrix G1a protein, play a vital role in regulating 
osteoclast, osteoblast activity while pyrophosphate and Fetuin-A bind to or 
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sequester serum calcium and minerals to prevent crystal growth and deposition 
(Cozzolino et al. 2008; Mazzaferro et al. 2011).  
With the exception of matrix G1a protein these calcification inhibitors are correlated 
with arterial stiffness in stage 5 CKD (Nemcsik et al. 2012). This may be due to 
potent calcification inhibitors like Fetuin-A being down-regulated by inflammation 
(Memoli et al. 2007), while low molecular weight solutes like pyrophosphate are 
possibly removed by the dialysis procedure itself (Lomashvili et al. 2005). Serum 
concentration of bone-morphogenetic protein-7, which prevents VSMC 
differentiation into cells with an osteoblast phenotype (Lund et al 2002) also declines 
with renal failure (Wang et al 2001). In addition, uraemia potentiated levels of 
fibroblast growth factor-23, a protein that regulates phosphate homeostasis and 
vitamin D synthesis have also been implicated (Nemcsik et al. 2012).  
Figure 1.13 Mechanisms of increased arterial stiffness (image adapted from 
LookingForDiagnosis.com, 2014). 
 
Figure abbreviations: AGE - advanced glycation end product; MMP – matrix metalloprotease; VSMC – 
vascular smooth muscle cell; ICAM – intracellular adhesion molecule. 
As can be seen, although agreed risk factors for arterial stiffness are relatively few 
the underlying biological mechanisms are not only complex in the number of factors 
involved but also in the way they interact (McIntyre 2007). Notably, traditional CV 
risk factors such as smoking, cholesterol, gender and triglycerides do not appear to 
contribute to arterial stiffness in CKD. This is consistent with a systematic review of 
77 studies by Cecilja and Chowienczyk (2009), which found the independent 
contribution of such risk factors was either small, or insignificant. Interestingly, 
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although presence of CKD is a predictor of increased arterial stiffness (London et al. 
1992; Blacher et al 2003; Wang et al 2005) and incidence of CV events (Zoccali et 
al 2011), uraemia specific variables (serum phosphate, calcium phosphate product, 
dialysis dosage) are not independently associated (Lilitkarntakul et al 2011).  
Pharmacotherapy has been the mainstay of vascular health management in stage 5 
CKD. Reassuringly, use of non-calcium based phosphate binders halts or slows 
progression of coronary and aortic calcification among incident and prevalent HD 
patients (Chertow et al. 2002; Block et al. 2005). In addition, aggressive blood 
pressure management has been shown to reduce mortality risk for HD patients who 
respond with a decline in aortic PWV (Guerin et al. 2001).   
1.2.3.6 Arterial stiffness and arteriosclerosis 
Although aortic calcification occurs throughout the CKD trajectory it appears that 
clinically detectable signs occur only after HD initiation. There is agreement that 
radiograph and computerised tomography (CT) determined abdominal aorta 
calcification is predictive of higher PWV of maintenance HD patients (London et al; 
2005; Raggi et al. 2007; Temmar et al. 2010) but not in pre-dialysis patients 
(Lemmos et al. 2007; Temmar et al. 2010). However, some studies have observed 
very modest or no association between VC and arterial stiffness in samples of HD, 
PD and stage 4 CKD patients (Chesterton et al 2005; Sigrist et al. 2006). Although 
CT imaging and scoring techniques similar to those of Temmar et al. (2010) were 
employed in these studies, the superior femoral artery was imaged instead, which is 
more muscular and less elastic than the aorta. Therefore, it might be expected that 
the haemodynamic effects of medial calcification at this part of the vascular tree 
would be less pronounced. Moreover, there is agreement that compared to other 
sections of the vascular tree, calcification of the abdominal aorta is more strongly 
associated with aortic PWV (McEniery et al. 2009; Raggi et al 2007).  
Aortic calcium score determined by CT explains 3% of the variance in aortic PWV of 
asymptomatic adults, while age, MAP, heart rate and estimated GFR account for a 
further 48% (McEniery et al. 2009). The relative contribution of aortic calcification to 
PWV of HD patients was not quantified by Temmar et al. (2010), but it is speculated 
that it may be amplified given its higher prevalence and severity in stage 5 CKD. In 
addition, there is evidence that large artery calcification determined by CT 
independently predicts left ventricular mass (Nitta et al 2004) and is associated with 
impaired baroreceptor reflex sensitivity of HD patients (Chesterton et al 2005). The 
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Table 1.18 Arterial calcification in stage 5 CKD: prevalence; prognostic utility; determ
inants. 
Study 
Sam
ple (n) 
Age 
(yr) 
M
/F 
HD 
vintage 
M
ethod 
Artery 
Prevalence 
Findings 
V
erbeke et al 
2011 
H
D
 &
 P
D
 (1076) 
E
vent 
N
o event 
 59.2 
68.1 
 59/41 
62/38 
 17 
29 
 Lum
bar radiograph. 
S
em
i-quantitative 24 
point severity score 
 A
bdom
inal 
aorta  
 N
ot stated 
Fatal and non-fatal events over 2 years: C
alcification severity 
tertile 2, R
R
 3.68 (C
I 1.36 – 10.00, p < 0.001); tertile 3, R
R
 
8.64 (3.53 - 21.16, p < 0.001) 
 
Tem
m
ar et al  
2010 
H
D
 (47) 
C
K
D
4-5 (51) 
C
K
D
2-3 (52) 
65 ±13 
70 ±13 
65 ±11 
 
60/49 
63/37 
58/42 
N
ot 
reported 
C
T - A
gatston score 
system
 >1m
m
 > 130 
hounsfield units 
R
adiograph 
A
bdom
inal 
aorta 
N
ot stated 
C
alcification scores highest for H
D
 (p = 0.001) 
PW
V
 determ
inants  
C
K
D
 2 - 5: age, M
A
P
, D
M
, r 2 = 0.47 
H
D
: age, M
A
P
, D
M
, C
alcification score, r 2 = 0.49 
S
igrist 
et 
al 
2007 
H
D
 (60)  
P
D
 (28)  
C
K
D
 4 (46) 
60 ±15 
61 ±14 
60 ±14 
 
70/30 
60/40  
56/44 
 
36 ±25 
34 ±23 
 
C
T - A
gatston score 
system
 >1m
m
 > 130 
hounsfield units 
 
S
uperficial 
fem
oral 
artery 
N
ot stated 
C
alcification progression greatest for H
D
 group com
pared to 
P
D
 and C
K
D
4 at 12 (p = 0.002) and 24 m
onths (p = 0.01) 
D
eterm
inants of V
C
 progression – gender, age, tim
e 
averaged ALP
, lipid low
ering drugs, beta blockers r 2 = 0.64  
R
aggi 
et 
al 
2007 
H
D
 (131) 
55.2  
 
50/50 
50.4 
Lum
bar radiograph. 
S
em
i-quantitative 24 
point severity score 
Thoracic & 
A
bdom
inal 
aorta 
N
ot stated 
A
bdom
inal but not thoracic aorta calcium
 scores 
independently associated w
ith higher PW
V (p = 0.004)  
O
kuni 
et 
al 
2007 
H
D
 (515) 
60± 12  
59/41 
95 ±75 
Lum
bar radiograph – 
presence/absence of 
calcification 
A
bdom
inal 
aorta 
56.5%
 
A
ll cause m
ortality R
R
 2.07 (1.21-3.56, p = 0.008) C
V
 
m
ortality R
R
 2.39 (C
I 1.01-5.66, p = 0.048). M
ean follow
-up 
51 ± 17 m
onths. 
S
igrist 
et 
al 
2006 
H
D
 (60)  
P
D
 (28)  
C
K
D
 4 (46) 
60 ±15 
61 ±14 
60 ±14 
70/30 
60/40  
56/44 
36 ±25 
34 ± 23 
 
C
T - A
gatston score 
system
 >1m
m
 > 130 
hounsfield units 
S
uperficial 
fem
oral 
artery 
73%
 
71%
 
47%
 
PW
V
 not associated w
ith calcification score. 
C
alcification score and radial dorsalis PW
V r = 0.34 (p < 
0.001). 
D
eterm
inants of V
C
 -A
ge, gender, C
a-P
 product, D
M
, r 2 = 
0.48. 
C
hesterton 
et al 2005 
40 H
D
 
62 ±2.1 
28/12 
40 ± 3.9 
C
T - A
gatston score 
system
 >1m
m
 > 130 
hounsfield units 
 
S
uperficial 
fem
oral 
artery 
64%
 
C
alcification not correlated w
ith age or H
D
 vintage. N
ot 
associated w
ith arterial stiffness. 
P
eople w
ith V
C
 had significantly low
er B
R
S
 3.43±0.38 
vs 5.67±0.76 (p  = 0.01) 
Taniw
aki 
et 
al 2005 
H
D
 
184 D
M
 
483 no D
M
 
 
 65 ±9 
59 ±12 
 
 67/33 
59/31 
 
 
57.7 ±46.5 
139.0 
±91.5 
 
C
T – scoring system
 
not stated 
A
orta 
section 
not 
stated 
N
ot stated 
A
ortic calcification of diabetics v non-diabetics: H
D
 vintage 
<60 m
onths 53.2±22.2 vs 39.2±26.0%
, (P
<0.001); 60-120 
m
onths 63.2±20.5 vs 43.4± 27.9%
, P
<0.001) 
D
eterm
inants A
C
I – A
ge, gender, H
D
 vintage, D
M
, blood 
pressure, cholesterol, C
a-P
 product. R
2 = 0.27 
N
itta 
et 
al 
2004 
H
D
 (49) 
60±1.6
0  
55/45 
115.2 ±9.6 
C
T – scoring system
 
not stated 
A
orta 
section 
not 
stated 
N
ot stated 
C
alcification index independent predictor of left ventricular 
m
ass index along w
ith B
P
, PW
V
. r 2 = 0.33  
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ramifications of altered ventricular morphology are well recognised but the 
baroreceptor reflex is part of autonomic cardiovascular control and vital in short-term 
blood pressure regulation. 
1.2.3.7 Calcification prevalence and progression  
Age attendant calcification of the large capacitive arteries is well documented in 
older adults (Yu and Blumethal 1963; Post et al. 2007), but it is more severe and 
more prevalent among people with stage 5 CKD of all ages (Guerin et al. 2001; 
London et al. 2003; Sigrist et al. 2007; Raggi et al. 2007). Moreover, medial 
calcification has been observed in middle-aged and young adults with CKD in the 
absence of traditional CV risk factors (London et al. 2003). People receiving 
maintenance HD also demonstrate more profound vascular calcification compared 
to individuals receiving PD and those with stage 4 CKD (Sigrist et al. 2006).  
Worryingly, by the time dialysis is commenced at least half of people show some 
degree of large artery calcification (Guerin et al. 2001; Sigrist et al. 2006) a 
proportion that increases up to almost three quarters among prevalent HD patients 
(Chesterton et al. 2005; Sigrist et al. 2006). In comparison, prevalence of large 
artery calcification among non-uraemic individuals is 37% or less (Kauppila et al. 
1997). A longitudinal study confirmed that once dialysis is initiated further vascular 
calcification ensued with people receiving HD demonstrating a more pronounced 
degree of progression over two years compared to PD and people with stage 4 CKD 
(Sigrist et al. 2007).  
Presence of medial calcification of the large conduit arteries is also independently 
predictive of survival in the HD population (table 1.18). Radiographic identification of 
the presence of calcification of the aorta and pelvic arteries more than doubles the 
risk of mortality and non-fatal CV events among uraemic individuals over follow-up 
periods of two to seven years (London et al. 2003; Okuni et al. 2007; Verbeke et al. 
2011). Moreover, not only was two year mortality highest among HD participants in 
a mixed cohort of HD, PD and stage 4 CKD patients but progression of VC 
determined by CT was also independently predictive of mortality (Sigrist et al. 2007). 
1.2.3.8 Arterial stiffness, physical activity and cardiorespiratory fitness 
Although clinical correlates of aortic PWV have been explored the potential 
behavioural mediators of large artery stiffness have not been investigated in stage 5 
CKD. Physical activity (PA) and cardiorespiratory fitness (CRF) are implicated in 
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survival in mortality in stage 5 CKD (O’Hare et al. 2003; Sietsema et al. 2004; 
Tentori et al 2010; Matsuzawa et al. 2012), but the mechanism by which higher 
levels of both mediate improved survival has not been elucidated.  Exercise 
mediated changes in traditional CV risk factors are generally believed to confer 
better outcomes. However observed improvements are modest, and at least 40% of 
CVD risk reduction associated with physical activity in healthy individuals (Mora et 
al. 2007) and cardiac patients (Taylor et al. 2006) remains unexplained (figure 1.14). 
Summative improvements in risk factors may be particularly beneficial in disease 
states, however accumulating evidence indicates that exercise aimed at improving 
CRF has a direct effect on vascular function. It is believed a certain amount of PA is 
required to maintain normal vascular health, as inactivity is associated with 
increased arterial stiffness (Gando et al. 2010a), and endothelial dysfunction 
(Thijssen et al. 2009; Wang 2005; Green et al. 2004; Suvorava et al. 2004).  
Figure 1.14 Relative CVD risk reduction associated with PA (adapted from 
Thijssen et al. 2010, p. 846). 
 
Currently there is a paucity of research regarding how PA and CRF relate to 
vascular health in stage 5 CKD. Much of what is known comes from cross-sectional 
studies in the general population with few data pertaining to clinical populations. 
Review of the literature shows considerable heterogeneity of arterial stiffness 
measures employed (tables 1.19 and 1.20). However, there is overwhelming 
agreement that indices of arterial stiffness of apparently healthy adults are inversely 
associated with PA levels estimated via accelerometry (Edwards et al. 2012; Aoyagi 
et al. 2010, Gando et al. 2010a, Kozakova et al. 2007, Sugawara et al. 2006) and 
self-report questionnaires (van de Laar et al. 2010, Boreham et al 2004).  
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Table 1.19 Sum
m
ary of studies exploring the relationship between indices of arterial stiffness and physical activity. 
Study 
Sam
ple (n) 
Age 
M
/F 
Arterial stiffness outcom
e/s 
Findings 
Jennersjo et al 
2012 
D
iabetes (327) 
60.5 ±3.2 
69/31 
A
ortic PW
V 
 
P
edom
eter steps/day and PW
V
 borderline association r = -0.11 (p = 0.066). 
E
dw
ards 
et 
al 
2012 
D
iabetes 
and 
O
bese (548) 
18 ±3.3 
37/63 
A
ugm
entation 
Index, 
aortic 
PW
V
, 
brachial 
artery 
distensibility 
 
H
abitual P
A
 (accelerom
eter cpm
) independently associated w
ith A
I and 
brachial distensibility (p < 0.05).  
P
hysical activity associated w
ith PW
V (correlation not stated) but significant 
interaction w
ith diabetes status observed. 
V
an de Laar et 
al 2010 
H
ealthy (373) 
13.1 ±0.8 
N
ot 
stated 
C
arotid artery stiffness 
Longitudinal follow
 up at age 
36 
S
tiffer carotid arteries significantly associated w
ith less tim
e in self-reported 
vigorous but not in light-to-m
oderate intensity P
A
 betw
een adolescence and 
young adulthood. 
A
oyagi 
et 
al 
2010 
H
ealthy (198) 
73.5 ±4.6 
 
45/55 
C
ardio-fem
oral PW
V 
B
rachio-tibial PW
V 
 
C
ardio-fem
oral and delta brachio-tibial velocities significantly low
er in 
participants exceeding 6,600 steps/day and/or > 16 m
in/day of P
A
 at >3 
M
E
Ts over one year. 
G
ando 
et 
al 
2010a 
H
ealthy (538) 
49 ± 0.4 
32/68 
A
ortic PW
V 
 
A
ccelerom
eter estim
ated m
oderate P
A
 independently associated w
ith PW
V 
of m
iddle-aged adults (p value not stated).  
Light P
A
 independently associated w
ith PW
V of older adults (p value not 
stated). Interaction of fitness level in older adults.  
Light P
A
 and PW
V in older unfit subjects (r = -0.47, p < 0.01). PW
V
 higher in 
low
-light P
A
 level group than high-light P
A
 level group after norm
alizing for 
tim
e spent in m
oderate to vigorous P
A
 (P < 0.01).  
K
osakova et al 
2007 
H
ealthy (432) 
43 ± 8 
38/62 
C
arotid artery stiffness 
U
ltrasound  
A
ccelerom
eter estim
ated P
A
 (cpm
) inversely associated (r = -0.20 to -0.25, p 
< 0.001) and independent predictor of carotid stiffness (p < 0.05) 
S
ugaw
ara et al 
2006 
H
ealthy (103) 
64 ± 7 
 
0/100 
C
arotid artery stiffness 
 
A
ccelerom
eter estim
ated light, m
oderate, vigorous P
A
 correlated w
ith carotid 
stiffness (r = -0.26, -0.26, -0.23 respectively, p  < 0.05). M
oderate and 
vigorous P
A
 independently associated w
ith carotid stiffness (p < 0.01). 
B
oreham
 et al 
2004 
H
ealthy (405) 
22.6 ± 1.6 
50/50 
A
ortoiliac PW
V  
A
ortodorsalis pedis PW
V 
 
S
elf-reported sports related PA
 only independently associated aortodorsalis 
pedis PW
V at group level (p < 0.05). Leisure tim
e P
A
 independently 
associated w
ith PW
V in m
ales only (p < 0.05). 
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Table 1.20 Sum
m
ary of studies exploring the relationship between indices of arterial stiffness and cardiorespiratory fitness.  
Study 
Sam
ple (n) 
Age 
M
/F 
Arterial stiffness outcom
e/s 
Findings 
Lane 
et 
al 
2013 
H
aem
odialysis 
(42) 
44.5 ± 5.0 
N
ot 
stated 
A
ortic PW
V 
A
rterial elastance 
S
huttle w
alk distance and PW
V
 r = -0.39 (p = 0.02); arterial elastance r = 
-0.42 (p = 0.004). P
W
V
 independently associated w
ith w
alk distance β = -
14.68 (p = 0.012) 
Jae 
et 
al 
2010 
M
etabolic 
syndrom
e (867) 
H
ealthy (168) 
52.0 ± 6.0 
 
100/0 
B
rachial ankle PW
V 
 
V
O
2 m
ax independently associated w
ith baPW
V
 in m
en w
ith m
etabolic 
syndrom
e (β = -0.22, p < 0.05) and w
ithout (β = -0.12, p < 0.05).  
N
o significant difference in baPW
V
 betw
een unfit m
en w
ithout and fit m
en 
w
ith m
etabolic syndrom
e (p = 0.81) 
G
ando et al 
2010b 
H
ealthy (159) 
41.5 ±5.5 
0/100 
B
rachial 
ankle 
PW
V, 
A
ugm
entation index 
Interaction betw
een age and VO
2 peak in arterial stiffness indices (p < 
0.01). O
lder adults w
ith higher fitness had low
er arterial stiffness 
B
oreham
 
et 
al 2004 
H
ealthy (405) 
22.6 ± 1.6 
50/50 
A
ortoiliac PW
V  
A
ortodorsalis pedis PW
V 
V
O
2 m
ax independently associated w
ith arterial stiffness indices (p < 0.01)  
B
onapace et 
al 2003 
C
ardiom
yopathy 
(90) 
62 ± 11 
55/45 
A
ortic PW
V 
V
O
2 m
ax and PW
V: group r = -0.39 (p < 0.001); ischaem
ic r = -0.33 (p = 
0.02); non-ischaem
ic r = -0.55 (p = 0.005). PW
V independent predictor of 
C
R
F r 2 = 0.34 (p = 0.04) 
Ferreira et al 
2002 
H
ealthy (351) 
36·5 ± 0·6 
 
48/52 
A
ortic 
and 
fem
oral 
artery 
com
pliance, distensibility. 
V
O
2 m
ax and carotid artery com
pliance r = 0·19 (p = 0·02); fem
oral artery 
com
pliance r = 0·18 (p = 0·03); distensibility of carotid r = 0·16 (p = 
0·047) but not fem
oral artery. 
Tanaka et al 
2000 
H
ealthy (151) 
47.7 ±1.0 
100/0 
C
arotid artery com
pliance 
 
V
O
2m
ax  and carotid arterial com
pliance r = 0.44 (p < 0.005); β stiffness 
index r = -0.45 (p < 0.005).  
A
rterial com
pliance of endurance-trained m
iddle-aged and older m
en 20 - 
35%
 higher than recreationally active and sedentary peers (p < 0.01). 
Tanaka et al 
1998 
H
ealthy (53) 
48.4 ±2.0 
0/100 
A
ortic 
PW
V, 
C
arotid 
A
ugm
entation index 
V
O
2 m
ax and PW
V r = -0.66, carotid AI r = -0.53 (p < 0.001). V
O
2 m
ax 
independently associated w
ith PW
V
 and A
I (p < 0.001) 
V
aitkevicius 
et al  1993 
H
ealthy (146) 
54.3 ±17.0 
 
63/37 
A
ortic PW
V 
A
ugm
entation Index 
 
A
rterial 
stiffness 
of 
endurance 
trained 
older 
adults 
(54-75years) 
significantly low
er than sedentary peers (A
I 36%
 low
er, PW
V
 26%
 low
er, 
p < 0.0001) despite sim
ilar blood pressures. 
V
O
2 m
ax and PW
V:  m
en r = 0.34 (p < 0.01); w
om
en r = 0.49 (p < 0.01). 
V
O
2 m
ax not independently associated w
ith PW
V due to age interaction 
V
O
2 m
ax and A
I: m
en r = 0.34, (p < 0.001); w
om
en r = 0.74 (p < 0.0001). 
V
O
2 m
ax independently associated w
ith A
I (p = 0.001) along w
ith age. 
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Habitual PA indicated by accelerometer activity counts is independently associated 
with arterial stiffness of adolescents (Edwards et al. 2012) and middle-aged adults 
(Kosakova et al. 2007). In addition, there appears to be a differential effect of PA 
intensity on arterial stiffness with respect to age. Studies following participants from 
adolescence to adulthood indicate vigorous activity only is predictive of arterial 
stiffness among young healthy adults (van de Laar et al. 2010; Boreham et al. 2004) 
while moderate PA is inversely correlated in samples of middle-aged and older 
adults (Sugawara et al. 2006; Aoyagi et al. 2010; Gando et al. 2010a). Moreover, 
subgroup analysis by Gando et al. (2010a) indicated greater amounts of time spent 
in light PA (< 3 METs) attenuated arterial stiffening of older adults even after 
adjustment for time spent in moderate and vigorous PA, especially in unfit 
individuals (Gando et al. 2010a). This may be because CRF declines with 
advancing age and thus light PA determined by accelerometer is ‘harder’ in relative 
terms for older adults compared to younger adults. Interestingly, Jennersjo et al. 
(2012) found no association between steps/day and aortic PWV of obese individuals 
but this may be due to underestimation of activity by pedometry in obese 
populations (Tyo et al. 2011). 
A moderate correlation between a surrogate measure of aerobic fitness determined 
via a shuttle walk test and aortic PWV has been observed in a sample of 
maintenance HD patients (Lane et al. 2013). This is in agreement with associations 
observed in samples of apparently healthy middle-aged adults (Tanaka et al. 2000) 
and older adults with dilated cardiomyopathy (Bonapace et al. 2003). Several 
studies have shown CPET measured CRF is independently associated with large 
artery stiffness of non-uraemic individuals (Vaitkevicius et al. 1993; Tanaka et al. 
1998; Boreham et al. 2004; Jae et al. 2010). Moreover endurance trained seniors 
with higher CRF demonstrate attenuated arterial stiffness compared to sedentary 
peers despite similar blood pressures (Tanaka et al. 1998; Gando et al. 2010b). 
Endothelial function, which represents the functional component of arterial stiffness 
is also strongly associated with CRF in non-uraemic adults (Palmieri et al. 2005). 
Boreham et al. (2004) contend that higher CRF mediates the relationship between 
PA and arterial stiffness in young adults. However, the authors employed self-
reported PA, which is arguably susceptible to greater measurement exposure error 
compared to CPET measured CRF. Consequently, lower accuracy and reliability of 
subjectively estimated PA may have adversely affected the strength of association 
with arterial stiffness in multivariable analysis. The work of Chen et al. (1998) 
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indicates ventricular systolic and aortic function form an important coupling, which is 
physiologically matched for optimum cardiac efficiency. Stiffer vessel walls 
adversely affect cardiac function by increasing aortic impedance to stroke volume 
from the left ventricle (Shibata et al. 2008) resulting in a stiffer ventricle in people 
with CKD (Edwards et al. 2008) and invariably leading to LVH (Foley et al. 1998). 
Aortic stiffness is independently predictive of VO2peak in people with dilated 
cardiomyopathy (Bonapace et al. 2003) and a physical performance estimate of 
CRF in a sample of maintenance HD patients (Lane et al. 2013). Taken together it 
appears CRF is more likely an expression of increased aortic stiffness rather than a 
mediator in stage 5 CKD.   
Given the number of studies showing arterial stiffness is associated with PA and 
CRF it is of great concern that the HD population is characterised by high 
prevalence of low levels of both (O’Hare et al. 2003; Tentori et al. 2010; Painter et al 
2011; Parsons and King-van Vlack 2009). By extension, observed associations 
between indices of large artery stiffness and fitness level and PA may explain why 
the latter are predictive of survival in the HD population. However, whether habitual 
PA mediates improved survival in stage 5 CKD has not been explored. Research in 
this area is warranted to provide additional support for KDOQI recommendations 
pertaining to activity counseling for management of CVD risk in this population.  
1.2.3.9 Summary and research questions 
Although arterial stiffening is a pathophysiological process that is driven by 
advancing age (O’Rourke and Hashimoto 2007), accelerated vascular aging is a 
putative phenotype of stage 5 CKD (London et al. 2011, Pannier et al. 2005). 
Arterial stiffening observed in uraemia may be viewed as the manifestation of age 
associated decline in extracellular composition of the vessel wall, chronic elevation 
of central pressure, bone demineralization, and reduced glycaemic control. 
Progressive vascular calcification and increased arterial stiffness have been 
observed with greater dialysis duration in prospective studies (Sigrist et al. 2007; 
Avramovski et al. 2013), however, HD vintage has not been identified as a risk 
factor. Importantly, habitual PA and higher CRF are implicated in survival of 
maintenance HD patients (Sietsema et al. 2004; Tentori et al. 2010; Matsuzawa et 
al. 2012). It is possible the relationship between higher CRF and PA levels and 
lower mortality risk in CKD may be mediated via the formers’ influence on a CV 
intermediate endpoint such as arterial stiffness. Aortic PWV and AI have prognostic 
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utility in stage 5 CKD (London et al. 2001a; Blacher et al. 2003; Pannier et al. 2005; 
Verbeke et al. 2011) and are increasingly being adopted as intermediate endpoints 
to assess effectiveness of intervention studies targeting CV health. Standardisation 
of the most appropriate arterial stiffness outcome is necessary to enable meaningful 
synthesis of findings from existing and future studies. 
What is the relative contribution of habitual physical activity to indices of 
central arterial stiffness of people receiving maintenance haemodialysis? 
Which measure of arterial stiffness is most appropriate for monitoring 
vascular health of maintenance haemodialysis patients?  
Given that progressive vascular calcification, greater prevalence of LVH and 
higher mortality risk are observed with longer dialysis duration, is HD vintage 
a predictor of arterial stiffness in stage 5 CKD?  
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Chapter 2: General methods 
2.1 Recruitment 
2.1.1 Ethical approval 
The studies undertaken conformed to the Declaration of Helsinki and were approved 
by the West of Scotland Research Ethics Committee (appendix I a), research and 
development department at Monklands Hospital, Airdrie (appendix I b), and Queen 
Margaret University, Edinburgh. Potential participants who registered interest in the 
studies were provided with a study information sheet (appendix I c) with a Flesch 
Reading Ease score (Flesch 1948) equating to a reading age for someone 13 to 15 
years old (score = 63.3). People who agreed to participate were again informed of 
the assessment methods and procedure verbally and allowed a seven day ‘cool-off’ 
period. Written informed consent (appendix 1 d) was obtained from participants prior 
to study participation.  
2.1.2 Participants 
A convenience sample was recruited from men and women undergoing 
maintenance haemodialysis therapy (thrice weekly) for the treatment of stage 5 
chronic kidney disease (CKD). Potential participants were recruited from a single 
renal dialysis unit at Monklands Hospital, and were approached initially by the 
medical team responsible for their care. Pamphlets advertising the study (appendix 
1 e) were distributed among people undergoing maintenance HD by nursing staff at 
the renal unit. A recruitment pack comprising a study information sheet, consent and 
participant contact form was given to those who subsequently registered interest. 
Participants had to be aged 18 years or over (no upper age limit) and be able to 
ambulate a minimum of 10 metres. Ambulation with a walking aid was acceptable. 
People with dementia or severe cognitive impairment were excluded from 
participation. Treating physician approval prior to taking part in the study was 
mandatory to ensure all participants were medically stable for physical performance 
assessments.  
2.2 Measurement of vascular indices of health 
2.2.1 Blood pressure  
Brachial blood pressure (BP) was measured using an AND Model UA-767 digital 
oscillometric blood pressure monitor (A&D instruments Ltd, Oxfordshire), which has 
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documented clinically acceptable validity and reliability (Rogoza et al. 2000). Blood 
pressure and resting heart rate were measured following 15 minutes of complete 
rest (Appel et al. 2002; Jones et al. 2003) in a quiet room. Participants were 
positioned semi-recumbent (40° head up). The width of the monitor cuff bladder was 
approximately 40% of the arm circumference and was placed on the bare non-
arteriovenous fistula arm 2 - 3 cm from the elbow crease as per the manufacturer’s 
instructions (figure 2.1).  
Figure 2.1 Blood pressure cuff position (A&D Instruments Ltd, [undated], p. 
12). 
 
Shirt sleeves were rolled above the cuff so as not to constrict the arm. The arm from 
which BP was measured was supported on a pillow at the same level as the heart 
(Appel et al. 2002; Jones et al. 2003). Blood pressure (mm Hg) and resting heart 
rate (beats/min) was determined from an average of three measures with a two 
minute inter-measurement interval (Jones et al. 2003).  
2.2.2 Aortic pulse wave velocity 
Carotid femoral pulse wave velocity (PWV) was measured using a Vicorder 
(Skidmore Medical Ltd, Bristol, UK). Apparatus calibration was undertaken prior to 
the study using a manometer as described in section 1.7 of the Vicorder manual 
(Skidmore Medical Ltd 2009). Participants were positioned according to Vicorder 
protocol recommendations: supine with head up (30° from horizontal plane), and 
with a small towel roll under the knees for comfort as required. Table 2.1 outlines 
standardisation of participant testing conditions.  
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Table 2.1 Standardisation of participant assessment conditions (Laurent et al. 
2006). 
Confounding factor In practice 
Room temperature  Controlled environment kept at 22 ± 1°C. 
Vascular tone At least 10 min rest in recumbent position prior to measurement. 
Time of the day Similar time of the day for repeated measurements (± 1 hour). 
Smoking, eating Participants refrain from smoking, ingesting food and beverages 
containing caffeine at least 3 hours prior to assessment. 
Alcohol Refrain from drinking alcohol 10 hours before assessment. 
Speaking, sleeping Participants may neither speak nor sleep during measurement 
Position Supine position (30º head up as per Vicorder protocol manual). 
White coat effect Influence on blood pressure and pressure-dependent stiffness. 
Cardiac arrhythmia Be aware of possible disturbance. 
PWV measurement required the placement of two pressure cuffs, one over the 
carotid artery and the other over the femoral artery on the ipsilateral side. The 
carotid artery was palpated by positioning one or two fingers between the larynx and 
the anterior border of the sternocleidomastoid muscle at the level of the cricoid 
cartilage. In palpating the pulse, the degree of pressure applied to the artery was 
varied until maximum pulsation was appreciated (Felner 1990). The proximal cuff 
was then fitted with the transducer over the palpated carotid site (figures 2.2 and 
2.3).  
Figure 2.2 Carotid pressure cuff 
placement (Skidmore Medical Ltd, 
2009, p. 49). 
Figure 2.3 Femoral pressure cuff 
placement (Skidmore Medical Ltd, 
2009, p. 49). 
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The femoral pressure cuff was placed around the right thigh as high as practicable 
(figure 2.3). The distance from the suprasternal notch to the top of the femoral cuff 
was measured to represent the aortic artery path in accordance with Vicorder 
manual instructions (figure 2.4). Obesity or large breast size can result in inaccurate 
aortic arterial path measurement consequently influencing the absolute value of 
PWV (Laurent et al. 2006). To nullify the effect of body contours, the distance from 
the suprasternal notch to the femoral cuff was therefore measured with an 
anthropometer (Huybrechts et al. 2011).  
Figure 2.4 Participant PWV assessment position and Vicorder analysis screen. 
 
Parameters required for PWV were entered (systolic and diastolic BP, arterial path 
distance) as per the Vicorder protocol manual, section 6.2 (Skidmore Medical Ltd, 
2009). Participants were habituated to pressure cuff inflation and then allowed to 
rest for 15 minutes. PWV calculations are displayed after two complete screens of 
continuous pulse wave monitoring. The Vicorder calculates a rolling average of 
PWV over subsequent cardiac cycles (figure 2.5). Instantaneous measurements of 
an oscillating system are influenced by preceding wave forms, therefore PWV 
values were recorded after a 10 second period equating to approximately 15 cycles 
(Frimodt-Moller et al. 2008). Measures were repeated in triplicate with a two minute 
interval (Savage et al. 2002). The mean PWV value was reported with measures 
outside two standard deviations discarded from analysis (Hickson et al. 2009).  
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Figure 2.5 Example of participant PWV measurement in process. 
 
2.2.3 Augmentation index 
Augmentation Index (AI) was measured using the same Vicorder unit employed for 
PWV measurement. Participant position and standardisation of measurement 
conditions were the same as those for PWV. As with PWV measurement, 
participants rested recumbent for 15 minutes prior to assessment to reduce potential 
confounding effects of PA induced changes in vascular tone (Dawson et al. 2009) 
Parameters required for pulse wave analysis screen were entered (systolic and 
diastolic BP, analysis site) as per the Vicorder protocol manual, section 7.1 
(Skidmore Medical Ltd, 2009).  
A pressure cuff was placed around the non-arteriovenous fistula arm 2 - 3 cm above 
the elbow crease (figure 2.6). Once in position, the cuff was inflated and the 
Vicorder commenced AI measurement. The Vicorder starts displaying AI measures 
continuously after optimum cuff pressure is reached (figure 2.7). Vicorder calculated 
mean AI was recorded after a 10 second period (Frimodt-Moller et al. 2008) and 
repeated in triplicate with a two minute interval in between (Savage et al. 2002). As 
with PWV measurement, mean AI was reported with measures outside two standard 
deviations discarded from analysis (Hickson et al. 2009). 
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Figure 2.6 Vicorder cuff position for Augmentation Index measurement. 
 
Figure 2.7 Example of participant augmentation index measurement. 
 
Measures of vascular stiffness (PWV and AI) were taken on a non-dialysis day to 
minimise the influence of dialysis mediated volume alterations on waveform analysis 
(Covic et al. 2000). Medications such as those used to manage hypertension, 
congestive heart failure, cholesterol, diabetes and advanced glycation end products 
are known to influence measurement of arterial stiffness (Shimamoto and 
Shimamoto 1995; Kelly et al. 2001; Agata et al. 2004; Laurent et al. 2006, Williams 
et al. 2006). However, asking participants to abstain from medications the day 
before assessment was not indicated for reasons of safe medical management. In 
addition, half-life of vasoactive medications can often be 12 hours or more (Kelly 
and O’Malley 1990). Therefore, participants’ medications were recorded to assist 
discussion of results. 
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2.3 Assessment of physical function by physical performance tests 
2.3.1 Hand-grip strength: apparatus, set up and procedure 
Apparatus for the grip strength assessment included a JAMAR hand dynamometer 
(Lafayette Instrument Company®, Lafayette USA) a chair with arm rests and a digital 
stopwatch. Prior to commencing the test the hand-grip dynamometer was adjusted 
to the desired hand spacing: the handle base rested on the first metacarpal (heel of 
palm), while the handle rested midway along the four fingers (Mathiowetz et al. 
1984; Roberts et al. 2011). The participant sat with their shoulder adducted against 
the side of their body elbow flexed at 90°. The dynamometer was held in the hand to 
be tested with the forearm resting on the chair arm in the neutral position (0° 
pronation), and wrist between 0° and 30° extension with 0° to 15° ulnar deviation 
(figure 2.8) (Mathiowetz et al. 1984; Roberts et al. 2011).  
Figure 2.8 Standardised grip strength test position. 
 
Explanation was provided to the participant regarding the grip strength assessment 
sequence. A script standardised for the grip strength test was as follows: “Please sit 
with your back against the chair and your arm to be tested resting on the arm rest. 
Keep your elbow bent at 90° and in at your side with your hand forward of the edge 
of the armrest. During the test I would like you to squeeze the handle like this”. A 
grip test was demonstrated and the dynamometer then passed to the participant. 
“Hold the handle with the indicator dial facing slightly up and away from you. I will 
ask you to squeeze the handle for five seconds when I say squeeze. During that 
time I will encourage you to give a maximum effort until I ask you to stop. Please do 
not hold your breath during the test, instead breath out”. 
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Participant understanding of the test instructions was checked by asking them to 
repeat the instructions. The peak-hold needle on the dynamometer was reset to 
zero, and the start of the grip test was cued with: “Are you ready? Squeeze!” While 
the participant was squeezing the dynamometer handgrip they were strongly 
encouraged to give a maximum effort with the following script “squeeze as hard as 
you can,... harder,... harder,...relax” (Mathiowetz et al. 1984). 
Grip strength testing of the arterio-venous fistula arm can be carried out as long as 
the fistula is well healed (Koufaki and Kouidi 2010). Three attempts with each hand 
were performed with 30 - 45 seconds of recovery in between each attempt. Grip 
strength was recorded to the nearest kg of force and the peak-hold needle was 
reset to zero each time. The best performance of the six efforts was recorded for 
data analysis (Roberts et al. 2011). 
2.3.2 Sit-to-stand five test – apparatus, set up and procedure 
Apparatus for the sit-to-stand five test (STS5) included a height adjustable straight-
backed chair with rubberised leg ends to prevent slippage. The chair had no 
armrests or seating cushion, and approximate seating area dimensions were: height 
45 cm; width 50 cm; depth 40 cm (Csuka and McCarty 1985). The chair back was 
placed against the wall to prevent movement and the participant was seated in the 
middle of the chair, with back straight and feet approximately shoulder width apart. 
To ensure angular and linear work was constant between participants, the height of 
the chair was adjusted so that knee flexion angle was 100 - 105° and the ankles 
were positioned in 10° dorsiflexion (Cheng et al. 1998). If required, one foot was 
permitted to be placed slightly ahead of the other to aid balance.  Arms were folded 
across the front of the chest and the test was performed either barefooted, or in low-
heeled shoes.  
Explanation was provided to the participant regarding the sequence and the 
outcome of the test. Participants were instructed to look straight ahead and to stand 
up with their weight evenly distributed between both feet. The participant was 
reminded that they must come to a full stand position with knees straight and that 
their performance would be timed by the tester (figure 2.9).  
 Figure 2.9 Sit-to-stand five test. 
 
The STS5 protocol script was as follows. “When I say ‘go’ you may stand up to a full 
standing position and sit down again as quickly as you can without using your arms. 
Repeat this movement four more times as quickly as you are able. The test ends 
when you sit for the fifth and final time. At this point please remain sitting. Timing will 
start when I say ‘go’ and finish when you sit down for the fifth and final time”. 
Participant understanding of the test instructions was checked, and the tester 
subsequently cued the start of the test with “ready, set, go”. Timing of the STS5 
commenced on the “go” command and concluded as soon as the participant sat 
down after the fifth and final stand (Schaubert and Bohannon 2005). Time taken to 
complete the STS5 was recorded with a digital stopwatch to the nearest tenth of a 
second. The STS5 test was repeated twice, following the same procedure with a 
one minute rest interval in between tests. The last or best performance was 
recorded for data analysis (Schaubert and Bohannon 2005).  
2.3.3 Timed up-and-go test – apparatus, set up and procedure 
Apparatus for the timed up-and-go (TUAG) test included a chair with arms 
(approximate seat height 46 cm with arm height 65 cm). A marker cone was placed 
three metres from the armchair marking the end of the walking course. Prior to the 
test the walking surface was inspected to ensure it was free from slip and trip 
hazards. A digital stopwatch was used to measure the time taken by the participant 
to stand up, walk three metres, turn level with the marker cone, and return to sit 
down in the chair again (Podsiadlo and Richardson 1991). Participants completed 
the TUAG independently and were allowed to use a walking aid if required.  
98  
Explanation was provided to the participant regarding the sequence and the 
outcome of the test. The timed up-and-go test script was as follows: “Please sit with 
your back against the chair with your arms resting on the arm rest. If you require a 
walking aid you may keep this close at hand but please do not hold the aid prior to 
the test. When I say go, you may stand up, walk to the cone on the floor, when you 
are level with the cone, turn and walk back to the chair and sit down. Walk at a safe 
and comfortable walking speed, but do not run. Timing will start when I say ‘go’ and 
finish once you have returned and sat down” (figure 2.10).  
Figure 2.10 Timed up-and-go test procedure 
 
 
Participant understanding of the test instructions was checked by asking them to 
repeat the instructions and they were then familiarised with the TUAG by walking 
through the test (Shumway-Cook et al. 2000). The tester subsequently cued the 
start of the test with “ready, set, go”. Timing of the TUAG was commenced on the 
“go” command and concluded as soon as the participant returned from the marker 
cone and their buttocks contacted the seat. Test time was recorded to the nearest 
tenth of a second. The participant repeated the test after a 15 - 30 second rest and 
the second or best performance was recorded for data analysis. Whether the 
participant required a mobility aid was also recorded (Shumway-Cook et al. 2000). 
2.3.4 Incremental Shuttle Walk Test – apparatus, set up and procedure 
A proxy measure of cardiorespiratory fitness (CRF) was determined by physical 
performance during an incremental shuttle walk test (ISWT) (Singh et al. 1992). The 
original test contained 12 levels (1020 m). However, as the study population might 
include younger, active individuals, the modified shuttle walk test, which has three 
99  
more levels (1500m) allowing participants to run was used to reduce possible ceiling 
effect threats (Bradley et al. 1999). Apparatus for the modified shuttle walk test 
included: two marker cones; portable CD stereo system; Modified Incremental 
Shuttle Walk CD (Leicester Hospital, Leicester UK); Polar heart rate monitor (Polar 
Electro oy Kempele, Finland). The ISWT was performed in a low use section of 
corridor in the renal unit with sufficient floor area for a 10 metre long walking course, 
allowing adequate space to perform turns around the marker cones (Singh et al. 
1992). The walking surface was inspected prior to use to ensure it was flat and free 
from slip and trip hazards. A 10 metre walking course was measured and marked 
with the marker cones placed 0.5 metres from each end to avoid the need for abrupt 
changes in direction (figure 2.11). 
Figure 2.11 Marked 10 metre course for ISWT. 
 
 
2.3.4.1 Standardisation of participant pre-test conditions  
In order to optimise test validity, an attempt was made to control factors known to 
influence physiological response by informing participants how to prepare for the 
test in a pre-appointment letter. To minimise the effects of diet induced 
thermogenesis participants were asked to refrain from ingesting food and beverages 
containing caffeine in the three hours prior to assessment as well as abstain from 
ingesting alcohol in the 10 hours prior to the measurement session (ACSM 2010; 
McArdle et al. 2010).  Participants were also asked to avoid strenuous forms of 
activity during the 24 hours prior to the test (McArdle et al. 2010) to minimise 
physiological effects from intense PA on the ISWT. For participant safety and later 
data analysis, heart rate response was monitored throughout the ISWT using a 
Polar heart rate monitor (Polar Electro oy Kempele, Finland). The monitor belt was 
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positioned as pictured in figure 2.12. Atomized spray was placed on the monitor belt 
contact points to assist skin conductivity of heart rate signal.  
Figure 2.12 Wear position of Polar heart rate monitor belt. 
 
2.3.4.2 Test Procedure 
Track one of the ISWT CD provided participants with a standardised script 
explaining the sequence of the test and outcome. The CD instructed participants to:  
“Walk at a steady pace aiming to turn around the cone at one end of the course 
when you hear the signal.... You should continue to walk around the cones until you 
feel that you are unable to maintain the required speed.”  A practice walk is 
recommended for the test as a learning effect has been identified (Singh et al. 1994; 
Morales et al. 1999; Dyer et al. 2011). In order to balance this consideration with 
time constraints participants were allowed to walk the first two levels in order to 
familiarise themselves with the course and pacing strategy. Prior to starting the 
ISWT participants were familiarised with the BORG rating of perceived exertion 
scale (Borg 1998) using a uniform script with the scale (appendix II). Participant 
rating of perceived exertion and reason for ISWT cessation was recorded at the test 
endpoint. 
The start of the ISWT was signalled by a triple bleep and thereafter the CD emitted 
a bleep at regular intervals to regulate the time allowed for each shuttle. Participants 
were reminded that they should aim to match their walking pace so that they turned 
round the marker cone at each end of the course with the sound of the bleep. Each 
level of the ISWT lasted for one minute. The start of the next level was indicated by 
a triple beep and the walking speed was incrementally increased (0.17 m/s) by the 
addition of an extra shuttle.   
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2.3.4.3 Incremental Shuttle Walk test endpoint 
Endpoint of the test was determined by the participant, for example when they 
became too breathless to maintain the required walking speed (Singh et al. 1994). 
Indication for the tester to discontinue the assessment was failure of the participant 
to complete the shuttle in the time allowed. If the participant was less than 0.5 
metres from the cone when the bleep sounded they were given another 10 metre 
length to recover the ‘lost’ distance. If the participant was unable to do this then the 
test was discontinued. A cool-down period was undertaken following the test, during 
which the participant walked slowly around the course four more times to avoid 
possible hypotensive syncopal attacks associated with abrupt cessation of exercise 
(Friedwald and Spence 1990). Monitoring of participants continued until heart rate 
and blood pressure indices had returned to pre-test levels (ACSM 2010). To ensure 
participant safety the following additional criteria indicating the endpoint of a 
physical performance test (ACSM 2010) were adhered to: 
x Onset of angina or angina like symptoms. 
x Shortness of breath, wheezing, leg cramps, or claudication. 
x Signs of poor perfusion: light headedness, confusion, ataxia, pallor, 
cyanosis, nausea, or cold and clammy skin. 
x Failure of heart rate to increase with increased exercise intensity. 
x Participant request to stop test. 
x Physical or verbal manifestations of severe fatigue. 
x Failure of the testing equipment. 
2.3.4.4 Scoring and reporting the Shuttle Walk outcomes 
Shuttle walk test distance was derived from the number of completed levels and 
shuttles was recorded. For example if the participant finished after the 3rd completed 
shuttle of the 7th level this was recorded as: 
6 completed levels + 3 completed shuttles 
Distance walked by the participant was calculated from the ISWT manual:  
                        6 completed levels = 33 shuttle lengths (33 x 10m) 
                 3 completed shuttles = 3 shuttle lengths (3 x 10m) 
Distance walked = 360 metres 
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The outcome of the ISWT was reported in metres. A CRF value (ml/kg/min) was 
also calculated from ISWT performance using the peak walking velocity achieved 
during the test and the following ACSM (2000) equation. A fitness value in metabolic 
equivalents (METs) was subsequently derived by dividing this value by 3.5 (McArdle 
et al. 2010).   
Walking: VO2 = (0.1 (walk velocity) + 1.8 (walk velocity) (fractional grade) + 3.5 
Running: VO2 = (0.2 (walk velocity) + 0.9 (walk velocity) (fractional grade) + 3.5 
2.4 Self-reported/subjective physical function outcomes 
2.4.1 Duke Activity Status Index  
A subjective indication of physical function was obtained using the Duke activity 
status index (DASI) (Hlatky et al. 1989). The questionnaire was administered to 
participants during their non-dialysis day assessment visit. Participants were asked 
to read the questionnaire instructions on the first side before filling out the DASI 
questionnaire on the reverse side of the form. They were then asked to answer each 
item as honestly as possible indicating yes or no for each item with a tick or cross. 
The DASI questionnaire (appendix III) contains 12 items from simple activities of 
daily living to participation in more physically demanding leisure time pursuits. The 
scores for each item are weighted according to their approximate physiological cost. 
Completed DASI questionnaires were entered on a spreadsheet and a score out of 
58.2 was derived. A higher score indicated a better level of functional capacity to 
perform activities of daily living. If the completed questionnaire contained a ‘missed 
item’, a value was imputed based on a ratio of completed items using the equation 
below (Field 2013). If there were more than two missed items the questionnaire was 
ruled invalid and not used for data analysis. 
Final score = (Initial score/(12-number of missed items)) x 12 
A cardiorespiratory fitness (CRF) value was also derived from participant scores 
using the following formula developed by the authors of the DASI (Hlatky et al. 
1989):  VO2 (ml/kg/min) = (DASI score x 0.43) + 9.6 
2.4.2 Kidney Disease Quality of Life – Short FormTM 
The UK English (version 1.2) Kidney Disease and Quality of Life Short FormTM 
(KDQOL-SF™) was used to measure perceived quality of life. The instrument was 
developed by the RAND corporation (Hays et al. 1995) and contains the Medical 
Outcomes Short Form 36 (MOS-SF 36) at its core. The MOS-SF 36 contains eight 
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domains covering: physical function; physical role limitation; emotional role 
limitation; vitality (fatigue/energy); emotional function; social function; body pain; 
perception of general health. Twelve domains relating specifically to participants 
experience of chronic kidney disease stage 5 also comprise the KDQOL-SF which 
include: symptoms; burden and effect of kidney disease; work status; sleep; sexual 
function; cognitive function; work status; social interaction and support; staff 
encouragement; satisfaction with care; general health. This self-administered 
questionnaire was given to participants during a scheduled HD therapy session (the 
third dialysis session of the week) following an inter-dialytic period of one day. 
Completion instructions for the questionnaire were situated on pages two and three 
of the form. Sight impaired participants were allowed assistance from a family 
member to complete the KDQOL-SF.  
Once completed participants placed the questionnaire in a sealed envelope and 
returned it to the nursing staff for collection. Answers from the completed 
questionnaires were entered into a spreadsheet containing the KDQOL-SF™ 
Version 1.3 scoring programme obtained online from www.rand.org. The 
spreadsheet subsequently aggregated scores for the different domains of the 
KDQOL-SF™ and transformed them linearly to a 0 - 100 range. Domain scores 
were an average of all items in the subscale answered by the participant with 
missing items not taken into account (Hays et al. 1995). Higher scores indicated 
better health related quality of life status. Output also included two summary scores 
based on weighted results from the different domains: the physical component 
summary score (PCS) and mental component summary score (MCS). The PCS was 
employed as a measure of self-reported physical function.  
2.4.3 Leicester Uraemic Symptom Scale 
The Leicester Uraemic Symptom Scale (LUSS) (Wright et al. 1994) was employed 
to reflect participant perception of the number, frequency and intrusiveness of 
uraemic symptoms experienced. The LUSS was developed in the UK and therefore 
expected to have greater cultural validity. Symptom number, frequency and severity 
are reported to be greater following a period of two non-dialysis days (Nelson-
Danquah et al. 2010). The LUSS was administered during the second HD therapy 
session of the week following one non-dialysis day to reflect a more stable period of 
symptom experience. Three scores were obtained from the 10 item LUSS (appendix 
IV). The number of uraemic symptoms experienced (LUSS 1) was indicated by a 
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simple additive score (range 0 - 10). In part one of the LUSS, frequency of each 
symptom (LUSS 2) was rated on a five point Likert scale (0 = never to 4 = everyday) 
and a summative score was derived (range 0 - 40). Symptom intrusiveness (LUSS 
3) was rated in part two, again on a five point Likert scale (0 = not at all intrusive to 4 
= extremely intrusive). An overall symptom burden score was derived (LUSS 4) by 
adding scores for symptom frequency and burden together. Higher scores indicated 
greater condition related symptom burden.  
2.5 Assessment of physical activity 
2.5.1 Actigraph Accelerometer 
The Actigraph GT3X (Actigraph Corp, Pensacola, FL) is a triaxial accelerometer 
(figure 2.13) that has been commercially available since 2009. The GT3X is a solid-
state accelerometer, which uses an integrated micromachined monolithic integrated 
circuit chip (polysilicon) to detect body acceleration. An advantage of the GT3X over 
earlier uniaxial Actigraph monitors (7164 and GT1M) is that it is able to measure 
movement in three planes via a triaxial capacitive micromechanical system (John 
and Freedson 2012). The sensor is suspended by springs over the surface of silicon                                                                                       
wafer and provides a resistance against acceleration forces (Analog Devices 2007). 
Body accelerations within a range of 0.05 - 2.0g are recorded in three individual 
orthogonal planes of movement (vertical, mediolateral, anteroposterior) and the raw 
data are then converted into activity counts. Higher activity counts result from 
greater or more frequent accelerations.  
Figure. 2.13 Actigraph GT3X accelerometer (Actigraph Corp, Pensacola, FL). 
 
 
The device also filters the raw data so that only movements within a given frequency 
(0.25 - 2.5Hz) are recorded. The Actigraph samples at a rate of 30 Hz and data can 
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be recorded over epochs of varying lengths from upwards of one second. The GT3x 
has an inclinometer function, enabling detection of different body postures, however, 
classification accuracy is fair to good (AUC = 0.60.6 - 66.7) (Carr and Mahar 2012), 
with standing periods often misclassified as sitting (McMahon and Brychta 2010). 
Therefore, inclinometer output was not reported. 
The GT3X monitors were recharged and initialised using a laptop PC. During 
initialisation all monitor functions were enabled so that the GT3X could record 
movement in both uniaxial and triaxial formats, as well as step counts. The GT3X 
was initialised to capture data over 15 second epochs to improve detection of 
intermittent bouts of moderate to vigorous activity (McClain et al. 2008) and was 
programmed to commence data collection following the participant’s physical 
assessment. One waist mounted Actigraph monitor was used to monitor a 
participant’s habitual physical activity.  
Figure 2.14 Wear position of Actigraph GT3X monitor. 
 
2.5.2 Actigraph GT3X wear protocol 
Participants were given uniform scripted instructions on wear time and positioning of 
the GT3X both verbally and in a leaflet (appendix V a). The GT3X may be worn on 
the wrist, however there is a risk of increased participant reactivity and tampering 
with the monitor in this position (Trost et al. 1998). Recommended accelerometer 
placement is as close as possible to the body’s centre of mass (Puyau et al. 2002), 
with monitor placement on the lower back or the hip providing comparable levels of 
output (Trost et al. 2005). Haemodialysis patients have an additional 12 to 15 hours 
spent seated or reclined imposed upon them, therefore comfort and consequent 
wear compliance were also considerations. The GT3X was positioned on the non-
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dominant hip in the mid axillary line just above the anterior superior iliac spine 
(Figure 2.14) (Yngve et al. 2003; Trost et al. 2005; Lyden et al. 2011). The GT3X 
was worn during waking hours for eight days following the participant’s physical 
assessment. The monitor was to be removed for bathing, showering, swimming and 
replaced again straight afterwards. Participants were also asked to note times when 
the monitor was put on and taken off using the wear log on the back of the monitor 
wear instruction sheet (appendix V b). The GT3X was collected from the participant 
on the eighth day after their physical assessment during a routine hospital visit for 
HD therapy. Data were downloaded from the monitor using proprietary Actilife 
software (version 5.8.3) onto a laptop PC.  
2.5.3 Actigraph GT3X data cleaning  
Once downloaded from the GT3X each participant’s accelerometry data collected 
over nine days was cleaned prior to analysis. The first day of wear (assessment 
day) was deemed a practice day and not included for analysis due to possible 
increased participant reactivity. The last day of data when the monitor was collected 
was also removed. The first stage of the data cleaning process involved 
identification of spurious data. A threshold of 20,000 counts/min is deemed the 
upper limit of physical activity (PA) that is physiologically possible (Colley et al. 
2010). An activity count above this threshold is believed to be biologically 
implausible and suggests an error with the activity monitor.  Minute-by-minute visual 
inspection of participant GT3X PA files was performed and accelerometry data 
>20,000 counts/min were discarded from analysis.   
2.5.4 Determination of Actigraph GT3X wear time 
Actigraph monitor wear time was determined using the Actilife 5 software. Wear 
time assessment is regarded as key to determining participant compliance and 
whether data should be used for analysis. Monitor non-wear time was determined 
from a predefined number of zero counts per minute (cpm) in the accelerometery 
data. Wear time is reported to vary with non-wear time definition. For example, 
shorter periods of consecutive zeroes to denote non-wear time can result in fewer 
hours of wear time (Evenson and Terry 2009). Importantly non-wear time and very 
sedentary activity register as zero counts in accelerometer output. It has been 
observed that older adults, in particular those who are sedentary, can accumulate 
large periods of time without recording activity counts while wearing an 
accelerometer (Hutto et al. 2013). In addition periods of non-wear may occasionally 
107  
contain an epoch of spurious activity counts considered not to be wear time but 
rather movement of the monitor when not worn (Evenson and Terry 2009). The 
above factors have important ramifications for sedentary populations such as CKD 
5, where periods of prolonged inactivity such as HD therapy sessions and television 
watching may be erroneously classified as non-wear time and not sedentary time. 
Shorter periods of zero counts (ie: 20 consecutive zeroes) denoting non-wear are 
more appropriate for children (Masse et al. 2005). A threshold of 100 consecutive 
zero counts with allowance for two minutes of <100 counts has been recommended 
for monitoring adults (Troiano et al. 2008). Thresholds of 90 to 180 minutes of 
consecutive zero counts provide a stable assessment of wear hours and enable 
optimal data retention in middle aged and older adults with and without knee 
osteoarthritis (Song et al. 2010; Hutto et al. 2013). Moreover, 60 and 180 
consecutive zero counts with allowance for a minute of spurious activity data (<100 
cpm) are similarly accurate in classifying non-wear and sedentary time in sedentary 
office staff (Oliver et al. 2011). Haemodialysis therapy sessions vary in length from 
three to five hours, with people often remaining motionless or sleeping during that 
time. Consequently, non-wear time was determined by a threshold of 150 
consecutive zero count minutes with allowance for less than one minute of spurious 
data of <100 cpm.  
Participant data were inspected after application of the wear time filter to ensure all 
dialysis sessions were appropriately classified as sedentary time and not non-wear 
periods. Accumulating more than 18 hours monitor wear per day has been deemed 
to be outside regular waking hours and a criterion for data exclusion (Alhassan et al. 
2008). In the event that the monitor was worn for more than this threshold a logical 
‘waking hour’ day was triangulated using a combination of the following: monitor 
wear log; reported bedtimes from the Stanford seven-day recall questionnaire; and 
the first lie-to-stand and last stand-to-lie transitions from simultaneously recorded 
Activpal accelerometer data. Data outside the determined waking wear hours 
derived from bed mobility or nocturnal mobility was excluded from analysis.    
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Figure 2.15 Graphic presentation of participant GT3X data for one day. 
 
2.5.5 Categorisation of Actigraph GT3X activity counts  
Actigraph activity count output (figure 2.15) can be converted into categories 
reflecting the intensity of PA measured. Time spent in PA of differing levels of 
intensity (figure 2.16) was derived using the encumbent Actilife software cutpoints 
for light, lifestyle, moderate, vigorous and very vigorous PA developed by Freedson 
et al (1998). Time spent sedentary was determined via an activity count of less than 
100 cpm (Matthews et al. 2008). Minute values for the different categories of PA 
intensity were normalised as a percentage of wear time so that PA outcomes could 
be compared across participants and with other populations (Hinkley et al. 2012). 
Actigraph activity counts and estimated step counts were reported as counts per 
day and similarly normalised to counts per minute of wear.  
Figure 2.16 Participant GT3X data output following Actilife categorisation into 
PA intensity. 
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2.5.6 ActivPALTM activity monitor 
The ActivPALTM accelerometer (PAL Technologies Ltd, Glasgow) is an activity 
monitor, which objectively estimates time spent in various PA behaviours (ie: sitting, 
standing, walking, sit to stand transitions, and steps) as opposed to intensity of PA. 
The monitor contains a uniaxial piezoresistive accelerometer which registers 
posture output and steps taken from thigh inclination. Time spent in different 
postures, transitions and steps performed are derived via algorithms embedded in 
the ActivPALTM system software. The ActivPALTM can collect data at a frequency of 
10Hz and has enough battery life and memory capacity to record PA data for more 
than eight days. The ActivPALTM monitors were recharged and initialised via a PAL 
Technologies Ltd docking station using the manufacturer’s proprietary software 
installed on a laptop PC. The ActivPALTM was initialised to capture data over 15 
second epochs to synchronise with the Actigraph and was set up to start data 
collection following the participant’s physical assessment.  
2.5.7 ActivPAL wear protocol 
Participants were given uniform scripted instructions on wear time and positioning of 
the ActivPALTM both verbally and in a leaflet (appendix V a). Small and unobtrusive 
(about the size of a book of matches), the monitor was worn as per the instructions 
of PAL Technologies: on the front mid-line of the thigh a third of the way between 
the hip and knee of the non-dominant leg (figure 2.17). The monitor was held in 
place by a PALstickie TM and a short length of hypoallergenic tape or 3M 
TegadermTM transparent dressing.  
Figure 2.17 ActivPALTM monitor and wear position. 
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The ActivPALTM was worn during waking hours for eight days following the 
participant’s physical assessment. The monitor was to be removed for bathing, 
showering, swimming and replaced again straight afterwards. Participants were also 
asked to note times when the monitor was put on and taken off using the wear log 
on the back of the monitor wear instructions (Appendix V b). The ActivPALTM was 
collected from the participant on the eighth day after their physical assessment 
during a routine hospital visit for HD. Data were downloaded onto a laptop PC using 
the proprietary ActivPALTM process and presentation software (Version 6.4.1).  
2.5.8 ActivPALTM data cleaning and classification of physical activity 
behaviours 
As with the Actigraph data, the first day of ActivPAL wear was excluded from 
analysis as a practice day and the following seven days were used for analysis. 
Participants’ ActivPALTM data collected during free-living activity was processed 
using the ActivPALTM Intelligent Activity ClassificationTM software which uses 
proprietary algorithms to classify raw monitor data into periods spent sitting, 
standing, and walking. Figure 2.18 illustrates how the ActivPALTM software 
generates graphic representations of activity behaviours for each day of the week.  
Figure 2.18 ActivPALTM software presentation (V6.4.1) of physical activity 
behaviour (ACTIVPAL³ ™ OPERATING GUIDE, p. 9). 
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Step counts, transitions and energy expenditure (MET.h) can also be derived from 
participants’ ActivPALTM data. The graphic output enabled files to be scrutinised for 
monitor malfunctions, identifying if the device had been worn upside down, and 
implausible data such as extended periods without steps being registered. The 
ActivPALTM operating guide states that a minimum duration of 10 seconds is 
required to register sitting and standing events. The ActivPALTM software calculates 
cadence as an average over 10 strides, and participants had to achieve a cadence 
of 20 steps per minute or greater before a walking event would be registered. A 
cadence below this threshold was not classified as walking. 
Raw ActivPALTM data was exported to an Excel spreadsheet presenting the PA data 
in 15 second epochs. Participant data were then processed through a macro that 
determined sitting, standing and walking time in minutes. Time spent in these 
behaviours for a particular day was then converted into a percentage of monitor 
wear time determined as the period between the first sit-to-stand transfer and the 
last stand-to-sit transfer for that day. In addition PA counts and steps per day were 
subsequently reported per minute of monitor wear time.  
2.5.9 Stanford 7-Day Recall questionnaire 
The Stanford 7-day recall (7DR) questionnaire (Sallis et al. 1985) was used as a 
subjective/self-report method of estimating participant PA. The 7DR was chosen on 
the basis of favourable comparative psychometric properties and fitness for purpose 
(Terwee et al. 2010) in the HD population. The 7DR questionnaire (appendix VI) 
was administered via a one-to-one semi-structured interview format during a 
scheduled dialysis appointment. The interviewer preparation guidelines and the 
standardised script that accompanies the 7DR format (Sallis et al. 1985) were 
followed during questionnaire administration.  
The 7DR was used to estimate participants’ recollection of time spent in PA, 
strength and flexibility activities over the previous seven days. Time spent sleeping 
as well as frequency, duration, and intensity of PA (both leisure and work related) 
were recorded. Sleep time was defined as the period from when participants went to 
bed until they again got up to commence their daily activities (Sallis et al. 1985). 
Participants were made aware of how moderate to very hard intensity physical 
activity was differentiated from light intensity PA in order to exclude the latter (Sallis 
et al. 1985).  
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Time spent in discrete PA intensity levels (moderate, hard or very hard) per day was 
reported in minutes as long as the bouts were of 10 minutes duration or greater 
(Sallis et al. 1985). Type of PA engaged in was also recorded so that an energy 
expenditure value could be estimated as an outcome (table 2.2). Physiological cost 
in METs for each activity reported was obtained from the Compendium of Physical 
Activities (Ainsworth et al. 2011) and multiplied by the number of minutes for the 
activity to derive an energy expenditure value in MET minutes. 
Table 2.2 Calculation of physical activity energy expenditure from 7DR. 
Tuesday Activity MET cost Calculation 
Morning 20 minutes hoovering 3.5 20 x 3.5 = 70 MET mins 
Afternoon Attended dialysis therapy    
Evening 25 minute walk with dog 3.0 25 x 3.0 = 75 MET mins 
Tuesday total PA related energy expenditure  145 MET minutes 
 
2.6 Biochemistry  
Biochemical results from the closest routine monthly bloods to each assessment 
(within the nearest two week period) were recorded for each participant. Bloods 
were taken in accordance with Scottish Renal Registry/Renal Association protocols 
and analysed in Monkland hospital’s laboratory. Markers of clinical health monitored 
for during this project were: dialysis adequacy (urea reduction ration), haemoglobin, 
haematocrit, C-reactive protein, albumin, serum phosphate, corrected serum 
calcium, parathyroid, pre-dialysis creatinine. Blood results were obtained from the 
renal unit electronic patient record system (SERPR).  
2.7 Medications 
The number of prescribed medications at the time of each assessment was 
recorded for analysis of study outcomes. In addition, type and dose of vasoactive 
medications were also noted for subsequent discussion of results. Weekly 
prescribed dose of erthyropoiesis stimulating agents (ESA) such as darbepoetin alfa 
or aranesp as well as iron supplementation was recorded. Participant medication 
information was drawn from the renal unit’s electronic patient record system 
(SERPR). 
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2.8 Comorbidity score 
A simple additive comorbidity score was used to reflect the presence or absence of 
co-existing conditions at the time of assessment. Information regarding whether 
participants had a history of hypertension, diabetes, heart disease was drawn from 
the electronic patient records system (SERPR). Scores were not adjusted for 
severity of disease. Participants would therefore receive a comorbidity score of zero 
to three. 
2.9 Anthropometric measurements 
Participant weight was measured with a calibrated Salter 9018S electronic scale  
(Salter Housewares, Kent). Participants were instructed to dress in light clothing 
(shorts and shirt) and remove shoes before standing in the centre of the scale 
platform. Body mass was recorded to the nearest tenth of a kilogram (Eston and 
Reilly 2009). Height of participants was measured with a Leicester Height Measure 
stadiometer (Invicta Plastics Ltd, Leicester) in an upright standing position. 
Participants were instructed to stand with their back, buttocks and heels of both feet 
touching the stadiometer. The head was oriented in the Frankfurt plane with the 
lower border of the eye socket and the upper border of the ear opening aligned 
horizontally. Participants were then instructed to ‘stretch upward’ through their neck 
and head, take a full breath and briefly hold. The measurement rule was then 
lowered until it rested on the vertex of the head firmly, but without extreme pressure 
and height measurement taken to the nearest 0.05cm (Eston and Reilly 2009). Body 
mass index (BMI) was subsequently calculated using the following equation:  
BMI = mass (kg) / height (m)2.  
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Chapter 3: Minimum wear time recommendations for accelerometers 
3.1 Introduction 
Findings from epidemiological studies indicate level of self-reported physical activity 
(PA) is implicated in life expectancies of people receiving maintenance 
haemodialysis (HD) therapy for stage 5 CKD (O’Hare et al. 2003; Stack et al. 2005; 
Tentori et al. 2010). However, while PA questionnaires are expedient, cost-effective 
and nomothetically useful, they are susceptible to reporting error (Troiano et al. 
2008; Townsend et al. 2010; Colley et al. 2011). Moreover, they have recognised 
limitations with quantifying activity at the lower end of the PA spectrum and time 
seated (Prince et al. 2008; Celis-Morales et al. 2012), which is a now a recognised 
risk factor for poor health outcomes (Owen et al. 2010; Thorp et al. 2011). 
Consequently, there has been a shift towards increased use of objective 
assessment tools such as pedometers and accelerometers to estimate PA in stage 
5 CKD. A range of activity monitor derived PA outcomes such as activity counts, 
steps taken, and energy expenditure are associated with health status and physical 
function in the HD population (Johansen et al. 2001a; Masuda et al. 2009; Kutsuna 
et al. 2010; Cupisti et al. 2011). One study even identified that a threshold of 50 
minutes per day of all PA (>1.8 METs) estimated by accelerometer was 
independently predictive of improved survival among HD patients (Matsuzawa et al. 
2012). 
While general instrument validity has been established for many of these 
accelerometer assessment methods, there remains a need for standardisation of 
data reduction guidelines regarding accelerometer wear time. Minimum wear 
recommendations are necessary to ensure PA data are sufficiently reliable so that 
the ability to detect relationships with other variables is not diminished and 
conclusions drawn are not limited (Baranowski et al. 2008). Furthermore, reliable 
estimates of habitual PA are crucial for monitoring purposes to stratify risk, detect 
PA behaviour change, as well as to enable appropriate comparison and/or synthesis 
of findings across PA studies.  
3.1.1 Accelerometer wear days and wear time 
Participants in PA health studies are typically asked to wear accelerometers over 
seven consecutive days (Kristensen et al. 2010; Colley et al. 2011; Feinglass et al. 
2011; Tudor-Locke et al. 2011d; Esliger et al. 2012), but despite reminders and 
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incentives, wear compliance is often variable (Baranowski et al. 2008; Rich et al. 
2013). Moreover, monitor wear time during the day is usually discretionary and thus 
subject to variation both within and between participants (Hinkley et al. 2012). 
Investigators are therefore faced with important methodological considerations 
regarding how many hours of wear constitute a ‘valid’ day and how many days of 
accelerometer wear are required to provide reliable estimates of habitual PA and 
sedentary time (Masse et al. 2005; Troiano et al. 2008; Ojiambo et al. 2011).  
Importantly, there is a trade off between applying criteria that are stringent enough 
to ensure data integrity while at the same time facilitating retention of an adequately 
representative sample size for subsequent analyses (Catellier et al. 2005; Hinkley et 
al. 2012). Even small differences in required wear time criteria can impact PA 
estimates as well as the number of participants retained, thereby potentially biasing 
sample representativeness (Masse et al. 2005; Chen et al. 2009; Tudor-Locke et al. 
2011d; Toftager et al. 2013). Statistically based imputation methods may be 
employed to manage missing or incomplete data. However, performance of these 
algorithms is governed by the proportion of missing data, and difficulties with 
determining whether data are missing at random or not missing at random (Catellier 
et al. (2005). An alternative to deleting incomplete participant PA data is to establish 
the minimum required accelerometer wear time that reflects an individual’s habitual 
activity with acceptable reliability. The first part of this process is to determine intra-
individual PA variability between days (Baranowski and de Moor 2000). Intuitively, 
the greater the inter-day variability of estimated PA behaviours, the higher the 
number of wear-days and hours of accelerometer wear per day that will be required.  
3.1.2 Accelerometer data reduction methods in CKD health research 
Many of the previous studies using motion sensors to characterise PA of HD 
patients have lacked uniformity of methods. Number and type of days monitored 
(dialysis, non-dialysis, weekend) varies widely, often with no stated rationale. 
Studies employing arm-mounted devices have adopted 24-hour PA monitoring 
protocols (Baria et al. 2011; Mafra et al. 2011; Avesani et al. 2012), while the 
remainder required participants to wear hip mounted devices during waking hours. 
Notably, more than 80% of CKD studies did not define the number of wear hours 
required to ‘rule in’ a valid day, thus it would appear they have not explicitly at least, 
taken into account the effects of participants’ discretionary wear on PA outcomes. 
Ten hours monitor wear is the most widely adopted standard to rule in a ‘valid day’ 
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(Trost et al. 2005; Tudor-Locke et al. 2011d), but there are indications less stringent 
wear thresholds may also provide sufficient outcome reliability in populations 
characterised by low PA (Chen et al. 2009). Accelerometer wear recommendations 
exist for sub-populations including: children (Ojiambo et al. 2011; Rich et al. 2013) 
asymptomatic adults (Matthews et al. 2002; Cook and Lambert 2008; Hart et al. 
2011c) and low-active, overweight individuals (Chen et al. 2009). However, there 
are currently no minimum wear guidelines for clinical populations like stage 5 CKD.  
Accelerometer data reduction in stage 5 CKD is beset with an additional challenge 
associated with treatment mode mediated variability of habitual PA. Patients are 
less active on dialysis days due to enforced inactivity during HD (Majchrzak et al. 
2005), which effectively ‘clamps’ inter-patient PA variability for three days per week. 
Therefore it is possible wear time requirements may differ between dialysis and non-
dialysis days. The influence of weekend PA variability may be a consideration when 
deciding whether to exclude participants. Debate remains with some studies arguing 
inclusion of at least one weekend day is necessary (Gretebeck and Montoye 1992; 
Ojiambo et al. 2011), while others contend there is no additional benefit to outcome 
reliability (McClain et al. 2010; Reid et al. 2013). This issue is perhaps more 
complex for HD patients, as some individuals are required to attend for treatment on 
a day which may represent a ‘typical’ weekend day for some and not for others.  
3.1.3 Summary 
Published guidance for PA surveillance via accelerometry is available for 
asymptomatic adults and children. However, no consensus recommendations 
presently exist for accelerometer data reduction methods in stage 5 CKD, and there 
appears to be low awareness of their importance. In light of strong evidence linking 
PA with health outcomes in stage 5 CKD and increased use of accelerometers, 
there is a need to establish data processing guidelines to underpin reliable 
estimation of habitual PA and sedentary behaviours.  
The objectives of this study were to:  
x Define the minimum number of days of accelerometry monitoring necessary 
to provide reliable estimates of habitual PA and sedentary behaviours of 
people undergoing maintenance HD. 
x Determine a threshold for the minimum recommended accelerometer wear 
time hours required to define a valid data day for stage 5 CKD HD patients.  
x Report the impact of different wear criteria on sample size retention. 
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3.2 Methods 
3.2.1 Study design and participant recruitment 
This was a reliability study involving 72 self-selected volunteer participants 
undergoing maintenance HD therapy for stage 5 CKD. Participants were recruited 
from an NHS outpatient HD unit at Monklands Hospital, Airdrie. Written informed 
consent was obtained. Approval for this study was obtained from the West of 
Scotland Research Ethics Service, Glasgow and Monklands Hospital Research and 
Development department, Airdrie (appendices I a and I b). 
3.2.2 Objective measurement of physical activity outcomes 
Physical activity data was collected for this study between November 2011 and 
August 2013. Physical activity was measured objectively via an Actigraph GT3X 
triaxial accelerometer (Actigraph Corp, Pensacola, Florida) and an ActivPAL 
accelerometer (PAL Technologies Ltd, Glasgow). ActivPAL and Actigraph 
accelerometers were synchronised and initialised using the proprietary software for 
each accelerometer installed on the same laptop (general methods 2.5.1 and 2.5.6). 
Participants wore both monitors as per general methods sections 2.5.2 and 2.5.7 
during waking hours over a period of eight days, and a monitor wear log 
(appendices V a and V b) recorded when the monitors were put on and removed. 
Accelerometers were retrieved from participants on day nine, which coincided with a 
routine HD appointment and data downloaded . 
3.2.3 Data cleaning Actigraph GT3X 
Wear time was to reflect a week of habitual PA, which included three dialysis days, 
and four non-dialysis days (comprising two midweek and two consecutive 
interdialytic days). Actigraph files were scrutinised for spurious data (general 
methods 2.5.3) and monitor wear time (general methods 2.5.4). Figure 3.3 
describes the data cleaning and participant data inclusion process.   
3.2.4 Data cleaning ActivPAL 
ActivPAL data files were scrutinised implausible data and instances of monitor 
malfunction, and then exported to a Microsoft Excel spreadsheet to enable accurate 
determination of monitor wear times (general methods 2.5.8). The wear times were 
then entered into a Microsoft Excel macro, and time spent in different PA behaviours 
as a percentage of wear time for each day as well as, postural transitions, step 
counts and energy expenditure were derived.  
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 Figure 3.1 Flowchart of PA data cleaning and inclusion for reliability analysis.  
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3.2.5 Categorisation of physical activity 
Actigraph estimated sedentary time was defined as an activity count <100 cpm 
(Evenson et al. 2008; Matthews et al. 2008) while activity counts above this cutpoint 
were categorised as activity and thus contributed to estimated total PA time. Time 
spent in activity associated with a health enhancing effect was categorised as 
moderate to vigorous PA (MVPA) as superior inter-instrument reliability has been 
observed for this variable (McClain et al. 2007). The Freedson et al. (1998) cutpoint 
of ≥1952 cpm was used to determine MVPA.  
ActivPAL estimated time in sitting/lying was used for the equivalent determination of 
time spent sedentary in line with the definition of sedentary behaviour as “a group of 
behaviours that occur whilst sitting or lying down and that require very low energy 
expenditure” (Pate et al. 2008). ActivPAL measured time in total PA was therefore 
derived from time spent in standing activities (walking, washing dishes, etc) in 
recognition of the fact that energy expenditure of postural skeletal muscle is greater 
than the <1.5 MET threshold defining sedentary behaviour (Pate et al. 2008). 
Energy expenditure (EE) outcomes calculated by the proprietary ActivPAL and 
Actigraph software and steps taken during the monitoring period for both devices 
was also reported. ActivPAL recorded (sit-to-stand) transitions were also reported.   
3.2.6 Data Analysis 
Actigraph derived PA outcome variables are reported as daily averages and include: 
sedentary time; total PA; moderate to vigorous PA (MVPA); steps; triaxial activity 
counts. Reported ActivPAL PA behaviours include: sit/lie time, stand time, stepping 
time, step counts, sit-to-stand transfers, and energy expenditure. All PA indices 
were normalised to total wear time to adjust for intra and inter-individual variation in 
wear time (Hinkley et al. 2012) as per general methods section 2.5.5. Transitions 
recorded by ActivPAL were normalised to hours of wear time.   
The variance due to the hour or day effect was nested within subjects. Reported 
data were tested for normality using a Kolmogorov Smirnov test and presented as 
mean and standard deviation (SD) for continuous variables or median and 
interquartile range (IQR) for non-normally distributed data. To establish any 
treatment/non-treatment day effects accelerometer outcome data were tested for 
differences between dialysis days and non-dialysis days. Average values for each of 
the PA indices for dialysis days (three day average) and non-dialysis days (four day 
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average) were calculated and analyses performed for each hourly increment of wear 
time threshold from >4 hours to >10 hours wear per day (appendices VII and VIII).  
Based on whether the data fulfilled the assumptions for parametric analysis 
differences in PA outcomes variables between different conditions (ie: dialysis 
versus non-dialysis days) were analysed using either a paired t-test or the Wilcoxon 
signed rank test (non-parametric equivalent). Level of significance was set at p < 
0.05. Effect sizes were calculated to indicate the importance of any observed 
difference via Cohen’s d (Equation 3.1) or Pearson’s r (Equation 3.2) for parametric 
and non-parametric tests respectively.  
Equation 3.1 Cohen’s d parametric effect size calculation  
        (Cohen 1988) 
Equation 3.2 Pearson’s r non-parametric effect size calculation 
       (Field 2012)  
Table 3.1 Below shows the thresholds for small, medium and large effect sizes 
for Pearson’s r and Cohen’s d (Cohen 1988; Cohen 1992). 
Effect Size Small Medium Large 
Variance explained 1 % 9 % 25 % 
Pearson’s r 0.1 0.3 0.5 
Cohen’s d 0.2 0.5 0.8 
Inter-day differences across the same condition (ie: dialysis days only) were 
examined using either a repeated measures analysis of variance (ANOVA) for 
normally distributed data with the calculated F value indicating the ratio of the 
systematic variance to the unsystematic variance (Field 2012). A Friedmans ANOVA 
(non-parametric equivalent) was employed for non-normally distributed data.  
3.2.7 Calculation of accelerometer outcome variable reliability 
To address the principal aim of this study, intra-class correlation coefficients (ICC) 
were computed to assess the variability of each accelerometer derived behaviour 
index across days of the week, based on increasing periods of wear time from four 
hours to >10 hours per day. The ICC calculation is a parametric test requiring data 
to be normally distributed. Physical activity variables defined as non-normally 
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distributed were therefore transformed according to the direction of their skew using 
either log transformation (positive skew) or square transformation (negative skew). 
The average measure and single measure reliability (ICCSM) values were calculated 
for each PA variable on dialysis and non-dialysis days for every incremental wear 
threshold increase of one hour from four to ten hours. A two way random effects 
model (ICC 2,1) was employed where days were the random effect as the intention 
was to generalise calculated ICCs to other days of a similar condition within the 
same sample (Equation 3.3). In this equation σb is the ‘between participant’ variance 
and σw represents the ‘within participant’ variance. An ICC value approaching 1.0 
indicates that the variability of observed outcomes is between- rather than within- 
participants. Average measure reliability values are reported to demonstrate stability 
of a given PA variable over three or four days (condition dependent) while the single 
measure ICC was employed in subsequent recommended wear time computations.  
Equation 3.3 Intraclass correlation coefficient  
 
ICCSM  =  σb2 / (σ b2 + σw2) 
(Shrout and Fleiss 1979) 
3.2.8 Calculation of required accelerometer wear time 
Minimum wear time recommendations were subsequently calculated by applying the 
Spearman Brown Prophecy formula (Equation 3.4) to the ICCSM. The influence of 
incrementally increasing monitor wear time, and application of different levels of 
reliability were examined to demonstrate the implications of applying different criteria 
on computed wear time recommendations. The following levels of reliability were 
employed to determine wear recommendations: 0.70; 0.80; 0.90. In equation 3.4 ‘N’ 
equals the recommended number of wear days and ICCD is the desired reliability 
level and ICCSM is the single measure of reliability.   
Equation 3.4 Spearman-Brown prophecy formula  
N=[ICCD (1-ICCD)] [(1-ICCSM) ICCSM] 
(Stanley and Angoff 1971; Trost et al. 2005) 
If the number of computed days was above a whole round number, the required 
wear time was rounded up to the next whole number as a conservative measure to 
ensure a minimum reliability criterion was maintained. The number of participants 
achieving the defined wear threshold was also calculated. 
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3.2.9 Calculation of a ‘standard’ wear day 
Activity monitor wear times may vary between populations, therefore a ‘standard’ 
wear day was calculated according to the 80/70 method, whereby a standard day is 
defined as 80% of the time that 70% of participants wore their monitors. (Catellier et 
al. 2005; Masse et al. 2005). As habitual PA of people with stage 5 CKD is 
influenced by the unavoidable imposition of HD therapy sessions, a standard day 
was calculated for both dialysis and non-dialysis days.  
3.3 Results 
Participant characteristics are shown in table 3.2. Age of participants ranged from 24 
to 87 years. Female participants made up a third of the overall sample while 
diabetes was present in nearly a quarter. Biomarkers of health and dialysis 
adequacy were within target ranges recommended by the UK renal Association 
guideline 2010. Minute by minute scrutiny of each of the 70 Actigraph accelerometer 
data files revealed no instances of physiologically implausible data. Thirteen 
participants were identified as having one or more days containing >18 hours of 
wear, for which logical waking-hour wear times were determined.  
Table 3.2 Demographic and clinical characteristics of the sample.  
 Total sample Males Females 
n = 70 46 24 
Diabetes  16 (23%) 11 (24%) 5 (21%) 
Age (years)  55.9 ± 15.7 
55.00 (44.0 - 70.5) § 
58.8 ± 16.2 
60.00 (49.8 - 73.0) § 
50.2 ± 13.3 † 
47.50 (42.3 - 54.3) 
BMI (kg/m2) 28.6 ± 6.4 † 
27.7 (24.3 - 31.7) 
28.0 ± 4.7 
28.0 (24.5 - 30.6) § 
29.7 ± 8.8 
26.5 (23.6 - 34.9) § 
Albumin (g/L)  38.6 ± 4.1 † 
39.0 (36.0 - 42.0) 
38.8 ± 4.4 † 
39.5 (36.0 - 42.0) 
38.3 ± 3.7 
39.0 (36.0 - 41.0) § 
Hb (g/dL)  11.3 ± 1.0 11.4 ± 1.0 11.0 ± 0.9 
Dialysis adequacy 
(URR %)  
71 (66 - 75) 69.00 (65.8 - 73.0) 75.0 (70.1 - 79.0) 
Dialysis vintage 
(months)  
15.8 (6.8 - 32.0) 17.2 (8.2 - 31.1) 9.4 (5.4 - 34.2) 
§ Data normally distributed, median and interquartile range reported for comparison 
†Data not normally distributed, mean and standard deviation reported for comparison 
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3.3.1 Accelerometer wear compliance 
Overall compliance with Actigraph accelerometer wear was good with 51 (73%) 
participants wearing their monitor for seven consecutive days and a minimum of four 
hours on each day. Better compliance was observed on dialysis days with 63 (90%) 
wearing the monitors for all three dialysis days compared to 54 (77%) participants 
for all four non-dialysis days. No instances of monitor malfunction were observed. 
Fewer participants (n = 44, 63%) returned seven consecutive days of accelerometry 
data for the Activpal due to a combination of lower wear compliance and monitor 
malfunctions. As with the Actigraph monitor, wear compliance for the Activpal was 
better on dialysis days (n = 55, 79%) compared to non-dialysis days (n = 47, 67%).   
3.3.2 Actigraph outcome variables  
Normality of the seven-day averaged Actigraph outcome variables was assessed via 
Kolmogorov-Smirnov test as the sample size was >50. Only monitor wear time and 
minutes of time spent sedentary were normally distributed (appendix VII). The 
remaining accelerometer output indices (total PA, MVPA, activity counts, steps) 
were non-normally distributed (appendix VII).  Accelerometer wear time and 
sedentary minutes were normally distributed variables for both the dialysis and non-
dialysis day conditions. Sedentary time percentage and total PA (minutes and 
percentage of wear) were normally distributed for the non-dialysis day condition 
(appendix VII). All remaining Actigraph output variables were non-normally 
distributed. Table 3.3 presents the descriptive data for the Actigraph variables. 
3.3.3 ActivPAL outcome variables 
Normality of the seven-day averaged ActivPAL outcomes was assessed via 
Shapiro-Wilk test as the sample size <50. Monitor wear time, sit/lie and standing 
(mins/day), transfers and daily EE were normally distributed (appendix VIII). The 
remaining ActivPAL outcomes (stepping time and steps/day) and all indices 
normalised to wear time were non-normally distributed. Normality of PA variables for 
the dialysis and non-dialysis conditions was assessed via Kolmogorov-Smirnov and 
Shapiro-Wilk tests respectively (appendix VIII). Daily wear and EE were normally 
distributed. Minutes and percentage of sit/lie time, stand time percentage and 
transitions/hr for the dialysis day condition were normally distributed as was non-
dialysis standing (mins). The remaining PA variables were non-normally distributed. 
ActivPAL accelerometer output data are presented descriptively in table 3.4. 
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 Table 3.3 Actigraph accelerom
eter-derived estim
ates of PA and sedentary behaviour for stage 5 CKD HD patients. [norm
ally 
distributed data are presented as M
ean ± SD, and non-norm
ally distributed data as M
edian (IQR)].  
Condition 
7 Days (n = 51) 
Dialysis (n = 63) 
Non-dialysis (n = 54) 
Dialysis vs Non-dialysis 
Effect size 
W
ear tim
e (m
in)  
798.8 ± 103.1 
863.7 ± 124.9 
750.2 ± 111.8 
t(50 ) = 11.40 p < 0.001  
d = 1.60 
Sedentary (m
in)  
669.3 ± 114.5 
670.5 (573.5 - 745.0) § 
744.7 ± 114.8 
749.3 (662.4, 819.2) § 
612.8 ± 134.5 
602.3 (528.3, 714.9) § 
t(50 ) = 8.69 p < 0.001  
d = 1.22 
Sedentary (%
) 
83.4 ± 8.9
† 
85.0 (78.9 - 90.2) 
86.4 ± 6.6
† 
87.2 (83.2, 91.0) 
81.2 ± 11.0 
83.9 (75.0, 89.0) § 
 
Z = -5.04   p < 0.001   
 
r = 0.71 
Total P
A (m
in)  
129.5 ± 69.9
† 
119.3 (84.4,154.5) 
119.0 ± 69.9
† 
103.3 (81.2, 142.6) 
137.4 ± 75.5 
125.1 (86.9, 183.1) § 
 
Z = -2.93   p = 0.003   
 
r = 0.41 
Total P
A (%
) 
16.6 ± 8.9
† 
15.0 (9.8, 21.1) 
13.6 ± 6.6
† 
12.8 (9.0, 16.8) 
18.8 ± 11.0 
16.1 (11.0, 25.0) § 
 
Z = -5.04   p < 0.001   
 
r = 0.71 
M
V
PA (m
ins) 
7.4 (2.1, 18.7) 
6.1 (2.2, 10.6) 
7.5 (1.8, 19.2) 
Z = -2.89   p = 0.004   
r = 0.40 
M
V
PA (%
) 
0.9  (0.3, 2.3) 
0.7 (0.3, 1.4) 
0.9 (0.2, 3.0) 
Z = -3.21   p = 0.001   
r = 0.45 
Triaxial counts 
238457 (137399, 345520) 
205964 (131019, 274379) 
252010 (148901, 378802) 
Z = -3.77   p < 0.001   
r = 0.53 
Triaxial cpm
  
303 (176, 397) 
233.3 (151.4, 327.1) 
322.1 (202.8, 473.0) 
Z = -5.54   p < 0.001   
r = 0.78 
Steps 
2303 (1048, 3876) 
1935 (959, 2666) 
2370 (1115, 4391) 
Z = -3.05   p = 0.002   
r = 0.43 
Steps/m
in 
2.8 (1.5, 5.0) 
2.2 (1.4, 3.6) 
3.3 (1.5, 5.4) 
Z = -4.04   p < 0.001   
r = 0.57 
§  D
ata norm
ally distributed, M
edian and interquartile range reported for com
parison.  
† D
ata not norm
ally distributed, M
ean and standard deviation reported for com
parison. 
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 Table 3.4 ActivPAL accelerom
eter-derived estim
ates of PA and sedentary behaviour for stage 5 CKD HD patients. [norm
ally 
distributed data are presented as M
ean ± SD, and non-norm
ally distributed data as M
edian (IQR)]. 
Condition 
7 Days (n = 44) 
Dialysis (n = 55) 
Non-dialysis (n = 47) 
Dialysis vs Non-dialysis 
Effect Size 
W
ear (m
in)  
801.7 ± 107.6 
856.51 ± 134.8 
745.05 ± 124.0 
T(43 ) = 5.565 p < 0.001  
d =1.20 
Sit/Lie (m
in)  
701.8 ± 120.05 
812.4 (714.2, 876.4)  § 
698.3 ± 122.6 
694.57 (607.5, 785.16) § 
524.7 ± 149.9
† 
532.4 (469.9, 642.9) 
 
Z = -5.532   p < 0.001  
 
r = 0.83 
Sit/Lie (%
) 
74.89 ± 12.069
† 
76.9 (69.1, 84.1) 
81.7 ± 9.5 
82.97 (76.7, 87.4)  § 
70.0 ± 15.9
† 
71.56 (62.2, 82.6) 
 
Z = -5.053   p < 0.001  
 
r = 0.76 
Step Tim
e (m
in)  
44.5 (29.2, 63.0) 
32.1 (22.8, 47.7) 
51.2 (29.6, 73.7) 
Z = -4.260   p < 0.001  
r = 0.64 
Step Tim
e (%
) 
4.06 (3.0, 6.3) 
3.91 (2.8, 5.6) 
6.6 (4.1, 10.6) 
Z = -5.053  p < 0.001  
r = 0.76 
Stand (m
in) 
197.3 ± 95.6 
175.3 (127.5, 247.4)  § 
158.3 ± 94.5 † 
141.0 (101.1, 197.2) 
220.5 ± 113.1 
213.0 (128.1, 283.5)  § 
 
Z = -3.980  p < 0.001  
 
r = 0.60   
Stand (%
) 
25.1 ± 12.1
† 
23.06 (16.0, 30.9) 
18.3 ± 9.5 
17.03 (12.6, 23.27)  § 
30.0 ± 15.9 † 
28.4 (17.4, 37.8) 
 
Z = -4.878  p < 0.001  
 
r = 0.74 
Transitions (day) 
31.0 ± 10.1 
29.3 (22.8, 37.8)  § 
30.5 ± 10.7
† 
28.3 (23.3, 37.3) 
34.5 ± 10.6 
33.25 (27.0, 41.3)  § 
T(43 )= -2.842 p = 0.007  
d = 0.61 
Transitions (hr)  
2.6 ± 0.8
† 
2.5 (2.1, 2.9) 
2.1 ± 0.7 
2.05 (1.7, 2.5)  § 
2.9 ± 1.0
† 
2.80 (2.3, 3.2) 
 
Z = -5.123   p < 0.001  
 
r = 0.77 
Steps/day 
3242 (1909, 4615) 
2189 (1493, 3577) 
3594 (2055, 5854) 
Z = -3.769   p < 0.001  
r = 0.57 
Steps/m
in 
4.2 (2.5, 6.1) 
2.76 (1.8, 3.7) 
4.9 (2.6, 8.3) 
Z = -4.621   p < 0.001  
r = 0.70 
M
ETm
in/day 
1121.9 ± 172.2 
1164.6 ± 215.6 
1066.3 ± 180.5 
Z = -3.349   p = 0.001  
r = 0.50 
M
ETm
in/m
in 
1.37 (1.33, 1.42) 
1.34 (1.31, 1.36) 
1.40 (1.33, 1.49) 
Z = -4.831   p < 0.001  
r = 0.73 
§  D
ata norm
ally distributed, M
edian and interquartile range reported for com
parison.  
† D
ata not norm
ally distributed, M
ean and standard deviation reported for com
parison. 
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3.3.4 Actigraph outcome variable analysis of day effect 
Table 3.3 presents the results from statistical testing to determine the effect of 
different conditions (dialysis versus non-dialysis days) on accelerometer output 
variables. Mean accelerometer wear time across the seven days was 798.8 min ± 
103.1 min (13.3 hours ± 1.7 hours), however average monitor wear time for dialysis 
days (863.7 min ± 124.9) was significantly longer (p < 0.001) compared to non-
dialysis days (750.2 min ± 111.8) as indicated by paired t-test (large effect). 
Participants spent significantly more time sedentary on dialysis days (large effect) 
compared to non-dialysis days both in overall minutes (figure 3.2) and as a 
percentage of wear time (p < 0.001).  Non-parametric comparison using the 
Wilcoxon signed rank test demonstrated less time was spent in total PA on dialysis 
days compared to non-dialysis days in minutes (medium effect, p = 0.003) and as a 
percentage of wear time (large effect, p < 0.001). In addition accelerometer counts 
per minute and steps per minute of wear time were also significantly greater (large 
effect, p < 0.001) on non-dialysis days compared to dialysis day. These findings 
remained consistent when incremental increases in monitor wear thresholds four to 
10 hours were applied (appendix IX)  
Table 3.5 Determination of Actigraph-derived PA outcome variable differences 
across the same condition (dialysis and non-dialysis days).  
Condition Dialysis Days only Non-Dialysis Days only 
Wear (min)  0.93, F(2,124) = 2.38 p = 0.10 0.94, F(3, 51) = 1.01 p = 0.40 
Sedentary(min)  0.92, F(2,124) = 2.50 p = 0.09 0.98, F(3, 51) = 0.38 p = 0.78 
Sedentary (%) X2(2) = 0.13              p = 0.94 0.95, F(3, 51) = 0.86 p = 0.47 
Total PA (min)  X2(2) = 0.87              p = 0.65 0.90, F(3, 51) = 1.86 p = 0.15 
Total PA (%) X2(2) = 0.13              p = 0.94 0.95, F(3, 51) = 0.86 p = 0.47 
MVPA (min) X2(2) = 2.76              p = 0.25 X2(2) = 5.29             p = 0.15 
MVPA (%) X2(2) = 0.98              p = 0.61 X2(2) = 4.29             p = 0.23 
Triaxial counts/day X2(2) = 4.03              p = 0.13 X2(3)= 4.96              p = 0.18 
Triaxial cpm  X2(2) = 2.32              p = 0.31 X2(3)= 3.27              p = 0.35 
Steps X2(2) = 0.15              p = 0.93 X2(3)= 5.59              p = 0.20 
Steps/min X2(2) = 0.60              p = 0.74 X2(3)=1.31               p =0.73 
Results of statistical testing for differences across the same condition (dialysis or 
non-dialysis days) are presented in table 3.5. Data from 63 participants were used to 
determine whether there was a significant day effect for Actigraph PA outcomes 
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across dialysis days only, while data from 54 participants was used for non-dialysis 
days. A one-way repeated measures ANOVA revealed that there was no significant 
day effect on accelerometer wear time (p = 0.10), and minutes spent sedentary 
across the three dialysis days (p = 0.09).  The same result was observed for monitor 
wear (p = 0.40), sedentary time (minutes, p = 0.78 and percentage, p = 0.47) and 
total PA (minutes, p = 0.15 and percentage, p = 0.47) across the four non-dialysis 
days. Friedman’s ANOVA indicated no significant day effect for percentage of 
sedentary time (p = 0.94), total PA (minutes, p 0.65 and percentage, p = 0.94), 
MVPA (minutes, p = 0.25 and percentage, p = 0.61) triaxial counts (per day, p = 
0.13 and per minute, p = 0.31) or steps performed (per day, p = 0.93 and per 
minute, p = 0.74) for the dialysis day condition. Accordingly, the same non-
parametric test showed no significant day effect for MVPA (minutes, p = 0.15 and 
percentage, p = 0.23), triaxial counts or steps (per day, p = 0.18 and per min, p = 
0.35) performed for the non-dialysis day condition. 
Figure 3.2 Graph of Actigraph estimated time (minutes) spent in sedentary and 
total PA for dialysis versus non-dialysis days (median and IQR). 
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3.3.5 ActivPAL outcome variable analysis of day effect 
Results presented in table 3.4 show ActivPAL estimated PA outcomes were 
significantly different on dialysis days compared to non-dialysis days. Mean 
accelerometer wear time across the seven days was 801.7 ± 107.6 min (13.4 hours 
± 1.8 hours). ActivPAL wear time was significantly longer (p < 0.001) on dialysis 
days (856.51 ± 134.8) compared to non-dialysis days (745.05 ± 124.0). In addition 
significantly fewer sit-to-stand transfers were performed on dialysis days as 
indicated by paired t-test (medium effect, p = 0.007). Non-parametric comparison 
using the Wilcoxon signed rank test was employed for the remaining ActivPAL PA 
indices. Significantly more time was spent seated or lying on dialysis days compared 
to non-dialysis (large effect, p < 0.001) while less time was spent in PA involving 
standing both in overall minutes (figure 3.3) and as a percentage of wear time (large 
effect, p < 0.001). Participants spent more time stepping, performed more steps, 
and had higher estimated energy expenditure on non-dialysis compared to dialysis 
days (p < 0.001) with large effect sizes uniformly observed.  
Table 3.6 Determination of ActivPAL-derived outcome variable differences 
across the same condition (dialysis and non-dialysis days).  
Condition Dialysis Days Non-Dialysis Days 
Wear (min)  0.99,F(2,108) = 0.21  p = 0.10 0.98,F(3, 44) = 0.36 p = 0.79 
Sit/Lie (min)  0.99,F(2,108) = 0.33  p = 0.72 X2(2) = 2.21            p = 0.53 
Sit/Lie (%) 0.98,F(2,108) = 0.51  p = 0.09 X2(2) = 6.65            p = 0.08 
Stand (mins) X2(2) = 1.56              p = 0.46 F(2.1, 97.7) = 0.83     p = 0.45 
Stand (%) 0.98, F(2,108) =0.52  p = 0.60 X2(2) = 6.65            p = 0.08 
Stepping (min)  X2(2) = 0.44              p = 0.80 X2(2) = 3.33            p = 0.34 
Step Time (%) X2(2) = 1.78              p = 0.41 X2(2) = 1.90            p = 0.59 
Transitions/day X2(2) = 0.15              p = 0.93 0.89,F(3, 44) =1.96  p = 0.14 
Transitions/hr  0.23, F(1.7,92) = 0.35 p = 0.67 X2(3)= 5.221           p = 0.16 
Steps/day X2(2) = 0.436            p = 0.80 X2(3)= 3.817           p = 0.28 
Steps/min X2(2) = 1.782            p = 0.41 X2(3)= 0.932           p = 0.82 
EE/day 0.99,F(2,108)= 0.15   p = 0.86 F(2.4, 108.6) =1.96    p = 0.14 
EE/min X2(2) = 2.218            p = 0.33 X2(3) = 2.719          p = 0.44 
 
Results of ANOVA analysis examining differences across the same condition (table 
3.6) revealed that there was no significant day-effect on accelerometer wear time, 
time seated/lying, standing, transitions per hour, and energy expenditure per day 
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across the three dialysis days. Similarly, no significant differences were observed for 
monitor wear, standing time (minutes), transitions (per day) and daily EE across the 
four non-dialysis days. Non-parametric Friedman’s ANOVA also showed no 
significant day effect for the remaining ActivPAL outcome variables across either the 
three days of the dialysis condition or the four days of the non-dialysis condition. 
Figure 3.3 Graph of ActivPAL time spent sitting/lying and in standing activities 
for dialysis days versus non-dialysis days (median and IQR). 
 
3.3.6 Actigraph outcome variable reliability analysis 
Tables 3.5.1 and 3.5.2 show the average measure intraclass correlation coefficients 
for each accelerometer outcome variable for dialysis days and non-dialysis days 
respectively. Single and average measure ICCs were stable between >4 and >10 
hours wear on dialysis days (appendix XI). A trend for higher reliability is observed 
with incremental increases in wear time for most of the PA variables with sedentary 
minutes showing the most noticeable improvement. Physical activity outcome 
variables on non-dialysis days are similarly stable. Reliability coefficients for some of 
the variables decline slightly as the sample size available for analysis drops below 
50. Physical activity outcome variables with the highest reliability are triaxial activity 
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counts and step counts while the variable with lowest reliability is estimated minutes 
of sedentary time.  
Table 3.7 Actigraph average measure ICC values for outcome variables over 
three dialysis days.  
Hours of wear >4 >5 >6 >7 >8 >9 >10 
Cases (n=) 63 63 62 60 57 55 53 
Sedentary mins 0.66 0.66 0.71 0.77 0.84 0.83 0.81 
Sedentary % 0.91 0.91 0.91 0.92 0.92 0.92 0.93 
Total PA mins 0.90 0.90 0.91 0.91 0.92 0.92 0.92 
Total PA % 0.90 0.90 0.91 0.92 0.92 0.92 0.92 
MVPA mins 0.92 0.92 0.93 0.92 0.92 0.92 0.92 
MVPA % 0.91 0.91 0.91 0.91 0.91 0.91 0.91 
Triaxial cpd 0.92 0.92 0.93 0.93 0.93 0.93 0.93 
Triaxial cpm 0.93 0.93 0.93 0.94 0.94 0.94 0.94 
Steps/day 0.95 0.95 0.95 0.95 0.95 0.95 0.95 
Steps/min 0.95 0.95 0.95 0.95 0.95 0.95 0.95 
Table 3.8 Actigraph average measure ICC values for outcome variables over 
four non-dialysis days. 
Wear time >4 >5 >6 >7 >8 >9 >10 
Cases (n =) 54 52 52 51 40 38 32 
Sedentary mins 0.83 0.81 0.81 0.82 0.85 0.85 0.84 
Sedentary % 0.93 0.93 0.93 0.93 0.92 0.92 0.89 
Total PA mins 0.92 0.93 0.93 0.93 0.92 0.92 0.90 
Total PA % 0.94 0.94 0.94 0.94 0.94 0.94 0.92 
MVPA mins 0.95 0.95 0.95 0.95 0.95 0.94 0.94 
MVPA % 0.95 0.95 0.95 0.95 0.95 0.94 0.94 
Triaxial cpd 0.94 0.94 0.94 0.94 0.93 0.93 0.93 
Triaxial cpm 0.95 0.95 0.95 0.95 0.95 0.95 0.94 
Steps 0.95 0.96 0.96 0.96 0.95 0.95 0.95 
Steps/min 0.96 0.96 0.96 0.96 0.96 0.96 0.95 
3.3.7 ActivPAL outcome variable reliability analysis 
Average measure ICCs for ActivPAL outcome variables on dialysis days and non-
dialysis days are presented in tables 3.9 and 3.10. Single measure (appendix XII) 
and average measure ICCs are relatively stable between >4 and >10 hours wear on 
both dialysis and non-dialysis days. Physical activity variables on non-dialysis days 
show a trend for declining reliability with higher thresholds of monitor wear, 
particularly from six hours as the number of datasets diminishes below 45 (table 
3.9). Time spent seated/lying (minutes per day) shows consistently lower reliability 
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for both dialysis and non-dialysis days than other outcomes but when normalised to 
wear time this variable has the same reliability as percentage of time spent in 
standing activities.   
Table 3.9 ActivPAL average measure ICC values for outcome variables over 
three dialysis days.  
Hours of wear >4 >5 >6 >7 >8 >9 >10 
Cases (n =) 55 55 52 51 51 49 44 
Sit/Lie mins 0.72 0.72 0.80 0.81 0.81 0.82 0.87 
Sit/Lie % 0.94 0.94 0.94 0.94 0.94 0.94 0.94 
Stand mins 0.87 0.87 0.87 0.88 0.88 0.85 0.87 
Stand % 0.94 0.94 0.94 0.94 0.94 0.94 0.94 
Stepping mins 0.90 0.90 0.92 0.92 0.92 0.91 0.91 
Stepping % 0.91 0.91 0.91 0.91 0.91 0.91 0.91 
Steps/day 0.90 0.90 0.92 0.92 0.92 0.91 0.91 
Steps/min 0.91 0.91 0.91 0.91 0.91 0.91 0.91 
Transitions/day 0.76 0.76 0.82 0.80 0.80 0.76 0.80 
Transitions/hr 0.76 0.76 0.79 0.78 0.78 0.77 0.83 
EE/day 0.78 0.78 0.87 0.88 0.88 0.87 0.92 
EE/min 0.93 0.93 0.94 0.94 0.94 0.93 0.95 
Table 3.10 ActivPAL average measure ICC values for outcome variables over 
four non-dialysis days. 
Hours of wear >4 >5 >6 >7 >8 >9 >10 
Cases (n =) 47 45 43 43 37 34 24 
Sit/Lie mins 0.84 0.82 0.84 0.84 0.80 0.81 0.77 
Sit/Lie % 0.90 0.90 0.89 0.89 0.88 0.86 0.89 
Stand mins 0.89 0.90 0.88 0.88 0.88 0.85 0.90 
Stand % 0.91 0.90 0.88 0.88 0.87 0.85 0.88 
Stepping mins 0.91 0.92 0.92 0.92 0.91 0.90 0.91 
Stepping % 0.93 0.93 0.92 0.92 0.91 0.91 0.91 
Steps/day 0.92 0.93 0.93 0.93 0.92 0.91 0.92 
Steps/min 0.93 0.93 0.93 0.93 0.92 0.92 0.91 
Transitions/day 0.82 0.83 0.83 0.83 0.82 0.76 0.73 
Transitions/hr 0.88 0.89 0.89 0.89 0.89 0.87 0.84 
EE/day 0.70 0.79 0.81 0.81 0.81 0.75 0.83 
EE/min 0.93 0.94 0.94 0.94 0.92 0.92 0.91 
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3.3.8 Actigraph outcome variable wear time recommendations 
Tables 3.11 to 3.14 show the computed wear times for accelerometer outcome 
variables according to wear time to define a valid day and application of desired 
level of reliability (0.70, 0.80, 0.90). The more stringent the desired reliability, the 
greater the number of days and hours of wear within those days hours required. In 
general the more hours the monitor is worn the fewer days are required. For this 
sample of HD patients just under one dialysis day with a minimum of seven hours 
wear is required to achieve a reliability level of 0.80 for sedentary behaviour on 
dialysis days (table 3.11). Similarly one dialysis wear day with a slightly lower 
threshold of six hours is required to reliably estimate total PA (table 3.12). For non-
dialysis days more than one day but less than two days wear is required to achieve 
a reliability level of 0.80 for sedentary behaviour and total PA. In contrast to the wear 
threshold for dialysis days, inclusion of accelerometer datasets with as little as four 
hours of data does not appear to increase the number of days required for reliable 
estimates of sedentary behaviour and total PA (normalised to wear time) on non-
dialysis days. Furthermore, a wear time threshold of seven hours may decrease the 
required number of non-dialysis days to reliably measure total PA to just one. 
Wear time requirements vary depending on the PA outcome variable. Activity counts 
and steps per minute required just one dialysis day and one non-dialysis day with 
inclusion of datasets with as few as four hours wear (tables 3.13 and 3.14). Two 
dialysis and one non-dialysis days are required for reliable estimation of MVPA 
normalised to wear time (appendix XIV a). When time spent sedentary is not 
normalised to wear time, required number of wear days for a reliability of 0.80 
increases substantially to three dialysis and three non-dialysis days with a minimum 
wear threshold of eight hours per day (appendix XIII a). Wear time required for total 
PA in minutes per day increases slightly to two dialysis days and two non-dialysis 
days (appendix XIII b). In contrast computed wear for MVPA in minutes per day is 
slightly less at one dialysis and one non-dialysis day allowing inclusion of datasets 
with as little as six hours/day (appendix XIII c). Wear time requirement for activity 
counts per day remains unchanged at one day of each condition as long as a 
minimum wear threshold of six hours is observed (appendix IV b). Likewise 
recommended wear for reliable measurement of steps/day remains unchanged at 
one dialysis and one non-dialysis day as long as a wear threshold of five hours is 
observed (appendix IV c). 
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 Table 3.11 Com
puted Actigraph wear for sedentary tim
e (percent). 
 
Table 3.12 Com
puted Actigraph wear for total PA (percent). 
Dialysis Day Sedentary %
 
Non-Dialysis Day Sedentary %
 
 
Dialysis Day Total PA %
 
Non-Dialysis Day Total PA %
 
n = 
W
ear 
hours 
Days required for 
desired reliability 
n = 
W
ear 
hours 
Days required for 
desired reliability 
 
n = 
W
ear 
hours 
Days required to 
achieve reliability 
n = 
W
ear 
hours 
Days required to 
achieve reliability 
0.7 
 0.8 
0.9 
0.7 
0.8 
0.9 
 
0.7 
0.8 
0.9 
0.7 
0.8 
0.9 
63 
4h 
0.69 
1.19 
2.67 
54 
4h 
0.74 
1.26 
2.84 
 
63 
4h 
0.59 
1.01 
2.26 
54 
4h 
0.59 
1.02 
2.29 
63 
5h 
0.69 
1.19 
2.67 
52 
5h 
0.70 
1.21 
2.72 
 
63 
5h 
0.59 
1.01 
2.26 
52 
5h 
0.59 
1.02 
2.29 
62 
6h 
0.67 
1.15 
2.58 
52 
6h 
0.70 
1.21 
2.72 
 
62 
6h 
0.55 
0.94 
2.11 
52 
6h 
0.59 
1.02 
2.29 
60 
7h 
0.58 
0.99 
2.24 
51 
7h 
0.68 
1.16 
2.62 
 
60 
7h 
0.53 
0.91 
2.05 
51 
7h 
0.57 
0.97 
2.19 
57 
8h 
0.57 
0.98 
2.21 
40 
8h 
0.79 
1.35 
3.05 
 
57 
8h 
0.52 
0.89 
2.00 
40 
8h 
0.64 
1.10 
2.47 
55 
9h 
0.58 
1.00 
2.24 
38 
9h 
0.80 
1.38 
3.10 
 
55 
9h 
0.51 
0.88 
1.98 
38 
9h 
0.62 
1.06 
2.38 
53 
10h 
0.56 
0.96 
2.16 
32 
10h 
1.15 
1.97 
4.43 
 
53 
10h 
0.52 
0.89 
2.00 
32 
10h 
0.82 
1.41 
3.17 
 
Table 3.13 Com
puted Actigraph wear for triaxial counts/m
inute. 
 
Table 3.14 Com
puted Actigraph wear for steps/m
inute. 
Dialysis Day Triaxial cpm
 
Non-Dialysis Day Triaxial cpm
 
 
Dialysis Day Steps/m
in 
Non-Dialysis Day Steps/m
in 
n = 
W
ear 
hours 
Days required to 
achieve reliability 
n = 
W
ear 
hours 
Days required to 
achieve reliability 
 
n = 
W
ear 
hours  
Days required to 
achieve reliability 
 
W
ear 
hours  
Days required to 
achieve reliability 
0.7 
0.8 
0.9 
0.7 
0.8 
0.9 
 
0.7 
0.8 
0.9 
n = 
0.7 
0.8 
0.9 
63 
4h 
0.53 
0.91 
2.04 
54 
4h 
0.44 
0.76 
1.71 
 
63 
4h 
0.38 
0.65 
1.47 
54 
4h 
0.44 
0.76 
1.70 
63 
5h 
0.53 
0.91 
2.04 
52 
5h 
0.45 
0.77 
1.74 
 
63 
5h 
0.38 
0.65 
1.47 
52 
5h 
0.41 
0.71 
1.59 
62 
6h 
0.52 
0.89 
2.01 
52 
6h 
0.45 
0.77 
1.74 
 
62 
6h 
0.38 
0.64 
1.45 
52 
6h 
0.41 
0.71 
1.59 
60 
7h 
0.47 
0.81 
1.82 
51 
7h 
0.44 
0.76 
1.70 
 
60 
7h 
0.36 
0.61 
1.38 
51 
7h 
0.41 
0.71 
1.59 
57 
8h 
0.47 
0.80 
1.80 
40 
8h 
0.51 
0.87 
1.97 
 
57 
8h 
0.35 
0.60 
1.35 
40 
8h 
0.50 
0.85 
1.91 
55 
9h 
0.46 
0.80 
1.79 
38 
9h 
0.51 
0.87 
1.97 
 
55 
9h 
0.35 
0.60 
1.35 
38 
9h 
0.49 
0.84 
1.89 
53 
10h 
0.45 
0.77 
1.73 
32 
10h 
0.58 
0.99 
2.23 
 
53 
10h 
0.35 
0.59 
1.33 
32 
10h 
0.51 
0.87 
1.97 
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3.3.9 ActivPAL outcome variable wear time recommendations 
Computed wear times for ActivPAL outcome variables according to desired level of 
reliability (0.70, 0.80, 0.90) are presented in tables 3.15 to 3.18. Spearman-Brown 
Prophecy calculations indicate just one dialysis day is required to obtain reliable 
ActivPAL estimates of time spent seated/lying and in standing activities as a 
percentage of monitor wear time (tables 3.15 and 3.16). Moreover, the number of 
wear days required remains unchanged when datasets with as low as five hours 
wear are included. Computations for the same outcomes on non-dialysis days 
indicate two days are required when accelerometry data with as few as four hours 
wear are included (tables 3.15 and 3.16).  Wear time required starts to increase 
beyond two days above thresholds of seven hours and five hours (for sit/lie and 
stand time respectively) as the number of datasets available for analysis drops 
below a sample size of 45. Estimated steps per minute requires just over two 
dialysis and two non-dialysis wear days to achieve a reliability level of 0.80 (table 
3.17), while similarly reliable estimates of energy expenditure can be obtained from 
just one day of each condition (table 3.18).  
Recommended number of wear days are generally greater for ActivPAL outcome 
variables not adjusted for wear time. A full week of ActivPAL wear is required to 
achieve clinically acceptable reliable estimates of minutes per day spent 
seated/lying (appendix XV a). For reliable estimates of minutes per day spent in 
standing activities the computed requirement is slightly less at two dialysis days and 
three non-dialysis days (appendix XV b). Meanwhile, two days of each condition are 
recommended for stepping time (appendix XV c and XVI a) and steps taken per day 
(appendix XVI b).  A full week is recommended to reliably estimate sit-to-stand 
transfers with a minimum of six hours monitor wear per day (appendix XVI c). Using 
the same minimum wear threshold of six hours, daily energy expenditure estimates 
can be derived reliably from two dialysis days and four non-dialysis days of 
ActivPAL data (Appendix XVII a and XVII b). 
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 Table 3.15 Com
puted ActivPAL wear for sit/lie tim
e (percent). 
 
Table 3.16 Com
puted ActivPAL wear for stand tim
e (percent). 
Dialysis Day  
Non-Dialysis Day  
 
Dialysis Day  
Non-Dialysis Day  
n = 
W
ear 
hours 
Days required for 
desired reliability 
n = 
W
ear 
hours 
Days required for 
desired reliability 
 
n = 
W
ear 
hours 
Days required to 
achieve reliability 
n = 
W
ear 
hours 
Days required to 
achieve reliability 
0.7 
0.8 
0.9 
0.7 
0.8 
0.9 
 
0.7 
0.8 
0.9 
0.7 
0.8 
0.9 
55 
4h 
0.47 
0.80 
1.80 
47 
4h 
1.01 
1.74 
3.90 
 
55 
4h 
0.47 
0.80 
1.80 
47 
4h 
0.95 
1.63 
3.66 
55 
5h 
0.47 
0.80 
1.80 
45 
5h 
1.04 
1.78 
4.01 
 
55 
5h 
0.47 
0.80 
1.80 
45 
5h 
0.98 
1.69 
3.80 
52 
6h 
0.47 
0.80 
1.80 
43 
6h 
1.12 
1.93 
4.34 
 
52 
6h 
0.47 
0.80 
1.80 
43 
6h 
1.27 
2.18 
4.90 
51 
7h 
0.46 
0.79 
1.77 
43 
7h 
1.12 
1.93 
4.34 
 
51 
7h 
0.46 
0.79 
1.77 
43 
7h 
1.27 
2.18 
4.90 
51 
8h 
0.46 
0.79 
1.77 
37 
8h 
1.33 
2.27 
5.12 
 
51 
8h 
0.46 
0.79 
1.77 
37 
8h 
1.44 
2.47 
5.57 
49 
9h 
0.48 
0.83 
1.86 
34 
9h 
1.48 
2.54 
5.72 
 
49 
9h 
0.48 
0.83 
1.86 
34 
9h 
1.66 
2.85 
6.42 
44 
10h 
0.42 
0.72 
1.62 
24 
10h 
1.16 
1.99 
4.48 
 
44 
10h 
0.42 
0.72 
1.62 
24 
10h 
1.31 
2.25 
5.05 
 
Table 3.17 Com
puted ActivPAL wear for steps/m
inute. 
 
Table 3.18 Com
puted ActivPAL wear energy expenditure/m
in. 
Dialysis Day  
Non-Dialysis Day  
 
Dialysis Day 
Non-Dialysis Day  
n = 
W
ear 
hours 
Days required to 
achieve reliability 
n = 
W
ear 
hours 
Days required to 
achieve reliability 
 
n = 
W
ear 
hours 
Days required to 
achieve reliability 
 
W
ear 
hours 
Days required to 
achieve reliability 
  
0.7 
0.8 
0.9 
  
0.7 
0.8 
0.9 
 
  
0.7 
0.8 
0.9 
n = 
  
0.7 
0.8 
0.9 
55 
4h 
0.72 
1.24 
2.80 
47 
4h 
0.67 
1.14 
2.57 
 
55 
4h 
0.54 
0.93 
2.09 
47 
4h 
0.54 
0.93 
2.09 
55 
5h 
0.72 
1.24 
2.80 
45 
5h 
0.67 
1.14 
2.57 
 
55 
5h 
0.54 
0.93 
2.09 
45 
5h 
0.54 
0.93 
2.09 
52 
6h 
0.67 
1.15 
2.59 
43 
6h 
0.70 
1.19 
2.68 
 
52 
6h 
0.49 
0.83 
1.88 
43 
6h 
0.49 
0.83 
1.88 
51 
7h 
0.65 
1.12 
2.52 
43 
7h 
0.70 
1.19 
2.68 
 
51 
7h 
0.48 
0.82 
1.84 
43 
7h 
0.48 
0.82 
1.84 
51 
8h 
0.65 
1.12 
2.52 
37 
8h 
0.79 
1.35 
3.05 
 
51 
8h 
0.48 
0.82 
1.84 
37 
8h 
0.48 
0.82 
1.84 
49 
9h 
0.73 
1.25 
2.81 
34 
9h 
0.83 
1.41 
3.18 
 
49 
9h 
0.50 
0.85 
1.92 
34 
9h 
0.50 
0.85 
1.92 
44 
10h 
0.71 
1.21 
2.72 
24 
10h 
0.87 
1.50 
3.37 
 
44 
10h 
0.41 
0.70 
1.57 
24 
10h 
0.41 
0.70 
1.57 
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3.3.10 Actigraph and ActivPAL standard wear day calculation 
The 70th percentile of the averaged Actigraph wear times dialysis days and non-
dialysis days was 932 minutes and 827 minutes respectively. For the ActivPAL 
similar wear times of 947 minutes and 814 minutes (dialysis and non-dialysis days 
respectively) were observed. A standard wear day was then defined as 80 percent 
of these values. This translated to 757 minutes (12.6 hours) for Actigraph and 756 
minutes (12.6 hours) for ActivPAL on dialysis days and 662 minutes (11.0 hours) 
and 651 minutes (10.9 hours) for Actigraph and ActivPAL respectively on non-
dialysis days. This result is a more stringent criterion than the 10 hour/day standard 
commonly adopted for data reduction. 
Table 3.19 illustrates participant compliance with accelerometer wear according to 
the number of days monitors were worn and for each wear threshold to define a 
valid day from a minimum of six hours to the widely applied standard of 10 hours. 
Clearly, the more stringent the wear time requirement the greater the percentage of 
the sample that would be excluded from final analyses.  All participants returned 
Actigraph PA data containing at least one dialysis day with a minimum of 10 hours 
wear, and all but two (97.1 %) for the ActivPAL. Comparatively fewer participants 
returned Actigraph and ActivPAL monitors with at least two non-dialysis days and 10 
hours wear (87.1% and 84.3% respectively). The number of individuals retained for 
final analyses is therefore governed by the number participants returning sufficient 
non-dialysis day wear. Application the ‘70/80 rule’ standard wear-day criterion as 
calculated for this sample would have a similar or more pronounced effect on 
reducing participant retention. 
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 Table 3.19 Num
ber of participants (n, %
) according to m
inim
um
 daily wear tim
e thresholds and wear days for Actigraph and 
Activpal accelerom
eter data. 
 M
onitor wear criteria 
>6 hours 
>7 hours 
>8 hours 
>9 hours 
>10 hours 
  
Actigraph 
Activpal 
Actigraph 
Activpal 
Actigraph 
Activpal 
Actigraph 
Activpal 
Actigraph 
Activpal 
D
ialysis days ≥1 
70 (100) 
69 (98.6) 
70 (100) 
69 (98.6) 
70 (100) 
69 (98.6) 
70 (100) 
68 (97.1) 
70 (100) 
68 (97.1) 
D
ialysis days ≥2 
68 (97.1) 
64 (91.4) 
68 (97.1) 
64 (91.4) 
67 (95.7) 
64 (91.4) 
67 (95.7) 
63 (90) 
65 (92.9) 
63 (90) 
D
ialysis days = 3 
63 (90) 
52 (74.3) 
60 (85.7) 
51 (72.9) 
57 (81.4) 
51 (72.9) 
55 (78.6) 
49 (70) 
53 (75.7) 
44 (62.9) 
  Non-dialysis days ≥2 
66 (94.3) 
66 (94.3) 
65 (92.9) 
66 (94.3) 
63 (90) 
64 (91.4) 
63 (90) 
62 (88.6) 
61 (87.1) 
59 (84.3) 
N
on-dialysis days ≥3 
63 (90) 
62 (88.6) 
62 (88.6) 
58 (82.9) 
57 (81.4) 
57 (81.4) 
56 (80.0) 
54 (77.1) 
53 (75.7) 
51 (72.9) 
N
on-dialysis days = 4 
52 (74.3) 
43 (61.4) 
51 (72.9) 
43 (61.4) 
40 (57.1) 
37 (52.9) 
38 (54.3) 
34 (48.9) 
32 (45.7) 
24 (34.3) 
138  
3.4 Discussion 
3.4.1 Overview of findings 
Clinical and demographic characteristics of the participants included for analysis in 
the present study are broadly similar to those reported for the wider Scottish HD 
population in the Scottish Renal Registry Report 2013. Median age was younger 
than the median reported for the dialysis unit (57 versus 64 years) and the Scottish 
HD population (SRRR 2013) but broadly similar to previous PA studies undertaken 
in this population (Johansen et al. 2001a; Stack and Murthy 2008; Masuda et al. 
2009; Nowicki et al. 2010; Cupisti et al. 2011; Avesani et al. 2012). Diagnosed 
diabetics made up a slightly smaller proportion of the study sample (23%) compared 
that of the wider UK HD population (28%) (UKRR 2012).   
This is the first study to propose minimum accelerometer wear time guidance for 
data reduction to enable reliable estimation of habitual PA and sedentary behaviour 
of people with stage 5 CKD receiving maintenance HD. Moreover, it is also the first 
study to recommend minimum wear times for the ActivPAL accelerometer. The 
principal findings are that using either the Actigraph or ActivPAL accelerometer, a 
minimum of one dialysis day and two non-dialysis days should provide a reliable 
objective estimate of habitual PA and sedentary behaviour in this sample of 
maintenance HD patients. A minimum of seven hours wear to define a valid day was 
necessary for the Actigraph while computed minimum wear for the ActivPAL 
indicated it was possible to include days with as little as five hours wear. Previous 
studies have observed that the PA of week days is more similar than when weekend 
PA data were added and have recommended that weekend wear should be 
included (Gretebeck and Montoye 1992; Ojiambo et al. 2011). However, no 
statistically significant difference was observed between total PA on mid-week inter-
dialytic days and the two consecutive inter-dialytic days, which in other populations 
might normally be defined as weekend days. The recommendations here are thus 
made in terms of the number of dialysis and non-dialysis days required to provide 
reliable estimates of habitual PA.   
These findings are important as seven days is a commonly prescribed monitoring 
period (Kristensen et al. 2010; Colley et al. 2011; Feinglass et al. 2011; Tudor-Locke 
et al. 2011a; Esliger et al. 2012) and a valid wear day standard of ≥10 hours has 
been widely adopted (Trost et al. 2005; Tudor-Locke et al. 2011a). Data reduction 
using these default criteria would produce extremely reliable estimates of PA and 
139  
sedentary behaviour (ICCs ranging from 0.90 to 0.94). However, the trade-off would 
be a catastrophic loss of data, with the exclusion of over two thirds to three quarters 
of participants, a scenario which is not uncommon. Colley et al. (2010) reported that 
application of a similarly stringent a wear criteria would have resulted in a similar 
level of participant exclusion (42% - 73% depending on age) from final analyses in 
the Canadian Health Measures Study. Importantly, the relatively high number of 
participants who wore their Actigraph and ActivPAL accelerometers for the 
prescribed seven day period (73% and 63% respectively) with the loss of four 
accelerometers indicates that objective measurement of habitual PA of maintenance 
HD patients is feasible.  
3.4.2 Recommended wear time for estimation of total physical activity 
The number of recommended wear days to predict total PA is in agreement with 
findings from previous PA reliability studies employing older uniaxial Actigraph 
accelerometers (Actigraph 7164 and CSA 7164). Using a lower cutpoint of >50 cpm 
Hart et al. (2011c) observed three days of wear were required for reliable estimates 
of minutes of total PA in a similar sized sample of 52 older, asymptomatic adults 
(69.3 ± 7.4 years) during a 21 day monitoring protocol. Three to four days and four 
to five days of Actigraph wear has been recommended for reliable estimation of total 
PA determined by a higher cutpoint (>500 cpm) in samples of apparently healthy 
older adults (Matthews et al. 2002) and young to middle-aged rural and urban adults 
(Cook and Lambert 2008). Notably, the cited studies used 12 and 10 hour daily wear 
thresholds respectively. The discrepancy in required wear time between this study 
and that of Cook and Lambert (2008) is likely mediated by the combination of a 
different TPA cutpoint in the cited study, and greater variability of daily PA observed 
in younger age groups compared to older adults. Moreover, PA of participants in the 
present study is effectively clamped on dialysis days with a predetermined period of 
inactivity and daily routine organised around HD therapy, thus limiting intra-day 
variability. In addition, although the cited studies employed similar if older Actigraph 
models, reliability analyses were performed on minutes of total PA only as opposed 
to normalising outcomes to wear time, which takes into account potential effects of 
variation in daily wear on accelerometer output.  
3.4.3 Recommended wear time for estimation of sedentary behaviour 
Monitor wear requirements for accurate estimation of sedentary behaviour found 
elsewhere in the literature contrast to the three days recommended here. Using a 
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higher cutpoint for sedentary behaviour (<500 cpm) Matthews et al. (2002) observed 
that seven days of CSA 7164 accelerometer wear were required to reliably estimate 
time spent sedentary in a sample of middle aged adults. Although different cutpoints 
for sedentary behaviour were employed by Cook and Lambert (2008) and Hart et al. 
(2011c) (<500 cpm and <50 cpm respectively) both studies reported five days were 
needed for their respective samples of young and older adults using similar uniaxial 
Actigraph accelerometers. Notably, a higher wear requirement of eight to nine days 
is recommended for similarly reliable estimates of sedentary time in children 
(Ojiambo et al. 2011). A possible explanation for the disparity in findings is that 
reliability analyses of the present study were performed on data normalised to wear 
time, which take into account wear time variation. Much of non-wear time is 
suggested to be sedentary behaviour (Tudor-Locke et al. 2011a), therefore the 
contrasting recommendations are likely to be mediated primarily by intra-individual 
variation in monitor wear relative to inter-individual variation. To support this 
explanation, the computed reliability coefficients for sedentary behaviour or sit/lie 
time in the current study were noticeably lower than other PA outcome variables 
(appendices XI and XII). Consequently recommended wear time for reliable 
estimation of minutes of time spent sedentary or seated/lying for this sample of HD 
patients was found to be similarly inflated at six days (minimum of eight hours 
wear/day) and seven days (minimum of seven hours wear/day) for Actigraph and 
ActivPAL accelerometers respectively (appendices XIII and XV).  
3.4.4 Recommended wear time for activity counts 
These data indicate that just two days wear (one dialysis and one non-dialysis) are 
required for reliable triaxial activity count output which provides a gross measure of 
all PA. Only one other wear-time reliability study was located that employed triaxial 
accelerometry. Using generalizability theory Coleman and Epstein (1998) found 
three to four days of accelerometer wear produced acceptable levels (G*>0.77 and 
G*>0.82 respectively) of generalisability for Tri-Trac-3D accelerometer activity count 
output in a sample of low-active young men. Gretebeck and Montoye (1992) 
simulated triaxial accelerometer output with three uniaxial Caltrac accelerometers. 
Spearman Brown prophecy calculations in the cited study indicated that two days 
wear would achieve a reliability level of 0.83 in 30 apparently healthy young men.  
Overall, required wear time for acceptable triaxial activity count reliability in the 
present study is similar to that reported for older uniaxial Actigraph accelerometers 
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employed across a range of ages. Matthews et al. (2002) recommended that two to 
three days of wear were sufficient to provide a reliability of 0.80 for activity counts 
per minute in healthy adults. Similarly, Cook and Lambert (2008) and Evenson et al. 
(2012) reported three days of monitor wear were required for reliable uniaxial activity 
count output in samples of middle- and older-aged asymptomatic adults 
respectively. In general, greater variability of PA attributed to younger adults, and 
greater movement sensitivity of triaxial accelerometry may likely account for slight 
differences in wear time recommendations (for activity counts) with previous studies. 
Again, the importance of performing analyses on data normalised to account for 
wear time variation is underlined by large-scale accelerometer reliability studies 
involving children; which report similar wear time recommendations of two or three 
days (Rich et al. 2013 and Mattocks et al. 2008 respectively).  
3.4.5 Recommended wear time for estimation of MVPA 
In terms of PA that is known to provide a health enhancing effect, three days of 
Actigraph wear (two dialysis and one non-dialysis) are required to reliably estimate 
MVPA of the present sample of HD patients. This is in agreement with the results of 
Matthews et al. (2002) who reported three to four days of monitor wear were 
recommended for healthy middle aged men and women. In contrast, Cook and 
Lambert (2008) reported that four to five days were required to achieve acceptable 
reliability for MVPA in their sample of younger rural and urban adults. Required wear 
time appears to decrease with increasing PA intensity and advancing age with 
observations that MVPA is often planned and less variable in older adults (Rowe et 
al. 2007). Despite a similar age demographic, Hart et al. (2011c) reported that just 
two days of accelerometer wear were required for their sample of older adults. The 
discrepancy between required wear for MVPA recommended in the present study 
and the cited study is perhaps reconciled when taking into consideration the 
different daily routines unique to the HD population. An imposed medical therapy 
routine and commonly reported symptoms of post-dialysis fatigue potentially inhibits 
all PA for this population three days per week. Activities potentially denied due to the 
influence HD therapy such as shopping or recreational PA, are then possibly 
planned to be undertaken on non-dialysis days.  
3.4.6 Recommended wear time for estimation of steps 
The number of steps performed per day is often used as a motivational method of 
improving general PA levels, moreover thresholds of >9000 steps, <5000 steps, and 
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3500 - 5000 steps per day are associated with normal weight, obesity and chronic 
conditions respectively (Tudor-Locke and Myers 2001; Tudor-Locke et al. 2011a). 
Recommended wear time for reliable estimates of steps taken provided by either the 
Actigraph GT3x or ActivPAL monitors has not previously been examined. Notably, 
reliability for this variable was as high as other accelerometer outcomes in this 
study. The required wear times of three days (one dialysis and two non-dialysis 
days) for Actigraph and four days for ActivPAL (two dialysis and two non-dialysis 
days) respectively to achieve a reliability of 0.80 for this participant sample are 
similar to those reported in pedometer reliability studies. Three and four days of 
pedometer wear has been recommended for middle-aged (Tudor-Locke et al. 2005) 
and older adults (Hart et al. 2011c). However, just two wear days were 
recommended by Rowe et al. (2007) who observed with the exception of a Sunday, 
no significant differences in daily step counts of older adults of more advanced age 
(74.0 ± 9.5 years). The discrepancy in required wear compared to the present study 
is likely due to inter-day variance induced by the influence of HD therapy on habitual 
PA. In contrast Kang et al. (2009) reported five consecutive or six random days were 
necessary based on a year of continuous pedometry monitoring. The disparity is 
perhaps due to a much smaller sample (n = 23), younger participants and 
seasonality contributing to greater measurement variability in the cited study.  
3.4.7 Defining a valid wear day and impact on participant retention  
Guidance regarding hours of accelerometer wear per day is crucial in determining 
which days are included in any subsequent analyses. The findings of this study 
indicate that a minimum of seven hours wear is required to define a valid day when 
using the Actigraph accelerometer to estimate time in sedentary behaviour and PA. 
In contrast minimum wear calculations for the ActivPAL indicate that accelerometry 
data based on as little as four hours wear per day may be included for the 
characterisation of most behaviour outcomes. Applying the rubrics derived via the 
Spearman-Brown formula here would thus enable over 90% of the Actigraph and 
Activpal datasets to be included for final analyses (table 3.20).  
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 Table 3.20 Num
ber (and %
) of participants included according to m
inim
um
 daily wear tim
e and m
inim
um
 num
ber of wear days. 
W
ear tim
e criteria 
>6 hours 
>7 hours  
>8 hours  
>9 hours 
>10 hours  
 R
ecom
m
ended 
Actigraph 
Activpal 
Actigraph 
Activpal 
Actigraph 
Activpal 
Actigraph 
Activpal 
Actigraph 
Activpal 
D
ialysis days ≥1 
70 (100) 
69 (98.6) 
70 (100) 
69 (98.6) 
70 (100) 
69 (98.6) 
70 (100) 
68 (97.1) 
70 (100) 
68 (97.1) 
N
on-dialysis days ≥2 
66 (94.3) 
66 (94.3) 
65 (92.9) 
66 (94.3) 
63 (90) 
64 (91.4) 
63 (90) 
62 (88.6) 
61 (87.1) 
59 (84.3) 
Participants included 
66 (94.3) 
66 (94.3) 
65 (92.9) 
66 (94.3) 
63 (90) 
64 (91.4) 
63 (90) 
61 (87.1) 
61 (87.1) 
59 (84.3) 
 
 Stringent 
Actigraph 
Activpal 
Actigraph 
Activpal 
Actigraph 
Activpal 
Actigraph 
Activpal 
Actigraph 
Activpal 
D
ialysis days = 3 
63 (90.0) 
52 (74.3) 
60 (85.7) 
51 (72.9) 
57 (81.4) 
51 (72.9) 
55 (78.6) 
49 (70.0) 
53 (75.7) 
44 (62.9) 
N
on-dialysis days = 4 
52 (74.3) 
43 (61.4) 
51 (72.9) 
43 (61.4) 
40 (57.1) 
37 (52.9) 
38 (54.3) 
34 (48.9) 
32 (45.7) 
24 (34.3) 
Participants included 
49 (70.0) 
39 (55.7) 
47 (67.1) 
38 (54.3) 
39 (55.7) 
35 (50.0) 
35 (50.0) 
32 (45.7) 
29 (41.4) 
22 (31.4) 
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Minimum wear thresholds required to define a valid day in the current study contrast 
with several studies advocating ≥10 hours for accelerometers, a standard which has 
been widely employed (Troiano et al. 2008; Colley et al. 2010; Semanik et al. 2010; 
Tudor-Locke et al. 2011d).  However, the 10 hour threshold was adopted from the 
research of Masse et al. (2005) who derived this benchmark from work on sample 
retention according to different non-wear algorithms and not reliability analyses. As 
Tudor-Locke et al. (2012) observed, the standard was further enshrined due to 
subsequent application to accelerometry data from the National Health and Nutrition 
Examination Study (NHANES) and inclusion into the accompanying SAS syntax. 
Obviously, using a widely adopted wear criterion increases the ability to compare 
findings with previous health-related PA studies. However, it is important to bear in 
mind some of the unique characteristics of the HD population which include: high 
average age; high prevalence of multi-morbidity and pathology-related symptoms 
including fatigue; muscle weakness; shortness of breath; low motivation to engage 
in PA. It may be thus impractical to expect all indivduals to consistently comply with 
≥10 hours day More recently, shorter wear thresholds of six to eight hours have 
been recommended as acceptable for preadolescents (Steele et al. 2009; Jago et 
al. 2010; Ojiambo et al. 2011), and overweight individuals (Chen et al. 2009).  
Altering minimum wear time criteria is reported to significantly affect PA outcomes in 
adults (Herrmann et al. 2013; Toftager et al. 2013). However, although the influence 
may be less profound in low-active populations, it may still have a significant impact 
on sample size retention (Miller et al. 2013). Another important facet to consider is 
that HD therapy imposes a four-hour period of inactivity. Moreover, activity counts 
(for morning HD patients) during the two hours after a dialysis session are higher 
than the equivalent time on a non-dialysis day, comparatively lower in hours three 
and four post-dialysis, and not significantly different thereafter (Majchrzak et al. 
2005). Therefore, including days with just four hours wear for ActivPAL would 
appear to be counter-intuitive when seeking to accurately characterise dialysis day 
PA outcomes in particular, especially if there are data from just one dialysis day 
available. Therefore, a higher minimum wear time threshold for both 
accelerometers, which balances the need for acceptable reliability while retaining a 
sample size that is sufficiently representative, might be more appropriate. Rich et al. 
(2013) reported that a wear threshold of seven to eight hours provided stable 
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estimates of PA in children but nonetheless recommended a higher threshold (10 
hours) that both maximised reliability and sample size retention (85%).  
Using the three-day standard derived in the present study and insisting on ≥10 
hours wear/day advocated by Troiano et al. (2008) or the ‘80/70 rule’ determined 
criterion would reduce participant data retention from 93% and 94% to 87.1% and 
84% for Actigraph and ActivPAL respectively, and may introduce a source of bias 
into final analyses. Applying a threshold of eight hours wear would still achieve a 
clinically acceptable level of reliability of 0.80 with the advantage of allowing at least 
90% datasets to be included for analyses regardless of accelerometer. Thus a daily 
wear time recommendation shorter than the widely adopted 10 hour minimum may 
provide an adequate balance between sufficient scientific rigour and sample size 
retention for this sample of stage 5 CKD HD patients. Using a similar wear criteria 
(four days wear with >8 hours/day) Chen et al. (2009) observed a comparable 
retention rate (93%) among low active participants recruited for a weight loss trial.  
3.4.8 Study limitations 
A limitation of this study was the moderate sample size based on self-selected 
volunteers drawn from a single Scottish renal dialysis unit. The average age of this 
participant sample was lower than the Scottish and UK HD populations (UKRR 
2012; SRRR 2013). Ideally there should have been an even number of males and 
females to generalise findings adequately, however the sample recruited is close to 
the real world gender split of HD patients (UKRR 2012). Additionally, applying the 
target number of days derived here to all studies of PA involving HD patients will 
have inherent limitations. Intra-class correlation coefficients are known to be sample 
specific due to the magnitude of inter and intra-individual PA variability of different 
populations. Therefore caution should be exercised when generalising these results 
to the wider HD population. There are some additional limitations attached to PA 
data derived from accelerometry. Swimming activities are not captured and 
detection of non-ambulatory activities such as cycling is limited (Chen and Bassett 
2005). None of the participants in this sample reported swimming activities during 
the study period, however three participants did report cycling as part of their weekly 
PA. There are limitations attached to the reliability studies performed on the 
ActivPAL data. Required wear for outcomes on non-dialysis days in particular 
increased with more stringent wear time thresholds as the sample size declined and 
outcome variability increased. Minimum wear recommendations for ActivPAL 
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outcomes on non-dialysis days are based on the assumption that had the sample 
size been larger the required wear would have been at least the same as that 
observed for the four and five hour thresholds.  
3.4.9 Clinical and research implications 
Accelerometer wear protocols for health-related PA studies involving HD patients 
have lacked uniformity and rationale, with data reduction procedures rarely stated. 
These data indicate that with the application of the minimum wear time 
recommendations reported in the current study, accelerometry data for at least 90% 
of participants may be retained, with a clinically acceptable level of reliability. 
Importantly, these findings demonstrate that missing or incomplete PA data due to 
variability in activity monitor wear does not necessarily mean compromised final 
analyses due to excessive data exclusion. Using these guidelines to assist with 
imputation of missing data, with either the mean observed values or one of the 
imputation methods suggested by Catellier et al. (2005) warrants further exploration.  
Notably, these recommendations may have implications with regard to future study 
design such as guiding length of monitoring period to reduce participant burden. 
However, purposive sampling of three specific days may potentially introduce a 
source of bias and is suggested as an area for further research. Monitor wear 
guidelines presented here are recommended with the caveat that they are minimum 
requirements only in order to achieve a clinically acceptable level of reliability of 
0.80. A criticism often levelled at self-report estimates of PA is that these 
instruments lack precision and are of limited use at an individual level (Loney et al. 
2011). Accelerometry may conceivably be used in the future as an adjunct to 
existing routinely assessed health indices to further stratify risk and optimise health 
interventions for this population. It is therefore reassuring that a week of monitor 
wear produced reliability values for Actigraph and ActivPAL outcome variables (0.92 
- 0.96 and 0.90 - 0.94 respectively when normalised to wear time) close to the 
reliability level of 0.95 suggested as sufficient for individual use by Nunally (1978).  
A wide range of published cutpoints exist to categorise Actigraph output into 
sedentary behaviour or various intensities of PA, each providing substantially 
different estimates (Strath et al. 2003). Currently there is no consensus guidance 
regarding the optimal thresholds to use. Consequently, researchers face limitations 
when attempting meaningful and reliable synthesis of accelerometer-based PA 
studies. However, while cutpoints for PA and sedentary behaviour may vary, it is 
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clear that, when accelerometer output variables are normalised to wear time, 
reliability values and wear time recommendations presented in the present study are 
consistent with those found in the wider literature (Mattocks et al. 2008; Chen et al. 
2009; Hinkley et al. 2012; Rich et al. 2013). Lastly, seasonality, which is reported to 
affect accelerometer output reliability in postal workers (Washburn et al. 1989) and 
children (Corder et al. 2008) was not investigated in this sample and is suggested 
as an area of further research in the stage 5 CKD HD population. 
3.5 Conclusion 
Accelerometry is increasingly being adopted to monitor PA behaviour and examine 
mechanisms of PA-mediated health outcomes in the HD population. Guidelines 
regarding accelerometer data capture and reduction are therefore important to 
ensure that derived PA outcome variables are reliable. Recommended 
accelerometer wear times vary according to different PA outcomes. However, 
regardless of whether Actigraph or ActivPAL accelerometers are employed, data 
from one dialysis day and two non-dialysis days should be sufficient to yield reliable 
estimates of total PA and sedentary behaviour in comparable stage 5 CKD HD 
patients. Although inclusion of accelerometry data with as few as four hours of 
monitor wear does not appear to adversely impact reliability of some PA outcomes, 
a minimum of eight hours wear is deemed more appropriate. These 
recommendations reconcile the tension between sufficient measurement rigour and 
retention of a meaningful sample size for final analyses. It is emphasised that stated 
wear time recommendations are a minimum requirement only, to achieve a clinically 
acceptable level of reliability for PA outcomes, and that reliability sufficient for use at 
an individual level will more likely be realised from a seven day wear protocol.  
What is known about this topic: 
x Participant mounted accelerometers are increasingly being employed for 
physical activity surveillance in health-based studies.  
x Accelerometer wear time guidelines are available for children and 
asymptomatic adults. 
What this study adds: 
x Clear recommendations pertaining to methodological considerations 
regarding the use of accelerometers employed for estimating physical 
activity and sedentary behaviour of people receiving HD therapy for stage 5 
CKD. 
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Chapter 4: Concordance of physical activity methods  
4.1 Introduction 
Questionnaires have commonly been employed to characterise PA of people 
receiving HD with more than two thirds of published studies using a range of self-
report methods. Notably, large-scale epidemiological studies have demonstrated 
that a single question regarding exercise frequency is predictive of mortality in the 
haemodialysis (HD) population (O’Hare et al. 2003; Tentori et al. 2010). However, 
objective methods of PA assessment have enabled deeper insights into patterns of 
PA (Majchrzak et al. 2005), and have contributed the majority of what is known 
regarding relationships between PA levels and traditional CVD risk factors in the HD 
population. For example, indices of PA estimated by pedometers and 
accelerometers are inversely associated with BMI, cholesterol, triglycerides, 
inflammation and diabetes (Majchrzak et al. 2005; Zamojska et al. 2006; Masuda et 
al. 2009; Nowicki et al. 2010; Mafra et al. 2011; Avesani et al. 2012).  In addition, 
findings from HD health studies show accelerometer derived PA outcomes are 
associated with markers of health status such as nutrition (Johansen et al. 2000; 
Zamojska et al. 2006; Cupisti et al. 2011) and bone mineral density (Ota et al. 
1997). Intuitively, PA underpins aspects of physical function such as gait speed of 
HD patients (Johansen et al. 2001a; Masuda et al. 2009), which is also predictive of 
mortality risk (Afilalo et al. 2010).   
While research into PA mediated health benefits for people with stage 5 CKD has 
become more sophisticated there is no uniformity regarding assessment methods 
employed. Moreover, despite the number of studies undertaken in uraemia, which 
include PA outcomes, there is a paucity of studies examining concordance of 
diverse assessment methods employed, collectively limiting direct comparisons and 
synthesis of study findings. The only study comparing PA assessment methods 
reported a moderate association (r = 0.59, p < 0.001) between total daily energy 
expenditure (EE) estimated from the Stanford Seven-Day Recall (7DR) 
questionnaire and accelerometer activity counts (Johansen et al. 2001b). However, 
level of agreement between meaningful outcomes such as volume of PA associated 
with a health enhancing effect was not undertaken to establish whether objective 
and subjective estiamtes could be used interchangeably in this population. 
A shortcoming of health studies in the stage 5 CKD population that have employed 
PA questionnaires, has been their inability to accurately quantify participants’ 
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sedentary behaviour. Participants have instead been categorised as sedentary 
according to predefined criteria (ie; less than one exercise bout per week, or tertile 
splits). This is important as sedentary behaviour is now defined as any waking 
behaviour characterized by an energy expenditure of ≤1.5 metabolic equivalents 
(METs) while in a sitting or reclining posture (SBRN 2012). Crucially, 
accelerometers are able to capture patterns of inactivity in a way that current self-
report methods are not able to replicate (Pate et al. 2008; Celis-Morales et al. 2012; 
Clark et al. 2009).  
4.1.1 Accelerometer estimation of activity and sedentary behaviour  
Of the motion sensors currently available only the ActivPAL and Actigraph 
accelerometers have the ability to characterise sedentary behaviour. Data from PA 
studies using the latter have already demonstrated important associations between 
objectively measured sedentary behaviour and cardiometabolic risk in the general 
population (Healy et al. 2008a, Healy et al. 2008b). The Actigraph (Pensacola, 
Florida, USA) family of monitors (7164, GT1M, GT3x) convert body motion into 
activity counts and use an activity count cutpoint to categorise PA and sedentary 
behaviour. Notably these monitors have been used in large epidemiological studies 
such as NHANES (Matthews et al. 2008) and research exploring the adverse health 
effects of sedentary behaviour (Healy et al. 2008a; Healy et al. 2008b). The 
ActivPAL (PAL Technologies Ltd, Glasgow) is a more recently developed 
accelerometer which employs inclinometry to monitor time spent seated/lying 
(sedentary) or in standing activities (physical activity) and postural transitions (sit-to-
stand).  
Concordance of ActivPAL and Actigraph estimates of sedentary behaviour and total 
PA has been evaluated in samples of pre-schoolers (Martin et al. 2011), school 
children (Ridgers et al. 2012), adolescents (Matthews et al. 2013), and a wide age 
range of adults (Hart et al. 2011c; Kozey-Keadle et al. 2011; Lyden et al. 2012; 
Clemes et al. 2012). Findings vary regarding the level of agreement between these 
devices, with little uniformity of Actigraph cutpoints employed (range <50 to <1100 
cpm), due in part to differing definitions of sedentary behaviour, some of which 
include silent standing (Martin et al. 2011). Moreover, previous studies have 
predominantly been conducted in apparently healthy individuals. As yet no studies 
involving people with long-term conditions such as stage 5 CKD have examined 
whether similar outcomes from these monitors agree closely enough to be used 
 150 
interchangeably. In addition, an advantage of the Actigraph is that it is able to 
categorise activity counts into levels of PA intensity. Activity count output from the 
ActivPAL is not currently utilised but if outcome agreement were acceptable, 
established Actigraph based cutpoints for categorising PA intensity may theoretically 
be employed for this monitor. 
4.1.2 Summary 
Physical activity is implicated in numerous health outcomes of people receiving HD 
for stage 5 CKD. Clearly, accurate assessment of PA is indicated in the HD 
population to examine PA mediated mechanisms of health and to identify those at 
risk of poor outcomes. Currently there is no standardised approach to characterising 
habitual PA of the HD population. Moreover, accumulating evidence regarding the 
adverse health effects of sedentary behaviour indicates that objective monitoring of 
this outcome should be undertaken to complement PA health research and 
interventions. Therefore there is a need to examine the level of agreement between 
of accelerometers capable of estimating both sedentary behaviour and PA 
outcomes in the HD population to assist with standardisation of assessment 
methods. In addition, there is a large amount of PA data pertaining to the stage 5 
CKD HD population that has already been collected using self-report. It would be 
advantageous to determine whether subjective estimates of PA agree closely 
enough with accelerometry to enable pooling of results. 
The objectives of this study were to: 
x To examine the concordance of subjective (Stanford 7 Day Recall 
questionnaire) and objective (Actigraph GT3X) methods of estimating 
physical activity of people with stage 5 CKD.  
x To examine the concordance of Actigraph GT3X and ActivPAL estimates of 
sedentary behaviour and similar PA outcomes of people with stage 5 CKD.  
x To examine the concordance of subjective and objective estimates of energy 
expenditure derived from the Stanford 7 Day Recall, Actigraph GT3X and 
ActivPAL. 
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4.2 Methods 
4.2.1 Study design and participant recruitment 
The present study was conformed to the ethical principles of the Declaration of 
Helsinki. Ethical approval was obtained from the West of Scotland Research Ethics 
Committee and the Monklands Hospital Research and Development Department. 
This was a concordance study involving a cohort of 73 self-selected volunteer 
participants undergoing maintenance HD therapy for stage 5 CKD recruited from 
an NHS outpatient HD unit at Monklands Hospital, Airdrie. Written informed 
consent was obtained from each participant prior to study commencement.  
4.2.2 Subjective and objective estimation of physical activity outcomes 
Physical activity data of the participants in this study was collected between 
November 2011 and August 2013. This comprised, for each patient, the concurrent 
acquisition of PA behaviour data obtained objectively via Actigraph GT3X 
(Actigraph Corp, Pensacola, Florida) and ActivPal (PAL Technologies Ltd, 
Glasgow) accelerometers and subjectively using the Stanford 7-day recall (7DR) 
questionnaire (Sallis et al. 1985). The ActivPAL and Actigraph accelerometers 
were synchronised and configured to collect data over 15 second epochs (McClain 
et al. 2008) using the proprietary software for each accelerometer installed on the 
same PC laptop. The accelerometers were worn as per general methods sections 
2.5.4 and 2.5.8 during waking hours, which was recorded via a monitor wear log 
(appendices Va and Vb).  Both acelerometers were retrieved from participants on 
day nine coinciding with a routine HD appointment and data were downloaded 
using the proprietary Actilife and ActivPAL software. The 7DR was also 
administered on this day as per general methods section 2.5.9.   
4.2.3 Data cleaning for Actigraph and ActivPAL accelerometers 
Data cleaning of Actigraph GT3X and ActivPAL was undertaken as per general 
methods sections 2.5.3 to 2.5.8. ActivPAL and Actigraph wear times were checked 
for agreement to enable accurate comparison of shared outcomes. Where a 
difference in monitor wear times was observed, the on or off time was adjusted to 
ensure the wear period for both accelerometers was synchronised. Only participants 
with seven days of accelerometer data and a minimum of eight hours wear/day were 
included for concordance analyses with the 7DR. Figure 4.1 describes the data 
cleaning and inclusion process for  7DR, Actigraph GT3x and ActivPAL PA data. 
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Figure 4.1 Flowchart of patient participation, accelerom
eter data cleaning, and data inclusion for concordance 
analyses.  
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4.2.4 Categorisation physical activity outcome variables 
Similar Actigraph and ActivPAL outcomes were categorised as per section 3.4.5 in 
chapter three. Subjective estimates of PA obtained via the 7DR (Blair et al. 1985) were 
collated according to the standardised script (Sallis et al. 1985) accompanying the 
questionnaire (appendix VI b). Self-report information regarding the dimensions of 
participants’ PA such as frequency, duration and intensity were used to derive an 
energy expenditure (EE) value for the seven-day monitoring period to be compared with 
ActivPAL and Actigraph estimates. The physiological cost of PA categorised as 
moderate to very hard intensity was assigned using the Compendium of Physical 
Activities (Ainsworth et al. 2011). Energy expenditure was subsequently calculated 
using the duration of the activity as per equation 4.1 (Ainsworth et al. 2000). 
Equation 4.1 Seven Day Recall EE for moderate to very hard PA 
Physiological cost of activity (METs) x activity duration (minutes) = EE (MET minutes) 
4.2.5 Energy expenditure output comparisons 
A direct comparison between the EE estimations of each method is made challenging 
due to the idiosyncratic way each instrument derives its EE value. The Actilife software 
estimates EE for the Actigraph from moderate to vigorous physical activity (MVPA) 
using the Freedson et al. (1998) equation (equation 4.2) in kilocalories (kcals). The 7DR 
also derives EE from MVPA and although the most straightforward calculation is for 
MET minutes (equation 4.1) an outcome value in kcals may also be calculated 
(equation 4.3). 
Equation 4.2 Actilife EE calculation for moderate to vigorous PA 
If CPM > 1951 then: 
       kcals/min = Scale × (0.00094 × CPM + (0.1346 × BM - 7.37418)) 
where: 
          CPM = Counts per minute 
          BM = Body mass in kg 
(Freedson et al. 1998) 
Equation 4.3 Calculation of kcals from 7 Day Recall questionnaire MVPA 
kcals/min = Activity MET value x 3.5 x body weight (kg) / 200  
EE (kcals) = kcals/min x Activity duration 
(Ainsworth et al. 2000) 
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The ActivPAL provides an EE value in MET minutes calculated from total wear time 
which includes sedentary as well as active periods. The 7DR also provides an EE 
estimate in MET minutes but only for bouts of MVPA which meet a minimum threshold 
of 10 minutes. In order to compare 7DR and ActivPAL EE outcome values, EE from 
MVPA (equation 4.1) was added to EE derived from estimated time in light PA 
(equation 4.4) using the 1.5 MET threshold (Pate et al. 1996; Leenders et al. 2000). In 
order to account for time spent sedentary during HD therapy, four hours of sedentary 
EE (one sedentary minute = 1 MET min) (Leenders et al. 2000) were substituted in for 
time otherwise defined as light PA on the three dialysis days. 
Equation 4.4 Seven Day Recall waking hour EE (MET minutes) 
Dialysis Day Total MET mins = (MVPA METmins) + 1.5 x (Light PA mins – 240) + 240                    
Non-Dialysis Day Total MET mins = (MVPA METmins) + 1.5 x Light PA mins                     
In order to achieve a direct comparison between ActivPAL and Actigraph estimates of 
EE for the same period of wear an EE value including light PA and sedentary time had 
to be calculated for the latter. An Actilife software option allows the combined use of the 
Freedson et al. (1998) equation and the Williams Work Energy equation (Williams 
1998) to estimate EE from all PA recorded by the Actigraph (equation 4.5).  
Equation 4.5 Actigraph total PA EE 
If CPM > 1951 then: 
                                kcals/min = Scale × (0.00094 × CPM + (0.1346 × BM - 7.37418)) 
If CPM < 1951 then: 
                                kcals/min = CPM × 0.0000191 × BM 
where:  
          CPM = Counts per minute 
          BM = Body mass in kg 
(Williams 1998) 
To compare ActivPAL and Actigraph EE estimates in the same units the Ainsworth et 
al. (2000) equation for converting METs into kcals/min (equation 4.3) was adapted to 
convert Actigraph kcals/min into METs (equation 4.6). The MET value was then 
multiplied by the number of Actigraph categorised light to vigorous PA minutes. This 
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value was added to the resting metabolic equivalents for each minute of Actigraph 
defined sedentary time (one sedentary minute = 1 MET minute) to derive total EE in 
MET minutes for Actigraph monitor wear time.  
Equation 4.6 Actigraph physical activity kcal conversion to MET minutes 
((Actigraph PA kcals / total PA minutes) x 200) / body mass) / 3.5 = METs/minute  
4.2.6 Data Analysis 
The following Actigraph derived outcome variables are reported as daily averages for 
the seven day study period: sedentary time, total PA, moderate to vigorous PA (MVPA), 
step counts, uniaxial activity counts and energy expenditure. Seven day averages of the 
outcomes for the ActivPAL are: sit/lie time, stand time, step counts, uniaxial activity 
counts and energy expenditure. All PA indices obtained via accelerometry were also 
normalised to wear time to adjust for intra and inter-individual variation in monitor wear 
(Hinkley et al. 2012). Normality testing of PA outcome variables was undertaken using a 
Shapiro-Wilk as the sample was less than 50 participants. Outcomes were reported as 
mean values and standard deviation (SD) for parametric variables or median values 
and interquartile range(IQR) for non-normally distributed data.  
Table 4.1 Similar outcome variables for objective and subjective PA assessment 
methods. 
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Agreement of similar outcome variables from each PA instrument illustrated in table 4.1 
was assessed using the following three statistical approaches: correlational analysis, 
Bland-Altman analysis, tests for significant outcome value differences. Although 
correlational analysis provides an indication of the strength of the linear relationship of 
two variables it does not reflect systematic differences and whether the instruments 
from which the outcomes were derived may be used interchangeably (Oliver et al. 
2007). Therefore, Bland-Altman analysis was undertaken to calculate the 95% limits of 
agreement (LOA) (1.96 times the standard deviation of the differences) (Bland and 
Altman 1986). Although this technique is not a statistical test, it provides an indication of 
the relative measurement bias between the assessment tools. Moreover, if the 
differences between the measures lie within LOA that are clinically important, the two 
methods may be used interchangeably (Bland and Altman 1986). Bland-Altman plots 
were also examined for proportional bias between the two methods by regressing the 
outcome value differences with the averages. A relationship indicating the existence of 
proportional bias indicates that the methods do not agree equally through the range of 
measurements (i.e. the limits of agreement will depend on the actual measurement). 
Bland and Altman (1986) also suggest that when a relationship between the differences 
and averages of the two measures is found in the form of a significant regression line 
slope, that the regression-based 95% limits of agreement should be provided. Finally, a 
paired t-test or Wilcoxon signed-rank test (non-parametric equivalent) was employed 
(depending on outcome variable distribution) to determine whether there was a 
significant difference in shared outcome values.  
4.3 Results 
4.3.1 Physical activity assessment compliance 
Participants with seven consecutive days of data for each PA assessment method were 
included for analyses. Of the 70 participants who took part and wore the 
accelerometers, 7DR derived subjective estimates of PA were obtained for 69 
individuals. One person was unable to recall PA for more than two days of the study 
period. Accelerometer wear compliance over the seven day study period was greater 
for Actigraph (n = 51, 73%) compared to ActivPAL (n = 44, 63%). The number of 
participants (with seven days of PA data for both accelerometers) retained for 
concordance analyses of ActivPAL and Actigraph outcomes (was reduced to just over 
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half the recruited sample (n = 37) due to instances of participants wearing one or other 
of the monitors for fewer than seven days (figure 4.1). Figure 4.1 shows the sample 
differed slightly for analyses of shared outcomes between the Actigraph and 7DR (n = 
39) and ActivPAL and 7DR (n = 35). 
4.3.2 Participant descriptives 
The reader is referred to table 3.2 in chapter 3 for a full descriptive presentation of 
demographic and clinical characteristics of the 70 participants who took part in this 
study. Overall, clinical characteristics of the participants included for analyses were 
similar to the initially recruited (larger) sample (table 4.2). Average age was slightly 
higher but range remained the same (25 to 87 years). In addition there was a lower 
percentage of female participants, and HD vintage was older.  
Table 4.2 Demographic and clinical characteristics of the total study sample and 
by PA assessment method concordance subgroup. 
 Total Sample 7 DR / Actigraph ActivPAL / 
Actigraph 
7DR / ActivPAL 
n = (M / F %) 70 (66/34) 39 (72/28) 37 (78/22) 35 (80/20) 
Diabetes  16 (23%) 10 (26%) 8 (22%) 7 (20%) 
Age (years)  55.9 ± 15.7 58.4 ± 16.1 57.7 ± 16.0 59.9 ± 16.2 
BMI (kg/m2) 27.7 (24.3 - 31.7) 29.2 (24.9 - 31.8) 28.3 (± 4.5) 28.3 ± 4.5 
Albumin (g/L)  39.0 (36.0 - 42.0) 39.0 (36.0 - 41.0) 39.0 (36.0 - 41.0) 39.0 (36.0 - 41.0) 
Hb (g/dL)  11.3 ± 1.0 11.5 ± 0.8 11.4 ± 0.9 11.5 ± 0.8 
HD adequacy (%)  71 (66 - 75) 71 (66 - 75) 72 (67 - 74) 71.0 (66.0 - 74.0) 
HD vintage (mths)  15.8 (6.8 - 32.0) 19.3 (9.2 - 37.3) 19.3 (9.1 - 42.0) 17.5 (9.2 - 37.3) 
 
A Shapiro-Wilks test indicated all 7DR outcome variables except calculated light PA 
were non-normally distributed (appendix XVIII). Accelerometer outcome variables were 
non-normally distributed except for ActivPAL sit/lie minutes and Actigraph sedentary 
minutes. Descriptive statistics for sedentary behaviour and PA outcomes obtained from 
each PA assessment method are presented in table 4.3. 
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Table 4.3 Accelerometer and 7 DR derived (daily average) estimates of PA and 
sedentary behaviour outcomes for people with stage 5 CKD [normally distributed 
data are reported as mean ± SD and non-normally distributed data as median 
(IQR)].   
Outcome ActivPAL Actigraph Seven Day recall 
Sedentary (min) 592.9 ± 108.4 610.1 ± 118.2   
Sedentary (%) 78.1 (71.7 - 84.5)  78.6 (73.4 - 86.9)   
Light PA (min) 
  
115.9 ± 57.8 †† 863.9 ± 96.4 
  108.1 (78.5 - 139.4)  822.9 (786.4 - 887.9) † 
Moderate PA (min) 8.1 (1.9 - 20.6)  22.1 (5.4 - 63.2) 
Vigorous PA (min) 0.04 (0.0 - 0.1) 0 
MVPA (min) 8.1 (2.0 - 20.9)  22.1 (6.4 - 63.2) 
Total PA (min) 171.8 (109.5 - 235.9)  159.1 (108.2 - 224.9)   
Total PA (%) 21.9 (15.5 - 28.4)  21.4 (13.1 - 26.6)   
Steps / day 3103  (1703 - 4643) 2931 (1295 - 4407)   
Steps / minute 4.1 (2.3 - 6.4)  3.9 (1.8 - 5.7)   
Counts/day 632636 (288660 - 1043874) 100162 (41002 - 142092)    
Counts/min 803 (433 - 1301) 128 (51 - 180)   
EE (kcals)   12.0 (4.0 - 78.3) 108.7 (36.8 - 376.6) 
EE (MET mins) 1144.1 ± 150.6 
  
1331.2 ± 177.0†¥ 
  1145.0 (1030.2 - 1290.7) § 1333.9 (1270.7 - 1455.0) ¥ 
EE (MET mins) 1093.8 ± 190.3 780.6 ± 131.3   
§  Variable normally distributed. Median (IQR) reported for comparison purposes. 
† Variable not normally distributed. Mean (±SD) reported for comparison purposes. 
¥ Adjusted ‘total day’ energy expenditure 
Table 4.4 summarises the results of statistical testing for differences between similar 
outcomes from each PA assessment method. A paired t-test revealed Actigraph and 
ActivPAL estimated sedentary minutes were significantly different, while a Wilcoxon 
signed-rank test found no significant difference as a percentage of monitor wear time. 
No significant differences were observed between Actigraph and ActivPAL estimates of 
time in total PA (both minutes/day and as a percentage of wear time) using the 
Wilcoxon signed-rank test. A paired t-test revealed a significant difference between 
ActivPAL and Actigraph estimated EE. Non-parametric tests of differences for the 
remaining non-normally distributed accelerometer outcomes showed step count 
estimates (per day and per minute of monitor wear time), uniaxial activity counts output 
(per day and per minute) and EE were significantly different. A significant difference 
was observed between all shared PA intensity categories estimated subjectively by the 
7DR and objectively by the Actigraph, as well as the collapsed category of MVPA. 
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Subjective and objective estimates of EE derived via the ActivPAL and 7DR 
questionnaire respectively also exhibited a significant difference. In general effect sizes 
for all observed differences between PA assessment methods were large except for 
ActivPAL and Actigraph estimated minutes of sedentary time, which was small. 
Table 4.4 Results of statistical testing for differences between similar outcome 
variables of different physical activity assessment methods. 
Activity variable ActivPAL Actigraph Seven Day Recall 
Sedentary (min)  (36) t = -2.277  p = 0.029, d = 0.38 
  Sedentary (%)       Z = -1.098  p = 0.056  
Light PA   (38) t = 44.14  p < 0.001, d = 14.14 
Moderate PA   Z = -5.196   p < 0.001, r = 0.83 
Vigorous PA   Z = -4.142   p < 0.001, r = 0.66 
MVPA   Z = -4.605   p < 0.001, r = 0.74 
Total PA (min) Z = -1.924  p = 0.054 
  Total PA (%) Z = -1.908  p = 0.056 
Steps/day Z = -4.594   p < 0.001, r = 0.76   
Steps/min Z = -4.376   p < 0.001, r = 0.72   
Activity counts/day Z = -5.303   p < 0.001, r = 0.87   
Activity counts/min Z = -5.303   p < 0.001, r = 0.87   
  (36) t = 25.096, p < 0.001, d = 4.1   
Energy Expenditure   Z = -4.865, p < 0.001, r = 0.78 
 (35) t = 8.7, p < 0.001, d = 1.47 
4.3.3 Concordance of Actigraph and ActivPAL outcome variables 
Figures 4.2 and 4.3 show a strong relationship between ActivPAL and Actigraph 
estimates of minutes spent sedentary (Pearson’s r = 0.92, p < 0.001) and as a 
percentage of wear time (Spearman’s rho = 0.81, p < 0.001). The relationship remained 
the same for sedentary minutes on dialysis days (r = 0.92, p < 0.001) and non-dialysis 
days (Pearson’s r = 0.93, p < 0.001) when the data were plotted according to the 
different conditions (appendices XIX a and XIX c). The correlation for sedentary 
behaviour percentage as a percentage of wear time was slightly weaker on dialysis 
days compared to non-dialysis days (Spearman’s rho = 0.77, p < 0.001 versus 0.81, p < 
0.001 respectively) (appendices XIX g and XIX i). 
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Figure 4.2 Actigraph versus ActivPAL 
estimated sedentary time (mins). 
Figure 4.3 Actigraph versus ActivPAL 
estimated sedentary time (% of wear). 
    
Bland-Altman analysis shows Actigraph estimated more minutes of sedentary time 
(figure 4.4) with a mean bias of +17.2 minutes (LOA: +107.1 mins to -72.8 mins). Mean 
bias on dialysis days was lower at +6.4 minutes (LOA: +98.1, -85.4), and higher on non-
dialysis days (+25.3 minutes, LOA: +123.6, -73.0) (Appendices XIX b and XIX d). 
Bland-Altman analysis of estimated sedentary behaviour as a percentage of wear time, 
showed a mean daily bias of + 2.0% (LOA: +13.3, -9.4%) for Actigraph over ActivPAL 
(figure 4.5). On dialysis days the mean bias was lower at 0.4% (LOA: +11.4, -10.4) and 
higher on non-dialysis days at 3.7 % (LOA: +17.2, -9.8) (appendices XIX f and XIX h). 
Figure 4.4 Bland-Altman plot Actigraph 
and ActivPAL sedentary time (mins/day). 
Figure 4.5 Bland-Altman plot Actigraph 
and ActivPAL sedentary time (% wear). 
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Figures 4.6 and 4.7 show ActivPAL estimated standing time correlated strongly with 
Actigraph estimated minutes of total PA (Spearman’s rho = 0.84, p < 0.001) and as a 
percentage of wear time (Spearman’s rho = 0.81, p < 0.001) respectively. Associations 
for minutes of standing and total PA were stronger on non-dialysis days compared to 
dialysis days (Pearson’s r = 0.88 and Spearman’s rho = 0.83, p < 0.001 respectively) 
(appendices XIX i and XIX k). As a percentage of wear time the correlations were also 
slightly stronger on non-dialysis days compared to dialysis days (Spearman’s rho = 0.83 
and 0.78, p < 0.001 respectively) (appendices XIX m and XIX o). 
Figure 4.6 Actigraph versus ActivPAL 
estimated total PA (mins/day). 
Figure 4.7 Actigraph versus ActivPAL 
estimated total PA (% wear). 
    
Figure 4.8 Bland-Altman plot Actigraph 
and ActivPAL total PA (mins/day). 
Figure 4.9 Bland-Altman plot Actigraph 
and ActivPAL total PA (% day). 
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Figure 4.8 shows the Actigraph estimated fewer minutes in total PA with a mean daily 
bias of -16.3 minutes (+73.4, -106.4). When normalised to wear time (figure 4.9) this 
difference translated to a mean bias of -2.0% (LOA: +9.4, -13.4). The systematic bias 
was lower on dialysis days compared to non-dialysis days (appendices XIX j and XIX l) 
for both minutes of total PA (-5.5 minutes, LOA: 86.4, -97.4 versus -24.4 minutes, LOA: 
73.9, -122.8) and as a percentage of wear time (-0.6%, LOA: 10.4, – 11.6 versus -3.0%, 
LOA: 10.3, -16.4) (appendices XIX n and XIX p).  
Figure 4.10 Actigraph versus ActivPAL 
estimated steps/day. 
Figure 4.11 Bland-Altman plot Actigraph 
and ActivPAL estimated steps/day. 
  
ActivPAL and Actigraph estimated steps/day correlated strongly (Spearman’s rho = 
0.95, p < 0.001) (figure 4.10) and remained similarly strong on dialysis days 
(Spearman’s rho = 0.89, p < 0.001) and non-dialysis days (Spearman’s rho = 0.94, p < 
0.001) (appendices XX a and XX c). Bland-Altman analysis shows fewer steps/day 
estimated by Actigraph compared to ActivPAL (figure 4.11) with a substantial mean bias 
of -638 steps/day (LOA: +576, -1852). Mean bias was lower on dialysis days (-422 
steps) with narrower limits of agreement (+615, -1458) and higher on non-dialysis days 
(-800 steps, LOA: +655, -2255) (appendices XX b and XX d).  
Non-parametric analysis revealed average daily uniaxial activity counts recorded by 
ActivPAL were strongly correlated with Actigraph counts (figure 4.12) (Spearman’s rho 
= 0.95, p < 0.001). Relationships between the two accelerometers for uniaxial activity 
count output remained similarly strong on dialysis (rho = 0.93, p < 0.001) and non-
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dialysis days (rho = 0.93, p < 0.001) (appendices XX e and XX g). The Bland-Altman 
plot (figure 4.13) shows ActivPAL recorded more uniaxial activity counts compared to 
the Actigraph (mean bias +701,193 counts/day, LOA: 196,4879, -562,493). The 
disparity between the accelerometers increased proportionally (Spearman’s rho = 0.99, 
p < 0.001) with greater volume of PA. Mean bias on dialysis days was lower (+593,986 
counts/day, LOA: +1,220,442, -32,471) and higher on non-dialysis days (+781,598 
counts/day, LOA: 2,152,418, -589,221) (appendices XX f and XX h). However, the 
same linear increase in activity count differences was observed for both conditions 
Figure 4.12 Actigraph versus ActivPAL 
uniaxial activity counts/day. 
Figure 4.13 Bland-Altman plot Actigraph 
and ActivPAL uniaxial activity counts/day. 
   
When ActivPAL and Actigraph activity counts were normalised to wear time as counts 
per minute (cpm) the correlation was similar to that observed for average daily activity 
counts (Spearman’s rho = 0.94, p < 0.001) (figure 4.14). The association between the 
two accelerometers for this outcome remained similarly strong on dialysis (rho = 0.92, p 
< 0.001) and non-dialysis days (rho = 0.92, p < 0.001) (appendices XX i and XX k). 
Bland-Altman analysis (4.15) shows that the ActivPAL registered more activity counts 
per minute compared to the Actigraph with a mean daily bias of +913 counts/min (95% 
LOA = +2,520, -694). As with activity counts per day, the difference in counts per 
minute increased in a linear fashion (Spearman’s rho = 0.99, p < 0.001) as average 
volume of PA measured increased. On dialysis days the mean bias was +676 
counts/day (LOA: +1,876, -523) while on non-dialysis days it was +1,090 counts/day 
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(LOA: 3,091, -909). The same linear increase in activity counts/min was observed on 
both dialysis and non-dialysis days (appendices XX j and XX l). 
Figure 4.14 Actigraph versus ActivPAL 
uniaxial counts/min. 
Figure 4.15 Bland-Altman plot Actigraph 
and ActivPAL uniaxial counts/min. 
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4.3.4 Concordance of the 7-day Recall questionnaire and Actigraph  
No relationship was observed (p > 0.05) between 7DR questionnaire and the 
Actigraph accelerometer for estimated light PA. Mean daily values for 7DR and 
Actigraph estimates of light PA were 863.9 ± 96.4 and 115.9 ± 57.8 minutes 
respectively resulting in a large significant difference between these two 
assessment methods (table 4.4). No further analysis was undertaken for this 
outcome. 
Figure 4.16 7DR versus Actigraph 
estimated MVPA mins/day. 
Figure 4.17 Bland-Altman plot 7DR and 
Actigraph estimated MVPA mins/day. 
    
Figure 4.16 shows a moderate correlation between 7DR and Actigraph estimated 
MVPA (Spearman’s rho = 0.55, p < 0.001). Associations of similar strength were 
observed between the two measures on dialysis days (rho = 0.53, p < 0.001) and 
non-dialysis days (rho = 0.49, p < 0.001) (appendices XXI a and XXI c). Bland-
Altman analysis (figure 4.17) revealed that self-reported MVPA was on average 26.0 
minutes (95% LOA: +91.6, -39.6) greater per day compared to objective 
accelerometer estimates. In addition a regression line indicates a strong positive 
relationship between daily MVPA averages and differences (Spearman’s rho = 0.77, 
p < 0.001). As the amount of MVPA estimated increases the observed difference 
between MVPA values derived by each instrument becomes greater. On dialysis 
days observed mean bias was lower at +11.2 minutes/day (LOA: +68.1, - 45.7) and 
higher on non-dialysis days +37.0 minutes/day (LOA: +119.5, -45.4). For both 
dialysis and non-dialysis days a similar positive regression line was observed 
reiterating a similar divergence of outcome values with increasing MVPA volume for 
both conditions (appendices XXI b and XXI d).  
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4.3.5 Concordance of energy expenditure estimates by each instrument 
Initial analysis of the relationship between EE estimated by ActivPAL (waking hour 
MET minutes) and Actigraph (MVPA derived kcals) revealed a moderate association 
(Spearman’s rho = 0.52, p < 0.001). Actigraph estimated kcals were converted to 
MET minutes and MET minutes for accelerometer sedentary time was added to 
derive a comparable total daily EE value from monitor wear time. A strong 
correlation (figure 4.18) was observed between values from the two accelerometers 
(Pearson’s r = 0.95, p < 0.001). The association remained similarly strong on 
dialysis days (Spearman’s rho = 0.97, p <0.001) and non-dialysis days (Pearson’s r 
= 0.93, p < 0.001) (appendices XXI e and XXI g). 
Figure 4.18 ActivPAL versus 
Actigraph estimated METmins/day. 
Figure 4.19 Bland-Altman plot Actigraph 
and ActivPAL estimated METmins/day. 
   
Actigraph estimated EE was lower than Actigraph as determined by Bland-Altman 
analysis (figure 4.19) with a mean bias of -313.1 MET minutes/day (LOA: -164.4, -
462.1). The mean bias and LOA were similar on dialysis days and non-dialysis days 
(-313 MET mins/day, LOA: -166.8, -466.5 and -310.7 MET mins/day, LOA = 143.4, -
478.0 respectively. A strong correlation between the averages and differences of the 
measures was also found (Pearson’s r = 0.79, p < 0.001) indicating greater 
difference in estimated EE between the accelerometers with higher EE values 
(appendices XXI f and XXI h). 
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Figure 4.20 7DR versus ActivPAL 
estimated METmins/day. 
Figure 4.21 Bland-Altman plot 7DR and 
ActivPAL estimated METmins/day. 
  
ActivPAL and 7DR total daily EE outcomes (figure 4.20) correlated moderately 
(Pearson’s r = 0.71, p < 0.001), and was similarly strong on dialysis days 
(Spearman’s rho = 0.72, p < 0.001) and non-dialysis days (Pearson’s r = 0.71, p < 
0.001) (appendices XXI i and XXI k and 4.7.3). Bland-Altman analysis (figure 4.21) 
shows comparatively higher estimation of EE by the 7DR with a mean daily bias of 
+187.1 MET mins/day (LOA: +437.0, -62.7 MET mins/day). Observed bias was 
lower on dialysis days (95.1 MET mins/day, LOA: 363.3 to -173.1 MET mins/day) 
and higher on non-dialysis days (256.2 MET mins/day, LOA: 549.7 to -37.3 MET 
mins/day) (appendices XXI j and XXIl).  
Figure 4.22 7DR versus Actigraph 
estimated kcals/day. 
Figure 4.23 Bland-Altman plot 7DR 
and Actigraph estimated kcals/day. 
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A moderate correlation was observed between 7DR estimated MET minutes and 
Actigraph estimated kcals from MVPA (Spearman’s rho = 0.57, p < 0.001, n = 39). 
The observed association was similar (figure 4.22) upon conversion of 7DR MET 
minutes to kcals (Spearman’s rho = 0.59, p < 0.001). Non-parametric correlations 
remained the same for estimated EE on dialysis days (rho = 0.59, p < 0.001) and 
non-dialysis days (rho = 0.60, p < 0.001) (appendices XXI m and XXI o). Higher 
estimates of EE were derived via the 7DR compared to the Actigraph (figure 4.23) 
with a mean bias of 149.9 kcals/day (LOA: 514.5 to -220.8 kcals/day). Mean bias 
was lower on dialysis days (61.5 kcals/day, LOA: 363.2 to -240.2 kcals/day) and 
higher on non-dialysis days (210.9 kcals/day) with wider LOA (704.8 to -283.2 
kcals). Regression analysis also showed a moderate relationship (Spearman’s rho = 
0.67, p < 0.001) between the averages and differences of the two methods 
indicating a proportional increase in measurement disparity as MVPA related EE 
increased. On non-dialysis days the relationship was stronger (Spearman’s rho = 
0.77, p < 0.001) while on dialysis days a trend was observed (rho = 0.32, p = 0.05) 
(appendices XXI n and XXI p). 
Concordance of ActivPAL and Actigraph derived stepcounts was further explored 
using age, which is a recognised determinant of gait speed. A moderate inverse 
correlation (Pearson’s r = -0.66, p < 0.001) was observed between participant age 
and Actigraph stepcounts as a percentage of ActivPAL estimates (figure 4.24). 
Figure 4.24 Age versus Actigraph estimated stepcounts as a percentage of 
ActivPAL estimates. 
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4.4 Discussion 
4.4.1 Overview of findings 
A variety of subjective and objective methods have been used in previous health 
studies to characterise PA and sedentary behaviour of people with stage 5 CKD. 
This study is the first to evaluate the level of agreement between three different 
methods of estimating PA outcomes and sedentary behaviour. The principal findings 
of this study are that subjective and objective estimates of PA correlate modestly. 
Overall, agreement is poor with the amount of MVPA obtained via the 7DR 
significantly higher than estimates derived via the Actigraph and wide limits of 
agreement (LOA). Moderate to strong associations were found between the 7DR 
and objective estimates of EE. However, large significant differences in EE values 
and wide error limits were apparent with Bland-Altman analysis, as well as a 
proportional increase in measurement disparity with higher EE values. Despite 
strong linear associations between the Actigraph and ActivPAL estimates of 
sedentary behaviour and PA and low relative estimate bias, overall level of 
agreement was poor. Remaining PA outcomes (step counts, EE, activity counts) 
derived via the Actigraph and ActivPAL also demonstrated strong associations, but 
large significant differences and wide LOA indicated poor concordance. While 
adjustments may be made for estimate bias between accelerometer outcome 
values, these data indicate that there is considerable risk of error if ActivPAL and 
Actigraph outcomes are used interchangeably.   
4.4.2 Relationship between Actigraph and ActivPAL step count estimates  
A strong association between ActivPAL and Actigraph GT3x estimated step counts 
(Spearman’s rho = 0.95, p < 0.001) in the present study compares favourably with 
that of Feito et al. (2012). The authors reported a correlation of r = 0.85 (p < 0.001) 
between these devices during two days of free living conditions in a sample of 49 
normal and overweight adults. Despite the strong correlation in the current study, 
Actigraph recorded significantly fewer steps (mean bias -638 per day) than ActivPAL 
and 95% LOA were large (+576 to -1852 steps). A criterion measure was not 
employed in the present study to determine which monitor had the more precise 
estimate of step counts during seven days of ‘free-living’ due to feasibility issues. 
Findings from controlled studies using direct observation as a criterion may help to 
explain the large disparity in accelerometer step counts observed.  
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There is agreement that at moderate to brisk walking speeds, ActivPAL and 
Actigraph estimated stepcounts do not differ significantly from directly observed 
steps (Ryan et al. 2006; Sorti et al. 2008; Harrington 2011; Feito et al. 2012) or each 
other (Harrington et al. 2011). However, these criterion validity studies also concur 
that later model Actigraphs (GT1M, GT3x) show a propensity to underestimate 
steps taken as gait decreases below 1.0 m/s (Sorti et al. 2008; Harrington 2011; 
Feito et al. 2012). Although precision of the ActivPAL is also influenced by cadence 
slower than this threshold, an error level of 2% or less is reported (Ryan et al. 2006), 
however the Actigraph GT3X underestimates directly observed steps by up to 40% 
during slow ambulation (Sorti et al. 2008; Feito et al. 2012). It is believed that hip 
mounted acclerometers are especially susceptible inaccuracy at slower ambulation 
speeds due to reduced magnitude of vertical accelerations (Feito et al. 2011).  
Importantly, age is a recognised determinant of gait speed (Bohannon 1997), and 
the HD population is characterised by both advanced average age and CKD 
mediated acceleration of ageing processes (Johansen et al. 2003b). Notably, the 
inverse correlation (Pearson’s r = -0.66, p < 0.001) between age and Actigraph 
stepcounts as a percentage of ActivPAL estimates observed in this study has not 
been previously documented. In addition when compared to non-uraemic peers, HD 
patients exhibit slower self-selected and maximum gait speeds corresponding to 
66% and 64% of normative values respectively (Painter et al. 2000). Slower 
ambulation characteristic of indoor mobility may have also contributed. ActivPAL 
step count accuracy is slightly lower for indoor compared to outdoor mobility (96.1% 
and 99.6% respectively) of healthy adults (Busse et al. 2009). Indoor PA or activities 
of daily living tend to be of lower intensity (Ainsworth et al. 2000) and more 
intermittent (Orendurf et al. 2008). Compared to treadmill protocols, cadence 
indoors is unlikely to be continuous, consisting instead of smaller steps to avoid 
obstacles (ie: sidesteps) or to maintain balance thus resulting in slower gait speed 
and shorter stride lengths. These factors may result in lower vertical translocation of 
the trunk (Actigraph) or limb (thigh) deflection (ActivPAL) and “steps” not conforming 
to accelerometer algorithms possibly may not identified/counted. Haemodialysis 
patients spend a considerable proportion of their week in a hospital. Taken together 
it is suggested that lower precision of the Actigraph at slower gait speeds would 
have a more pronounced effect on accuracy of steps taken estimated by this device 
in the HD population, and thus largely explains the observed disparity in the present 
study.  
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4.4.3 Actigraph and ActivPAL Sedentary and Active time estimates 
ActivPAL and Actigraph estimates of sedentary behaviour correlate strongly both in 
minutes (Pearson’s r = 0.92, p < 0.001) and as a percentage of wear time 
(Spearman’s rho = 0.82, p < 0.001). This is in agreement with previous 
Actigraph/ActivPAL concordance studies reporting moderate to strong correlations 
for sedentary behaviour (range r = 0.68 to 0.81) during free-living situations in pre-
school age children (Martin et al. 2011) and adults (Clemes et al. 2012; Matthews et 
al. 2013). Actigraph estimated on average 17.2 more minutes of sedentary time per 
day compared to ActivPAL in the present study, which is similar to the results of  
Matthews et al. (2013) (bias +13.2 to +19.2 mins/day) in a larger study of 216 
adults. Other studies have consistently found Actigraph estimates significantly 
higher amounts of sedentary time compared to ActivPAL during free-living 
conditions (Hart et al. 2011a; Hart et al. 2011b; Clemes et al. 2012) than observed 
in this study (mean systematic bias range: +44 to +132 mins/day). A lower, non-
significant bias of +5.2 mins/day was reported by Ridgers et al. (2012) using the 
Actigraph GT3X in a sample of school age children. However, the monitoring period 
in the latter study was comparatively short (390 minutes) as it was limited to the 
length of a school day, which may have reduced bias magnitude. In contrast to the 
present study, Martin et al. (2011) found Actigraph estimated sedentary behaviour 
(expressed as a percentage of wear time) for pre-school children was lower than 
ActivPAL (-4.3% and -2.1% corrected/uncorrected estimates). Differing findings are 
likely due to the authors employing a higher cutpoint (<1100 cpm) and a different 
interpretation of sedentary behaviour compared to the current consensus definition.  
Bland-Altman analysis (figure 4.5 and 4.6) revealed relatively wide LOA of minutes 
and percentage of time spent sedentary around the systematic bias (90 mins and 
11.4% respectively). However, this result is comparatively lower than LOA observed 
in previous studies employing the same cutpoint (<100 cpm), which range from 143 
to 570 mins/day (Hart et al. 2011a; Hart et al. 2011b; Ridgers et al. 2012; Matthews 
et al. 2013) and 18.6% to 19.4% per day when normalised to monitor wear time 
(Martin et al. 2011). A lower sedentary behaviour cutpoint of <50 cpm suggested by 
Crouter et al. (2006) is reported to offer the most favourable specificity and 
sensitivity for detecting sitting/lying time of adults during free-living conditions 
(Clemes et al. 2012). However, while a lower cutpoint ameliorates mean bias 
between these devices, observed LOA remain wide at over two hours either side of 
the mean bias (Hart et al. 2011b; Clemes et al. 2012).  
 172 
4.4.4 Actigraph and ActivPAL Total PA agreement 
The strong correlation observed between ActivPAL and Actigraph estimates of total 
PA (Spearman rho = 0.84, p < 0.001) and no significant difference is consistent with 
the findings of Matthews et al. (2013) who reported similarly strong associations (rho 
= 0.74 and 0.79 for men and women respectively. Similarly, Matthews et al. (2013) 
also reported no significant difference between Actigraph and ActivPAL estimates in 
their larger sample of 216 adults. However, LOA in the cited study were 
considerably wider (-135 to 182 mins/day and -132 to 137.4 mins/day for men and 
women respectively) than those observed here. Conversely, Hart et al. (2011b) 
found that ActivPAL PA estimates were significantly lower (56.1 minutes/day) than 
estimates derived from an earlier Actigraph (7164) using the >100 cpm cutpoint. A 
higher cutpoint employed by Hart et al. (2011b) resulted a much lower non-
significant difference of 11.8 minutes/day. However the definition of PA employed 
differed from the present study by comparing only ActivPAL estimates of ‘walking’ 
time and Actigraph ambulatory activity defined as >259 cpm.    
4.4.5 Summary of ActivPAL and Actigraph outcome concordance 
This is the first study to evaluate concordance of ActivPAL and Actigraph 
accelerometer estimates of TPA and sedentary behaviour in a clinical population. 
Regardless of the reason for observed discrepancies between the present study 
and findings in the wider literature, the unifying feature of all studies is the wide LOA 
reported. This is of principal concern as such high levels of random error (reflecting 
biological variation) between these two accelerometers at the individual level 
indicates their concurrent use would make accurate determination of behaviour 
change and stratification of risk extremely difficult. Poor agreement is probably due 
to the distinctive methods that each monitor employs to estimate PA and sedentary 
behaviour. The Actigraph uses an activity count cutpoint to differentiate these 
behaviours while ActivPAL employs inclinometry. Importantly, the Actigraph has 
been observed to record just 11 cpm for standing and washing dishes (Kozey et al. 
2010), which is substantially below the <100 cpm threshold for sedentary behaviour. 
Consequently some routine light activities may be erroneously classified as 
sedentary behaviour by this device. Notably, studies employing direct observation, 
as a criterion measure during controlled and free living conditions, indicate that 
classification of sedentary behaviour by ActivPAL is more precise compared to 
Actigraph regardless of cutpoint applied and manipulation of monitor sensitivity (Hart 
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et al. 2011b; Kozey-Keadle et al. 2011; Lyden et al. 2012). Taken together it 
appears that regardless of cutpoint choice, size and direction of measurement bias, 
there is general agreement a large amount of biological variation exists between 
these two accelerometers and that the ActivPAL likely provides a more precise 
proxy measure of sedentary behaviour.  
4.4.6 ActivPAL and Actigraph activity count agreement 
Activity counts derived from both accelerometers for the same wear periods were 
very strongly associated (Spearman’s rho = 0.95, p < 0.001). This finding is in 
agreement with a smiliarly strong correlation between ActivPAL and Actigraph GT3x 
activity counts during controlled PA (rho = 0.96, p < 0.01) reported by Dowd et al. 
(2012). Notably, these data demonstrate that although strongly correlated, a 
significant disparity exists between the activity counts generated by each monitor. 
Moreover, ActivPAL recorded proportionately more activity counts with greater 
amounts of PA. Such a substantive difference would appear to be unusual as the 
ActivPAL is a uniaxial accelerometer. The explanation for the disparity may be due 
to the positioning of the ActivPAL on a limb segment where greater movement and 
accelerations might be expected compared with the Actigraph recordings of trunk 
translocation. The challenge of using accelerometry to provide an objective measure 
of PA is in converting activity counts into outcomes that are meaningful and 
interpretable units (Troiano 2006). As such calibration studies for accelerometers 
like the Actigraph convert counts into PA intensity, step counts or EE. Although not 
currently part of formal ActivPAL output, activity counts from this monitor could 
potentially be categorised into PA intensity similar to the Actigraph. In light of the 
poor agreement between ActivPAL and Actigraph activity counts it is expected that 
cutpoints for categorising PA intensity for the former will be quite different. Dowd et 
al. (2012) determined the MVPA threshold for ActivPAL as >2997 cpm via indirect 
calorimetry in a sample of 30 adolescent females, which is considerably higher than 
the Freedson et al. (1998) equivalent for Actigraph uniaxial activity counts (>1952 
cpm).    
4.4.7 Subjective and objective estimation of light physical activity.  
No relationship was observed between subjective and objective measures of light 
PA estimated by 7DR and Actigraph respectively. Light PA derived from the 7DR 
was significantly higher compared to Actigraph estimates. In contrast Leender et al. 
(2000) and Sirard et al. (2000) reported no significant difference between 7DR light 
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minutes and Actigraph (CSA 7164) derived values in samples of young adults 
monitored over seven days of free-living. The disparity is due to the cited study not 
obtaining an accelerometer value for time spent sedentary and defining all activity 
outside moderate to vigorous as light PA. Similarly the 7DR defines light PA as the 
time outside summated sleep and moderate to very hard PA for each day (Sallis et 
al. 1985), which thus erroneously categorises sedentary behaviour as light PA. Such 
an assumption ignores the fact that for the HD population a large proportion of 
dialysis days are spent unavoidably inactive due to the dialysis procedure itself 
(approximately 16 hours/week). Moreover, many individuals may experience 
condition related symptoms of fatigue, which is associated with further periods of 
sedentary behaviour (Gordon et al. 2011; Bonner et al. 2010).  
4.4.8 Concordance of Actigraph and 7-day Recall MVPA  
A moderate correlation (rho = 0.55, p < 0.001) was observed between 7DR and 
Actigraph GT3X estimated time in MVPA. This result sits near the middle of reported 
correlations (range r = 0.26 to 0.73) between the 7DR and older Actigraph 
(Ainsworth et al. 2000; Timperio et al. 2003; Johson-Kozlow et al. 2006) and Tri-
Trac R3D (Hayden-Wade et al. 2003) accelerometers in similar sized samples of 
asymptomatic middle-aged to older adults. Moreover, it is strikingly similar to the 
corelation (r = 0.54, p < 0.001) reported by Garfield et al. (2011) who evaluated 
concordance of the 7DR with the Sensewear Armband monitor in chronic 
obstructive pulmonary disease patients. Overall the strength of association 
observed in the present study compares favourably with the average for pooled PA 
questionnaire and objective measure concordance studies (r = 0.37) reported by 
Prince et al. (2008).  
A large statistically significant difference was found in the present study between 
7DR and Actigraph estimated MVPA with the 7DR providing on higher average daily 
estimates relative compared to the Actigraph (+26 mins/day). This result is in 
agreement with previous studies also showing similarly large differences in daily 
MVPA estimates of 16.5 to 35.3 mins/day between the 7DR and accelerometry for 
people with severe mental illness (Soundy et al. 2007) and asymptomatic adults 
(Timperio et al. 2003). In contrast no significant differences were observed in larger 
studies comparing estimates from CSA 7164 (Actigraph forerunner) monitors and 
the 7DR in larger samples of middle-aged adults (Leenders et al. 2000; Johnson-
Kozslow et al. 2006). The discordance in results is difficult to reconcile as all studies 
 175 
including the present one employed the same MVPA cutpoint and cognitive 
interview technique (Sarkin et al. 1997) to recall PA. Nevertheless, as observed in 
the present study, all previous concordance studies reporting LOA between 7DR 
and accelerometer derived MVPA estimates agree that they are wide enough to 
exceed recommended weekly PA associated with a health enhancing effect 
(Timperio et al. 2003; Johnson-Kozlow et al. 2006; Soundy et al. 2007). 
Theoretically the systematic error observed in the present study could be corrected 
however, random error either side of the mean bias is more than twice daily PA 
recommendations (-39.6 to 91.6 minutes) indicating MVPA values from the 7DR and 
Actigraph may not be used interchangeably at an individual level.  
Notably, the proportional relationship between the differences and averages of the 
7DR and Actigraph MVPA estimates observed in the present study (Spearman’s rho 
= 0.77, p < 0.001) was similar in strength to that reported by Hayden-Wade et al. 
(2003) (r = 0.71, p value not stated). Moreover visual inspection of the Bland-Altman 
graph of Johnson-Kozlow et al. (2006) also suggests a similar trend for 
overestimation with higher levels of PA, however their data were not tested for a 
possible relationship. Activity estimates obtained via Actigraph in the present study 
were summated from shorter 60-second epochs while the 7DR only records bouts of 
MVPA in multiples of 10 minutes. It is speculated the disparity between 7DR and 
Actigraph estimates would likely increase further if Actigraph estimated MVPA had 
been similarly been derived from valid bouts defined as ≥10 minutes. Overall, these 
findings agree with similar concordance studies that show poor agreement between 
7DR and accelerometer estimates of MVPA thus preventing their concurrent use at 
an individual level (Timperio et al. 2003; Johson-Kozlow et al. 2006; Soundy et al. 
2007).  
4.4.9 Why are 7-day Recall and Actigraph estimates of MVPA so different? 
Several factors have likely contributed to the wide disparity observed between 
Actigraph and 7DR estimates of MVPA in the present study. In the case of low-
active participants the scoring instructions of the 7DR may be implicated in higher 
estimates as epochs of MVPA meeting the minimum threshold of 10 minutes are 
rounded up to 15 minutes. Therefore participants only just achieving 10 minutes of 
MVPA would have their scores inflated by up to fifty percent but this appears to 
have affected only three particpants. Another possible explanation is that 
participants may have overestimated time spent in MVPA or misclassified PA 
 176 
intensity (ie: light as moderate). Measurement error associated with PA assessment 
is reported to increase with greater contribution of lower intensity PA to habitual 
activity (Durante and Ainsworth 1996). In contrast, hard or very hard PA is 
associated more strongly with objective measures due to being well defined and 
scheduled in nature and therefore easier to recall (Durante and Ainsworth 1996; 
Richardson et al. 2001; Timperio et al. 2003). Nonetheless, overestimation of PA 
greater than 4.5 METs has been documented during two days of room calorimetry 
monitored living (Buchowski et al. 1999). Furthermore, misclassification of PA 
intensity has been observed with heart rate monitoring in sedentary adults (Duncan 
et al. 2001). 
It is also possible Actigraph may have underestimated MVPA, as hip mounted 
accelerometers are unable to detect increased gradient while walking (Melanson 
and Freedson 1995), or accurately categorise PA intensity for activities such as 
cycling and load bearing activities (ie: resistance exercise, carrying loads) 
(Westerterp 1999; Welk 2002). In addition, it is not possible to wear the Actigraph 
GT3x while swimming. Inspection of the 7DR records revealed that none of the 
included participants reported instances of swimming or resistance exercise, and 
just three reported cycling activity, of whom only one reported it as their main 
exercise activity. It would appear the disparity in estimates is thus more likely to be a 
combination of recognised determinants of recall accuracy (ie: age, gender, weight 
status, cognitive function, social desirability) (Irwin et al. 2001; Klesges et al. 2004) 
and relative misclassifcation of activity intensity.  
The interview script for the 7DR is designed to calibrate responses by providing 
examples to anchor participant classification of PA. However participants may still 
have applied relative intensity definitions based on perceived exertion. 
Misclassification differences may have arisen due to broad application of the 
Actigraph cutpoint for MVPA, which was developed from a relatively small sample of 
50 healthy, normal weight, young men and women by Freedson et al. (1998). 
Aerobic fitness, biomechanical efficiency, and resting metabolic rate decline as 
people get older (Fitzgerald et al. 1997; Byrne et al. 2005; Kozey et al. 2010), and in 
those who are more sedentary (Duncan et al. 2001). Consequently, an activity at a 
given ‘absolute intensity’ will require a greater ‘relative’ percentage of VO2max with 
advancing age. Recent research supports the validity of the Freedson et al. (1998) 
cutpoints for ‘absolute’ measures of moderate and vigorous PA in 20 - 69 year olds, 
but not adults older than 69 (Miller et al. 2010). Furthermore, when expressed 
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relative to an individual’s maximum aerobic fitness and age, moderate and vigorous 
PA intensity cutpoints were significantly different (Miller et al. 2010). Several 
cutpoint calibration studies employing calorimetry have suggested normalising PA 
intensity thresholds to co-morbidities such as diabetic and weight status (Lopes et 
al. 2009; Aadland and Anderssen 2012). Notably, Timperio et al. (2003) reported 
higher associations between self-reported and accelerometer estimated moderate 
PA of overweight men and women when the cutpoint was lowered from 3.0 METs 
≥1952 cpm to 2.5 METs or ≥1334 cpm. Therefore, it is possible that the Freedson et 
al. (1998) cutpoints, may have underestimated MVPA in this sample of HD patients, 
a clinical population which is characterised by advanced average age and high 
prevalence of multi-morbidity.  
4.4.10 Concordance of 7-day Recall and ActivPAL energy expenditure 
Previous studies have examined concordance of 7DR and Actigraph outcomes, 
however this study is the first to evaluate agreement of energy expenditure (EE) 
estimates obtained from the 7DR, ActivPAL and Actigraph GT3x simultaneously. 
Moreover, it is also the first to compare ActivPAL estimates with a self-report 
method. While a strong correlation (Pearson’s r = 0.76, p < 0.001) was observed 
between 7DR and ActivPAL, EE values from the 7DR were significantly higher than 
ActivPAL waking hour estimates (+286 MET mins/day, LOA = -9.0 to 580 MET 
minutes). It is difficult to determine which method may provide the more valid 
estimate due to the absence of a criterion EE measure. A shortcoming of the 7DR is 
that it assumes time outside sleep, and MVPA, is spent in light PA with no 
allowance for sedentary behaviour. Categorising 120 minutes of each dialysis day 
as resting EE was a conservative approach to enable known periods of sedentary 
behaviour to be correctly included. Therefore, comparatively higher EE estimation 
by the 7DR was inevitable, however any further attempts to manipulate EE 
estimation for sedentary behaviour beyond this level would have been prone to bias. 
While the 7DR may have overestimated EE, it is just as possible the ActivPAL 
underestimates EE. Only one study was located examining the criterion validity of 
ActivPAL EE estimation. Harrington et al. (2011) found ActivPAL significantly 
underestimated EE compared to indirect calorimetry at all walking speeds (from 3.2 
to 7.0 km/h) during a treadmill protocol in a sample of 62 young women. ActivPAL 
calculates the wearer’s EE from an algorithm based on step rate. However 
Harrington et al. (2011) argue that an equation based on ActivPAL activity counts 
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would be more valid given its closer association with indirect calorimetry compared 
to cadence (r = 0.75, p < 0.001 vs r = 0.59, p < 0.001 respectively).  
4.4.11 Concordance of Actigraph and 7-day Recall energy expenditure 
Actigraph and 7DR estimated EE were moderately associated in the present study 
(Spearman’s rho = 0.59, p < 0.001), which is in agreement with similar 7DR 
concordance studies reporting moderate correlations (range r = 0.43 to 0.60) in 
samples of asymptomatic middle-aged adults (Richardson et al. 2001; Soundy et al. 
2007) and people with peripheral arterial disease (McDermott et al. 2000). Leenders 
et al. (2000) observed a comparatively stronger correlation (r = 0.82 p < 0.001) 
between MVPA-based EE from the 7DR and Actigraph (CSA7164). The reason for 
this discrepancy may be due to their sample being very similar in characteristics to 
individuals recruited by Freedson et al. (1998) for development of Actigraph EE 
equations. Stronger associations ranging from r = 0.76 to 0.83 have also been 
reported in smaller samples of healthy adolescents (Allor and Pivarnik 2001), adults 
(Miller et al. 1994; Matthews and Freedson 1995) and people with COPD (Garfield 
et al. 2011). Comparatively stronger correlations observed in the latter studies may 
be due to data smoothing effect mediated by whole day EE estimates. In support of 
this theory Matthews and Freedson (1995) found markedly different correlations for 
total daily- and MVPA-based EE estimates (r = 0.77 and r = 0.55 respectively).  
Overall, low agreement was observed between 7DR and Actigraph estimates of EE 
in the present study. The disparity between the methods was mediated largely by 
the divergence in EE values on non-dialysis days as no significant difference was 
observed between the measures on dialysis days (Z = -1.814, p = 0.70). 
Heterogeneity of accelerometers used in previous studies and inconsistent 
standardisation of EE outcome hamper direct comparison with the bias and LOA 
observed in the present study. However, results presented here are in agreement 
with several studies showing 7DR estimated EE outcomes are significantly higher 
than equivalent values obtained from three different accelerometers (Miller et al. 
1994; Matthews and Freedson et al. 1995; Leenders et al. 2000; Allor and Pivarnik 
2001). Moreover, despite observing a high correlation Leenders et al. (2000) also 
found Actigraph estimated significantly lower EE with a mean bias of -4.3 
kcals/kg/day (LOA = -5.7, -2.6). Normalising EE values in the present study to body 
mass revealed a lower mean bias (-1.7 kcals/kg/day) but wider LOA (-5.9 to 2.4 
kcals/kg/day). Notably, the Bland-Altman analysis of Allor and Pivarnik (2001) 
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revealed a proportional relationship between 7DR and Caltrac estimated EE 
(kcals/hr) similar to that observed in the present study. As EE increased so too did 
the difference between the measures. 
4.4.12 Concordance of ActivPAL and Actigraph energy expenditure 
Concordance of ActivPAL and Actigraph EE estimates has not been previously 
examined. Overall, low agreement was found between the two accelerometers for 
this outcome despite a strong correlation. Actigraph EE values were significantly 
lower than the ActivPAL and LOA were thus unsurprisingly wide. It is likely that 
discordance between Actigraph and ActivPAL estimated EE is mediated by several 
factors. Each accelerometer employs a different method to calculate this outcome. 
Actigraph uses an algorithm based on activity counts while the ActivPAL derives an 
EE estimate from step rate. Although the positioning of the devices is different, it is 
speculated that EE estimates from both monitors would perhaps agree more closely 
if the ActivPAL used an equation based on activity counts as recommended by 
Harrington et al. (2011). Another contributing factor may be the EE equation 
employed by the Actilife software, which was developed using an earlier generation 
of Actigraph (7164). It has been documented that this earlier Actigraph model has 
comparatively greater sensitivity to lower frequency movements in the light PA 
range, while later models such as the GT3x require comparatively greater 
movement to elicit a non-zero count (Rothney et al. 2008). Intuitively, lower monitor 
sensitivity and an attendant bias toward misclassifying light PA as sedentary would 
result in lower estimated EE by the Actigraph GT3X. Lastly, triaxial output from the 
Actigraph should in theory be more sensitive to movement than uniaxial, and may 
possibly provide a more valid EE estimate. The Actilife software is able to derive an 
EE value from triaxial activity counts. However, outcome values are a composite of 
EE calculated from MVPA triaxial activity counts and light PA derived from uniaxial 
counts using the Williams Work Energy Equation (Williams 1998). Furthermore, the 
Actilife software does not provide a triaxial cutpoint for sedentary behaviour, which 
precludes a calculation similar to that undertaken for uniaxial counts in the present 
study. 
4.4.13 Energy expenditure concordance summary. 
Controlled studies employing indirect calorimetry during walking protocols and 
activities of daily living indicate that existing Actigraph EE equations based on single 
linear regression models (Freedson et al. 1998; Swartz et al. 2000; Hendelman et 
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al. 2000) and two regression models (Crouter et al. 2006) underestimate EE (Welk 
et al. 2000; Slootmaker et al. 2009; Albinali et al. 2010). Furthermore each of the 
equations produce different EE values because they have been calibrated on 
different activities and different populations. Consequently accuracy of EE 
estimation using the Actigraph will likely depend on type of typical PA and 
population sample. Criterion validity studies of the 7DR with doubly labelled water 
show moderate correlations (range r = 0.47 to 0.52), with either no significant 
difference between the measures (Bonnefoy et al. 2001; Leenders et al. 2001) or a 
significant overestimation by self-report (Mahabir et al. 2006). However, wide LOA 
are uniformly observed with the accompanying recommendation that use of 7DR EE 
estimates at an individual level is limited. Leenders et al. (2001) evaluated the 
criterion validity of both the 7DR and Actigraph (CSA 7164) simultaneously and 
found estimated EE derived solely from PA by both measures correlated moderately 
(r = 0.42 to 0.55, p < 0.05) with doubly labelled water (DLW) measures. Although 
DLW and 7DR values were not significantly different, the Actigraph significantly 
underestimated EE by an average of 59%, however, LOA for both were equally 
wide. In light of poor concordance between estimates from all three instruments 
evaluated in the present study and documented low agreement with criterion 
measures there is little to recommend any one method over the other. 
4.4.14 Clinical implications and further research. 
Poor agreement between subjective and objective methods of estimating MVPA 
observed in this study and in the general literature have important implications for 
the use of either method to stratify risk or monitoring the effect of health 
interventions. The systematic bias between the measures may theoretically be 
corrected, however LOA are so wide that it would be difficult to stratify risk or 
identify change with respect to therapeutic PA recommendations. Furthermore, 
current consensus guidelines of 30 minutes MVPA on most days are based on 
findings from epidemiological studies examining associations between self-reported 
PA and lower CV mortality (Pate et al. 1995). Low agreement between subjective 
and objective measures of MVPA observed here and in the general literature 
suggests that PA dosage to reduce CV mortality risk using the latter will likely differ 
to current guidelines. Moreover there are indications that existing PA health 
guidelines intended for asymptomatic individuals may require re-calibration for 
people living with stage 5 CKD. Accelerometer studies involving Japanese HD 
patients demonstrate that accumulating 50 minutes or more of all intensities of PA is 
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independently associated with lower mortality risk (Matsuzawa et al. 2012) and 
maintaining the ability to ambulate (Kutsuna et al. 2010).  
Importantly, the 7DR defines all free-living behaviour outside MVPA and sleep as 
light PA and does not differentiate it from sedentary behaviour. Hence, not only 
would this questionnaire erroneously classify all HD patients as meeting the 50 
minutes/day of total PA threshold it is unable to quantify a behaviour metric 
(sedentary time) now independently associated with health outcomes. The 
Actigraph provides a reliable, objective, but imperfect, estimate of PA using the 
Freedson et al. (1998) cutpoint, which probably underestimates activity (MVPA) 
associated with a health enhancing effect in older adult and clinical populations with 
lower cardiorespiratory fitness (Duncan et al. 2001; Lopes et al. 2009; Miller et al. 
2010). Further population specific calibration of Actigraph cutpoints is recommended 
to better utilise the triaxial output of this device in order to better characterise PA. 
This would assist in delineating dose response relationships between PA and health 
outcomes appropriate to people with stage 5 CKD.   
Estimation bias for sedentary behaviour and PA values between Actigraph GT3X 
and ActivPAL monitors is low and could possibly be corrected using a measurement 
error model. However, the observed LOA are worryingly wide and more critical as 
they reflect a large amount of random error (just over three hours), which cannot be 
easily corrected with such a model. Consequently, their concurrent use to stratify 
risk or detect meaningful change in sedentary behaviour and total PA is not 
recommended. For example, the overall error margin for this outcome is more than 
three times wider than a threshold of ≥50 minutes/day of total PA, which is 
independently associated with reduced mortality risk (Matsuzawa et al. 2012) and 
mobility (Kutsuna et al. 2010). Moreover, using total PA values interchangeably 
would make detection of a clinically meaningful improvement of 10 minutes/day 
associated with an incremental 22% reduction in mortality risk (Matsuzawa et al. 
2012) highly unlikely. Evidence suggests alternate Actigraph cutpoints such as <50 
cpm (Crouter et al. 2006; Clemes et al. 2012) may ameliorate bias between 
ActivPAL and Actigraph sedentary estimates but they are unlikely to substantially 
improve random error (the inherent biological variability in physical activity 
behaviour) due to the fundamentally different method each device employs.  
Criterion validity studies employing direct observation in controlled and free-living 
conditions demonstrate superior precision of the ActivPAL in classifying sedentary 
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behaviour and standing activities compared to Actigraph regardless of cutpoint 
employed and manipulation of monitor sensitivity (Hart et al. 2011b; Kozey-Keadle 
et al. 2011; Lyden et al. 2012). Arguably more precise estimates of these 
behaviours would likely result in better statistical power during analyses involving 
this outcome and thus indicate ActivPAL as the preferred monitor. However, studies 
using Actigraph monitors have identified important associations between sedentary 
behaviour and breaks in sedentary behaviour and health indicators (Healy et al. 
2008a; Healy et al. 2008b; Gaya et al. 2009). Moreover, estimates of total PA (>1.8 
METs) from waist-mounted accelerometers are predictive of mortality and mobility in 
the HD population (Kutsuna et al. 2010; Matsuzawa et al. 2012).  
Wide LOA observed between ActivPAL and Actigraph step count estimates means 
direct comparison and synthesis of literature employing either device is problematic. 
Furthermore, concurrent use of these monitors to detect change during health 
interventions and stratify risk is unwise. Importantly, a PA level of <4040 steps/day 
among HD patients is associated with levels of serum high density lipoprotein (<1.03 
mmol/L) predictive of increased CVD risk (Masuda et al. 2009). Although an 
individual might record 3500 steps with the Actigraph the ActivPAL value may be 
anywhere between 5352 and 2924. In addition, an increase of 1000 steps/day is 
independently associated with meaningful reductions blood pressure in type 2 
diabetes (Manjoo et al. 2010) and 10% lower risk of metabolic syndrome (Sisson et 
al. 2010). Although minimum detectable change for the ActivPAL is 45 steps 
(Dahlgren et al. 2010), an additional 2428 steps would have to be performed in 
order to detect a meaningful increase if these devices were used concurrently.  
Criterion validity studies indicate ActivPAL step count estimates have the highest 
precision of available ‘field’ methods (Grant et al. 2006; Ryan et al. 2006; Harrington 
et al. 2011; Feito et al. 2012). Furthermore, in light of the finding that ActivPAL and 
Actigraph GT3X step count agreement declines with advancing age, use of the latter 
device to monitor step counts of people with stage 5 CKD is not indicated. This 
recommendation is made with the caveat that an earlier version of the Actigraph 
(CSA7164) is reported to have superior step count validity (Le Masurier et al. 2004; 
Kozey et al. 2010; Feito et al. 2012). Similar step count accuracy may possibly be 
achieved with the GT3X by applying the low frequency filter extension and is 
suggested as an area worthy of further exploration.  
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One advantage of the Actigraph accelerometers is their extensive use in health 
studies to categorise PA intensity using activity count cutpoints. A potential 
advantage of cutpoints calibrated for the ActivPAL is the adoption of one monitor 
that can categorise PA intensity in addition to having superior accuracy in estimating 
sedentary behaviour, step counts and transitions compared to the Actigraph GT3X. 
These data indicate currently available uniaxial cutpoints may not be applied to the 
ActivPAL activity count output. To optimise utility of output from this device 
population specific calibration that allows ActivPAL activity counts to be categorised 
into different levels intensity should be undertaken. This might also facilitate easier 
comparison of PA derived EE estimates with other accelerometers.  
Poor levels of agreement were observed between 7DR, ActivPAL and Actigraph 
estimates of EE in the present study. There is general agreement in the literature 
that current EE prediction equations for ActivPAL and Actigraph underestimate EE 
compared to ‘gold standard’ measures (Leenders et al. 2001; Albinali et al. 2010; 
Harrington et al. 2011) while the 7DR provides higher estimates, and demonstrates 
a similar lack of precision (Bonnefoy et al. 2001; Leenders et al. 2001; Mahabir et al. 
2006). Low criterion validity is likely mediated by these instruments not taking into 
account participant characteristics (ie: age, gender, adiposity, efficiency of 
movement, environmental and geographic conditions), which explain 64% of the 
observed variation in total EE in healthy individuals (Plasqui et al. 2005). Inherent 
limitations of questionnaire-based EE estimates calculated from the Compendium of 
Physical Activities have been highlighted by Kozey et al. (2010). Consequently the 
true EE for someone with stage 5 CKD may not be accurately determined by either 
accelerometers or self-report. Therefore neither method can presently be 
recommended over the other to provide a proxy measure of individual EE during 
free-living conditions. Accelerometer and self-report estimates of EE may have a 
useful role in comparing standardised estimates to rank individuals but they may not 
be used interchangeably in the stage 5 CKD population.  
4.4.15 Study limitations 
The sample included for final analysis in the present study was of moderate size but 
similar to previous studies evaluating the concurrent validity of ActivPAL and 
Actigraph. While participants’ demographic and clinical characteristics are similar to 
those reported for the Scottish HD population (SRRR 2013), caution is advised 
when generalising these findings given the degree of gender bias (72 - 80% male 
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depending on outcome). This may have resulted in higher associations between 
subjective and objective estimates of MVPA, as self-report accuracy is reportedly 
lower for women (Richardson et al. 2001; Timperio et al. 2003). However, gender 
differences in PA recall accuracy reported in the literature are largely attributed to 
greater male participation in vigorous activities which are more easily recalled 
(Durante and Ainsworth 1996; Richardson et al. 2001), which was not a feature 
apparent in this study. In addition, gender did not influence correlations between 
objective and subjective MVPA estimates during exploratory post-hoc analysis.     
Waist and lower limb mounted accelerometers will likely miss aspects of PA that 
involve upper body movement and may lack sensitivity in detecting additional EE 
attached to load carrying or walking on an incline. However, walking is the most 
prevalent form of PA during free-living (Troiano et al. 2008) and was the most 
commonly reported activity in this sample of HD patients. Furthermore, 
improvements in PA measurement precision with simultaneous upper limb 
monitoring are slight and offset by the burden of cost and additional data processing 
of an extra accelerometer (Swartz et al. 2000). Due to time constraints and a desire 
to minimise participant burden measures of individuals’ resting metabolic rate were 
not employed to assist with EE estimates. Lastly, these findings are presented with 
the caveat that this is a concordance not a criterion validity study. None of the PA 
assessment methods evaluated here are recognised as ‘gold standard’. 
Recommendations regarding instrument selection for monitoring sedentary time and 
PA behaviour in stage 5 CKD are thus based on the weight of findings from the 
present study and the general literature, and summarised in table 4.5.  
Table 4.5 Assessment methods recommended for behavioural outcomes. 
 ActivPAL Actigraph 7DR 
Sedentary time +++ ++ NA 
Light PA NA + - 
Mod-vig PA NA + + 
All PA (all postures) ++ +++ - 
PA (standing only) +++ ++ - 
Steps taken +++ ++ NA 
Energy Expenditure + + + 
Key: NA not applicable, - not recommended, + cautiously recommended, ++ moderately 
recommended, +++ highly recommended 
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4.5 Conclusion 
Overall findings from the present study underline the point that while correlational 
analysis indicates the strength of the linear relationship between two outcomes it 
does not accurately reflect their level of agreement. Actigraph and 7DR estimates of 
PA may not be used interchangeably nor may PA data of HD patients obtained via 
subjective and objective methods be pooled presently. Accelerometry is the 
preferred method for PA surveillance given its superior ability to differentiate light 
and sedentary behaviour. Accelerometer choice will depend on the outcome of 
interest. Actigraph and ActivPAL may not be used concurrently to estimate 
sedentary behaviour and step counts, and on balance ActivPAL likely provides more 
valid estimates of these outcomes. However, this may not preclude the use of 
Actigraph GT3X to estimate PA and sedentary behaviour. If the desired outcome is 
PA associated with a health enhancing effect then the Actigraph GT3X is 
recommended with the proviso that cutpoints are appropriately calibrated to the 
target population. Actigraph output should otherwise be reported as activity counts 
per minute only. Energy expenditure estimates from all three methods should not be 
used interchangeably, but may still have a useful role at an epidemiological level. 
What is known about this topic: 
x Physical activity and sedentary lifestyles are implicated in life expectancies 
of HD patients. 
x There is little uniformity of methods used to assess PA in the stage 5 CKD 
population.  
x Information regarding concordance of assessment instruments to estimate 
PA outcomes and sedentary behaviour of people with stage 5 CKD is scant.   
What this study adds: 
x Subjective and objective estimates of PA investigated in the present study 
may not be used interchangeably in the CKD 5 population. 
x ActivPAL is likely a more precise instrument for estimating sedentary time 
and step counts in the HD population. 
x The Freedson et al. (1998) cutpoints for categorising Actigraph activity 
counts may be inappropriate for the HD population. 
x Actigraph output should be reported as counts per minute 
x Actigraph, ActivPAL and 7DR may not be used interchangeably for 
estimates of EE.  
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Chapter 5: Correlates of physical function in stage 5 CKD 
5.1 Introduction 
5.1.1 Severity and prevalence of impaired physical function 
Stage 5 chronic kidney disease (CKD) is characterised by severely reduced physical 
function compared to non-uraemic peers across all three levels of the International 
Classification of Functioning, Disability and Health (ICF) model (body functions and 
structures, activity, participation) (WHO 2001). At a physiological level 
cardiorespiratory fitness (CRF) of HD partients is on average 60 - 70% of predicted 
VO2peak values (Cheema and Singh 2005; Johansen 2007; Parsons and King-Van 
Vlack 2009; Segura-Orti 2010; Smart and Steele 2011). In addition, indices of 
directly measured lower limb neuromuscular function are 22% to 45% lower than 
age-matched controls (Johansen et al. 2003a; Blake and O’Meara 2004). 
Measures of functional capacity obtained via physical performance-based tests of 
CRF are reported to be 61% lower than norm values (Greenwood et al. 2012), while 
composite measures of neuromuscular function and mobility such as the timed up-
and-go (TUAG) and self-selected gait speed reflect values for adults of more 
advanced age (Bohannon et al. 1995; Painter et al. 2000; Johansen et al. 2001a; 
Jamal et al. 2006; Greenwood et al. 2012). Moreover, proxy measures of endurance 
and lower limb power demonstrate more profound impairment among older 
maintenance HD patients (Painter et al. 2000).  
At a participation level, patient-reported outcomes of self-reported functional status 
are consistently well below norm values (DeOreo 1997; Painter et al. 2000; Tawney 
et al. 2000; Mapes et al. 2003). This is underlined by findings from the 
Comprehensive Dialysis Study showing functional status of almost all 1547 
participants at or below the 50th percentile for controls aged >70 years (Johansen et 
al. 2010b). Furthermore, prevalence of disability with one or more basic activities of 
daily living (ADL) among maintenance HD patients is significantly higher than 
community dwelling older adults (McAdams-Demarco et al. 2012). 
5.1.2 Predictive utility of physical function outcomes  
Reduced physical function across the spectrum of the ICF has profound implications 
for quality of life and prediction of health outcomes in the HD population (De Oreo 
1997; Stenvinkel et al. 2002; Mapes et al. 2003; Sietsema et al. 2004; Stack et al. 
2005; Jamal et al. 2006; McAdams-Demarco et al. 2012). A CRF level above a 
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threshold of 17.5 ml/kg/min is independently associated with significantly lower 
mortality among prevalent HD patients (Sietsema et al. 2004) and at all stages of 
the CKD trajectory (Gulati et al. 2012). Neuromuscular function tests from isolated 
muscle group contraction to composite measures of lower extremity power, balance 
and mobility assessments are similarly predictive. Low isometric grip strength 
assessed at the initiation of HD is independently associated with higher mortality 
among male patients (Stenvinkel et al. 2002). Poor TUAG performance (>10 
seconds) among elderly HD patients is associated with bone fractures (Jamal et al. 
2006) and an almost seven fold risk of dependency with one or more basic ADLs 
(Cook and Jassal 2008). Worryingly, slow sit-to-stand test times and high 
prevalence (65%) of slow gait (<1.0 m/s) in the HD population (Painter et al. 2000) 
are associated with higher risk of mortality, falls, hospitalisation and dependent 
living in older adults (Buatois et al. 2008; Tiedeman et al. 2008; Braden 2012).  
Large-scale studies also attest to the predictive utility of patient-reported functional 
status. Low physical component summary (PCS) scores (<25) from the SF-36 
questionnaire are associated with a 93% higher risk of death and 56% higher risk of 
hospitalisation (Mapes et al. 2003). Notably, a 10 point decrease in PCS score is 
associated a 25% increased risk of death within one year (Knight et al. 2003; Mapes 
et al. 2003), while five point increases are associated with incremental reductions in 
adjusted risk of 10% (DeOreo et al. 1997; Lowrie et al. 2003; Mapes et al. 2003). 
Worryingly, mortality risk among HD patients is more than threefold higher for 
individuals with one or more ADL disability compared to those without disability 
(McAdams-Demarco et al. 2012). Importantly, physical function remains predictive 
of hospital admissions, graft survival and mortality even after kidney transplant 
(Houle et al. 2002; Kutner et al. 2006; Yango et al. 2006).   
5.1.3 Justification for exploring correlates of physical function in CKD 5 
It appears that commencement of HD therapy precipitates a decline in physical 
function towards frailty and dependency (Johansen et al. 2010a), which persists to 
some degree even after uraemia has been reversed by kidney transplant 
(Greenwood et al. 2012). Identifying risk factors of poor physical function to 
accurately target health interventions for this condition should therefore be a priority. 
While physical function declines with age and comorbidity, people with stage 5 CKD 
experience a more profound decline and there are indications that this may be 
mediated by uraemia per se.  Difficulty in performing one chair rise and declining 
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self-reported functional status is significantly associated with increasing renal 
impairment (Chow et al. 2003; Kurella et al. 2004; Brodin et al. 2008). Furthermore, 
histological studies report evidence of uraemic myopathy induced via mechanisms 
of inflammation and protein catabolism (Ahonen et al. 1980; Brautbar et al. 1983; 
Diesel et al. 1990; Diesel et al. 1993), while HD dosage is also associated with 
physical function (Johansen et al. 2001a).  
Low physical activity (PA) is also believed to be a contributor to muscle wasting and 
impaired physical function via a potent triad of enforced inactivity (during HD 
therapy), fatigue (associated with uraemia and the HD procedure), and worsening 
comorbidity (UKRR 2012). Worryingly, only 13% of HD patients achieve 
recommended PA levels (Painter et al. 2011) and they are on average 35% less 
active than sedentary non-uraemic peers (Johansen et al. 2001b). Recent PA is the 
most important modifiable determinant of CRF (Bouchard and Perusse 1994) and 
several reviews concur that structured PA programmes improve physical function in 
stage 5 CKD (Parsons and King-van Vlack 2009; Segura-Orti 2010; Smart and 
Steele 2011). However, studies investigating the influence of habitual PA on 
contemporaneously assessed physical function in stage 5 CKD are either small in 
scale (Johansen et al. 2001a), or limited to just one outcome (Kutsuna et al. 2010).  
5.1.4 Summary 
Reduced physical function is highly prevalent amongst and implicated in the health 
outcomes of people with stage 5 CKD, facts that remain unchanged even after 
reversal of uraemia by kidney transplantation. Exploration of the determinants of 
physical function from routinely monitored clinical variables, and the specific 
contribution of PA, therefore appears warranted. Such observations may help inform 
recommendations regarding use of physical function outcome monitoring (and 
possibly interventions) to help ameliorate the decline towards frailty that many 
people receiving HD therapy for stage 5 CKD experience.  
The objectives of this study were to: 
x Explore the correlates of objective measures of physical function (physical 
performance) of people with stage 5 CKD. 
x Explore the correlates of subjective measures of physical function (self 
reported functional status) of people with stage 5 CKD. 
x Explore the influence of objectively estimated physical activity on objectively 
and subjectively determined physical function of people with stage 5 CKD. 
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5.2 Methods 
5.2.1 Study design, participant recruitment and inclusion/exclusion criteria 
This cross-sectional study was conducted in accordance with the ethical principles 
of the Declaration of Helsinki. Ethical approval was obtained from the West of 
Scotland Research Ethics Committee and the Monklands Hospital Research and 
Development Department. This was a prospective cohort study involving 80 self-
selected volunteer participants, aged >18 years, ambulant with or without a walking 
aid, and undergoing maintenance HD therapy for stage 5 CKD. Participants were 
recruited from an NHS outpatient HD unit at Monklands Hospital, Airdrie. 
Participants were screened by their physician to verify their eligibility for the study. 
The following exclusion criteria were applied: pregnancy, unstable cardiovascular 
conditions, recent cerebrovascular event, recent pulmonary thromboembolism, 
excessive inter-dialytic weight gain determined by physician, use of corticosteroids 
and anabolic therapies, recent pulmonary embolism, serum potassium >6 mmol/L, 
infection or course of antibiotics within one month of study period. Individuals were 
ineligible if they had diagnosed with dementia/severe cognitive impairment, or were 
not fluent in written and spoken English. Written informed consent was obtained 
from each participant prior to study commencement.  
5.2.2 Demographic and clinical measures 
Anthropometric and clinical measures (age, height, weight, BMI, resting heart rate, 
resting blood pressure) were taken prior to assessment of physical performance 
(general methods 2.1.3).  The following biochemistry measures were obtained from 
review of recent pre-dialysis blood tests (general methods 2.6.1): dialysis adequacy 
(urea reduction ration), haemoglobin, haematocrit, C-reactive protein, albumin, 
serum phosphate, corrected serum calcium, parathyroid, pre-dialysis creatinine. 
Other measures included a simple additive score of comorbidity, which was 
obtained from review of participants’ electronic hospital records.  
5.2.3 Assessment of physical function 
Physical function data for this study were collected between November 2011 and 
August 2013 and assessments were administered to participants during one session 
on an inter-dialytic day. Functional capacity was measured using physical 
performance measures of grip strength, lower limb power, functional mobility and 
cardiorespiratory fitness (CRF). These tasks were chosen as they are necessary for 
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performance of ADLs and are predictive of health outcomes for people with stage 5 
CKD and older adults. Grip strength of the dominant upper limb was obtained with a 
JAMAR dynamometer (Sammons Preston, Inc., Bolingbrook, IL) in a standardised 
sitting position with the best of three attempts recorded (general methods 2.3.1).  A 
proxy measure of lower limb power was obtained using the sit-to-stand 5 test 
(STS5). Participants completed five sit-to-stand movements as quickly as possible 
without upper limb assistance from a chair height standardised to their stature 
(general methods 2.3.2). The timed up-and-go test provided a composite measure 
of lower limb power, balance and functional mobility. Participants stood up from a 
standard height chair, walked three metres, turned once they had drawn level with a 
marker cone, returned and sat down (general methods 2.3.3). Participants were 
allowed the use of a walking aid as required. The fastest performance of two 
attempts at the STS5 and TUAG were recorded to the nearest tenth of a second. A 
proxy measure of CRF was obtained via a symptom limited incremental shuttle walk 
test (ISWT) as per general methods section 2.3.4. Participants’ heart rate response 
was monitored (general methods 2.3.4.1) throughout, and the test was terminated 
according to ACSM (2010) guidelines for exercise testing (general methods 2.3.4.4). 
Distance walked, final gait speed and a CRF level in metabolic equivalents (METs) 
derived from gait speed at test termination were recorded (general methods 
2.3.4.5). Measures of self-reported functional status were obtained via the Duke 
activity status index (DASI) (general methods 2.4.1) and from the summary physical 
component summary (PCS) score of the Kidney Disease Quality of Life - Short 
FormTM (KDQOL-SF) UK English version 1.2 (Hays 1994). The reader is referred to 
the general methods section for further information on questionnaire scoring.  
5.2.4 Measurement of physical activity  
Estimates of PA were obtained via triaxial accelerometry using the Actigraph GT3X 
(Actigraph Corp, Pensacola, Florida). Participants kept a wear log (appendix V b) 
and also wore an ActivPAL (PAL Technologies Ltd, Glasgow) monitor to accurately 
determine their Actigraph monitor wear time. Both monitors were synchronised and 
worn as per general methods sections 2.5.2 and 2.5.7 on their non-dominant side. 
Accelerometers were retrieved from participants on day nine, which coincided with a 
routine HD appointment and data were downloaded using the proprietary Actilife 
and ActivPAL software. Actigraph PA data were reduced as per general methods 
sections 2.5.4 and 2.5.8 and only participants with a minimum of eight hours monitor 
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wear on one dialysis day and two non-dialysis days were included for final analyses 
(as per recommendations of chapter 3). 
5.2.5 Data analysis 
Data analysis was undertaken using the Statistical Package for Social Science 
(SPSS, Illinois, USA), version 19.0. Sample characteristics are presented as mean 
and standard deviation (SD) or median and interquartile range according to being 
determined as parametric or non-parametric respectively by the results of 
Kolmogorov-Smirnov normality tests. Differences between groups for the same 
variable were tested using an independent t-test or Mann-Whitney U test for normal 
and non-normal data respectively. Associations between physical function 
measures and demographic and clinical variables were undertaken using Pearson 
product-moment correlation analysis. Variables associated with physical function 
outcomes, which had a correlation of >0.20 and a significance level of ≤0.05 were 
identified as candidate predictor variables. If the minimum ratio of variables to 
sample size for multiple regression analysis recommended by Harris (1985) was 
violated a selection process was employed to reduce the number of variables. 
Variables were not selected for entry to the multiple regression analysis if their β 
coefficient and confidence intervals approached zero. If variables exhibited 
collinearity, partial correlation analysis was used to select the most robust variable 
for model entry.  Backward stepwise regression analysis was used with the selected 
candidate variables. Physical activity was subsequently added to the model 
containing only the retained clinical and demographic variables to explore the 
possible contribution of this behaviour variable to the outcome. If PA was also 
retained in the model, the amount of outcome variance explained by this behaviour 
variable was reported. Statistical significance for multiple regression analysis was 
set at a two-tailed value of p < 0.05. The correlation between the dependent and 
independent variables are reported as well as the amount of variance explained. 
Adjusted r2 values are also reported, as the standard r2 value tends to inflate as a 
function of the number of predictor variables retained in the model (Altman 1995). 
The relative importance of variables retained in the prediction models was 
subsequently determined by separately entering each variable into the model to 
partition the variance explained. Residual analysis for each of the multiple 
regression analyses was also undertaken to check for outliers and that the 
assumptions for multiple linear regression analysis were not violated. 
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5.3 Results 
Figure 5.1 shows the process by which participants’ data was included for analysis. 
A total of 132 people registered interest in the study, of who 80 agreed to take part 
in physical performance testing. Four people did not attend their appointment and 
withdrew their consent, while four later declined the physical performance tests but 
agreed to complete the questionnaires. In total 56 people consented to complete 
only the questionnaire part of the study, and 72 people participated in the physical 
performance tests and questionnaire sections of the study. Return rate for the Duke 
and KDQOL-SF forms was lower in the questionnaire only group (93% and 80% 
respectively) compared to the exercise test group (100% and 96% respectively). Of 
the 72 participants who took part in the physical tests two people were unable to 
perform the STS5 test, and three people declined the shuttle walk test. Two 
participants declined or were unable to wear the Actigraph and another seven 
participants lacked sufficient accelerometer wear time for final analyses. A score for 
the DASI was successfully obtained for all participants in both groups. However, 
successful completion rate for the PCS was lower due to missed responses in the 
KDQOL-SF. Summary PCS scores were obtained for 65 of the 72 (90%) people 
who attended the physical performance tests, and 37 out 44 (84%) of the 
questionnaire only group. 
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Figure 5.1 Flowchart of patient participation and inclusion for m
ultiple regression analyses. 
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5.3.1 Sample characteristics 
Demographic and clinical characteristics for participants with minimum required 
monitor wear time are reported in table 5.1 and are not significantly different to the 
initially recruited sample of 72 participants (appendix XXII a). Participant age ranged 
from 24 to 87 years, with 35 percent of the sample aged 65 years or older. Women 
made up 37 percent of the sample, and were significantly younger (t(61) = 2.93, p = 
0.005) than men (50.5 ± 13.6 versus 61.6 ± 15.1 respectively). Diabetics accounted 
for 25 percent of the sample.  
Table 5.1 Demographic and clinical characteristics participants with sufficient 
PA data for final analyses. Data are presented as mean ± SD, or median (IQR) 
for normal and non-normally distributed data respectively. 
Characteristic Performance tests 
 Questionnaires 
only 
Age (years) 57.5 ± 15.5 62.8 ± 16.9 
Gender M/F (%) 40 / 23 (63/37) 24/27 (47/53) 
Body Mass Index (kg/m2) 28.7 ± 6.3  
Resting Heart rate (bpm) 71.7 ± 12.4  
Systolic (mmHg) 134.7 ± 23.8  
Diastolic  (mmHg) 75.5 ± 9.8  
Systemic pulse pressure  (mmHg) 53 (43 - 70)  
Mean arterial pressure (mmHg) 95.2 ± 11.9  
Haemodialysis Vintage (months) 14.8 (6.8 - 31.4) 14.7 (6.3 - 37.0) 
Renal Replacement Therapy Vintage (months) 25.9 (8.3 - 69.3) 20.2 (6.8 - 40.3) 
Haemoglobin (g/dL) 11.2 ± 1.0 11.0 ± 1.3 
Haematocrit  (%) 33.9 ± 3.2 33.6 ± 3.9 
C-reactive protein (mg/L)  0 (0 - 10.0) 8.0 (0 - 13.0) 
Dialysis Adequacy  (%) 71 (66 - 75) 72 (67 - 77) 
Albumin   (g/L) 39.0 (36.0 - 41.0) 37.0 (35.0 - 39.0) 
Troponin T   (ng/L) 37.0 (21.0 - 69.0) 54.0 (31 - 104) 
Corrected Calcium serum level  (mmol/L) 2.37 ± 0.17 2.37 ± 0.16 
Phosphate   (mmol/L) 1.40 ± 0.33 1.60 ± 0.84 
Parathyroid level  (mmol/L) 16.4 (9.7 - 30.9) 16.7 (8.1 - 29.1) 
Creatinine pre-dialysis   (μmol/L) 644 (546 - 856)  
Total number of medications 10 (8 - 12)  
Number of comorbidities,  (N) 1.0 ± 0.8  
x Hypertension (%) 35 (56)  
x Diabetes mellitus (%) 16 (24)  
x Cardiovascular disease (%) 13 (21)  
Duke activity status index 22.2 (15.5, 34.2) 17.8 (7.2, 25.0) 
KDQOL-SF Physical component score 32.9 (9.1) 31.4 (10.0) 
KDQOL-SF vitality 36.5 9 (23.1) 38.7 (23.6) 
Leicester Uraemic Symptom Scale 36.3 (17.3) 32.1 (17.8) 
In contrast women made up more than half of the questionnaire only group, while 
independent t-test revealed participants in this group were significantly older than 
those who undertook physical performance testing (t(122) = -2.42, p = 0.02). Mann-
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Whitney U test indicated troponin T and C-reactive protein levels were significantly 
higher in the questionnaire only group (U = 1326, p = 0.007 and U = 960, p < 0.001 
respectively) but there were no differences observed between the groups in terms of 
other biochemistry indices or dialysis vintage. Significantly lower DASI scores were 
observed for the questionnaire only group (U = 1191, p = 0.001) while KDQOL-SF 
physical component scores (PCS), self-reported vitality and symptom burden 
(LUSS) were not significantly different. 
Sample characteristics for physical function and PA are presented in table 5.2. Men 
recorded significantly higher hand grip strength, Duke activity status index, and PCS 
(t(61) = 6.62, p < 0.001, U = 298, p = 0.02 and U = 242, p = 0.03 respectively) 
compared to women. A large effect size was observed for HGS while medium effect 
sizes were seen for the DASI and PCS (appendix XXII b). Women were significantly 
more active than men (U = 306, p = 0.03) with a small to medium effect size 
observed (appendix XXII b) and were on average 8.7 years younger (t(71) = 2.33, p 
= 0.02). Mann Whitney U-test revealed that DASI scores for the questionnaire only 
group (median = 13.5, IQR = 7.2 - 25) were significantly lower than those performing 
the physical tests (U = 1237, p = 0.001). Although PCS scores for the questionnaire 
only group were generally lower (median = 29.5, IQR = 23.0 - 37.0) the difference 
was not statistically significant (U = 1177, p = 0.54). 
Table 5.2 Participant physical performance, self-reported physical function, 
and physical activity characteristics. Data are presented as mean ± SD, or 
median (IQR) for normal and non-normally distributed data respectively. 
Outcome Men & Women Men Women 
Grip strength (Kg) 30.9 ± 10.1 † 35.8 ± 8.1 22.35 ± 7.1 
Sit to Stand 5 test  (seconds) 11.7 (9.5, 15.5) †† 11.8 (9.5, 14.6) 11.14 (9.3, 16.4) 
Timed Up and Go test  (s) 7.62 (6.28, 10.8) † 8.08 (6.23, 10.8) 7.03 (6.3,13.3) 
Shuttle walk test distance (m) 280 (150, 430) †† 260 (140, 440) 335 (168,408) 
Duke Activity Status Index 22.2 (15.5, 34.2) † 27.0 (16.9, 36.7) 18.7 (10.7, 30.2) 
KDQOL-SF PCS 30.6 (24.7, 38.7) ††† 32.9 (27.4, 40.6) 27.8 (22.8, 32.4) 
Physical activity (Triaxial cpm) 289 (183 - 397) † 245 (147, 387) 322 (259, 450) 
†   n = 63, †† n = 61, ††† n = 58. 
5.3.2 Univariable associations with physical performance  
The number of clinical and demographic variables significantly associated with the 
range of physical performance attributes increased with greater complexity and 
physiological demand of the task (table 5.3). 
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Table 5.3 Univariable associations of dem
ographic and clinical m
easures with physical perform
ance outcom
es. 
  
Grip strength (n = 63) 
Sit-to-stand 5 (n = 61) 
Tim
ed up-and-go (n = 63) 
Shuttle walk test (n = 61) 
Variable 
U
nstandardized β 
(Low
er, U
pper Bound) 
r 
U
nstandardized β (Low
er, 
U
pper Bound) 
r 
U
nstandardized β 
(Low
er, U
pper Bound) 
r 
U
nstandardized β  
r 
(Low
er, U
pper Bound) 
W
eight 
0.21** (0.06, 0.36) 
0.34**  
N
ot associated 
N
ot associated 
N
ot associated 
H
eight 
0.24** (0.10, 0.38) 
0.40**  
N
ot associated 
N
ot associated 
N
ot associated 
G
ender 
-13.5***(-17.5, -9.4) 
-0.65*** 
N
ot associated 
N
ot associated 
N
ot associated 
Age 
N
ot associated 
0.16**(0.07, 0.26) 
0.40** 
0.16***(0.09, 0.24) 
0.48*** 
-6.92***(-9.97, -3.87) 
-0.51*** 
M
edications 
-0.9*(-1.65, -0.14) 
-0.29* 
0.70**(0.22, 1.19) 
0.36** 
0.34 (-0.06, 0.74) 
0.21* 
-23.09**(-38.81,-7.37) 
-0.36** 
C
reatinine  
0.02**(0.01, 3.16) 
0.36** 
N
ot associated 
-0.01*(-0.012, -0.001) 
-0.29* 
0.38**(0.10, 0.66) 
0.34** 
Album
in 
0.73*(0.12, 1.34) 
0.29* 
N
ot associated 
-0.64***(-0.93, -0.36) 
-0.50*** 
17.47**(4.5, 30.43) 
0.33** 
C
R
P
 
 
  
0.20**(0.06, 0.34) 
0.34** 
0.20**(0.08, 0.31) 
0.41** 
-6.62*(-12.03, -1.2) 
-0.30* 
C
om
orbidities 
 
  
 
  
1.88*(0.27, 3.49) 
0.29* 
-75.17*(-140.85, -9.5) 
-0.29* 
D
iastolic Bp 
 
  
 
  
-0.16*(-0.29, -0.03) 
-0.30* 
N
ot associated 
Troponin-T  
 
  
 
  
0.04***(0.03, 0.06) 
0.54*** 
-1.08**(-1.83, -0.33) 
-0.35** 
Phosphate  
 
  
 
  
-4.77* (-8.64, -0.9) 
-0.30* 
223.0**(67.0, 379.0) 
0.35** 
BM
I 
 
  
 
  
 
  
-9.21*(-17.64, -0.79) 
-0.27* 
Pulse pressure 
  
  
  
  
  
  
-3.08*(-5.39, -0.77) 
-0.33* 
 * p < 0.05, ** p < 0.01, ***p < 0.001 
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5.3.3 Univariable associations with self reported functional status 
Table 5.4 reports the results of correlation analyses between clinical and 
demographic variables, and scores derived from functional status questionnaires 
investigated in this study. 
Table 5.4 Univariable associations with self-reported functional status.  
  Duke Activity Status (n = 63) KDQOL PCS (n = 58) 
Variable 
Unstandardized β 
r 
Unstandardized β 
r (Lower, Upper bound) (Lower, Upper bound) 
Comorbidities -5.47* (-9.85, -1.09) 0.30*  -3.13* (-6.15, -0.12) -0.27* 
Creatinine  0.02* (0.002, 0.041) 0.28*  0.035  (0.007, 0.063) 0.32* 
Gender -7.38* (-14.65, -0.11) -0.25* -5.65* (-10.74, -0.56) -0.29* 
Medications -1.81** (-2.82, -0.8) -0.42**  Not associated 
CRP -0.16* (-0.30, -0.02) -0.28* Not associated 
Parathyroid  0.17* (0.002, 0.337) -0.25*  Not associated 
Albumin Not associated 0.77* (0.18, 1.35) 0.33* 
*p < 0.05, **p < 0.01, ***p < 0.001. CRP = C-reactive protein 
5.3.4 Associations between physical function status and physical activity  
All measures of physical function and functional status were associated with PA 
except hand-grip strength (HGS). Moderate correlations were observed for PA and 
physical performance while more modest associations were seen with self reported 
physical function (table 5.5). 
Table 5.5 Associations between physical activity, physical performance and 
functional status outcomes. 
Function outcome Unstandardized β 
r (Lower bound, Upper bound) 
Hand grip strength (kg) 0.001 (-0.01, 0.012) 0.12, p = 0.95 
Sit-to-stand 5 (s) -0.012 (-0.018, -0.005) -0.42*** 
Timed up-and-go (s) -0.010 (-0.015, -0.005) -0.46*** 
Shuttle walk distance (m) 0.626 (0.457, 0.795) 0.69*** 
Duke activity status index 0.016 (0.001, 0.031) 0.26* 
KDQOL-SF PCS 0.013 (0.003, 0.022) 0.32** 
* p < 0.05, ** p < 0.01, ***p < 0.001, n = 63 
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5.3.5 Hand-grip strength multiple regression analysis  
The following five variables associated with grip strength were retained and entered 
for multiple regression analysis: gender; number of medications; creatinine; albumin; 
weight; height. The subsequent model, which retained gender and albumin as 
predictor variables explained almost half of the variance in hand-grip strength (table 
5.6). Physical activity was not retained as a predictor when added to this model 
Table 5.6 Hand-grip strength multivariable regression models without and with 
physical activity as an additional predictor.  
Variable 
Unstandardized β  
(Lower, Upper bound) 
Unstandardized β 
(Lower, Upper bound) 
r2  
contribution 
Gender -13.50*** (-17.48, -9.42) -13.08*** (-16.97, -9.2) 0.39*** 
Albumin 0.60* (0.06, 1.13) 0.62* (0.15, 1.09) 0.06* 
Physical Activity Not added 0.005 (-0.003, 0.014) p = 0.22 
r  0.70 0.69  
r2 0.49 0.48  
r2 adjusted 0.47 0.46  
* p < 0.05, ** p < 0.01, ***p < 0.001 (n = 63)  
5.3.6 Sit-to-stand 5 multivariable regression analysis 
Variables entered for multiple regression analysis for STS5 performance were: age; 
number of medications; C-reactive protein; comorbidity score. 
Table 5.7 Results of sit-to-stand 5 multivariable regression analysis without 
and with physical activity as an additional predictor.  
Variable 
Unstandardized β 
(Lower, Upper) 
r2 
contribution 
Unstandardized β 
(Lower, Upper) 
r2 
contribution 
Age 0.14** (0.05, 0.24) 0.11** 0.10 (-0.01, 0.20) p = 0.07 
Medications 0.57* (0.11, 1.02) 0.07* 0.51* (0.06, 0.96) 0.07* 
Physical activity Not entered  -0.007* (-0.014, -0.001) 0.12* 
r 0.49  0.55  
r2 0.24  0.30  
r2 adj 0.21  0.26  
* p < 0.05, ** p < 0.01, ***p < 0.001 (n = 61) 
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Table 5.7 shows age and number of medications were retained in a model that 
explained 21 percent of the variance in STS5 performance. Slightly more of the 
variance (26%) was explained when PA was entered into the model containing age 
and number of medications. Notably, addition of PA resulted in age being relegated 
from the model. 
5.3.7 Timed up-and-go multivariable regression analysis 
The following variables were selected for multiple regression analysis of TUAG 
performance: age, diastolic blood pressure, C-reactive protein, albumin, troponin T, 
phosphate and comorbidity score. Serum creatinine, and number of medications 
had the lowest associations with task performance, and β coefficients (as well as 
confidence limits) which approached zero and were therefore not entered. 
Table 5.8 Results of timed up-and-go multivariable regression analysis 
without and with physical activity as an additional predictor.  
Variable 
Unstandardized β 
(Lower, Upper) 
Unstandardized β 
 (Lower, Upper) 
r2 
contribution 
Diastolic blood pressure -0.15** (-0.25, -0.05) -0.15** (-0.25, -0.05) 0.08** 
Albumin -0.43** (-0.69, -0.17) -0.43** (-0.69, -0.17) 0.10** 
Troponin T 0.03*** (0.02, 0.05) 0.03*** (0.02, 0.05) 0.16*** 
Physical Activity Not entered -0.004(-0.009, 0.000) (p = 0.065) 
r  0.69 0.71  
r2 0.48 0.51  
r2 (adjusted) 0.45 0.48  
* p < 0.05, ** p < 0.01, ***p < 0.001 (n = 63) 
Diastolic blood pressure, albumin and troponin T were retained in a model that 
explained almost 50% of the variance of TUAG performance (table 5.8). Whilst PA 
was moderately associated (r = 0.46, p < 0.001) with TUAG time at univariable level 
(β coefficient = -0.01 (-0.02, -0.01), p < 0.001), it was not retained as a predictor. 
5.3.8 Incremental Shuttle Walk Test multivariable regression analysis 
Ten variables were associated with ISWT of which, the following were entered for 
multiple regression analysis: age, BMI, number of medications, CRP, albumin, 
Troponin T, serum phosphate and creatinine. Number of medications was selected 
in preference to comorbidity number due to more favourable level of significance 
and stronger association with ISWT performance. Similar correlations were 
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observed for Troponin T and systemic pulse pressure with the ISWT and the former 
independent variables were moderately related to each other (r = 0.45, p < 0.001). 
Troponin T was selected for model entry following partial correlation analysis. 
Table 5.9 Results of shuttle walk test distance multivariable analysis with 
physical activity (average daily activity counts) as additional predictor. 
Variable 
Unstandardized β 
(Lower, Upper) 
r2 
contribution 
Unstandardized β 
(Lower, Upper) 
r2 
contribution 
Age -5.98*** (-8.85, -3.1) 0.22*** -3.57** (-6.09, -1.04) 0.06** 
BMI -8.62* (-15.54, -1.70) 0.07* -6.91* (-12.59, -1.23) 0.04* 
Medications -17.3* (-31.1, -3.4) 0.05* -11.5* (-22.6, -0.44) 0.03* 
Physical Activity Not entered  0.47*** (0.31, 0.64) 0.22*** 
r 0.63  0.79  
r2 0.40  0.62  
r2 adjusted 0.37  0.59  
* p < 0.05, ** p < 0.01, ***p < 0.001 (n = 61) 
Age, BMI and number of medications were retained in a model that explained 37% 
of the variance. Physical activity was retained when added to this model and 
subsequently increased the amount of variance explained to 59%.  
5.3.9 Self-reported functional status multiple regression analysis  
Determinants of functional status were derived from multiple regression analysis of 
the following seven candidate variables some of which were similar for each 
outcome: gender; number of medications; albumin; predialysis creatinine; 
comorbidity score; serum parathyroid hormone; C-reactive protein. Number of 
medications and C-reactive protein were retained in a model, which explained 
almost a quarter of the variance of DASI scores. A trend was observed for gender (p 
= 0.052) and comorbidities (p = 0.059). Similarly, almost a quarter of the shared 
variance of PCS scores from the KDQOL-SF was explained by a model containing 
gender, albumin and comorbidities. The addition of PA resulted in a non-significant 
r2 change of 0.01 and consequently did not increase the explanatory power of the 
model for the DASI questionnaire. In contrast, PA was retained in the model for the 
PCS at the expense of albumin, and subsequently increased the amount of variance 
explained to almost 30%.  
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Table 5.10 Results of self-reported functional status m
ultivariable analysis with physical activity as additional predictor. 
  
Duke activity status index † 
KDQOL-SF Physical Com
ponent Score †† 
Variable 
U
nstandardized β 
U
nstandardized β  
r 2 
U
nstandardized β 
r 2 
U
nstandardized β  
r 2 
(Low
er, U
pper)  
 (Low
er,U
pper) 
contribution 
(Low
er, U
pper) 
contribution 
 (Low
er, U
pper) 
contribution 
G
ender 
- 
- 
- 
-6.20* (-10.85, -1.55) 
0.08* 
-7.6** (-12.2, -2.9) 
0.13** 
Album
in 
- 
- 
 
0.74* (0.20, 1.28) 
0.10* 
0.51(- 0.05, 1.07)  
 0.04, p = 0.08 
C
om
orbidities 
- 
- 
 
-3.66* (-6.39, -0.92) 
0.07* 
-2.8* (-5.58, -0.47) 
0.05* 
M
edications. 
-1.53* (-2.53, -0.53) 
-1.37* (-2.39, -0.35) 
0.12** 
- 
 
- 
- 
C
R
P
 
-0.35*(-0.64, 0.06) 
-0.28* (-0.59, -0.03) 
0.07* 
 
 
- 
 
Physical Activity 
N
ot entered 
0.10 (-0.005, 0.025) 
p = 0.18 
N
ot entered 
 
0.01* (0.001, 0.021) 
0.06* 
r 
0.52 
0.54 
 
0.53 
 
0.58 
 
r 2 
0.27 
0.29 
 
0.28 
 
0.34 
 
r 2 adjusted 
0.23 
0.24 
 
0.24 
 
0.29 
 
p < 0.05, ** p < 0.01, ***p < 0.001 
† n = 63, †† n = 58 
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Table 5.11 shows that one quarter of participants undertaking physical performance 
assessments in the present study were classified as being frail overall according to 
criteria proposed by Fried et al. (2001) detailed in appendix (XXIX). One third to 
almost 90% of participants met individual frailty citeria derived via the outcomes 
employed in this study while less than 25% met the criteria for unintentional weight 
loss and low PA.  
Table 5.11 Number (percentage) of study participants meeting frailty criteria  
for the overall score (frail) and each component, by group and gender.  
  
Frail Weakness Walking Exhaustion Low weight Low PA 
(n = 73) (n = 72) (n = 69) (n = 69) (n = 73) (n = 63) 
All 18 (24.7 %) 23 (31.9 %) 26 (37.7 %) 54 (78.3 %) 2 (2.7 %) 13 (20.6 %) 
Men 12 (25.0 %) 15 (31.3 %) 17 (36.2 %) 34 (73.9%) 1 (2.1 %) 10 (25.0 %) 
Women 6 (24.0 %) 8 (33.3 %) 9 (40.9 %) 20 (87.0 %) 1 (4.0 %) 3 (13.0 %) 
 
5.4 Discussion 
5.4.1 Physical performance characteristics of the study sample 
Mean HGS values for men and women in the present study are consistent with 
those reported in larger samples of HD patients (Stenvinkel et al. 2002; Silva et al. 
2011), and predialysis patients (Pagels et al. 2008). Notably, mean HGS for men 
and women was considerably lower (19% and 28% respectively) than age 
equivalent normative values and even lower (6% and 8% respectively) than healthy 
individuals aged over 70 years (Bohannon et al. 2006c). Sit-to-stand 5 times in the 
current study were slower than those reported by Blake and O’Meara (2004), whose 
high functioning HD participants were still 38% slower than healthy controls. 
Moreover, 41% of participants had a STS5 time equivalent or slower than normative 
data for people aged 70 - 79 years (12.6 seconds) (Bohannon 2006a). Timed up-
and-go performances were slightly quicker than those reported for a more elderly 
sample (68.1 ± 7.1 years) of Japanese HD patients (Nonoyama et al. 2010). 
However, nearly 40% of our sample had TUAG times similar to those reported for 
adults aged 76 - 80 years (9.4 ± 2.4 years) (Bohannon 2006b; Pondal and del Ser 
2008). Thirteen (21%) participants had TUAG results at the lower end of ‘normal’ 
(>12 seconds) mobility (Bischoff et al. 2003). Worryingly eight participants recorded 
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times greater than 13.5 seconds, which is an established cutpoint for predicting 
elderly fallers (Shumway-Cook et al. 2000).  
The majority of participants (87%) had ISWT distances that were in the lowest 25th 
percentile reported for healthy middle-aged to older adults in the UK (Harrison et al. 
2013). Shuttle walk performances were comparable to those reported for a similar 
aged sample (56.6 ± 12.2 years) of 128 UK HD patients (247.7m ± 137.1) 
(Greenwood et al. 2012) but generally worse than people with chronic heart failure 
(422 ± 119 metres) of comparable age (Pulz et al. 2008). Worryingly, 40% of 
participants had a maximum gait speed at test termination lower than the minimum 
speed required to walk across a UK pedestrian crossing safely (1.2 m/s) (Asher et 
al. 2012). Scores for the DASI were also consistent with those reported in previous 
stage 5 CKD studies (Nonoyama et al. 2010; Greenwood et al. 2012) and slightly 
lower than values for pre-dialysis patients (Kurella et al. 2004). Importantly, PCS 
scores from the KDQOL-SF were also in line with those reported in the DOPPS 
project, the largest international study involving people with stage 5 CKD (Lopes et 
al. 2007). As a comparison with normative data, 83% of participant PCS scores in 
the present study were at or below the 25th percentile of age-equivalent norm values 
(Ware et al. 2007). Physical activity level of men in particular was at least 12% lower 
than that reported for more senior adults (Hamer et al. 2012). 
5.4.2 Overview of findings  
The average age of the study sample was 57.5 (±15.5) years but results of physical 
performance testing indicated that a high percentage of participants had a level of 
functional capacity similar to adults of more advanced age (>70 years). Physical 
performance declined with factors typically associated with chronic illness such as 
advancing age, comorbidity burden, number of medications, and low PA. Although 
aspects of physical performance were correlated with some variables associated 
with stage 5 CKD, efficiency of uraemic toxin removal had no influence. Clinical and 
demographic variables explained between a quarter and half of the variance in 
functional capacity obtained via the implemented range of physical performance 
tests. In contrast, less than a quarter of the variance of self-reported functional 
status was explained by clinical and demographic characteristics. Physical activity 
emerged as the most influential determinant of a proxy measure of cardiorespiratory 
fitness (CRF) and was independently associated with lower limb function and self-
reported functional status.  
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5.4.3 Hand-grip strength 
Gender and albumin explained almost half of the variance in HGS most of which 
was contributed by the former. There is agreement that albumin is an important 
proxy marker of nutritional status in the HD population (Heimburger et al. 2000; 
Kaysen et al. 2000) which is also predictive of mortality (Lowrie and Lew 1990; 
Leavey et al. 2000). The independent association of albumin with HGS is consistent 
with previous studies documenting a similar relationship between this outcome and 
nutritional status of hospital inpatients (Norman et al. 2005) and protein-energy 
malnutrition among HD patients (Stenvinkel et al. 2002).  
The model for HGS compares favourably with findings from the general literature 
showing age and gender as the principal determinants, accounting for around 30% 
of the variance of HGS in healthy individuals (Budziareck et al. 2008), older adults 
(van Lier and Payette 2003; Bot et al. 2012) and people with upper limb injury (Bot 
et al. 2012). None of these studies included markers of nutritional status as a 
candidate predictor variable, which may account for the discrepant findings. Notably, 
age was not associated with HGS at univariable level in contrast to the other 
physical performance measures. Further analysis revealed grip strength of female 
participants declined with advancing age but not in men. It is possible that males 
were more highly motivated and thus applied more effort to obtain better results, or 
despite adjustment for hand size the design of dynamometer was not suitable for 
women. It is perhaps more likely that this observation is due to onset of 
comparatively greater muscle capacity decline in women which is associated with 
menopausal transition (Carr 2003; Polotsky and Polotsky 2010).  
5.4.4 Sit-to-stand 5 
The modest amount of variance in STS5 performance explained by clinical and 
demographic variables here (26%) perhaps reflects the fact that knee extensor 
strength is the principal determinant of this task in community dwelling adults 
(Schenkman et al. 1996; Lord et al. 2002; Bohannon et al. 2010). This result is in 
keeping with a larger study of 669 community dwelling older adults, which found 10 
variables (sensorimotor function indices, weight, pain) accounted for just 34.9% of 
the shared variance (Lord et al. 2002). Haemodialysis dosage and serum albumin 
explained a higher proportion of shared variance (46%) in a similar sample of HD 
patients (Johansen et al. 2001a), while Bohannon et al. (2007) found age and BMI 
accounted 43.7% in a larger sample of 94 community dwelling older adults. Notably, 
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PA completely attenuated the effect of age and was the principal predictor of STS5 
performance in the present study. In contrast Johansen et al. (2001a) reported that 
PA was not independently associated with task outcome in their sample of HD 
patients. Participant characteristics for both studies were similar, but differences in 
statistical methods (forward versus backward stepwise regression, and treatment of 
PA data, Johansen et al. (2001a) quality control method not stated, and data not 
normalised to wear time) may have contributed to the disparity in findings. In 
addition, the cited study did not meet the minimum sample size requirement for 
multiple regression analysis recommended by Harris (1985).  
Importantly, these data are consistent with results from the UK Medical Research 
Council National Survey of Health and Development which found self reported PA 
was independently associated with STS5 performance of 2400 adults (Cooper et al. 
2011). Although, PA made the largest contribution to STS5 times, the amount of 
variance in task performance accounted for by the model was largely unchanged.  
Notably, the number of prescription medications remained independently associated 
with STS5 performance and its relative importance was not attenuated by the 
introduction of PA to the model. Medication number has not been previously 
documented as a predictor of the STS5. Although this test has been proposed as a 
proxy measure of lower limb power (Guralnik et al. 1994), there is evidence that 
postural stability is the strongest determinant of chair rise time in older adults 
(Lindemann et al. 2007). Furthermore, chair rise performance is also associated with 
standing balance in middle-aged men (Hardy et al. 2010), and older adults with and 
without functional limitations (Schenkman et al. 1996; Lord et al. 2002). Taking three 
or more prescription medications is associated with an adjusted increased risk of 
impaired balance in older adults of at least 74% (Agostini et al. 2004). Worryingly, 
the median number of medications for participants in the present study was 10 (IQR 
= 8, 12). It is therefore speculated that number of medications may have 
independently contributed to STS5 performance via the vector of balance.  
5.4.5 Timed up-and-go 
The moderate amount of variance explained (48%) by albumin, diastolic blood 
pressure, and tropinin-T compares favourably with findings from the general 
literature. Kwan et al. (2011) reported that 43.5% of TUAG performance was 
determined by indices of sensorimotor function, balance, psychological and health 
measures with leg strength contributing the largest percentage in a sample of 280 
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older adults (>65 years). In contrast Pondal and del Ser (2008) found just 25.8% of 
the variance was explained by age, gender, weight, cognitive impairment and 
nutritional status in TUAG performances of elderly (>70 years) community dwelling 
adults. 
The finding that a marker of nutritional status is a determinant of TUAG performance 
is in agreement with previous studies involving older adults showing mini-nutritional 
assessment is independently associated with TUAG times (Zeyfang et al. 2005; 
Ponda and del Ser 2008).  The presence of albumin as a marker of nutritional status 
is a biologically plausible predictor of task performance. However, it is less clear why 
an index of heart refilling and a putative biomarker of cardiac muscle damage should 
account for the majority of the variance explained.  
The TUAG correlated highly with the ISWT (Spearman’s rho = -0.85, p< 0.001), 
which suggests that similar factors may influence both tests although the TUAG is a 
short test of functional mobility and not CRF. Participants are exposed to an 
orthostatic challenge during the sit-to-stand transfer, which elicits an immediate 
increase in heart rate followed by an initial drop in blood pressure (Olufson et al. 
2008).  Retention of cardiac related variables might be considered consistent with 
short-term cardiovascular regulation in response to an orthostatic challenge. This is 
likely impaired in stage 5 CKD a condition characterised by reduced cardiovascular 
function (London et al. 2011).  
Notably, while PA was related to TUAG times at univariable level, it was not retained 
as a predictor in the final model due to the presence of Troponin T. This finding is 
surprising as B-natriuretic peptide expression (a biomarker of ventricular stress) was 
observed to be lower in maintenance HD patients following a structured PA 
programme (Toussaint et al. 2008a). It is possible that this negative result may be 
due to heteroscedasticity of the PA data.    
5.4.6 Incremental Shuttle Walk Test 
Explanatory power of the model for the ISWT containing age, BMI, and number of 
medications was significantly improved when PA was added as a predictor. 
Moreover PA explained a greater proportion of the variance than the other three 
variables combined. The same predictors explained a similar amount of the variance 
for gait speed at test termination and CRF in METs calculated from gait speed 
(appendices XXIII a and XXIII b). Johansen et al. (2001) and Kutsuna et al. (2010) 
also found that PA was a determinant of self-selected gait speed of HD patients, 
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which is correlated with CRF. Approximately 60% of the variance in ISWT 
performance was explained by age, BMI, number of medications and habitual PA in 
the present study. This is less than the model of Probst et al. (2012) who reported 
age, gender and BMI explained 71% of the variance in ISWT results of 246 healthy 
middle-aged adults. This discrepancy may be due to advanced age of participants in 
the present study and perhaps also psychosocial factors associated with a long-term 
condition, which may have affected motivation. Notably median self-perceived 
exertion score at test termination was just 13, which equates to ‘somewhat hard’ on 
the BORG scale while a score of 20 indicates maximum exertion (Borg 1998). 
Medication number emerged as a predictor of test performance, which is plausible in 
light of the influence of polypharmacy on standing balance (Agostini et al. 2004). 
Moreover, a high percentage of participants (78%) were prescribed heart pacing 
and/or antihypertensive medications. Presence or absence of medications such as β 
blockers has previously been reported as a predictor of CRF of similar age patients 
referred for hospital based exercise testing (Roy et al. 1992; Myers et al. 2001). 
Notably, average heart rate at test completion (as a percentage of predicted 
maximum) for participants was lower than the study of Probst et al. (2012) (64% 
versus 99% respectively).  
Overall, the model for the ISWT (a proxy measure of aerobic fitness) is in agreement 
with previous research showing age, body composition and PA are the principal 
drivers of CRF in healthy adults across a similar age range (Jackson et al. 1990; 
Matthews et al. 1999; Jurca et al. 2005). Moreover, the amount of variance in 
directly measured CRF explained by non-exercise predictive equations developed 
from these studies (58% to 74%) is comparable to the present study.  
5.4.7 Functional status – DASI and KDQOL-SF physical component score 
Overall, clinical and demographic variables explained a modest amount of the 
variance in self reported physical function. Gender, albumin and comorbidity number 
made a similarly important contribution to summary physical component scores of 
the KDQOL-SF. Clinical and demographic variables explained a similar amount of 
the variance in KDQOL-SF physical function subscale scores (28.9%) in a combined 
sample of 146 HD and peritoneal dialysis patients (Carmichael et al. 2000). 
Importantly, these results are consistent with findings from the much larger DOPPS 
study, which found gender, comorbidity status, albumin and age were independently 
associated with PCS scores (Lopes et al. 2007). Addition of PA slightly increased 
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the amount of variance explained and subsequently forced albumin from the model 
while at the same time attenuating the effect of comorbidity number. Interestingly, 
post-hoc analysis revealed the independent contribution of PA was mediated by a 
substantial main effect for gender. Although cause and effect cannot be established 
in a cross-sectional study, this finding suggests that functional status of males only 
may potentially be modified by habitual PA.  
The DASI questionnaire contains items weighted according to their approximate 
physiological cost, and scores are reported to correlate moderately with directly 
measured CRF (Struthers et al. 2008; Hlatky et al. 1989). Therefore it might be 
expected that determinants for the DASI would be similar to the ISWT. Medication 
number was a shared predictor of both outcomes, but it is less clear why the 
contribution of other factors notably PA was supplanted by polypharmacy when the 
influence of the latter on ISWT distance was attenuated by PA. Previous studies 
have identified combinations of age, sex, comorbidity score and history of heart 
failure as determinants of DASI scores in larger samples of middle-aged and elderly 
cardiac patients (Nelson et al. 1991; Jaeger et al. 1994). Furthermore, a relatively 
low amount of the variance in scores was explained but this is in agreement with a 
study of 438 middle aged cardiac patients, which accounted for just 18% of the 
variance in DASI scores (Nelson et al. 1991).   
The disparity in explanatory ability between the models for physical performance 
and self-reported functional status likely reflects a number of key differences. 
Physical performance tasks and self-report questionnaires assess different aspects 
of physical function from the ICF framework (functional capacity versus functional 
status). Second, comparatively lower reliability of self-reported physical function 
(Davey et al. 2003; Overend et al. 2010) will likely attenuate relationships between 
independent variables and questionnaire outcomes. Day of the week and method of 
administration are reported to influence questionnaire scores (Weingberger et al. 
1996; Lyons et al. 1999; Nelson-Danquah et al. 2010). Third, psychosocial factors 
influence both physical performance and self-reported function but its relative 
importance to the latter may arguably be greater (Carmichael et al. 2000; Lord et al. 
2002; Bean et al. 2011). Anecdotally, some participants expressed concern 
regarding the purpose of the questionnaires (in particular the DASI) despite 
reassurances of confidentiality. Almost half of participants (44%) required state 
sponsored support for subsistence living due to their health condition. It is 
speculated that such concerns may have impacted validity of some questionnaire 
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answers thereby constituting a form of bias, which can account for up to one third of 
total response bias (Sjöström et al. 1999). 
5.4.8 Physical activity an important determinant of physical function 
These data are in agreement with observations from the general literature 
documenting positive independent associations between self-reported PA and self-
reported function of middle aged adults (He and Baker 2004; Lahti et al. 2010) and 
objectively measured function of middle-aged adults (Lang et al. 2007). Independent 
association between objectively measured PA and self-selected gait speed of 
maintenance HD patients, which is similarly predictive of health outcomes has been 
previously reported (Johansen et al. 2001a; Kutsuna et al. 2010). Crucially, habitual 
PA was the principal modifiable determinant of ISWT and STS5 performance. This 
is important because the former is a proxy measure of CRF which is predictive of 
mortality in stage 5 CKD (Sietsema et al. 2004) while the latter has discriminative 
ability in identifying HD patients with fractures (Jamal et al. 2006). These outcomes 
are arguably also corrolaries of the two core components of frailty: exhaustion and 
weakness (Fried et al. 2001). Furthermore, adjusting for PA level either removed or 
attenuated the influence on physical performance capability of other predictors such 
nutritional status, medication number, and BMI. Notably, the latter has been 
employed as a proxy for unintended weight loss, another core component of frailty. 
This is the first study to document habitual PA as a determinant of PCS score from 
the KDQOL-SF, a measure of self reported physical function which is widely used in 
this clinical population. Importantly, there is a growing emphasis on patient-reported 
outcomes to complement traditional clinical outcomes such as mortality, non-fatal 
events, hospital admissions, and healthcare cost (Liem et al. 2007; Valderas et al. 
2008). However, it appears that only a small proportion of functional status may be 
directly influenced by the physiological effects of PA. Hand-grip strength was not 
associated with PA but this finding concurs with large scale studies of middle aged 
and older adults (Cooper et al. 2011; Rapp et al. 2012) and is likely due to hip 
mounted accelerometers not capturing upper limb activity. Overall, these data point 
to habitual PA as the modifiable factor of greatest relative importance for physical 
performance of this sample of HD patients. Importantly, this suggests a significant 
proportion of outcomes important in frailty and survival are mediated by a decline in 
habitual PA, which is reported to be on average 3.4% per month following HD 
commencement (Johansen et al. 2003b).  
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5.4.9 Nutritional status and physical function 
Higher serum albumin was independently associated with better HGS, TUAG 
performance and PCS score, and was moderately associated with the ISWT at 
univariable level. These data are in agreement with those of Johansen et al. 
(2001a), indicating nutritional status as a determinant of physical function of HD 
patients. There is considerable evidence that albumin and inflammation are closely 
linked in CKD (Johansen et al. 2003c; Kalentar-Zadeh et al. 2003; Fouque et al. 
2008) particularly in uraemic individuals with protein energy malnutrition (Stenvinkel 
et al. 2002; Kaizu et al. 2003; Castaneda-Sceppa et al. 2007; Carrero et al. 2008). In 
the present study inflammation (C-reactive protein) correlated moderately with 
albumin (Spearman’s rho = -0.40, p = 0.001) as well as physical function.   
Renal failure and HD therapy have both been implicated in decreased protein 
synthesis and increased protein degradation in people with stage 5 CKD (Ikizler et 
al. 2002; Raj et al. 2008). Muscle morphology changes observed in malnutrition are 
well documented with muscle biopsies showing selective atrophy of type II muscle 
fibres (anaerobic, glycolytic, fast twitch) (Norman et al. 2010). Notably, HD patients 
exhibit significant atrophy of all muscle fibre types compared to non-uraemic peers 
(Sakkas et al. 2003). As well as mediating a preferential loss of whole body protein 
from muscle mass (Heymsfield et al. 1982), malnutrition is believed to impair muscle 
function by causing fatigability and an altered pattern of muscle contraction and 
relaxation (Lopes et al. 1982). 
Simultaneous monitoring of serum potassium and magnesium levels was not 
undertaken in this study. However, the effect of electrolyte disturbances 
characteristic of stage 5 CKD (ie: hyperkalaemia) on functional capacity via impaired 
muscle membrane function should be considered. Elevated serum potassium is 
implicated in muscle fatigue during exercise (Sjested and Sjogaard 2000; Fraser et 
al. 2002) and is inversely associated with CPET measured CRF in stage 5 CKD 
(Sangkabutra et al. 2003). Reduced muscle sodium-potassium adenosine 
triphosphatase (ATPase) activity observed in uraemic rats (Bonilla et al. 1991) is 
believed to occur in humans (Brearley et al. 1993) and thus partly mediate impaired 
extrarenal potassium regulation. Hypermagnesaemia is extremely rare, however, 
hypomagnesaemia affects five percent of HD patients (Alhosaini and Leehey 2015) 
and may also adversely affect skeletal muscle membrane function as deficiency of 
this cation reduces sodium-potassium ATPase activity (Alhosaini and Leehey 2015). 
 211 
Additionally, β-adrenergic agonists often prescribed to manage blood pressure in 
stage 5 CKD elevate serum potassium levels (Kullmer and Kindermann 1985).  
5.4.10 The role of muscle mass, uraemia severity and anaemia  
Intuitively, muscle mass might be expected to be a determinant of physical function 
as it is linearly related to strength in healthy young and older adults (Overend et al. 
1992; Newman et al. 2003; Rolland et al. 2008). Moreover, muscle strength is a 
predictor of physical performance of HD patients (Diesel et al. 1993).  Although 
serum creatinine (employed as a gross marker of sarcopenia) was modestly 
associated with physical function it was not retained as an independent predictor, 
which is inagreement with the findings of Johansen et al. (2001a). Serum creatinine 
is largely determined by muscle mass in HD patients (Noori et al. 2011) but it is an 
indirect measure that may not reflect muscle architecture changes that occur in 
uraemic individuals (Ahonen 1980; Diesel et al. 1993; Johansen et al. 2003a; 
Sakkas et al. 2003). Higher fat infiltration of skeletal muscle and reduced contractile 
area are associated with lower muscle strength and reduced physical performance 
of HD patients (Johansen et al. 2003a) and older adults (Goodpaster et al. 2001; 
Visser et al. 2002; Visser et al. 2005; Delmonico et al. 2009). Although BMI is 
commonly used as an adiposity surrogate, recognised limitations in reflecting body 
composition (Pasco et al. 2012) may explain why it was not correlated with non-
endurance tasks. 
It has been proposed that declining physical function in CKD is largely mediated by 
uraemia (Diesel et al. 1993; Johansen et al. 2001a; Kurella et al. 2004; Brodin et al. 
2008).  However, while condition-related variables (albumin and inflammation) were 
associated with physical function, dialysis adequacy was not. This result contrasts 
with a previous study, which found dialysis dosage (KT/v) was an independent 
predictor of physical performance (Johansen et al. 2001a). It is possible that use of 
urea reduction ratio as a measure of dialysis adequacy in the present study instead 
of Kt/V may explain the divergent results. However, larger studies have found no 
association between HGS and Kt/V, or other dialysis-related biomarkers (Qureshi et 
al. 1998; Leal 2011). Moreover, no independent association between renal function 
and PCS scores was found in people with stage 3 to 5 CKD (Perlman et al. 2005). 
Partial correction of anaemia with erythropoiesis-stimulating agents is reported to 
significantly improve cardiopulmonary exercise test (CPET) measured CRF and self-
reported physical function of maintenance HD patients (Johansen et al. 2010). 
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However, haemoglobin and haematocrit level were not associated with physical 
performance outcomes and only weakly associated with DASI scores. This result 
concurs with previous studies showing no association between haematocrit and 
VO2peak of anaemic HD patients (Diesel et al. 1993) or functional capacity of 
individuals with partially corrected anaemia (Johansen et al. 2001a). Taken together 
it appears that physical function in this sample of HD patients was neither influenced 
by efficiency of uraemic toxin removal nor anaemia status per se. Instead, factors 
related to stage 5 CKD and indeed most long-term conditions (age, nutritional 
status, polypharmacy, PA) made a greater relative contribution.  
5.4.11 Clinical implications and further research 
As a whole these findings show there are a number of risk factors for low physical 
function across a range of physical function attributes in this sample of people with 
stage 5 CKD, many of which are potentially modifiable. Importantly habitual PA 
emerged as a determinant of function, which appeared to attenuate the influence of 
other predictors (ie: nutritional status, BMI, medications, age). Thus, strategies 
aimed at improving PA level and carefully managing the number of prescribed 
medications may likely improve physical performance outcomes, which are 
predictive of falls, fractures and premature mortality of people with CKD and older 
adults. Encouraging PA among maintenance HD patients is part of KDOQI 
recommendations for managing CV risk in this population (NKF 2005). Clearly, 
these data indicate PA has an equally important role in helping arrest the inexorable 
decline towards frailty that many people experience after starting HD therapy.  
There is ample evidence from the general literature supporting the nomothetic utility 
of functional status questionnaires, which arguably have greater relevance to 
disability and quality of life of people with stage 5 CKD than clinical indices of health. 
In addition, they can be completed by those unable, or too reticent to undertake 
physical performance testing. However, recognised shortcomings regarding 
reliability, response bias and appropriateness for patients with cognitive deficits 
(Guralnik et al. 1989) may limit their clinical utility. Furthermore, self-reported 
functional status was largely determined by factors other than clinical or 
demographic factors and habitual PA in this sample of HD patients. Consequently, 
more research is required before clinicians can invest in self-report measures and 
rely on the evidence provided by these outcomes for the benefit of their patients. If 
functional status is to be used as a primary outcome to monitor health and evaluate 
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PA health interventions it should not be used in isolation but in tandem with 
objective measures of functional capacity. 
The aim of this study was to explore the importance of routinely monitored 
demographic and clinical information as potential determinants of physical function 
as well as the relative importance of habitual PA as a behavioural variable. Around 
half the variance of physical performance and three quarters of the variance in 
functional status remains undetermined. Future studies may seek to address the 
contribution of psychosocial factors such as pain and fatigue, which were not 
investigated in this study but are known to be predictors of physical performance 
(van Lier and Payette 2003; Brown et al 2005; Bot et al. 2012).  
The ISWT was employed in this study as a proxy measure of CRF, which is 
predictive of mortality in the CKD population (Sietsema et al. 2004; Gulati et al 
2012). However, there are indications that ISWT distance may not be a good 
predictor of event free survival in CHF patients (Pulz et al. 2008). If this field test of 
CRF is to be adopted into clinical practice in line with KDOQI recommendations 
regarding monitoring of physical function, research is required to determine the 
predictive utility of the ISWT against CPET measured VO2peak.  
Hand-grip strength has been proposed as a simple physical function marker which 
reflects nutritional status of people with stage 5 CKD and mortality risk (Stenvinkel et 
al. 2002). However, although HGS is strongly associated (r = 0.77, p < 0.001) with 
total body protein measured directly by in vivo neutron activation analysis (Windsor 
and Hill 1988), the relative contribution of albumin to HGS was small. Moreover, 
there is currently no consensus threshold of HGS to define whether someone is 
normal or malnourished or at risk of premature mortality. Further research is 
warranted if HGS is to be employed diagnostically in the HD population. 
Medication number was implicated in physical performance but the individual 
influence of particular medications frequently used for cardiovascular management 
of stage 5 CKD patients, such as angiotensin converting enzyme (ACE) inhibitors 
and statins may be as important. Angiotensin enzyme polymorphisms influence 
skeletal muscle phenotype and functional properties in older adults as well as 
athletes (Lima et al. 2010; Gineviciene et al. 2011; Seto et al. 2011; Costa et al. 
2012). Furthermore, large-scale studies indicate that ACE inhibitors are 
independently associated with preservation of lower limb muscle mass and knee 
extensor strength of adults (Onder et al. 2006). Conversely, adverse effects of 
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cholesterol modifying drugs may include statin-induced myopathy (Tomaszewski et 
al. 2011). Exploration of commonly prescribed medications on phenotypic 
expression of genes associated with skeletal muscle response to PA is suggested.  
5.4.12 Limitations 
As this was a cross-sectional study definitive conclusions regarding causality cannot 
be made regarding the variables associated with the physical function outcomes 
investigated. Physical function measures were obtained from a single visit, which 
may have been influenced by acute fluctuations of mood, symptoms and/or health 
status (Nelson-Danquah et al. 2010). Repeated measures of physical function 
analysed as a time-dependent covariate would likely yield a more robust effect 
estimate for the multivariable models. At least one longitudinal study has however 
demonstrated an independent association between self-reported PA and functional 
status (SF-36 PCS) of middle-aged adults (Lahti et al. 2010). Moreover, there is 
agreement from several literature reviews that physical function of HD patients is 
significantly improved following structured PA programmes (Parsons and King-van 
Vlack 2009; Kosmadakis et al. 2010; Segura-Orti 2010; Smart and Steele 2011). 
Analyses were undertaken on a sample of self-selected participants while physical 
performance of individuals ineligible or unwilling to participate was undetermined. 
Although the percentage of female participants closely reflects the UK HD 
population (UKRR 2012) men made up the greater proportion of the sample. 
Therefore, these results should be generalised with caution to the wider HD 
population and may not be generalised to non-ambulatory patients. 
The study sample size fulfilled the minimum requirement for multiple regression 
analysis outlined by Harris (1985) but it was lower than the threshold recommended 
by Tabachnick and Fidell (2007) of 50 + 8(k) (where k is the number of independent 
variables). In addition, a limitation of stepwise regression is that it may be prone to 
overfitting the data, for example the model may fit better on the participant sample in 
which it was developed compared to individuals from outside the sample. This issue 
may be attenuated if the criterion for retaining a candidate variable is robust enough 
and is the reason why backward rather than forward stepwise regression was 
chosen in this analysis. Larger-scale prospective studies are recommended to 
support the validity of models reported in the present study. 
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5.5 Conclusion 
In light of the potential predictive ability of both subjective and objective measures of 
physical function, routine monitoring of these outcomes has been recommended to 
assist the management of this long-term condition. Importantly, the observations 
made in the current study indicate that several clinical and/or demographic factors 
related to stage 5 CKD influence physical function but overall PA appears to be the 
most important modifiable risk factor. Findings from this study therefore underscore 
the importance of current KDOQI guidelines encouraging the promotion of PA 
among people with stage 5 CKD to augment medical management. Moreover, early 
intervention is recommended to prevent what appears to be an inexorable decline 
towards frailty and poor outcomes once CKD severity requires HD therapy. Further 
research is also indicated regarding the predictive utility of field tests of physical 
performance if these outcomes are to be recommended as adjunct measurements 
alongside traditional clinical outcomes. Physical function questionnaires investigated 
in this study do not appear to be suitable for individual patient monitoring.  
What is known about this topic: 
x People with CKD 5 have significant impairment of physical function. 
x Physical function is predictive of health outcomes in this population.  
x Factors associated with a chronic condition and haemodialysis dosage are 
determinants of physical function of maintenance HD patients  
x Regular monitoring of physical function is recommended as part of condition 
management. 
What this study adds: 
x Efficiency of dialysis therapy per se does not influence physical function. 
x Physical activity underpins aspects of physical performance in stage 5 CKD. 
x Self-reported functional status of HD patients is heavily influenced by factors 
other than physical activity, demographic and clinical indices.  
x Further research regarding the prognostic utility of physical performance 
tests of functional capacity in stage 5 CKD is indicated. 
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Chapter 6: Correlates of arterial stiffness in stage 5 CKD 
6.1 Introduction 
6.1.1 Background 
Advances in medical management have incrementally improved the first year 
survival outlook of incident dialysis patients, however long term prognosis is bleak. 
Five-year survival rates are as low as 35% (UKRR 2010; USRDS 2010; Breidhardt 
et al. 2011; SRRR 2013) and life expectancies for people undergoing maintenance 
dialysis therapy aged over 50 years are reduced six fold compared to non-uraemic 
peers in the general population (UKRR 2012). High mortality is mediated largely by 
cardiovascular disease, which accounts for around 36 - 50% of deaths among 
maintenance HD patients (UKRR 2010; USRDS 2010; SRRR 2011). Alarmingly, 
incident cardiovascular (CV) events are at least three times higher among people 
with stage 5 CKD compared to the general population (Parfrey et al. 1996; Go et al. 
2004; Tonelli et al. 2006).  
6.1.2 Cardiovascular mortality and arterial stiffness. 
Atherosclerosis, which is characterized by occlusive lesions of the intima is only 
partially responsible for high CV morbidity and mortality in stage 5 CKD (London et 
al. 2002). A large proportion of increased CV risk has been attributed to 
arteriosclerosis, which affects the media layer of the aorta and large conduit arteries 
and increases vessel stiffness (London et al. 2002; Stenvinkel et al. 2008; London et 
al. 2011; Verbeke et al. 2011). Increased central arterial stiffness is believed to be 
the principal mechanism for isolated systolic hypertension (London et al. 1996; 
O’Rourke and Hashimoto 2007). The principal outcomes of chronically high systolic 
afterload are left ventricular hypertrophy (LVH) (Marchais et al. 1993; Toprak et al. 
2009), which is present in 75% of HD patients (Foley et al. 1995; Nitta et al. 2004) 
and impaired coronary perfusion during diastole (O’Rourke and Hashimoto 2007; 
Wang et al. 2007). Importantly, elevated blood pressure, diastolic dysfunction and 
LVH are independent predictors of CV morbidity and mortality of maintenance HD 
patients (Silberberg et al. 1989; Parfrey et al. 1996; Iseki et al. 1997). 
Carotid femoral pulse wave velocity (PWV), which is a surrogate measure of aortic 
artery stiffness is independently predictive of CV and all cause mortality among 
people with stage 5 CKD (Blacher et al. 1999; London et al. 2001a; Verbeke et al. 
2011). Moreover, it is similarly predictive of outcomes for people with hypertension 
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(Laurent et al. 2006), diabetes (Cruickshank et al. 2002) and older adults (Sutton-
Tyrell et al. 2005). Importantly, the predictive utility of PWV is independent of 
traditional and novel CV risk factors (Vlachopoulos et al. 2010). Augmentation index 
(AI) is another non-invasive vascular measure, which calculates the impact of wave 
reflections from the vascular periphery on the ascending aortic pressure waveform 
(O’Rourke and Kelly 1993). Wave reflections and aortic stiffness contribute to 
isolated systolic hypertension (London et al. 2001a) and are both independently 
associated with increased left ventricular mass of HD patients (Avolio et al. 1983; 
Marchais et al. 1993). Considered a composite measure of arterial stiffness, AI is 
also predictive of CV mortality among patients undergoing percutaneous coronary 
interventions (Weber et al. 2005) and HD patients independent of aortic PWV 
(London et al. 2001a).  
Although arterial stiffening is a pathophysiological process that is driven by 
advancing age (Benetos et al. 2002; Blacher et al. 2003; O’Rourke and Hashimoto 
2007), accelerated vascular aging is a putative phenotype of CKD 5 (Pannier et al. 
2005; London et al. 2011). Mechanisms involved in accelerated arterial stiffness are 
incompletely understood, however, pathogenesis is believed to be mediated largely 
by accelerated calcification of the media layer of central and conduit arteries 
(Blacher et al. 2001; Raggi et al. 2007; Sigrist et al. 2007; Temmar et al. 2010). 
Gender, blood pressure, diabetes, medications and genetic polymorphisms have 
also been associated with arterial stiffness (Blacher et al. 2003; Yasmin et al. 2006; 
Achimastos et al. 2007) but relatively few studies have explored the role of 
behavioural factors such as physical activity (PA). 
6.1.3 Arterial stiffness and physical activity 
Accumulating evidence indicates PA that improves or maintains cardiorespiratory 
fitness (CRF) attenuates age attendant vascular stiffening of adults of all ages 
(Vaitkevicius et al. 1993; Tanaka et al. 2000; Boreham et al. 2004; Aoyagi et al. 
2010; Gando et al. 2010b). There are also indications that light PA is beneficial in 
attenuating arterial stiffness of older adults (Gando et al. 2010a). Moreover, physical 
inactivity negatively impacts endothelial function and biological mechanisms which 
regulate vascular tone and contribute to remodeling of the arterial wall (Wang 2005; 
Green et al. 2004; Suvorava et al. 2004; Thijssen et al. 2009; Whyte and Laughlin 
2010). Importantly, stage 5 CKD is characterised by high prevalence of sedentary 
behaviour and low CRF (Johansen et al. 2000; Longenecker et al. 2002; Stack et al. 
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2005; Cupisti et al. 2010; Tentori et al. 2010) both of which are implicated in 
premature mortality (O’Hare et al. 2003; Sietsema et al. 2004; Matsuzawa et al. 
2012). Current KDOQI guidelines recommend encouraging PA among HD patients 
as part of cardiovascular health management (NKF 2005). However, there is a little 
data regarding the potential relationship between intermediate vascular endpoints 
that are predictive of mortality in stage 5 CKD and PA and CRF.  
6.1.4 Summary 
Despite advances in medical management of CKD 5 statistics highlight low survival 
outcomes due to disproportionately high CV morbidity and mortality. Increased 
arterial stiffness is proposed as one of the mechanisms responsible for CVD 
mortality among maintenance HD patients. Physical activity and CRF are implicated 
in longevity of maintenance HD patients and there is general consensus that PA 
which improves aerobic fitness directly benefits arterial health. However, there is 
presently a paucity of research exploring both behavioural and clinical correlates of 
arterial stiffness indices of maintenance HD patients.  
The objectives of this study were to: 
x Explore clinical and demographic correlates of indices of arterial stiffness of 
people with stage 5 CKD. 
x Explore the relationship between objectively measured physical activity and 
aerobic fitness and indices of arterial stiffness of people with stage 5 CKD. 
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6.2 Methods 
6.2.1 Study design, participant recruitment, inclusion/exclusion criteria 
The present study was conducted in accordance with the ethical principles 
described in the Declaration of Helsinki. Ethical approval was obtained from the 
West of Scotland Research Ethics Committee and the Monklands Hospital 
Research and Development Department. This was a cross-sectional cohort study 
involving 73 self-selected volunteer participants, aged >18 years, ambulant with or 
without a walking aid, and undergoing maintenance HD therapy for stage 5 CKD. 
Participants were recruited from an NHS outpatient HD unit at Monklands Hospital, 
Airdrie. Participants were screened by their physician to verify their eligibility for safe 
participation in the study. The following exclusion criteria were applied: pregnancy; 
unstable cardiovascular conditions, recent cerebrovascular event; recent pulmonary 
thromboembolism; excessive inter-dialytic weight gain determined by physician; use 
of corticosteroids and anabolic therapies; recent pulmonary embolism; serum 
potassium >6 mmol/L; infection or course of antibiotics within one month of study 
period. Individuals were ineligible if they had been diagnosed with dementia/severe 
cognitive impairment, or were not fluent in written and spoken English. Written 
informed consent was obtained from each participant prior to study commencement. 
6.2.2 Demographic and clinical measures 
Anthropometric and clinical measures (age, height, weight, BMI, resting heart rate, 
resting blood pressure) were taken prior to assessment of physical performance 
(general methods 2.1.3). Mean arterial pressure (MAP) was calculated using 
equation 6.1. 
Equation 6.1 Mean arterial pressure 
MAP = diastolic BP + [(systolic BP-diastolic BP)/3] 
(London et al. 2001a) 
The following biochemistry measures were extracted from participants’ electronic 
records of their most recent pre-dialysis blood tests (general methods 2.6.1): dialysis 
adequacy (urea reduction ration), haemoglobin, haematocrit, C-reactive protein, 
albumin, serum phosphate, corrected serum calcium, parathyroid, pre-dialysis 
creatinine. Other variables included a simple additive score of comorbidity, which 
was obtained from review of electronic hospital records (general methods 2.8.1).  
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6.2.3 Measurement of arterial stiffness. 
Carotid femoral pulse wave velocity (PWV) and augmentation index (AI) 
measurements were determined using a Vicorder (Skidmore Medical Ltd, Bristol). 
Assessment conditions were controlled as carefully as practicable (general methods 
2.2.2, table 2.1) and measurements were taken on a non-dialysis day with 
participants lying in a standardized position. Brachial blood pressure was obtained 
using an AND Model UA-767 digital oscillometric blood pressure monitor (A&D 
instruments Ltd, Oxfordshire) after 15 minutes of complete rest (general methods 
2.2.1). Triplicate PWV and AI measurements were obtained as per general methods 
sections 2.2.2 and 2.2.3. Aortic PWV was calculated by the Vicorder software using 
equation 6.2, while AI was determined from brachial artery pressure wave forms via 
a transfer function performed by the Vicorder software. Data regarding number of 
vasoactive medications for each participant was recorded (general methods 2.7.1) 
and explored as potential candidate variable in subsequent data analysis. 
Equation 6.2 Pulse wave velocity 
PWV = aortic path length (suprasternal notch to top of thigh cuff) divided by pulse 
wave transit time  
6.2.4 Assessment of cardiorespiratory fitness 
A proxy measure of peak CRF was obtained from a symptom limited incremental 
shuttle walk test (ISWT) as per general methods section 2.3.4. Participants’ heart 
rate response was monitored (general methods 2.3.4.1) throughout and the test was 
terminated according to (ACSM 2010) guidelines for exercise testing (general 
methods 2.3.4.4). Distance walked and perceived level of exertion according to the 
BORG scale (appendix II) at test termination were recorded. 
6.2.5 Assessment of physical activity 
Estimates of PA were obtained via triaxial accelerometry (general methods 2.5.1) 
using the Actigraph GT3X (Actigraph Corp, Pensacola, Florida). Participants kept a 
wear log (appendix V b). The Actigraph was worn over an eight day period (general 
methods 2.5.7) and retrieved on day 9 coinciding with a routine HD appointment. 
Actigraph PA data were reduced as per general methods sections 2.5.3 and 2.5.4. 
Only those participants with a minimum of eight hours monitor wear on one dialysis 
day and two non-dialysis days were included for final analyses (as per 
recommendations of chapter 3). 
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6.2.6 Data analysis. 
Data analysis was undertaken using the Statistical Package for Social Science 
(SPSS, Illinois, USA), version 19.0. Sample characteristics are presented as mean 
and standard deviation (SD) or median and interquartile range according to results 
of normality testing (Kolmogorov-Smirnov). Differences between groups for the 
same variable were tested using an independent t-test or Mann-Whitney U test for 
normal and non-normal data respectively. Univariable regressions between arterial 
stiffness indices and demographic and clinical variables were performed. Variables 
associated with arterial outcomes, which had a correlation of >0.20 and a 
significance level of ≤0.05 were identified as candidate predictor variables. If the 
minimum ratio of variables to sample size for multiple regression analysis 
recommended by Harris (1985) was violated a selection process was employed to 
reduce the number of variables. Variables were not selected for entry to the multiple 
regression analysis if their β coefficient and confidence intervals approached zero. If 
variables exhibited collinearity, partial correlation analysis was used to select the 
most robust variable for model entry.  Backward stepwise regression analysis was 
used with the selected candidate variables. Physical activity was subsequently 
added to the model containing only the retained clinical and demographic variables. 
Statistical significance for multiple regression analysis was set at a two-tailed value 
of p <0.05. Adjusted r2 values are also reported (Altman 1995).  
6.3 Results. 
6.3.1 Participation. 
Eighty people initially agreed to take part in the study. Seven people either did not 
attend their appointment or withdrew their consent for this study. Seventy three 
people underwent measurement of arterial stiffness and participated in the physical 
activity and physical performance part of the study. A measure of AI was unable to 
be obtained for one participant. Of those who participated in the vascular stiffness 
measures four people declined the shuttle walk test and three participants declined 
or were unable to wear the Actigraph. Another seven participants lacked sufficient 
accelerometer wear time for final analyses as defined by the recommendations of 
chapter three. Figure 6.5 illustrates patient participation and inclusion for multiple 
regression analyses. 
 
222 
Figure 6.1 Flowchart of patient participation and inclusion for m
ultiple regression analyses. 
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6.3.2 Sample characteristics 
Demographic and clinical characteristics for participants with minimum required 
monitor wear time are reported in table 6.1 and are not significantly different to the 
initially recruited sample of 72 participants (appendix XXIV).  
Table 6.1 Demographic and clinical characteristics of all participants (n = 73). 
Data are presented as mean ± SD, or median (IQR) for normal and non-
normally distributed data respectively. 
Characteristic  
Age (years) 55.6 ± 15.6 
Gender M/F (%) 48/25  
Weight 81.0 ±17.5 
Height 167.7 ± 16.6 
Body Mass Index (kg/m2) 28.5 ± 6.3 
Resting Heart rate (bpm) 72.0 ± 13.0 
Systolic (mmHg) 135.6 ± 24.5 
Diastolic (mmHg) 77.6 ± 12.0 
Systemic pulse pressure (mmHg) 52 (43 - 70) 
Mean arterial pressure (mmHg) 96.9 ±13.8 
Haemodialysis Vintage (months) 16.8 (6.7 - 32.7) 
Renal Replacement Therapy Vintage (months) 25.9 (8.1 - 68.8) 
Haemoglobin (g/dL) 11.2 ± 1.0 
Haematocrit (%) 33.9 ± 3.2 
C-reactive protein (mg/L)  0 (0 - 10.0) 
Dialysis Adequacy (%) 71 (66 - 75) 
Albumin (g/L) 39.0 (36.0 - 42.0) 
Troponin T (ng/L) 37 (20.5 - 69.5) 
Corrected Calcium serum level (mmol/L) 2.36 ± 0.17 
Phosphate (mmol/L) 1.43 ± 0.41 
Parathyroid level (mmol/L) 16.8 (9.9 - 30.6) 
Creatinine pre-dialysis (μmol/L) 683 (558 - 672) 
Number of vasoactive medications 2.0 (1.0 - 3.5) 
Number of comorbidities, (N) 1.0 ± 0.8 
x Hypertension (%) 42 (58) 
x Diabetes mellitus (%) 16 (22) 
x Cardiovascular disease (%) 14 (19) 
Pulse wave velocity (m/s) 7.5 (6.3 - 9.0)  
8.03 ± 2.3† 
Augmentation Index (%) ¥ 20.4 ± 7.5 
Shuttle walk test distance (metres)∞ 280 (170 - 440) 
Physical activity (based on daily average Triaxial cpm) € 289 (183 - 397)  
†data non-normally distributed, mean ± SD presented for comparison 
¥n = 72, ∞n = 69, €n = 63 
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Participant age ranged from 24 to 87 years, with 35 percent of the sample aged 65 
years or older. Participants with diagnosed diabetes accounted for 22 percent and 
women made up 34 percent of the sample. The average age of female participants 
(49.9 ± 13.1 years) was significantly younger (t(71) = 2.33, p = 0.02) than males 
(58.6 ± 16.1 years).  
Average measure intra-class correlation coefficients for intra-session measurements 
of PWV and AI were 0.99 (0.987 - 0.994) and 0.95 (0.919 - 0.964) respectively. The 
average intra-subject coefficient of variation for intra-session PWV was 3.1% and 
13% for AI. Non-parametric testing revealed PWV values for women were 
significantly lower than those for men for both the whole sample (U = 404, p = 0.02, 
n = 73) and the reduced sample of participants with sufficient PA data (U = 311, p = 
0.03, n = 63). Diabetic participants also had significantly higher PWV than non-
diabetics (U = 187, p < 0.001) and there was no significant difference in age 
between the two groups (U = 363, p = 0.22). Independent t-tests revealed no 
significant gender differences in AI values for the whole sample (t(70) = -0.61, p = 
0.55) and the reduced sample size of participants with sufficient PA data (t(60) = -
0.13, p = 0.90). Similarly, there were no significant differences in AI values between 
diabetic and non-diabetic participants (t(70) = -0.22, p = 0.83).  
Table 6.2 Arterial stiffness, physical activity and CRF status according to 
gender. 
Outcome Men (n = 48) Women (n = 25) 
Pulse wave velocity 8.4 ± 2.4† 
8.1 (6.7 - 9.9) 
7.3 ± 2.0† 
6.7 (6.2 - 8.0) 
Augmentation Index 20.0 ± 7.9¥ 21.1 ± 6.7 
Shuttle walk test distance (m) 270 (160 - 480)¥ 335 (168 - 408)₤ 
Physical activity (Triaxial cpm) 245 (147 - 387)∞ 322 (259 - 450)€ 
† Data not normally distributed mean ± SD presented for comparison. 
¥n = 47 ,∞n = 40, €n = 23, ₤n = 22 
6.3.3 Univariable analyses 
Eleven clinical and demographic variables were significantly associated with PWV at 
univariable level for the sample of participants (table 6.3). The strongest association 
was observed between age and PWV (Pearson’s r = 0.63, p < 0.001), while more 
modest associations were seen with the remaining clinical variables. Univariable 
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analysis yielded similar associations when performed on the participant sample with 
sufficient PA data for final analyses (appendix XXV a). Some slight changes were 
observed, for example, associations with diabetic status, troponin-t, serum 
phosphate, number of vasoactive medications, serum creatinine (postdialysis) and 
ISWT weakened slightly. In addition, associations with gender and comorbidities 
were no longer significant. Correlations with, age and HD vintage were slightly 
stronger, although the coefficient for the latter was lower, which could potentially 
reduce the contribution of this variable in a multivariable regression model.  
Table 6.3 Univariable associations with pulse wave velocity. 
n = 73 Unstandardized β 
(Lower, Upper) 
r2 
Age 0.09*** (0.07, 0.12) 0.40*** 
Systolic blood pressure 0.05*** (0.03, 0.07) 0.25*** 
Troponin-t  0.012** (0.005, 0.019) 0.14** 
Diabetic status 1.92** (0.71, 3.14) 0.12**  
Vasoactive Medications 0.44** (0.14, 0.74) 0.12** 
Phosphate  -1.86** (-3.10, -0.61) -0.11** 
Creatinine (predialysis) † -0.003* (-0.005, 0) -0.07* 
Creatinine (postdialysis) † -0.006* (-0.011, -0.001) -0.07* 
HD Vintage 0.022* (0.004, 0.04) 0.07* 
Comorbidities 0.75* (0.09, 1.41) 0.07* 
Gender -1.12* (-2.21, -0.02) -0.06* 
Shuttle walk (m) ∞ -0.004*** (-0.006, -0.002) -0.20*** 
Physical activity (cpm) -0.003*(-0.005, -0.001) -0.09** 
*p < 0.05, ** p < 0.01, ***p < 0.001 
†n = 71, ∞n = 69, €n = 63 
Fewer demographic and clinical variables were related to AI compared to PWV 
(table 6.4) and with more modest associations typically observed. Although the 
proxy measure of aerobic fitness (the ISWT) was significantly associated with this 
index of arterial stiffness, PA was not (p = 0.22).  
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Table 6.4 Significant univariable associations with augmentation index.  
n = 72 Unstandardized β 
(Lower, Upper) 
r2 
Height -0.14** (-0.24, -0.04) -0.10** 
Age 0.14* (0.03, 0.25) 0.09* 
BMI 0.34* (0.071, 0.61) 0.08** 
Heart rate (resting) -0.16* (-0.29, -0.03) 0.08** 
Haematocrit † 0.64* (0.11, 1.17) 0.08* 
Haemoglobin 1.713* (0.101, 3.326) 0.06* 
Shuttle walk (m) ∞ -0.009* (-0.017, -0.002) 0.09** 
Physical activity (cpm) -0.005 (-0.012, 0.003) 0.05, p = 0.11 
*p < 0.05, ** p < 0.01, ***p < 0.001 
†n = 71, ∞n = 68, €n = 62 
Results of univariable analysis performed with data for participants with sufficient 
activity monitor wear time were again similar. Slightly lower β coefficients and 
stronger correlations were observed for the following variables: age, height, ISWT, 
(appendix XXV b). However, associations with BMI and haematocrit were no longer 
significant and a slightly stronger association was observed for resting heart rate. 
Notably, no significant association was observed between PWV and AI for 
participants with values for both outcomes (n = 72) and those with the sufficient PA 
data (p = 0.15 and p = 0.38 respectively). 
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6.3.4 Pulse wave velocity multivariable regression analysis.  
The following candidate variables were entered for multivariable regression analysis 
with PWV as the dependent variable: age, number of vasoactive medications, 
diabetic status, serum phosphate, troponin T, HD vintage, systolic blood pressure, 
gender. Post-dialysis serum creatinine was selected over predialysis serum 
creatinine as the coefficient limits for the latter included zero.   
Table 6.5 Results of pulse wave velocity multivariable regression analysis 
with resulting model subsequently adjusted for PA and CRF level.   
 PWV Model (n = 73) 
PWV Model adjusted 
for PA (n = 63) 
PWV Model adjusted 
for CRF (n = 69) 
Variable 
Unstandardized β 
(Lower, Upper) 
Unstandardized β 
 (Lower, Upper) 
Unstandardized β 
 (Lower, Upper) 
Age 0.07*** (0.05, 0.10) 0.082*** (0.056, 0.108) 0.07*** (0.05, 0.10) 
Troponin-T  0.006* (0.001, 0.011) 0.003  (-0.003, 0.009) 0.005* (0, 0.011) 
HD vintage 0.014* (0.001, 0.026) 0.013 (-0.001, 0.027) 0.014* (0, 0.027) 
Systolic Bp 0.036*** (0.021, 0.05) 0.036*** (0.02, 0.053) 0.035*** (0.020, 0.051) 
Physical Activity Not entered 0  (-0.002, 0.002) 0  (-0.002, 0.002) 
r  0.79 0.77 0.78 
r2 0.62 0.59 0.61 
r2 (adjusted) 0.60 0.57 0.59 
*p < 0.05, ** p < 0.01, ***p < 0.001 
Over half of the variance in PWV values was explained by systolic blood pressure, 
HD vintage, troponin-T, and age (table 6.5). The addition of habitual PA level 
effected no significant change in the explained shared variance and was not 
significant in the model (p = 0.72). In addition, troponin-T was no longer 
independently associated with PWV (p = 0.27) and HD vintage was reduced to a 
trend (p = 0.06). In contrast the model remained unchanged after adjustment for 
CRF level (ISWT performance) and the latter was not retained as a significant 
predictor (p = 0.76).  
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6.3.5 Augmentation index multivariable regression analysis 
On the basis of preliminary univariable analyses the following six candidate 
variables were entered for multiple regression analysis for AI: age, height, 
haematocrit, haemoglobin, BMI and resting heart rate.  
Table 6.6 Results of augmentation index multivariable regression analysis 
with model subsequently adjusted for PA and CRF level. 
 AI model (n = 72) 
AI model adjusted for 
PA (n = 61) 
AI model adjusted for 
CRF (n = 67) 
 Variable 
Unstandardized β 
(Lower, Upper) 
Unstandardized β 
 (Lower, Upper) 
Unstandardized β 
 (Lower, Upper) 
Age 0.11* (0.01, 0.20) 0.08  (-0.02, 0.18) 0.12* (0.02, 0.22) 
Height -0.14** (-0.23, -0.04) -0.11* (-0.21, -0.02) -0.13** (-0.23, -0.04) 
BMI 0.36** (0.11, 0.61) 0.29* (0.02, 0.55) 0.37** (0.12, 0.63) 
Heart rate (rest) -0.20** (-0.32, -0.08) -0.25*** (-0.38, -0.12) -0.19** (-0.32, -0.07) 
Haemoglobin 1.42* (0.03, 2.82) 1.25 (-0.34, 2.83)  1.28  (-0.21, 2.76) 
PA not entered 0.001  (-0.01, 0.01) -0.002  (-0.01, 0.01) 
r  0.63 0.53 0.62 
r2 0.39 0.28 0.39 
r2 (adjusted) 0.35 0.24 0.34 
*p < 0.05, ** p < 0.01, ***p < 0.001 
One third of the variance in AI values was explained by age, height, BMI, and 
resting heart rate, with the latter making the largest relative contribution (table 6.6). 
Subsequent adjustment for PA level did not improve the model and the former was 
not retained as a predictor of AI (p = 0.86). In addition, when the sample size was 
reduced to only those individuals with sufficient PA data for analysis, age was no 
longer independently associated with AI and the variance explained consequently 
decreased. The addition of CRF level (ISWT performance) effected no significant 
change in the explained shared variance from the initial AI model and was not 
significant (p = 0.63).  
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6.4 Discussion 
6.4.1 Contextualising this sample of people with stage 5 CKD 
The average age of participants in the present study was broadly similar (either the 
same or up to four years higher) compared to mortality and exercise intervention 
studies with vascular outcomes previously undertaken in stage 5 CKD (London et al. 
1992; Blacher et al. 1999; London et al. 2001a; Blacher et al. 2003; Mustata et al. 
2004; Koh et al. 2010). The only exception being the study by Toussaint et al. 
(2008a) in which participants were at least a decade older. Length of time on 
dialysis in previous studies is difficult to compare as mean rather than median HD 
vintage are commonly reported despite standard deviations, which clearly indicate 
data are not normally distributed. 
Compared to previous vascular health studies undertaken in stage 5 CKD, 
participants in the present study demonstrated generally lower values for similar 
arterial stiffness indices. Average PWV values were at least 11% lower than those 
reported in exercise intervention studies (Toussaint et al. 2008a; Koh et al. 2010) 
and 7 to 30% lower than previous vascular health and mortality studies undertaken 
in stage 5 CKD (London et al. 1992; Blacher et al. 1999; London et al. 2001a; Shoji 
et al. 2001; Avramovski et al. 2013). Augmentation index values were similar to 
those reported by Koh et al. (2010) but 12% lower than those of London et al. 
(1992). However, average AI values in the present study were nearly one third lower 
than those reported for CKD patients not requiring renal replacement therapy (RRT) 
(Mustata et al. 2010), and HD patients in the exercise intervention study of 
Toussaint et al. (2008a). In addition, blood pressure indices for participants in the 
present study were at least 5% lower compared to earlier arterial stiffness studies 
involving people with stage 5 CKD (Blacher et al. 1999; London et al. 2001a; 
Toussaint et al. 2008a; Koh et al. 2010). Taken together it appears that participants 
in the present study have generally better vascular health as measured by indices of 
arterial stiffness compared to other samples of maintenance HD patients. 
Average measure intra-class correlation coefficients for the PWV and AI measures 
were both excellent. Coefficient of variation for PWV values obtained by the 
Vicorder in the present study (3.1%) was comparable to the 2.8% reported by 
Hickson et al. (2009) and 5% reported by Shoji et al. (2001) for the SphygmoCor 
device. Reassuringly it is also much lower than the 22% reported by van Leeuwen-
Segarceanu et al. (2010). The coefficient of variation for AI was 13%, which is 
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substantially higher than the 2.4% reported for AI measures obtained by 
SphygmoCor in healthy adults (Covic et al. 2000).  
6.4.2 Overview of findings 
The data from the current study concur with previous reports that age, and blood 
pressure are the principal drivers of the characteristic aortic artery stiffness of 
maintenance HD patients. Novel findings were that HD vintage and a biomarker of 
cardiac damage were also retained in a statistical model which accounted for over 
half of the variance in PWV values. Commonly reported determinants of AI including 
age, height and heart rate were also found to be independent predictors of AI in the 
present sample of maintenance HD patients. Just under a third of the variance was 
explained by a model, which also included serum haemoglobin and BMI as novel 
independent predictors of AI. Although PWV and time to the reflection point are 
thought to be the principal determinants of AI (Rossi et al. 2011) no significant 
association was observed between these vascular indices. Habitual PA and CRF 
were correlated with arterial stiffness at univariable level but neither emerged as an 
independent predictor in the multivariable analyses.   
6.4.3 Independent predictors of arterial stiffness 
6.4.3.1 Age and blood pressure 
Age and brachial systolic blood pressure appear to explain the majority of shared 
variance when entered separately into the PWV model. This is in agreement with a 
large body of studies reporting age and blood pressure indices as important PWV 
risk factors in larger and smaller cohorts of maintenance HD patients (Shoji et al. 
2001; Blacher et al. 2003 and Temmar et al. 2010 respectively), people with CKD 
not requiring RRT (Temmar et al. 2010) and a systematic review of 77 studies 
(Cecilja and Chowienczyk 2009). The physiological basis for age attendant increase 
in arterial stiffness is believed to be due to changes in the extracellular matrix of the 
arterial wall. Elastin cells are gradually lost or become calcified (Yu and Blumentahl 
1963) and there is an overproduction of abnormal collagen cells which start to form 
crosslinks (Greenwald 2007). In addition, degradation and fragmentation of the 
elastin lamellae from repetitive stress cycles subsequently places greater load on 
stiffer collagen fibres and changes arterial diameter (Benetos et al. 2002). Age 
perhaps represents the least modifiable risk factor for increased arterial stiffness. 
However, whether changes in the arterial wall extracellular matrix are due to the 
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aging process per se or associated with long-term exposure to other risk factors for 
vascular aging such as diabetes and blood pressure is uncertain (Chue et al. 2010). 
The independent association of systolic blood pressure with PWV in the present 
study is also consistent with overwhelming evidence highlighting blood pressure as 
a determinant of aortic stiffness in people with and without CKD (Laurent et al. 2005; 
Cecilja and Chowienczyk 2009). According to the Maxwell model, as transmural 
pressure rises and distends the artery there is progressively greater recruitment of 
collagen fibres and a concomitant reduction in elasticity (Bank et al. 1996). In 
addition, the role of hypertension in hypertrophy of the arterial media to maintain 
tensile stress within physiological limits (Laplace’s law) is well documented (Benetos 
et al. 1993; Dobrin 1995; Safar and Frohlich 2007). Wall thickness, elastic modulus, 
and vessel diameter are the principal factors in the Moens–Korteweg equation to 
calculate PWV. Importantly, elevated blood pressure is also inversely associated 
with endothelial function (Nigam et al. 2003), which provides functional regulation of 
aortic stiffness via vasomotor control (McEniery et al. 2006; Bruno et al. 2012). 
Indices of blood pressure were not associated with AI, which is in agreement with a 
previous study involving maintenance HD patients (London et al. 1992) and studies 
of hypertensive humans and animals (Safar et al. 2000). Moreover, there is 
evidence of a blood pressure independent association between AI and the ratio of 
extra cellular to intracellular fluid in CKD 5 (Lin et al. 2003).  
6.4.3.2 Haemodialysis vintage  
Haemodialysis therapy emerged as an independent risk factor for aortic arterial 
stiffness while dialysis adequacy was not correlated. Hotta et al. (2012) similarly 
observed HD vintage was correlated with brachial-ankle PWV (r = 0.32, p < 0.05). 
This result suggests that length of exposure to stage 5 CKD requiring HD therapy is 
a more important risk factor for vascular aging than efficiency of uraemic solute 
removal. There is consensus that accelerated vascular aging occurs in the presence 
of uraemia (London et al. 1990; London et al. 1992; Pannier et al. 2005; Avramovski 
et al. 2013) but this is the first time the relative contribution of exposure to HD 
therapy has been quantified. Worryingly, just six years of HD was needed to 
increase PWV by 1 m/s and thus mortality risk by 15% compared to 14.3 years of 
chronological age. No relationship was found between HD vintage and AI, which is 
surprising as this index is correlated with endothelial function which is also 
independently associated with HD vintage (Cheng et al. 2008). Progressive 
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concentric LVH occurs among maintenance HD patients (Foley et al. 2010) and 
contribution of HD vintage to increased arterial stiffness is a plausible reason why 
this happens. It is debatable whether this risk factor for aortic stiffness is modifiable, 
but the fact that total RRT vintage was not associated with PWV suggests it may be. 
Aortic stiffness appears to be ameliorated following kidney transplantation (Covic et 
al. 2003; Posadzy-Malaczynska et al. 2005) or its progression at least slowed 
(Zoungas et al. 2004; Bachelet-Rousseau et al. 2011). Whether this is due to 
lifestyle change or reversal of uraemia per se and improved blood pressure control 
(Bachelet-Rousseau et al 2011), reduced inflammation (Lima et al. 2011, Simmons 
et al. 2005) as well as favourable effects of restored prostaglandin synthesis on 
vascular tone is unclear.  
6.4.3.3 Troponin-T 
More regularly used as a biomarker for diagnosing acute coronary episodes, 
Troponin-t emerged as an independent predictor of PWV. Baia et al. (2011) also 
found high sensitivity Troponin-t was independently associated with PWV in older 
adults. It is more likely that this variable is an expression of the upstream effects of 
arterial stiffness rather than an influencing factor. Mechanistically, increased aortic 
stiffness is believed to result in faster incident and early return of reflected waves, 
which increase aortic and left ventricular pressure during systole (London et al. 
1996; O’Rourke and Hashimoto 2007). This result indicates that subsequent chronic 
increases in systolic stress not only cause deleterious changes in ventricular 
morphology and function (Marchais et al. 1992; Toprak et al. 2009) but also 
subclinical myocardial damage. Interestingly, these data indicate that aortic arterial 
stiffness but not wave reflections is a mediator of myocardial injury. This result 
suggests that a reduction in PWV may be more likely to reduce subclinical 
myocardial damage in this group of people with stage 5 CKD.  
6.4.3.4 Heart rate and arterial stiffness 
Resting heart rate was inversely associated with AI which is in agreement with 
findings from large-scale epidemiological studies (Janner et al. 2010; Chirinos et al. 
2011) and studies exploring AI response to heart rate induced by ventricular pacing 
(Stefanadis et al. 1998), atrial pacing (Wilkinson et al. 2000; Wilkinson et al. 2002) 
and dobutamine (Sharman et al. 2009). Mechanistically, it has been proposed that a 
faster heart rate shortens systole duration resulting in the reflected wave being 
shifted towards diastole thereby lowering height of the second systolic peak and 
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thus augmentation pressure (Wilkinson et al. 2002). It has also been suggested that 
there is a shortening of the rapid phase of ventricular ejection and consequently a 
reduction in ejection velocity (Wilkinson et al. 2002). However, wave reflections still 
return during systole with a higher heart rate suggesting shifts in wave form timing 
may not be the principle driving factor in AI (Sharman et al. 2009). Notably, an 
increase of 10 beats per minute equated to an incremental 2% reduction in AI in the 
present study. Larger incremental reductions were reported in the ACCT (McEniery 
et al. 2005) and heart rate manipulation studies (Wilkinson et al. 2000; Wilkinson et 
al. 2002) (5% and 4% respectively). The lower coefficient observed here may be 
due to the large percentage of participants on heart pacing medications. 
In contrast, resting heart rate was not a correlate of PWV in the present study but it 
has previously been independently associated with PWV of HD patients (Blacher et 
al. 2003) and healthy adults (Achimastos et al. 2007). The coefficient and 
univariable r2 for heart period reported by Blacher et al. (2003) were both very small 
(β = -0.0039 and r2 = 0.02, p < 0.001) and differing findings may be due to the 
comparatively smaller size of this study and thus lower statistical power to detect an 
association. However, studies specifically examining the effect of heart rate on PWV 
have shown that while changes in heart rate are inversely associated with ejection 
duration, aortic PWV is not affected (Wilkinson et al. 2000; Wilkinson et al. 2002). 
6.4.3.5 Haemoglobin and haematocrit and augmentation index 
Haematocrit and haemoglobin level were both correlates of AI with the latter 
retained as an independent predictor, which has not been previously reported. 
Although this result is novel, it may be considered consistent with studies 
demonstrating a significant increase in peripheral resistance and mean arterial 
pressure of maintenance HD patients following partial correction of anaemia 
(Steffen et al. 1989; Mayer et al. 1991). An increase in peripheral resistance would 
likely increase wave reflections and thus AI. Anaemia instead induces an ‘anoxic’ 
peripheral vasodilatory effect (Nichols and O’Rourke 2005), which would likely 
reduce the amplitude of retrograde pressure waves and augmentation pressure. 
6.4.3.6 Height and augmentation index  
Stature was independently and inversely correlated with AI which is in agreement 
with studies demonstrating wave reflections occur later in taller individuals (Smulyan 
et al. 1998; McGrath et al. 2001). Taller stature and concomitant greater effective 
length of the arterial system lengthens the distance to the reflection point, thereby 
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extending the time interval for the reflected wave. London et al. (1995) reported 
higher AI in their female participants was associated with shorter height and greater 
tapering of the abdominal aorta compared to men. In the present study males were 
significantly taller than female participants (U = 67.5, p < 0.001), however, no 
gender difference in AI values was found. The effects of shorter stature may have 
been partially offset by greater distensibility of peripheral arteries in younger women 
compared to men (London et al. 1995). Another suggested explanation is the 
influence of heart rate on AI. In small mammals a shorter time to the reflection point 
is paralleled by a shorter heart period (increased heart rate) to maintain optimal 
ventricular/vascular coupling (London et al. 1995). As resting heart rates of females 
were significantly higher than male participants (t(70) = 2.17, p = 0.03) this might 
account for why gender did not influence AI values despite differences in stature. 
6.4.3.7 Body mass index and augmentation index 
Body mass index was independently associated with AI in the present study, which 
has not been previously reported for stage 5 CKD patients. An increase of 5 kg/m2 
resulted in an incremental increase of 1.8 % in AI values, which is in keeping with a 
1.5% increase (p = 0.004) observed by Shim et al. (2011) for overweight older 
women. Body mass index is independently associated with declining endothelial 
function of peritoneal dialysis patients (Cheng et al. 2008), which is suggested as 
one of the mechanisms by which AI is influenced. Persistent mild inflammation, 
which is associated with obesity due to higher levels of pro-inflammatory cytokines 
released from adipose tissue (Fain 2006) may impair endothelial function and 
increase vascular tone. Endothelial function represents the functional component of 
arterial stiffness and is inversely associated with AI of healthy individuals (Nichols 
and O’Rourke 2005) and diabetics (Ravikumar et al. 2002). Another potential player 
is angiotensin II, which is observed to exert a greater vasoconstrictive response in 
adults with visceral obesity (Nielsen et al. 2004).  
Insulin resistance and hyperglycaemia related to obesity is also a plausible 
mechanism. Higher circulating levels of fatty acids and glucose may mediate an 
increase in nonenzymatic glycation of arterial wall collagen cells (Airaksinen et al. 
1993). Lastly, leptin released from adipose tissue is implicated in proliferation and 
migration of vascular smooth cells (Oda et al. 2001) and arterial calcification 
(Parhami et al. 2001). Moreover, this hormone is associated with arterial 
distensibility independent of endothelial function (Singhal et al. 2002).  
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6.4.4 Contextualisation of derived arterial stiffness prediction models 
The amount of PWV variance explained in the present study (60%) is similar to 
previous stage 5 CKD studies of Blacher et al. (2003) and Temmar et al. (2010) 
(57% and 49% respectively). It is also in line with results reported in large-scale 
studies of healthy adults (51% to 58%) by Yasmin et al. (2006) and Achimastos et 
al. (2007). Age, height, BMI and resting heart rate were independently associated 
with AI with which is consistent with findings from large epidemiological studies of 
apparently healthy individuals (van Trijp et al. 2004; Janner et al. 2010; Chirinos et 
al. 2011). The amount of variance explained in the present study (35%) sits near the 
middle of a wide spectrum of results reported in the general literature which range 
from 19% to 73% (van Trijp et al. 2004; Chirinos et al. 2011).  It is considerably less 
than the 58% reported for a mixed cohort of HD patients and controls (London et al. 
1992). However London et al. (1992) did not undertake subgroup analysis for 
participants with stage 5 CKD which may have yielded a different result. A larger 
subsequent study by the same research group involving only HD patients (London 
et al. 2001a) accounted for a lower amount of AI variance (49%) but still more than 
the present study. Although age of the study groups was similar, in the latter study 
the percentage of diabetic participants taking part was less than half that of the 
present study (10%). In addition, heart rate was used as the chronotropic variable in 
this study while both cited studies used left ventricular ejection duration. Sharman et 
al. (2009) reported that substitution of ejection duration for heart rate significantly 
improved their AI prediction model by a further 7%. Differing methods of wave form 
assessment and transfer functions may have also contributed to differing results. 
Previous studies employed doppler or SphygmoCor devices and tonometry of the 
radial artery while the Vicorder used in the current study employs oscillometry for 
wave form sampling of the brachial artery.  
Age was an important independent predictor of PWV in the current study, a fact that 
is well documented in the general literature (Cecilja and Chowienczyk 2009). The 
adjusted coefficient for age (β = 0.073) was similar to that reported by Blacher et al. 
(2003) in a larger study of 242 maintenance HD patients (β = 0.079) and the ACCT 
(β = 0.078) involving 1000 healthy participants (McEniery et al. 2005). In contrast, 
Temmar et al. (2010) and Townsend et al. (2010) reported higher coefficients for HD 
patients and people with CKD not requiring RRT (β = 0.15 and 0.11 respectively). 
Participants in these studies were on average six to 10 years older, which may 
account for some of this difference as the relationship between PWV and age 
 236 
increases in strength with advancing age (Mitchell et al. 2004; McEniery et al. 2005; 
Janner et al. 2010). Notably the largest coefficient reported in a larger sample of HD 
patients (β = 0.33) was by Shoji et al. (2001). The reason for the large disparity is 
unclear but may relate to the lower shared variance explained by their model (r2 = 
27, p < 0.001) and a higher proportion of female participants compared to the 
present study (59% versus 33% respectively).    
Age appeared to make a comparatively more modest independent contribution to AI 
when entered separately to the model (r2 change = 0.05, p < 0.05). Stronger 
univariable associations between age and AI are reported in the general literature (r 
= 0.41 to 0.58, p < 0.01) for younger adults (Kelly et al. 2001; Lemogoum et al. 
2004; Binder et al. 2006) than that observed here. Differing results may be due to 
important differential effects of age on these vascular indices. Findings from large-
scale studies such as the ACCT, Framingham Heart Study and the Copenhagen 
City Heart Study report curvilinear relationships between AI, PWV and age (Mitchell 
et al. 2004; McEniery et al. 2005; Janner et al. 2010). Augmentation index increases 
with advancing years until age 40 - 50, after which a plateau is observed, while the 
relationship between age and PWV increases after this point (McEniery et al. 2005; 
Janner et al. 2010).  
6.4.5 Correlates of arterial stiffness 
6.4.5.1 Gender 
Male gender was positively associated with PWV at univariable level but it was not 
retained as an independent predictor, which is in agreement with previous studies 
involving people with stage 5 CKD (London et al. 1992; Shoji et al. 2001; 
Beerenhout et al. 2003; Temmar et al. 2010) and healthy individuals (Vaitkevicius et 
al. 1993). In contrast, studies involving larger cohorts of HD patients (Blacher et al. 
2003), people with CKD not requiring RRT (Townsend et al. 2010) and healthy 
adults (McEniery et al. 2005; Achimastos et al. 2007) have reported gender as a 
determinant. Pulse wave velocity values for women in the present study were 
significantly lower than those for men, however the former were on average 8.7 
years younger, which may explain why gender was not a predictor after adjustment 
for age. Gender was not independently associated with AI in the present study, 
which is in line with a study of HD patients and controls by London et al. (1992). In 
contrast large epidemiological studies of apparently healthy individuals have 
reported gender as a determinant of AI (Janner et al. 2010; Chirinos et al. 2011). 
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Central arterial stiffness of premenopausal women is generally lower than men and 
is attributed to the influence of gender-related sex steroid hormones (Rossi et al. 
2011). However, gender differences in vascular stiffness rapidly diminish after 
menopause (Waddell et al. 2001; Mitchell et al. 2004). 
Differing findings regarding the independent influence of gender on arterial stiffness 
may possibly be attributed to the presence of CKD, which interrupts normal 
hormonal function. Interestingly, although over half of the women in this study would 
be classified as premenopausal (<50 years) (Rymer and Morris 2000) a Mann- 
Whitney U test revealed no significant gender difference in PWV values for 
participants aged <50 years (U = 78, p = 0.56). This suggests that either the 
beneficial vascular effects of female hormones may have been nullified by CKD 
related factors, or early onset of menopause which has also been reported in the 
HD population (Shanmugavadivoo and Shaariah 2003; Song et al. 2008). 
6.4.5.2 Diabetic status 
Diabetic participants were similar in age to non-diabetics (U = 363, p = 0.22) but 
demonstrated significantly higher PWV values (U = 187, p < 0.001), which is in 
agreement with a larger study of 265 maintenance HD patients (Shoji et al. 2001). 
Diabetes is believed to increase arterial stiffness via hyperglycaemia driven 
accumulation of advanced glycolated end products (AGEs), which mediate 
structural change in artery walls (Lakatta 2003; Konova et al. 2004). Another likely 
pathway is via inflammation induced endothelial dysfunction commonly observed 
with diabetes (Naka et al. 2012; Ravikumar et al. 2002; Tan et al. 2002), which 
elicits changes in arterial tone as well as structure. Numerous studies using a range 
of methodologies agree that diabetes is characterized by increased arterial stiffness 
throughout the vascular tree across all ages (Stehouwer et al. 2008).  
Despite being significantly correlated with PWV, diabetes did not emerge as an 
independent predictor in the current study in contrast to previous studies of people 
with CKD (Shoji et al. 2001; Temmar et al. 2010; Townsend et al. 2010). This 
discrepancy may be due to a smaller percentage of diabetic participants (22%) here 
compared to the cited studies, in which diabetics made up between one third to a 
half of participants. In addition, diabetic status and systolic blood pressure were 
moderately correlated (Spearman’s rho = 0.51, p < 0.001) and adjustment for the 
latter completely attenuated the association between diabetes and PWV (r = 0.09, p 
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= 0.44). It is suggested that higher blood pressure observed with diabetic status is 
probably why PWV was observed to be higher among diabetics in the present study. 
Surprisingly, AI and diabetic status were not correlated and there was no significant 
difference in AI values between diabetic and non-diabetic participants (t(70) = 0.22, 
p = 0.83). These results add to a growing body of studies which agree that aortic 
stiffness is higher in diabetics, but that a concomitant differential increase in AI does 
not necessarily occur. Values are either no different (Westerbacka et al. 2000; 
Ravikumar et al. 2002; Lacy et al. 2004; Schram et al. 2004) or lower (Cheng et al. 
2007) compared to controls. Crucially, diabetes is independently associated with 
higher CV mortality among HD patients (Shoji et al. 2001). Lack of association 
between diabetic status and AI is difficult to reconcile and raises doubt over its 
validity in a population characterised by high prevalence of this condition. 
6.4.5.3 Paradoxical and absent correlations 
Inflammation, high serum levels of phosphate and activation of the renin-angiotensin 
system are some of the putative mechanisms for increased arterial stiffness in stage 
5 CKD. Inflammation is significantly associated with CV risk and mortality among 
maintenance HD patients (Zimmerman et al. 1999; Shoji et al. 2001) but it was not 
correlated with PWV or AI (p = 0.09 and p = 0.22 respectively). Use of a high 
sensitivity assay of CRP may have yielded a different result. However, the weight of 
evidence suggests that inflammation has more profound influence on endothelial 
dysfunction (Fichtlscherer et al. 2000) and morphological changes to the arterial 
intima (Stenvinkel et al. 1999; Torzewski et al. 2000; Zoccali et al. 2000) than the 
tunica media. Importantly, arterial stiffening is driven largely by pathological changes 
in the latter (Blacher et al. 2001; London et al. 2003). Moreover, CRP is reported to 
be predictive of CV and all cause mortality among HD patients independent of aortic 
PWV (Shoji et al. 2001). Stage 5 CKD is independently associated with AI and PWV 
(London et al. 1992), however, efficiency of uraemic solute removal (URR) was not 
correlated with either index. This result suggests that uraemia per se does not 
mediate increased arterial stiffness of maintenance HD patients. It is possible that 
this may be because by the time dialysis is commenced at least 50% of patients 
show some degree large artery calcification (Guerin et al. 2001; Sigrist et al. 2006) a 
proportion that increases up to almost three quarters among prevalent HD patients 
(Chesterton et al. 2005; Sigrist et al. 2006). 
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Higher serum phosphate is implicated in aortic calcification in stage 5 CKD (Jono et 
al. 2000; Moe and Chen 2004) and is associated with CV and all-cause mortality in 
this population (London et al. 2005; Melamed et al. 2006). Paradoxically, serum 
phosphate, calcium and calcium phosphate product were inversely associated with 
aortic PWV. The reason for this is unclear as treatment of hyperphosphataemia with 
phosphate binders has been found to slow progression of aortic calcification 
(Chertow et al. 2002). Notably, Melamed et al. (2006) observed a higher mortality 
risk among HD patients whose phosphate levels declined over six months and 
suggested this may have been due to aggressive use of phosphate binders. No 
correlations were observed between serum parathyroid hormone and arterial 
stiffness indices. This result is consistent with a current lack of consensus in the 
literature regarding the contribution of these biomarkers to arterial calcification and 
mortality in stage 5 CKD (London et al. 2005; Melamed et al. 2006).  
Serum creatinine was inversely associated with PWV, which is at odds with a 
longitudinal study of treated hypertensives showing this biomarker was the most 
important determinant of PWV over six years (Benetos et al. 2002). In addition, 
number of vasoactive medications was positively related to PWV, while a trend was 
observed for ACE inhibitor use (r = 0.18, p = 0.06). The reason for latter is unclear 
as meta-analyses of ACE inhibitor use demonstrate modulation of the renin-
angiotensin system lowers arterial stiffness (Safar et al. 2004; Ong et al. 2011). 
6.4.5.4 Which index of blood pressure? 
In the current study, systolic blood pressure was independently associated with 
PWV in agreement with studies of healthy adults (Achimastos et al. 2007; Ronnback 
et al. 2007; Naka et al. 2012) and diabetics (Naka et al. 2012). However, MAP which 
represents the steady component of blood pressure and the main arbiter of arterial 
wall stress according to Laplace’s law is the most commonly reported predictor of 
PWV in HD studies (Beerenhout et al. 2003; Blacher et al. 2003; Temmar et al. 
2010) and people with CKD not requiring RRT (Townsend et al. 2010). Although 
MAP was a determinant of PWV in previous HD studies it was not a significant 
correlate at univariable level with either PWV (p = 0.08) or AI (p = 0.44) in the 
present study. In contrast, the Anglo-Cardiff Collaborative Trial (ACCT) (McEniery et 
al. 2005) and Atherosclerosis Risk in Young Adults study (van Trijp et al. 2004) 
indicated MAP was a determinant of AI. Contrasting findings are possibly due to 
relatively larger sample size of the latter studies and may also reflect the differential 
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effects of CKD on prevalence of vascular calcification. Interestingly, when MAP was 
substituted for systolic blood pressure in the PWV model and entered into the AI 
model it was retained as a predictor of both vascular indices (appendices XXVI a 
and XXVI b). Hypertension thus emerged as an independent risk factor for both 
vascular indices but there is also evidence of a bi-directional relationship with 
increased arterial stiffness implicated in the pathogenesis of systolic hypertension 
(Zieman et al. 2005; Tyberg et al. 2008). 
6.4.5.5 Relationship between pulse wave velocity and augmentation index 
Augmentation index and PWV were not significantly associated in the present study 
(Spearman’s rho = 0.17, p = 0.15), a surprising finding as both indices are proposed 
as local and composite measures of arterial stiffness respectively. This finding adds 
to a growing body of literature showing little consensus regarding the relationship 
between PWV and AI (Tanaka et al. 1998; Yasmin and Brown 1999; Kelly et al. 
2001; Lemogoum et al. 2004; Kullo et al. 2005; McEniery et al. 2005; Cheng et al. 
2007; Sakurai et al. 2007). It is suggested that the differential effect of aging on 
these indices in a clinical population of advanced average age is largely responsible 
for the observed lack of association. Moreover, extensive modelling by Westerhof 
and Westerhof (2012) demonstrated aortic stiffness increases wave reflection 
magnitude and AI, but that this increase diminishes with greater stiffness. 
In contrast London et al. (1992) found PWV and AI correlated moderately in a mixed 
cohort of HD patients and controls but no subgroup analysis was undertaken for 
participants with stage 5 CKD. A larger mortality study involving maintenance HD 
patients by the same research group reported PWV was an independent predictor of 
AI, however the coefficient and confidence intervals were not stated (London et al. 
2001). Although age demographic was similar, diabetic participants in the cited 
studies were either far fewer (10%) or absent (London et al. 2001a and London et 
al. 1992 respectively). This may be an important difference in light of the 
dissociation between PWV and AI values observed for diabetics. Furthermore, the 
present study included people with peripheral arterial disease (PAD), which may 
have resulted in higher AI for a given PWV due altered wave reflections from arterial 
obstructions or terminal aorta (Safar et al. 2007). Although Yasmin and Brown 
(1999) reported PWV was a determinant of AI, their findings indicated a clinically 
meaningful change in the former of 1 m/s was associated with an incremental 
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change of just 0.4% in AI (Yasmin and Brown 1999). Importantly, this result does 
not translate to an equivalent level of increased mortality risk. 
There is evidence that AI is more sensitive than PWV to volume change among HD 
patients (Vuurmans et al. 2002; Georgianos et al. 2013). Moreover, studies of 
healthy males (Kelly et al. 2001) and cardiac patients (Sakurai et al. 2007) have 
shown similar preferential sensitivity for AI to vasoactive drugs. Despite a similar 
percentage of treated hypertensive participants (52%) in the study of London et al. 
(2001a), participants in the current study demonstrated more favourable mean 
values for vascular outcomes (MAP, PWV, AI were 10.3%, 31% and 21.5% lower 
respectively). It is suggested participants’ antihypertensive regimens were better 
optimized and this difference may have influenced the AI-PWV relationship.  
6.4.6.1 Arterial stiffness and cardiorespiratory fitness 
The moderate inverse association (r = -0.45, p < 0.001) observed between PWV 
and the ISWT observed here is in agreement with similar findings in the general 
literature across a wide age range (Vaitkevicius et al. 1993; Tanaka et al. 2000; 
Boreham et al. 2004; Gando et al. 2010b. The correlation with AI was more modest 
(Pearson r = -0.31, p = 0.01) and lower than the moderate correlations reported 
between AI and cardiopulmonary exercise test (CPET) measured VO2max (r = 0.41 to 
0.63, p < 0.001) of healthy adults (Vaitkevicius et al. 1993; Tanaka et al. 1998).  
An important coupling has been proposed between ventricular systolic and aortic 
function, which is physiologically matched for optimum cardiac efficiency (Chen et 
al. 1998). Increased arterial stiffness negatively affects cardiac function by 
increasing aortic impedance to stroke volume from the left ventricle (Shibata et al. 
2008) contributing to LVH, and eventually heart failure (London et al. 1990; Nitta et 
al. 2004). It is suggested that the coupling between aortic stiffness and cardiac 
function thus mediates in part lower CRF which is highly prevalent in this population. 
Similarly, increased wave reflections are believed contribute to widening of central 
pulse pressure resulting in increased myocardial load and reduced coronary 
perfusion during diastole (London and Pannier 2010). This result may provide some 
physiological insight as to why CRF is predictive of premature mortality of people 
with CKD (Sietsema et al. 2004; Gulati et al. 2012). 
Aerobic fitness did not emerge as an independent predictor of PWV but this is 
consistent with a study of healthy sedentary adults of similar age (Vaitkevicius et al. 
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1993). In contrast observational studies following participants from adolescence to 
adulthood have reported an independent association between CPET measured 
CRF and PWV (Ferreira et al. 2003; Boreham et al. 2004). Notably, the result of 
Ferreira et al. (2003) pertained to peripheral but not central arterial stiffness, which 
is not predictive of CV mortality in stage 5 CKD (Pannier et al. 2005).  
In addition, the ISWT was not retained as an independent predictor of AI while 
Vaitkevicius et al. (1993) observed CPET measured VO2max was. Although 
participant age demographic was similar, participants’ aerobic capacity in the 
present study was considerably lower with nearly 90% of ISWT performances in the 
lowest 25th percentile of age equivalent norm values established by Harrison et al. 
(2013). Heteroscedasticity of the ISWT data and measurement error associated with 
employing a proxy measure of fitness are suggested as plausible explanations for 
the discrepant findings compared to the general literature. Arterial stiffness 
measures obtained from different devices, which are known to produce significantly 
different values (Hickson et al. 2009) and different methods of deriving AI values 
may have also contributed. Notably, although Vaitkevicius et al. (1993) found CRF 
to be predictive of AI, a 1 MET change in fitness equated to an incremental change 
of just 1.2% in AI (Vaitkevicius et al. 1993). Pragmatically such a change might not 
be greater than the measurement variability associated with AI in this study. 
Crucially a change of 10% in AI is equal to a 48% change in CV mortality risk 
(London et al. 2001a). In contrast, the study of Boreham et al. (2004) indicated a 
CRF change of 1 MET equated to a 0.5 m/s change in PWV. This amount of change 
not only comfortably exceeds measurement variability for this index but also 
represents a 7% increased risk of CV mortality (London et al. 2001a; Blacher et al. 
2003; Verbeke et al. 2011). Illustratively in order for AI to demonstrate a comparable 
level of CV risk a change of 2.5 METS would be required.  
6.4.6.2 Physical activity and arterial stiffness 
Physical activity was inversely associated with PWV which is in agreement with 
cross-sectional and observational studies showing significant associations between 
indices of central arterial stiffness and PA derived via accelerometry (Sugawara et 
al. 2006; Kozakova et al. 2007; Aoyagi et al. 2010; Gando et al. 2010b; Jennersjo et 
al. 2012) and self report (Boreham et al. 2004; van de Laar et al. 2010). Surprisingly 
PA was not correlated with AI. This result contrasts with the study of Edwards et al. 
(2012) and may be due in part to a considerably younger age demographic and use 
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of a different (uniaxial) accelerometer in the cited study. Importantly, habitual PA 
level was not independently predictive of either index of arterial stiffness in this 
sample of maintenance HD patients.  
This data suggest that arterial stiffness may not be refractory to manipulation of PA 
behaviour in maintenance HD patients. This is a disturbing result given the 
prognostic utility of arterial stiffness indices in this population (London et al. 2001; 
Shoji et al. 2001; Blacher et al. 2003; Verbeke et al. 2011) and that attenuation of 
PWV is associated with improved survival of people with stage 5 CKD (Guerin et al. 
2001). In addition, this finding appears to be at odds with studies reporting 
reductions in arterial stiffness following PA interventions involving HD patients 
(Mustata et al. 2004; Toussaint et al. 2008a), healthy postmenopausal women 
(Moreau et al. 2003; Sugawara et al. 2006), middle-aged and older men (Tanaka et 
al. 2000). It is possible that this ‘negative’ finding could reflect the relative 
homogeneity of PA behaviour (limited inter-individual variation) mediated via thrice 
weekly HD. It is also possible that variations in PA due to intercurrent illness and 
fluctuating symptoms commonplace in stage 5 CKD (Nelson-Danquah et al. 2010) 
may have influenced this relationship. 
Two behavioural outliers (appendix XXVII a) may have influenced the results, but 
subsequent analysis with these participants removed did not alter the models and 
the association with PA remained non-significant (p = 0.77). Accelerometers provide 
an objective estimate of PA but they do not capture all PA that might be beneficial to 
health (Troiano et al. 2008). Nevertheless, Kozakova et al. (2007) reported uniaxial 
PA counts/day were independently predictive of carotid artery stiffness in a large 
sample of middle-aged adults. Moreover, steps/day, light and moderate PA have 
been observed to independently attenuate carotid artery stiffness (Sugawara et al. 
2006) and aortic PWV (Aoyagi et al. 2010; Gando et al. 2010b) of older adults. 
Categorised accelerometer variables were not employed in the present study in light 
of the limitations regarding validity of these outcomes as discussed in chapter 4. 
However, re-analysis using discrete PA variables rather than a gross measure of 
general PA may not necessarily yield a different final result due to marked 
heteroscedasticity of the PA data in the present study. Inspection of the PA versus 
PWV scatterplot shows most participants at the lower end of the PA spectrum 
(appendix XXVII b), which was not evident in the studies of Aoyagi et al. (2010) and 
Sugawara et al. (2006).  
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6.4.7.1 Application of findings and further research 
Despite medical advances epidemiologic observations highlight poor longevity 
among people receiving maintenance HD therapy, an observation that is more 
pronounced among younger individuals. These data indicate that although uraemia 
per se does not appear to influence arterial stiffness the longer people remain on 
HD then they appear to be exposed to a greater risk of accelerated vascular aging. 
As a risk factor HD vintage is extremely challenging to address in light of the chronic 
shortage of replacement kidneys available for transplant. This finding underscores 
the need for further research regarding health interventions to augment current 
medical management and reduce the impact of HD vintage as a CV risk factor. 
Accumulating evidence indicates PA that maintains or improves CRF exerts a 
beneficial effect directly on the vascular system. However, the most salient finding of 
this study was that PA and CRF were not independently associated with arterial 
stiffness indices and thus may not be modifiable via these vectors. Larger cohort 
studies are recommended to validate these findings. Moreover, appropriately 
powered randomized control trials which manipulate the PA variable are required to 
test this hypothesis. In the interim it does raise questions over how PA mediates a 
beneficial influence on CVD mortality in stage 5 CKD. Pulse wave velocity is a 
measure of arterial wall structure, which has upstream effects on heart morphology 
and function (Nichols and O’Rourke 1998; Nitta et al. 2004). However, endothelial 
function regulates vascular tone and represents an important functional component 
of large artery stiffness in people with hypertension, diabetes and coronary artery 
disease (Nigam et al. 2003; Ravikumar et al. 2002; McEniery et al. 2006; Wallace et 
al. 2007; Bruno et al. 2012). It is possible PA ameliorates CV mortality risk via 
improved endothelial function in the absence of PWV changes, as observed in 
elderly hypertensive adults (Westhoff et al. 2007). Future studies investigating 
arterial health interventions in stage 5 CKD should consider using this index of 
vascular function as well as arterial stiffness. 
Absent associations with important independent CVD risk factors (ie: diabetic status, 
PA) as well as shortcomings of its formula and underpinning wave theory 
overshadow the validity of AI in CKD. Moreover, a differential effect of age on AI and 
PWV (Mitchell et al. 2004; McEniery et al. 2005; Janner et al. 2010) suggests the 
former may not be as sensitive an index in the CKD population, which is 
characterised by advanced age. Importantly, while AI is predictive of mortality in 
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stage 5 CKD (London et al. 2001a), the body of evidence supporting the predictive 
utility of PWV in stage 5 CKD and the general population is larger and well validated 
(London et al. 2001a; Blacher et al. 2003; Vlachopoulos et al. 2010; Verbeke et al. 
2011). Furthermore, there is evidence that lowering PWV reduces mortality of 
maintenance HD patients (Guerin et al. 2001). On balance, PWV is recommended 
as a more suitable arterial stiffness index than AI to assess the impact of 
interventions aimed at managing CVD risk in the stage 5 CKD population.   
Previous studies have documented that interdialytic weight gain is a determinant of 
24 hour ambulatory blood pressure of maintenance HD patients (Inrig et al. 2007; 
Agarwal and Light 2008). Independent association of blood pressure with arterial 
stiffness is not a novel finding but it does underline the importance of avoiding 
excessive interdialytic weight gain and optimising anti-hypertensive therapy. It is 
important to consider however, that lowering heart rate increases AI. Importantly, AI 
is associated with LVH, and both are predictive of CV mortality in stage 5 CKD 
(Silberberg et al. 1989; Foley et al. 1995; London et al. 2001a). Heart pacing 
medications are widely prescribed to manage hypertension in this population (64% 
in this sample) and are a mainstay of heart failure treatment. Meta-analyses support 
the benefits of beta-blockers in reducing all cause mortality (Bonet et al. 2000; 
McAllister et al. 2009) but none have evaluated their effect on risk of sudden cardiac 
death. Exploration of the distinct haemodynamic influences of different beta-
blockers on vascular stiffness/function and CVD mortality in stage 5 CKD is 
considered an area worthy of further research. 
A large percentage of the variance of PWV values remains unexplained. Previous 
studies have identified a genetic component to arterial stiffness. A polymorphism of 
the angiotensin II gene is reported to influence large artery stiffness (Benetos et al. 
1995). In addition genetic polymorphisms involved with higher elastolytic activity are 
suggested to influence aortic stiffness (Yasmin et al. 2006). Of particular relevance 
to stage 5 CKD is the fact that inflammation is associated with genotypes which may 
negatively affect elastic properties of large arteries (Yasmin et al. 2006). Further 
research to quantify the genetic influence on arterial stiffness and whether genotypic 
expression contributing to arterial stiffness may be modified in the HD population is 
indicated. 
Differences are apparent between arterial stiffness values obtained in the present 
study and those reported in the general literature, as well as the explanatory power 
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of the models in particular AI. This may be due in part to use of different devices 
which employ applanation tonometry (SphygmoCorTM), mechano-transducers 
(CompliorTM), or doppler flow. The Vicorder employed in this study uses oscillometry 
but is more portable, carries less time burden and is largely operator independent 
compared to other machines. However, while Vicorder is highly reliable and 
correlates well with the widely used SphygmoCorTM significant differences in arterial 
stiffness measures have been observed (Hickson et al. 2009; van Leeuwen-
Segarceanu et al. 2010; Kis et al. 2011; Shahin et al. 2013). A correction equation 
may be employed to improve PWV agreement between these devices but values 
still remain significantly different (Hickson et al. 2009). Future research should 
explore methods to enable wider comparison of similar vascular outcomes from 
different devices and establish the prognostic utility of Vicorder.  
6.4.7.2 Study Limitations 
Study findings were drawn from cross-sectional data only, therefore it is not possible 
to draw firm conclusions regarding causality between arterial stiffness and the 
independent predictors identified here except the risk factor of age. Findings may 
also have been influenced by participants’ medications, however for reasons of 
safety a prior 12 hour abstention period which may still have been insufficient to 
nullify all pharmokinetics was not indicated. Measures for participants’ clinical 
biochemistry were obtained within two weeks either side of the vascular measures. 
Values for these variables fluctuate as can the outcomes themselves. Repeated 
measures of vascular function analysed as a time-dependent covariate would likely 
yield a more robust effect estimate for the multivariable models. 
The study sample size fulfilled the minimum requirement for multiple regression 
analysis outlined by Harris (1985) but it was lower than the threshold recommended 
by Tabachnick and Fidell (2007) of 50 + 8(k) (where k is the number of independent 
variables). It is possible that independent contribution of metabolic parameters 
known to affect vascular function such as diabetes was not significant because of 
the low percentage of affected participants, which in turn may have led to a risk of a 
type II error.  
A strength of this study was the homogeneity of the sample as norm values of 
arterial stiffness and relative contribution of predictor variables vary according to 
ethnic background (Chirinos et al. 2011). However, although the study sample 
comprised just over one third of the HD unit and almost half of those who were 
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eligible, those who did not participate were significantly older.  Therefore while these 
findings may be generalised to similar UK HD populations caution is urged when 
applying them to older HD patients as the influence of age is likely to be amplified.  
6.5 Conclusion 
Arterial stiffness is an important predictor of CV and all cause mortality among 
people with stage 5 CKD. Apart from age, risk factors for AI and PWV are distinctly 
different. Additionally, concerns regarding validity of AI and its relatively weaker 
explanatory model, indicate aortic PWV as the preferred arterial stiffness outcome to 
monitor interventions to reduce CV risk in the HD population. It is suggested that 
increased arterial stiffness in stage 5 CKD may not be refractory to PA change. 
Studies of appropriate rigour are recommended to investigate manipulation of the 
PA variable and its effect on arterial stiffness. Future research exploring the effect of 
PA interventions on vascular health in stage 5 CKD should consider assessment of 
endothelial function to elucidate the relationship between PA, CRF and CV mortality 
in stage 5 CKD.     
What is known about this topic 
x Arterial stiffness is an established risk factor for increased CV mortality. 
x Stage 5 CKD is characterised by accelerated vascular aging including 
arterial stiffness. 
x Physical activity and CRF are independent predictors of longevity in CKD. 
x Physical activity that improves CRF attenuates age attendant arterial 
stiffening. 
What this study adds 
x Aortic PWV is indicated as a more appropriate measure of arterial stiffness 
compared to AI in stage 5 CKD. 
x Haemodialysis vintage is an independent risk factor for increased arterial 
stiffness. 
x Increased arterial stiffness may not be influenced by modification of PA 
behaviour or changes in CRF in stage 5 CKD. 
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Chapter 7: General Discussion 
7.1 Introduction 
Life expectancies for people receiving maintenance haemodialysis (HD) for stage 5 
chronic kidney disease (CKD) are significantly shortened due to disproportionately 
high cardiovascular (CV) morbidity and mortality. Physical activity (PA) and physical 
function (PF) are implicated in health outcomes and the literature is replete with 
examples of low levels of both in stage 5 CKD. Despite government strategies, 
health body recommendations and robust epidemiological evidence, counselling 
practices pertaining to PA and PF in renal care remain inconsistent. An aim of this 
project was to evaluate elements of contemporary practice relating to PA and PF. 
This was with a view to providing some recommendations to support healthcare 
providers and investigators in relation to selection and implementation of 
assessment methods that also reflect the current shift towards ‘person-focused’ 
care. Another aim was to explore whether PA behaviour and fitness may potentially 
be modifiable risk factors for arterial stiffness, an intermediate CV endpoint.  
7.2 Accelerometer minimum wear time recommendations 
Accelerometers are increasingly being adopted to characterise PA of maintenance 
HD patients, but there appears to be a general lack of awareness regarding the 
need for rigorous data reduction protocols that also ensure ecological validity. 
Objectives of this study were to determine the minimum accelerometer wear time 
required to estimate PA and sedentary behaviour with acceptable reliability, and 
report the impact of wear time criteria on sample retention. The aim was to 
standardise data reduction methods for accelerometer use in stage 5 CKD. 
7.2.1 Study findings  
Indices of PA were significantly higher on dialysis days compared to non-dialysis 
days, which is in agreement with previous research (Majchrzak et al. 2005; Baria et 
al. 2011; Avesani et al. 2012). Time spent sedentary was significantly greater on 
dialysis days which is unsurprising given the extended period of enforced sitting 
required for HD therapy. No significant differences were observed for Actigraph and 
ActivPAL outcomes across the same condition (ie: dialysis days and non-dialysis 
days only) and overall, average measure intra-class reliability coefficients for 
outcome variables normalised to wear time were high (range 0.76 to 0.96). There is 
debate regarding inclusion of ‘weekend’ days, but this result suggests such a 
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requirement is not indicated and is in agreement with studies showing no additional 
improvement in outcome reliability with weekend day inclusion for adults (McClain et 
al. 2010; Reid et al. 2013) and children (Penpraze et al. 2006; Rich et al. 2013).  
Accelerometer wear time requirements varied according to outcome variable as 
observed in the general literature (Gretebeck and Montoye 1992; Cook and Lambert 
2008; Hart et al. 2011c). Required wear time was lowest for reliable estimates of 
energy expenditure, steps taken and activity counts/minute (one dialysis day and 
one non-dialysis day) while one dialysis day and two non-dialysis days were 
required for indices of PA and sedentary behaviour from both monitors. Overall, it 
appears that regardless of accelerometer a minimum of three days wear (one 
dialysis day and two non-dialysis days) will allow sedentary behaviour and most PA 
indices (normalised to wear time) to be captured with an acceptable reliability level 
of 0.80. This result is in line with recommendations in the general literature of two to 
three days accelerometer wear for reliable PA estimates among middle-aged to 
older adults (Matthews et al. 2002; Rowe et al. 2007; Hart et al. 2011c). The only 
exception to this recommendation was ActivPAL estimated sit-to-stand 
transfers/hour, which required six days (three dialysis and three non-dialysis days).  
Wear time requirements were generally greater for behaviour indices when they 
were not normalised to daily wear time. A minimum of four days wear (two dialysis 
and two non-dialysis days) were required for reliable estimates of total PA 
minutes/day while the requirement for minutes of sedentary time was even greater 
at six days (three dialysis and three non-dialysis days). Again, this is line with 
recommendations in the general literature of five to nine days for the latter 
(Matthews et al. 2002; Cook and Lambert 2008; Ojiambo et al. 2011; Hart et al. 
2011c) and evidence that sedentary time variability is more susceptible to 
discretionary wear (Masse et al. 2005; Tudor-Locke et al. 2011b).  
Computations revealed days with as few as four to six hours accelerometer wear 
could be included, which contrasts with the widely adopted minimum standard of 10 
hours wear to ‘rule in’ a valid day (Tudor-Locke et al. 2012). However, this standard 
was derived from research on the effect of wear criteria on sample retention and not 
measurement reliability (Masse et al. 2005) and may be impractical for low active 
clinical populations. On balance, a minimum standard of eight hours wear was 
deemed appropriate due to the amount of time occupied by HD therapy and 
variation in PA patterns observed around this event (Majchrzak et al. 2005). A 
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similar daily wear threshold is recommended for low active overweight individuals 
(Chen et al. 2009; Miller et al. 2013).  
Table 7.1 Wear time criteria stringency versus sample size retention. 
Wear criteria 1≥ dialysis & 2≥ non-dialysis days, and ≥8 hours/day 
1≥ dialysis & 2≥ non-dialysis 
days, and ≥10 hours/day 
7 days and ≥10 
hours/day 
Monitor Actigraph ActivPAL Actigraph ActivPAL Actigraph ActivPAL 
Sample 
retained (%) 90 91.4 87.1 84.3 41.4 31.4 
7.2.2 Impact of wear time criteria on participant inclusion for analysis. 
These wear time criteria are proposed with the caveat that they are the minimum 
requirement only to achieve a clinically acceptable level of reliability. Results 
indicate seven days of monitoring would endow outcomes with reliability sufficient 
for measurement at an individual level (Nunally 1978). However, applying such a 
standard along with the 10 hour/day benchmark would reduce the present sample to 
less than 50% (table 7.1) of its original size, which is consistent with previous 
observations (van Coevering et al. 2005; Sirard and Slater 2009; Gemmill 2009). 
Statistical power would consequently be seriously compromised as well as sample 
representativeness. Applying the rubric recommended in this study enabled at least 
90% of participant PA data to be retained (table 7.1) with a clinically acceptable 
level of reliability. Application of the 10 hour wear threshold reduced participant 
numbers by three to six percent but without an appreciable increase in reliability. 
Table 7.2 Summary of key findings for chapter three. 
What is the minimum wear time 
for reliable estimates of PA and 
sedentary behaviour obtained 
via accelerometry? 
 
Indices of PA and sedentary behaviour are significantly 
different between dialysis and non-dialysis days but 
not across the same condition. 
Regardless of accelerometer used, a minimum of one 
dialysis day and two non-dialysis days with eight hours 
wear per day will provide reliable estimates of PA and 
sedentary behaviour normalised to wear time.  
What is the impact of minimum 
wear criteria on sample size? 
Applying these criteria allows 90% of participants to be 
retained for final analysis. 
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Figure 7.1 Graph of participants m
eeting threshold of total PA 
predictive of m
ortality and m
aintaining m
obility: Actigraph.   
Figure 7.2 Graph of participants m
eeting consensus PA guidelines 
associated with a cardio-protective effect: Actigraph.   
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7.2.3 Recommendations for clinical practice – application of findings  
High wear compliance over the 7-day monitoring period (63% and 73% for ActivPAL 
and Actigraph respectively) supports the feasibility of routine accelerometer use in 
the clinical, especially as this technology becomes cheaper. Crucially, these data 
indicate a minimum of three days wear is sufficient to characterise behaviour of 
maintenance HD patients with acceptable reliability. This is the first time clear 
recommendations have been proposed for the ActivPAL and for accelerometer use 
in the HD population. Data reduction guidelines have public health consequence as 
individuals with monitor wear below criteria required for non-clinical populations may 
be unnecessarily excluded from analyses. Conversely, insufficient wear time will 
adversely impact data reliability and the ability to draw appropriate conclusions 
(Baranowski et al. 2008) and dose-response relationships, which may shape health 
recommendations (Schatzkin et al. 2009). The value of these recommendations lies 
in their ability to reconcile the tension between scientific rigour and retention of a 
sample size that is both sufficient for subsequent analysis and ecologically valid. 
The utility of these recommendations is readily demonstrated in figures (7.1) and 
(7.2). After application of recommended data reduction criteria PA data were 
stratified according to thresholds associated with mortality risk and mobility in the 
HD population (Kutsuna et al. 2010; Matsuzawa et al. 2012) and a health enhancing 
effect for the general population (WHO 2010). The vast majority of participants 
performed sufficient activity of all intensities to reduce the risk of mortality and 
deteriorating mobility, but nearly 90% did not achieve the MVPA threshold 
recommended by consensus PA guidelines. The ability to accurately characterise 
individuals’ PA levels would allow healthcare providers to direct limited resources to 
those most at risk of poor outcomes. Minimum wear time recommendations were 
subsequently implemented in the studies exploring the specific contribution of PA to 
physical function and arterial stiffness of people receiving maintenance HD.  
7.3 Concordance of PA assessment methods 
Building on the minimum wear recommendations, concordance of similar outcomes 
from ActivPAL and Actigraph monitors was evaluated with the aim of determining 
whether they may be used interchangeably for PA surveillance in stage 5 CKD. A 
substantial amount of data pertaining to PA of HD patients has been obtained via 
questionnaires. Concordance of self-reported and accelerometer estimated 
outcomes was also evaluated with the aim of determining whether subjective and 
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objectively estimated PA data could potentially be pooled. 
7.3.1 Study findings -Concordance of Actigraph and ActivPAL  
Broad agreement between both accelerometers was found for similar PA outcomes 
and sedentary time. However, despite strong correlations, statistically significant 
differences were observed for almost all similar PA outcomes. Actigraph estimated 
minutes of sedentary time and steps taken were higher and lower respectively 
compared to ActivPAL estimates, which is in agreement with the general literature 
(Harrington et al. 2011; Hart et al. 2011a; Hart et al. 2011b; Feito et al. 2012; 
Ridgers et al. 2012; Matthews et al. 2013; Swartz et al. 2014). Furthermore, an 
Actigraph data sampling frequency of 15 seconds exacerbated sedentary time 
disparity closer to bias levels observed by other studies employing the same epoch 
length (Hart et al. 2011b; Swartz et al. 2014). Crucially, limits of agreement for all 
similar outcomes were so wide as to prevent their interchangeable use with random 
(biological) error often increasing proportionally as outcome values increased.  
7.3.2 Concordance of subjective and objective estimates of physical activity 
Moderate to strong correlations (range 0.55 - 0.71, p < 0.001) between similar 7DR 
and accelerometer outcomes in the present study compare favourably to the modest 
correlations (average r = 0.37 ± 0.25) reported in the general literature (Prince et al. 
2008). However, despite more favourable associations in the present study, large 
significant differences and wide limits of agreement indicate similar 7DR and 
accelerometer outcome values (MVPA minutes, EE) cannot be directly compared. 
The disparity in PA estimates is likely mediated by reporting error associated with 
self-report (Durante and Ainsworth 1996; Buchowski et al. 1999; Duncan et al. 2001; 
Loney et al. 2011) and recognised limitations of accelerometry in detecting cycling, 
upper limb activities, and increased work due to load and gradient (Prince et al. 
2008). Additionally, commonly used cutpoints for categorizing Actigraph data appear 
to be inappropriate for older adults and clinical populations (Miller et al. 2010; Hall et 
al. 2013), while both accelerometers underestimate EE compared to criterion 
measures (Leenders et al. 2001; Albinali et al. 2010; Harrington et al. 2011).  
7.3.3 Recommendations for clinical practice and research 
Concordance studies for these PA assessment tools have previously been 
undertaken, but this is the first to evaluate level of agreement of all similar outcomes 
from each method in CKD. Given its prognostic utility there is a strong case for PA 
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surveillance of clinical populations to be implemented as part of mainstream health 
assessment. However, investigators and renal healthcare providers need to know 
which instruments they can invest in for the benefit of their patients and to progress 
health research. Each of the assessment methods in this study offers different levels 
of information content with selection dependent on purpose and outcome of interest. 
7.3.4 Objective versus subjective physical activity assessment  
If the requirement is for a broad indication of compliance with PA guidelines on a 
nomothetic level then self-report methods are an expedient option. However, there 
is agreement that questionnaires are unsuited to monitoring PA at an individual level 
(Loney et al. 2011). Questionnaires frequently focus on a relatively narrow range of 
PA and energy expenditure neglecting lighter intensity ADLs, which appear to 
maintain mobility (Johansen et al. 2001a; Kutsuna et al. 2010) and confer survival 
benefits in the HD population (Matsuzawa et al. 2012). Questionnaires such as the 
7DR will likely exhibit a floor effect (Tudor-Locke and Myers 2001) in this population, 
which tends to operate at the lower end of the PA spectrum (Johansen et al. 2007). 
Furthermore, just three days of accelerometry data are required to characterise PA, 
which is markedly lower than 14 days for detailed PA logs which require activities to 
be painstakingly recorded across discrete epochs (Coleman and Epstein 1998; Hart 
et al. 2011c). Less burdensome 24 hour recall formats still require at least seven to 
ten days monitoring to achieve similar reliability (Matthews et al. 2001). Moreover, 
questionnaires are less accurate and reliable for characterising time seated 
compared to accelerometry (Criniere et al. 2011; Celis-Morales et al. 2012; Wang et 
al. 2013), which is crucial in light of accumulating evidence linking this behaviour 
with health outcomes independent of PA level (Owen et al. 2010; Thorp et al. 2011).  
A single question regarding exercise frequency is independently predictive of 
survival in stage 5 CKD, however activity monitors have enabled greater insight into 
activity patterns of HD patients (Majchrzak et al. 2005; Baria et al. 2011). Moreover, 
objectively estimated PA is more strongly associated with fatigue symptoms 
(Gordon et al. 2011), nutritional status (Johansen et al. 2000; Hung et al. 2002; 
Baria et al. 2011; Cupisti et al. 2011) and risk factors for CV morbidity and mortality 
(Johansen et al. 2003c; Masuda et al. 2009; Nowicki et al. 2010; Cupisti et al. 2011; 
Mafra et al. 2011; Avesani et al. 2012). Accelerometry has also demonstrated 
prognostic utility in the HD population (Kutsuna et al. 2010; Matsuzawa et al. 2012). 
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Taken together with their superior reliability and evident feasibility, activity monitors 
are recommended in preference to questionnaires. 
7.3.5 Choosing the ‘right’ accelerometer  
Accelerometer choice will depend on the outcome variables of interest. There is 
agreement from criterion validity studies employing direct observation that the GT3x 
is less accurate than earlier Actigraph models and ActivPAL for estimating steps 
taken particularly at slower speeds (Ryan et al. 2006; Harrington et al. 2011; Feito et 
al. 2012). Similarly, controlled and free-living studies employing direct observation 
agree ActivPAL has superior accuracy in classifying sedentary time compared to the 
Actigraph GT3x (Kozey-Keadle et al. 2011; Hart et al. 2011c; Ryde et al. 2012; 
Lyden et al. 2012). Taken together with findings from the present study, ActivPAL is 
recommended as the preferred monitor for estimating steps and sedentary time. 
Relegating the GT3x from monitoring sedentary behaviour and stepcounts is not a 
recommendation made lightly given the amount of population-based data and health 
studies employing Actigraphs. However, the majority of these studies employed 
earlier Actigraph models, which have greater sensitivity to low frequency movement 
and superior step count accuracy compared to the GT3x (Rothney et al. 2008; 
Kozey et al. 2010; Feito et al. 2012). While systematic bias between ActivPAL and 
GT3x may be ameliorated by manipulation of cutpoint, filter sensitivity or use of 
triaxial output, there is general agreement level of random error is not (Kozey-
Keadle et al. 2011; Lyden et al. 2012; Clemes et al. 2012; Aguilar-Farias et al. 
2014). A recent PA intervention study of 67 middle-aged adults found ActivPAL and 
GT3x sedentary estimates were similarly sensitive to change (Swartz et al. 2014). 
Thus investigators may still use the GT3x for this metric as long as they are 
cognisant estimates will be less precise than ActivPAL and that a correction factor 
cannot be applied to facilitate their interchangeable use.   
If the purpose is to monitor or explore the influence of time spent active, this 
outcome can be obtained from both the Actigraph GT3x and ActivPAL monitors. 
However, only the Actigraph is presently capable of categorising accelerometer 
output into different intensities. The limitations of current uniaxial Actigraph cutpoints 
are apparent from a growing body of research (Staudenmayer et al. 2009; Miller et 
al. 2010; Albinali et al. 2010; Hall et al. 2013), therefore PA output from this monitor 
should be reported as activity counts per minute. Although this outcome does not 
readily translate to current PA guidelines for a health enhancing effect (WHO 2010) 
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it nevertheless provides a gross, if dimensionless measure of overall activity volume 
and intensity. Although ActivPAL also records activity counts this outcome is not part 
of its formal output and requires more technical expertise to extract and process.  
Dual use of Actigraph and ActivPAL could provide a more rounded assessment of 
an individual’s activity behaviour in a similar manner to the multiple-sensor 
Intelligent Device for Energy Expenditure and Activity (IDEEA; MiniSun, Fresno, CA, 
USA). However, despite promising precision of the latter device (Zhang et al. 2004; 
Grant et al. 2006) Arvidsson et al. (2009) concluded a single accelerometer was 
more feasible for use in free-living conditions. Similarly, lower overall compliance for 
tandem Actigraph and ActivPAL wear in the present study together with extra data 
processing and cost burden indicate their simultaneous use is not a feasible option.  
7.3.6 Monitoring energy expenditure 
Choice of assessment method is more flexible for energy expenditure (EE), which is 
commonly employed for nutrition studies in stage 5 CKD (Cupisti et al. 2011; Baria 
et al. 2011; Mafra et al. 2011; Avesani et al. 2012). Although, broad agreement was 
observed for 7DR and accelerometer estimates of EE. there is overwhelming 
evidence that criterion validity of all instruments for this outcome is poor (Bonnefoy 
et al. 2001; Leenders et al. 2001; Mahabir et al. 2006; Harrington et al. 2011; 
Albinali et al. 2010). Inherent limitations of generalising EE estimates derived from 
the Compendium of Physical Activities (Ainsworth 2011) and assuming the same 
resting metabolic rate for all individuals have previously been highlighted (Kozey et 
al. 2010; Hall et al. 2013). While none of these instruments may provide an accurate 
proxy EE measure they may still serve a useful role in ranking participants.  
Table 7.3 Summary of key findings for chapter four. 
What is the level of 
agreement between 
subjective and objectively 
estimated PA outcomes in 
stage 5 CKD? 
What is the level of 
agreement between similar 
outcomes obtained via 
Actigraph GT3x and 
ActivPAL accelerometers? 
Moderate to strong correlations are observed between 
similar subjective and objective PA outcomes but large 
significant differences and wide limits of agreement 
indicate objective and subjective PA outcomes values 
cannot be directly compared or pooled. 
Similar outcomes from ActivPAL and Actigraph 
accelerometers correlate strongly but level of agreement 
analysis indicates they may not be used interchangeably. 
ActivPAL will likely provide more accurate estimates of 
steps taken and time spent seated. 
 257 
7.3.7 Physical activity monitoring recommendations and ‘big data’ 
This is the first time recommendations have been made regarding standardisation of 
PA assessment for people with stage 5 CKD. Not only are they intended to support 
investigators and healthcare providers with instrument selection but they should also 
help ensure integrity of PA data obtained. Outcome measure heterogeneity and 
quality assurance of data are increasingly important technical challenges faced by 
investigators attempting meaningful synthesis of PA data. These recommendations 
are timely in light of the inevitable application of ‘big data’ to health research 
(Raghupathi and Raghupathi 2014). Standardisation of PA assessment methods will 
better facilitate pooling of disparate/heterogeneous datasets to create an 
observational evidence base to answer research questions and potentially guide 
clinical practice and health policies. 
7.3.8 Routine monitoring of physical activity and sedentary behaviour 
An important issue facing healthcare providers is how PA monitoring may be 
implemented with minimal additional burden on limited resources, and personnel? 
Pedometers are a cheap and expedient option but are prone to underestimating 
steps taken especially in older adults with slower gait (Feito et al. 2012), lessening 
their suitability for the HD population. Piezo-electric accelerometers and gyroscopes, 
which were once technology only found in expensive research accelerometers are 
de rigueur in the latest generation of smart phones. In addition there has been a 
proliferation of PA promoting phone apps (Middelweerd et al. 2014) and 
bracelet/watch monitors capable of recording numerous physiological indices as well 
as PA, which can be synchronised to smartphones.  
Self-monitoring of PA using emerging technologies now available to consumers is 
an option that is congruent with Scottish Government health policy of encouraging 
individuals to become more involved in managing their own health and healthcare 
(Physical Activity Taskforce 2003). Importantly, ethernet connected smart phone 
apps offer ecological momentary assessment (EMA) making it feasible for the user 
to benefit from tailored and timely feedback based on their location (Middelweerd et 
al. 2014). A North American study documenting an increase in mobile media (non 
voice) use from 24 minutes to almost two and a half hours between 2010 and 2013 
(eMarketer 2013) indicates the potential for PA monitoring and health promotion.  
The Apple Watch (figure 7.3) is the latest example of smart communication 
technology featuring PA monitoring as a standard function. Notably the Watch 
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incorporates EMA and behaviour change techniques to promote PA as part of its 
design and function thereby driving repeat usage (‘stickiness’) and increasing 
awareness of health behaviours. A novel function of the Watch is its haptic feedback 
and visual cues prompting the wearer to break up extended periods of sitting. 
Accumulating evidence indicates the greatest health benefits may be attained simply 
by a shift from being sedentary (Chief Medical Officers 2011). Consequently, this 
simple function for monitoring and reducing sitting time may be the most salient 
application of a device like the Watch in stage 5 CKD. With the exception of the 
Apple Watch, smart technology PA ‘wearables’ are often less than one quarter the 
cost of research grade accelerometers used in the present study (appendix XXVIII). 
Figure 7.3 Apple watch. 
  
(Apple 2015) 
7.3.9 Research considerations for wear time and PA concordance studies 
A strength of the accelerometer wear time study is that actual wear time for each 
monitor was accurately triangulated (general methods 2.5.4). Limitations of the 
sample size with respect to Spearman Brown Prophecy calculations were apparent 
when wear time thresholds to define a valid day increased above eight hours. This 
tended to affect ActivPAL calculations more than Actigraph due to lower wear 
compliance and higher malfunction rate observed with the former. Consequently, 
recommended wear time for total PA and sedentary time estimated via ActivPAL is 
based on the assumption that reliability would be higher with a larger sample size as 
observed for Actigraph reliability coefficients.  
Reliability of categorised PA and sedentary behaviour outcomes obtained via the 
Actigraph were derived using the uniaxial cutpoints of Freedson et al. (1998) and 
Evenson et al. (2008) respectively. Wear time requirements may vary according to 
alternative cutpoints and prediction equations proposed for uniaxial (Swartz et al. 
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2000; Hendelman et al. 2000; Crouter et al. 2006; Crouter et al. 2010; Kozey-Keadle 
et al. 2011) and triaxial Actigraph output (Sasaki et al. 2011; Santos-Lozano et al. 
2013; Aguilar-Farías et al. 2014).  
The sample size available to evaluate accelerometer outcome agreement was 
approximately half that originally recruited due to variable adherence in wearing both 
monitors simultaneously for the prescribed period and device malfunctions. Although 
sample size was relatively modest the number of participants included was above 
the threshold of 32 recommended by Liao (2010) for agreement analysis. A more 
pronounced gender bias was evident in the reduced sample. It is unclear how this 
may have influenced the results as participant numbers did not permit meaningful 
gender specific analysis and is an area that merits consideration in future 
concordance studies. A strength of this study was that monitor wear times were 
synchronised to ensure that subsequent analyses were undertaken on 
accelerometer estimated outcomes over the same epoch. This is important, as few 
ActivPAL and Actigraph concordance studies have explicitly stated this was done, 
and those that have observe lower estimation discrepancies between the devices. 
A criterion measure was not employed in the PA concordance study, therefore 
definitive statements regarding precision of any of the measures evaluated have 
been avoided. Gold standard methods such as doubly labelled water, indirect 
calorimetry and direct observation are recognised criterion measures for proxy 
estimates of energy expenditure, PA categorisation, steps taken and sedentary time 
respectively. However, criterion measures are arguably less feasible for PA 
research in clinical populations. Consequently, recommendations regarding 
assessment methods were formulated based on observations from the present 
study, published criterion validity studies, and characteristics of the HD population.  
Consensus cutpoints for categorising PA and sedentary behaviour, and calculating 
EE from triaxial output of the Actigraph GT3x were not available at the time of 
analysis. Observed disparities between Actigraph and similar outcomes from the 
7DR and ActivPAL appear to reflect in part limitations of uniaxial cutpoints for PA 
and sedentary behaviour originally calibrated in samples of young, healthy adults 
Freedson et al. (1998) and children (Evenson et al. 2008).  
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Table 7.5 Summary of research considerations arising from chapters 3 and 4. 
x Modest sample size for wear time reliability and concordance analyses increasing 
observed outcome variability. 
x Actigraph triaxial output unable to be categorised for concordance evaluation with 
ActivPAL.   
x Limitations of Freedson et al. (1998) and Evenson et al. (2008) uniaxial cutpoints 
for categorising PA and sedentary behaviour from Actigraph data. 
x Gold standard measurement of similar PA and sedentary behaviour indices not 
feasible in free-living clinical population.  
7.3.10 Recommendations for future research – accelerometer wear time 
The three day minimum wear period recommended for these monitors to achieve 
acceptable reliability may potentially shape study design by shortened monitoring 
protocols to minimise participant burden and expedite data collection. However, 
potential bias of purposive sampling from just three days wear should be examined 
before investigators adopt this approach. Imputation methods for missing or partial 
accelerometer data developed by Catellier et al. (2005) could potentially be applied 
in CKD5 PA studies. Although an attractive technique there are recognised 
limitations regarding how to categorise ‘missingness’ of absent data and it is 
recommended that bias of this approach should be examined where possible before 
it is implemented. Given the smaller participant sample of ActivPAL data available 
for required wear time calculations it is suggested that recommended wear criteria 
for this monitor should be verified in a larger cohort of HD patients. 
Wear recommendations made here are for research grade accelerometers only and 
may differ for wearable monitors currently available to consumers and smartphone 
derived PA outcomes. It is conceivable the latter devices, which appear to have 
comparable validity to research grade monitors (Lee 2013; Storm et al. 2015) may 
be used as a more feasible PA surveillance method in stage 5 CKD. If consumer-
bought monitors are to be adopted then similar reliability studies should be 
undertaken to establish minimum wear recommendations for these devices in the 
HD population.    
7.3.11 Recommendations for future research – physical activity assessment  
An advantage of accelerometers is that estimates of PA and sedentary behaviour 
are not influenced by recall difficulties or reporting bias associated with 
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questionnaires. However limitations of categorised uniaxial Actigraph GT3x output is 
evident from studies in laboratory (Staudenmeyer et al. 2009; Albinali et al. 2010; 
Miller et al. 2010; Hall et al. 2013) and free-living conditions (Leenders et al. 2001; 
Crouter et al. 2013). Moreover categorised triaxial output does not appear to deliver 
anticipated greater precision in estimating PA (Vanhelst et al. 2012; Hislop et al. 
2012) and sedentary behaviour (Aguilar-Farías et al. 2014), particularly in older 
adults (Santos-Lozano et al. 2013). Crucially, most accelerometer cutpoints and 
prediction equations rely on single linear models that assume a static parametric 
relationship between body accelerations and greater physiological cost of diverse 
activities.  
Improved precision of Actigraph EE estimates (15% to 60%) has been reported for 
artificial neural networks (ANN) employing a more flexible model of activity type 
detection by drawing on information density of accelerometer signals 
(Staudenmayer et al. 2009; Albinali et al. 2010; Trost et al. 2012). If Actigraph GT3x 
triaxial output is to be categorised into meaningful behavioural outcomes for people 
with CKD then validity of ANN processed data should be evaluated. Research 
evaluating the potential benefits of processing of raw output to overcome reductions 
in sensitivity induced by proprietary band pass filtering (Chen et al. 2012) is also 
suggested. Concordance of similar outcomes between the GT3x and other 
monitoring methods should then be revisited.  
ActivPAL may potentially be employed to monitor activity behaviours and categorise 
PA intensity as the calibration study of Dowd et al. (2012) demonstrates. 
Furthermore, gyroscope and accelerometry data obtained from the ActivPAL could 
be integrated to improve accuracy of PA estimates as indicated by small-scale 
studies evaluating smartphones (Wu et al. 2012; Lee 2013; Shoaib et al. 2014). 
Calibration studies exploring integration of ActivPAL gyroscope and accelerometer 
data are warranted to evaluate the possibility of one monitor for estimating 
behaviours as well as categorising PA.  
It is forecast that by 2016 there will be one billion smartphone owners worldwide 
(ABIresearch 2015). An advantage of ‘ethernet’ connectivity of low cost consumer-
bought wearables is that regular health based PA monitoring should be more 
feasible. This has potentially huge benefits for ‘person focused’ care, which implies 
health care that is continuous, based on greater knowledge of the individual and not 
confined to medical visits (Starfield 2011). Feasibility studies of smartphone 
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connected existing and emerging ‘wearables’ such as ‘smart shoes’ (Edgar et al. 
2012; Dannicker et al. 2013) for routine PA surveillance in stage 5 CKD are urged.  
Prognostic utility of objectively estimated PA for mobility and all cause mortality has 
thus far only been demonstrated in two single centre studies involving no more than 
202 Japanese maintenance HD patients (Kutsuna et al. 2010; Matsuzawa et al. 
2012). If adoption of objective PA monitoring is to be encouraged as part of routine 
healthcare then multi-centre studies examining prognostic utility of accelerometer 
outcomes are crucial. Future studies should not only delineate the dose-response of 
different levels of PA intensity on health outcomes but also the effect of bout length.  
In light of increasing use of motion sensors for PA surveillance and promotion and 
overwhelming evidence of their poor concordance with questionnaires, existing PA 
guidelines developed from self-report data will likely require recalibration. Guidelines 
on sedentary behaviour published recently by Buckley et al. (2015) recommend 
accumulating two hours of standing or light activity per day with progression to a 
total of four hours. However, these recommendations are targeted at asymptomatic 
individuals in predominantly desk-based occupations. Given the unique 
characteristics of the HD population, research examining the prognostic utility of 
objectively estimated time seated, breaks in sitting and changes in these sedentary 
behaviour metrics is strongly urged to develop HD population specific guidelines.  
Findings from the previous studies resulted in the selection and implementation of 
the Actigraph GT3x monitor and data reduction criteria in subsequent studies 
exploring the relative contribution of PA to physical function and arterial stiffness.  
The Actigraph GT3X was selected as its activity count output provides an indication 
of PA intensity as well as volume. Moreover the Actigraph had no days lost to device 
malfunction whereas the ActivPAL had 35 lost data days. In addition Actigraph 
monitors have been employed in previous stage 5 CKD research (Greenwood et al. 
2012), as well as large population based studies (Matthews et al. 2008) allowing 
greater contextualisation. 
7.4 Physical function and stage 5 CKD  
Routine monitoring of PF has been recommended as part of health management in 
this population (NKF 2005) but there is little guidance as to how this should be 
achieved. There is a pressing need to identify the most useful PF outcomes to 
support renal healthcare providers in nephrology implement KDOQI 
recommendations. This study explored potential clinical and demographic correlates 
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of functional capacity across a wider spectrum of physical performance tests, with 
applicability to common daily activities than has previously been undertaken.  
7.4.1 Study findings 
A high proportion of participants exhibited impaired physical performance, similar in 
magnitude to findings from larger cohorts of maintenance HD patients (Stenvinkel et 
al. 2002; Nonoyama et al. 2010; Silva et al. 2011; Greenwood et al. 2012). 
Functional status indicated by the physical component summary (PCS) score of the 
KDQOL-SF was 7% lower than the average reported for the multi-continent Dialysis 
Outcomes and Practice Patterns Study (DOPPS) despite similar participant 
demographics (Mapes et al. 2003). Illustratively, test performances indicated at least 
40% of participants might be unable to cross a road safely and were generally lower 
than those for individuals 10 to 20 years more senior. Moreover functional capacity 
and self-reported functional status outcomes for at least 83% of participants were in 
the lowest 25th percentile for age equivalent norms. Worryingly, PCS scores 
indicated three quarters of the sample were at or below a threshold associated with 
50% higher mortality risk for HD patients over six years (Feroze et al. 2011).  
Condition specific variables (dialysis adequacy, anaemia status) per se did not 
influence PF in this sample of HD patients. Instead factors typically associated with 
other long-term conditions (age; multi-morbidity; polypharmacy; reduced muscle 
mass; nutritional status; inflammation) were correlated and contributed one quarter 
to a half of the explained variance. Number of correlated variables increased 
concomitantly with greater neuromuscular complexity and integrated physiological 
demand of the task. Notably, habitual PA made the greatest relative contribution to 
functional capacity (shuttle walk, sit-to-stand five) and attenuated or nullified the 
contribution of other variables (ie: number of medications, BMI, age). This result 
extends the findings of Johansen et al. (2001a) and Kutsuna et al. (2010) who 
observed habitual PA was a determinant of self-selected gait speed. This is 
important, as not only should PF outcomes have clinical utility but if they are to work 
in tandem with PA promotion strategies then ideally they should also be sensitive to 
behavioural change.  
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Table 7.6 Summary of key findings for chapter five. 
What are the correlates of 
physical performance 
measures of function in 
stage 5 CKD? 
Number of correlates increased with complexity of task.  
Factors typically associated with a long-term condition were 
correlated with physical function.  
What are the correlates self-
reported measures of 
function in stage 5 CKD? 
Multivariable models explained a quarter to a half of the 
variance in physical performance but less than 25% of the 
variance in self-reported functional status. 
What is the relative 
contribution of physical 
activity to physical 
performance and self-
reported measures of 
physical function in stage 5 
CKD 
Correlations with condition specific variables (anaemia 
status and dialysis adequacy) were notably absent. 
Habitual PA was independently associated with distance 
walked during the shuttle walk test and sit-to-stand five test 
time and made the largest relative contribution to the 
variance explained for each.  
PA attenuated or nullified the effect of other potential 
predictor variables notably age.  
PA was independently associated with PCS from KDQOL 
only but a significant main effect for gender was observed. 
7.4.2 Practical application of monitoring physical function – frailty 
Central to the concept of ‘person-focused care’ is recognition and appropriate care 
of the individual’s problems which are “often not diagnoses but rather symptoms and 
signs” (Starfield 2011, p. 65). A growing body of evidence underlines the importance 
of implementing routine monitoring of physical function as a ‘sixth vital sign’ in 
addition to traditionally monitored physiological indices (blood pressure, pulse and 
respiration rate, blood oxygen level, temperature) (Bierman 2001; Fritz and Lusardi 
2009). There is growing recognition of the importance of undiagnosed frailty on 
health outcomes of HD patients (Painter et al. 2013). Application of accepted frailty 
criteria using the outcomes employed here revealed one quarter of prevalent HD 
patients in this study were classified as frail, which is in agreement with previous 
research (Painter and Kuskowski 2013). This is important as adjusted mortality risk 
of people who present as frail at initiation of HD is more than doubled at one year 
(Johansen et al. 2007) and almost threefold higher for individuals who become frail 
over three years (McAdams-Demarco et al. 2013).  Early identification of frailty 
facilitated by PF monitoring may thus play a crucial role in early identification of 
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individuals at risk of poor outcomes. Timely interventions could then be targeted to 
ameliorate functional decline, and reduce the risk of hospitalisations and mortality.. 
7.4.3 Recommendations for clinical practice 
Overall, these data are supportive of KDOQI recommendation for incorporation of 
physical function outcomes as a standard part of clinical service. Quarterly and six-
monthly monitoring of physical function are recommended by Painter and Marcus 
(2013) and the KDOQI (NKF 2005) respectively. Whilst, the former is preferable the 
latter seems an appropriate minimum standard given a (10 point) decrease in PCS 
score over six months is predictive of 25% higher mortality risk at one year among 
HD patients (Knight et al. 2003). Physical function assessment is recommended as 
part of care during hospital inpatient stay due to intercurrent illness.  
7.4.4 Physical performance tests versus self-reported functional status 
Functional status questionnaires afford a unique ‘person centred’ perspective of an 
individual’s functional status, and there is ample evidence of their prognostic utility in 
stage 5 CKD (table 1.14, chapter 1). However, less than 25% of the variance in PCS 
and DASI scores was explained by demographic and clinical variables. This result is 
consistent with literature indicating functional status is more heavily influenced by 
psychosocial factors compared to physical performance (Carmichael et al. 2000; 
Lord et al. 2002; Bean et al. 2011). Notably, habitual PA made a limited contribution 
to functional status indicated by the PCS with a significant main effect for gender, 
suggesting this outcome may only be sensitive to behaviour change in males.  
Other recognised shortcomings of functional status questionnaires include lower 
reliability compared to physical performance tests (Davey et al. 2003; Overend et al. 
2010), response bias (Sjöström et al. 1999) and appropriateness for people with 
cognitive deficits (Guralnik et al. 1989). Questionnaire scores are also influenced by 
temporal variation (Nelson-Danquah et al. 2010) and method of administration 
(Weingberger et al. 1996; Lyons et al. 1999). Moreover, using functional status 
instead of physical performance to determine frailty has been shown to triple the 
percentage of HD patients with this diagnosis (Painter and Kuskowski 2013). The 
high participation rate observed in the present study (95 to 100% of consented 
participants) with no adverse events indicates physical performance testing is a 
feasible means of monitoring functional ability of people with stage 5 CKD. On 
balance, physical performance tests are recommended as the preferred option over 
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functional status in stage 5 CKD. If questionnaires are to be employed they should 
not be used in isolation but in tandem with the former.  
7.4.5 Which physical performance test/s? 
As with PA assessment, selection of physical performance test/s is determined by 
intended purpose, outcome, and whether it can be operationalised as part of routine 
care (Koufaki and Mercer 2009). The STS5 and TUAG are predictive of balance 
impairment (Whitney et al. 2005), bone fractures (Jamal et al. 2006), and falls 
(Shumway-Cook et al. 2000; Cook and Jassal et al. 2008; Tiedeman et al. 2008; 
Buatois et al. 2010; Wrisley and Kumar 2010) in the CKD and general population. 
The importance of their prognostic utility cannot be overstated given older adults in 
this population are beset with a falls incidence over three times higher than 
asymptomatic individuals (12.7% versus 4% respectively) (Desmet et al. 2004 and 
Hestekin et al. 2013 respectively). Additionally, slow TUAG times are incrementally 
predictive of premature mortality in CKD (Roshanraven et al. 2013). Neither test 
elicits a maximal cardiorespiratory response and they can be administered in under 
two minutes on a dialysis day visit. The TUAG and STS5 are recommended as the 
minimum standard for assessing physical function in stage 5 CKD.  
These data suggest the ISWT may be the more sensitive outcome for monitoring 
behavioural change and PA interventions. Moreover, it measures a wide level of 
ability making it less susceptible to ceiling effects (Painter and Marcus 2013) and 
arguably more suited to stratifying CV risk in younger individuals who experience the 
greatest relative reductions in life expectancy (SRRR 2011). However, due to 
fluctuations in fluid status this symptom-limited maximal walking test may only be 
performed safely on an interdialytic day. Attendance outside scheduled HD sessions 
could present a significant barrier to compliance given the high ‘did not attend’ rate 
observed during this project (39 of 112 scheduled appointments). Routine adoption 
of the ISWT in the HD population for younger individuals in particular is likely best 
achieved by incorporating this test into a non-dialysis day medical appointment.  
Physical activity was not independently associated with handgrip strength in the 
present study, however this test has prognostic utility with respect to nutritional 
status, CV and all-cause mortality (Al Snih et al. 2002; Stenvinkel et al. 2002; 
Qureshi et al. 2002; Rantanen et al. 2003; Wang et al. 2005; Dong et al. 2008) and 
is an easily attained core component of Fried’s frailty phenotype (Fried et al. 2001). 
Given the high prevalence of frailty in this population and its impact on health 
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outcomes it would seem prudent to deploy this expedient test for frailty screening if 
an individual is unable to undertake the STS5 or TUAG tests.  
One or all of these tests may be combined to provide a more comprehensive 
assessment to stratify for risk of CVD, falls and frailty. The short physical 
performance battery (SPPB) is a multiple test instrument with prognostic utility in the 
elderly (Guralnik et al. 1994) that has been employed in CKD (Hall et al. 2012; 
Abreo et al. 2014). A potential limitation of the SPPB is that it was designed primarily 
to assess lower limb function of older adults. Although stage 5 CKD is characterised 
by high average age, this demographic is bi-modally distributed (SRRR 2013) which 
may result in ceiling effects for the large proportion of younger people. Moreover the 
SPPB subtask with greatest prognostic value is the STS5 suggesting the balance 
and walk items may be less important in routine monitoring (Cesari et al. 2008).  
7.4.6 Future research recommendations 
The influence of polypharmacy on physical performance was highlighted in this 
study likely due its influence on balance impairment (Agostini et al. 2004). However, 
some blood pressure and cholesterol medications commonly prescribed in this 
population are known to have differential myopathic (Tomaszewski et al. 2011) and 
myo-protective effects (Onder et al. 2006) respectively. Lean muscle mass is linearly 
related to muscle strength (Overend et al. 1992; Newman et al. 2003; Rolland et al. 
2008), which is a determinant of PF in stage 5 CKD (Diesel et al. 1993). The effect 
of ACE inhibitors and statins on phenotypic expression of genes associated with 
skeletal muscle response to PA is considered an area worthy of further research.  
Physical performance tests selected for this study are predictive of health outcomes 
but additional data are required to support investment and reliance on the evidence 
provided by some of these tests for the benefit of people with stage 5 CKD. 
Handgrip strength is reportedly prognostic of health outcomes, but further research 
is required to delineate clinically important thresholds pertaining to mortality and 
malnourishment in CKD. Cardiorespiratory fitness above five METs obtained via 
cardiopulmonary exercise test (CPET) confers improved survival among 
maintenance HD patients (Sietsema et al. 2004) and across the CKD trajectory 
(Gulati et al. 2012). Although the Incremental Shuttle Walk Test (ISWT) is proposed 
as a proxy measure of CRF it does not possess equivalent predictive ability to CPET 
for people with CHF (Pulz et al. 2008). Further evaluation of the prognostic utility of 
the ISWT with respect to health outcomes in CKD is warranted.  
 268 
A dearth of studies support the prognostic utility of functional status outcomes in 
stage 5 CKD. However, habitual PA had little or no influence on the KDQOL-SF 
PCS and DASI scores respectively in this sample of HD patients. The Human 
Activity profile (HAP) (Fix and Daughton 1988) is more strongly associated with PA 
compared to SF-36 PCS scores of maintenance HD patients (Johansen et al. 
2001b). Moreover, it was independently predictive of mortality risk in the recent 
Comprehensive Dialysis Study (Johansen et al. 2013). The HAP also has superior 
sensitivity in detecting changing medical status in people who have undergone 
allogeneic hematopoietic stem cell transplantation (Herzberg et al. 2010). It is 
speculated the HAP may be more likely to fulfil criteria of sensitivity to physiological 
and behavioural change and should be explored.  
These data indicate habitual PA attenuates declining physical function, which is 
consistent with numerous studies reporting significant improvements in functional 
outcomes following structured PA interventions (Parsons and King-van Vlack 2009). 
However, it is not known whether subsequent improvements in PF translate to lower 
mortality and morbidity in stage 5 CKD. Research in this area is warranted but may 
prove challenging in a randomised controlled study of adequate length due to ethical 
considerations. Future health intervention studies with intermediate endpoints 
should also explore interactions with changes in physical function.  
7.5 Arterial stiffness and stage 5 CKD 
Cardiovascular disease (CVD) is the main threat to survival in stage 5 CKD 
mediated largely by increased central arterial stiffness, a strong predictor of CV 
mortality in this population (London et al. 2011; Verbeke et al. 2011). Physical 
activity and cardiorespiratory fitness (CRF) are implicated in CV and all cause 
mortality in stage 5 CKD but it is unclear whether they are potentially modifiable risk 
factors for arterial stiffness. .The objective of this study was to explore clinical and 
behavioural correlates of arterial stiffness in stage 5 CKD. 
7.5.1 Study findings 
Age and blood pressure were the principal drivers of aortic pulse wave velocity 
(PWV), which is in agreement with findings from large (Shoji et al. 2001; Blacher et 
al. 2003; Townsend et al. 2010) and small cohorts of maintenance HD patients, and 
people with less severe CKD (Temmar et al. 2010) and asymptomatic adults 
(Yasmin et al. 2006; Achimastos et al. 2010). This result is consistent with putative 
mechanisms of age-attendant changes in arterial extracellular matrix, as well as 
 269 
central pressure-mediated wall hypertrophy (Laurant et al. 2005) and loading of 
stiffer collagen fibres (Bank et al. 1996). Factors pertaining to fluid dynamics (height, 
heart rate, haemoglobin level, BMI) explained more of the variance in AI, which is in 
line with previous studies of HD patients (London et al. 1992; London et al. 2001a).   
Stage 5 CKD is independently associated with arterial stiffness (London et al. 1992) 
but this is the first time HD vintage has been identified as a predictor. Notably, less 
than six years of HD treatment exposure equated to an incremental increase of 1 
m/s and thus 15% higher mortality risk (Blacher et al. 2003) compared to a threshold 
of 14.3 years of chronological age increase. Importantly, this result corroborates 
closely with findings from a demographically similar cohort of 80 prevalent HD 
patients observing an average 0.6 ± 0.2 m/s increase in Doppler measured aortic 
PWV over three years (Avramovski et al. 2013). It is also consistent with studies 
showing increased severity and prevalence of vascular calcification (Sigrist et al. 
2007) and left ventricular hypertrophy following initiation of HD (Foley et al. 2010).  
Hypertrophic effects of chronically elevated blood pressure on arterial walls are well 
documented, but uraemia is also characterised by endocrine and metabolic 
dysregulation. Bone demineralisation mediates higher serum levels of phosphate, 
which has a direct calcifying effect on the tunica media (Jono et al. 2000). Dialysis-
induced physical inactivity and muscle atrophy (Johansen et al. 2003a) likely 
precipitates a cascade of insulin resistance and an increase of advanced glycation 
end products (AGEs). As well as having direct effects on arterial wall architecture 
AGEs generate reactive oxygen species quenching endogenous nitric oxide (a 
vasorelaxant) and provoke an immunological response (Zhang 2008). Inflammatory 
cytokines are implicated in vascular smooth muscle proliferation (Park and Lakatta 
2012), reduction of endogenous calcification inhibitors (Memoli et al. 2007) and 
endothelial dysfunction (Gunnett et al. 2005). In addition, dialysis may remove some 
endogenous calcification inhibitors (Lomashvili et al. 2005). It is speculated some or 
all of these factors conspire in concert to make uraemia especially pernicious to the 
structural and functional components of arteries.   
Notably, PA and a surrogate measure of CRF (the ISWT) were not retained in the 
multivariable models as additional predictors. Conversely, several studies report 
higher levels of PA independently predict lower carotid artery (Sugawara et al. 2006) 
and aortic stiffness (Aoyagi et al. 2010; Gando et al. 2010b) of older adults. Higher 
CRF independently attenuates central arterial stiffness of endurance trained seniors 
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(Vaitkevicius et al. 1993) and individuals followed from adolescence to adulthood 
(Ferreira et al. 2003; Boreham et al. 2004). Use of the ISWT in the present study 
instead of CPET derived VO2peak may partially explain the contrasting findings. In 
addition, heteroscedasticity of the ISWT and PA data and homogeneity of participant 
behaviour resulting in lower variability is speculated to have contributed  
A worrying implication is that central arterial stiffness, which is a strong predictor of 
mortality may not be modifiable with behaviour change at this stage of the CKD 
trajectory and that arteriosclerosis is irreversible. It is possible that mortality risk may 
only be ameliorated in HD patients who show a reduction in BP and PWV following 
aggressive pharmacological intervention (Guerin et al. 2001). Interestingly, a 
number of clinical markers believed to influence arterial calcification and stiffness in 
stage 5 CKD were either not correlated (c-reactive protein, serum calcium, 
parathyroid hormone) or paradoxically associated (serum phosphate, serum 
creatinine). It is speculated this may be because of the high prevalence of advanced 
calcification of the tunica media in the HD population (Sigrist et al. 2007).  
If habitual PA is the most important modifiable predictor of CRF and both are 
prognostic of outcomes, the question is by what vector do they confer improved 
survival in stage 5 CKD? Arterial stiffness is reported to have a large heritable 
component with genes responsible for arterial matrix proteins, endothelial function, 
renin-angiotensin-aldosterone axis, endogenous calcification inhibitors and 
inflammation implicated (Lacolley et al. 2009). An in vivo study of chronic aerobic 
exercise in a murine model found cardiac endothelial cell gene expression was up 
regulated while IL-6 gene expression was down regulated (Matsumoto et al. 2012). 
Notably higher serum levels of IL-6 levels are know to down-regulate Fetuin-A a 
potent systemic calcification inhibitor (Memoli et al. 2007). It is speculated that 
higher PA may mediate lower CV risk in CKD5 by modifying phenotypic expression 
of genetic determinants of arterial stiffness. Physical activity may be more closely 
related to biomarkers of putative arterial stiffness mechanisms as many of these 
factors have their genesis in physical inactivity. A three week pilot study of aerobic 
exercise involving elderly CHF patients found serum levels of matrix 
metalloproteases implicated in deleterious vascular remodelling were reduced while 
serum levels of endothelial progenitor cells increased (Gatta et al. 2010). 
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7.5.2 Indices of central arterial stiffness are not related in stage 5 CKD. 
The finding that PWV and AI were not related in this study adds to a growing body of 
conflicting literature regarding the relationship between these indices (Tanaka et al. 
1998; Yasmin and Brown 1999; Kelly et al. 2001; Lemogoum et al. 2004; Kullo et al. 
2005; McEniery et al. 2005; Cheng et al. 2007; Sakurai et al. 2007). Changes in AI 
are dependent on many factors and not just the amplitude of the reflected pressure 
wave and augmentation pressure, suggesting a mathematical flaw in the formula for 
this index (Cheng et al. 2007). Although aortic stiffness increases wave reflection 
magnitude and AI, this effect diminishes with greater PWV (Westerhof and 
Westerhof 2012). Moreover, invasive pulse wave analysis studies employing the 
reservoir-wave approach indicate substantial non-wave related effects of aortic 
volume on aortic pressure, and that wave reflection explains just 5.8% of AI variance 
(Tyberg et al. 2008; Tyberg et al. 2009). Thus, observed lack of association between 
AI and PWV is likely due to the way AI is calculated and its underpinning wave 
theory, which does not take into account the cushioning effect of the aorta. 
Table 7.7 Summary of key findings for chapter six. 
What are the correlates of 
arterial stiffness in stage 5 
CKD? 
 
Age and blood pressure independently predicted indices 
of arterial stiffness and were the principal determinants of 
aortic PWV. HD vintage also predictive of PWV in a model 
that explained 60% of the variance in this index. 
Heart rate, height and haemoglobin level make a greater 
relative contribution to augmentation index. 
What is the relative 
contribution of PA to indices 
of arterial stiffness in stage 5 
CKD? 
Habitual physical activity and a physical performance 
measure of cardio respiratory fitness correlated with 
arterial stiffness indices but were not retained as 
independent predictors when added to the multivariable 
models.  
Augmentation index and PWV are not related in this 
sample of maintenance HD patients. 
7.5.3 Recommendation for clinical practice – Which arterial stiffness index? 
There is general agreement PWV and AI demonstrate divergent trends with 
advancing age (Mitchell et al. 2004; McEniery et al. 2005; Janner et al. 2010) and 
dissociative findings for diabetics (Westerbacka et al. 2000; Ravikumar et al. 2002; 
Lacy et al. 2004; Schram et al. 2004; Cheng et al. 2007). Taken together with 
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findings from the present study, the weight of evidence suggests AI may not provide 
a valid indication of central arterial stiffness in stage 5 CKD, which is characterised 
by advanced average age and high prevalence of diabetes. Although AI is predictive 
of mortality in stage 5 CKD (London et al. 2001a), a larger body of studies supports 
the predictive utility of PWV in stage 5 CKD and the general population (Verbeke et 
al. 2011; Vlachopoulos et al. 2010; Blacher et al. 2003; London et al. 2001a). 
Furthermore, there is evidence that lowering of PWV reduces mortality of 
maintenance HD patients (Guerin et al. 2001). On balance, PWV is recommended 
as the preferred method of monitoring central arterial stiffness in the HD population. 
7.5.4 Research design considerations - physical function and arterial stiffness  
While the sample size met the minimum requirement for multiple regression analysis 
outlined by Harris (1985) it was lower than the threshold recommended by 
Tabachnick and Fidell (2007). It is possible that independent contribution of 
metabolic parameters known to affect vascular function such as diabetes was not 
significant because of the low percentage of affected participants, increasing type II 
error risk. Larger cohort studies are recommended to validate multiple regression 
models presented in the physical function and arterial stiffness chapters. Importantly 
these studies were cross-sectional, offering a contemporaneous snapshot of 
correlates of arterial stiffness, and therefore causation cannot be inferred. In addition 
candidate biomarkers for multivariable analysis were limited to routine clinical health 
indices due to resource and budgetary constraints. Consequently, the discussion 
regarding physical function and arterial stiffness mechanisms is presented in context 
of findings from the general literature and remains speculative. 
Characteristics of participants in the present study were similar to the international 
DOPPS project, and broadly representative of the Scottish and UK HD populations 
except for age, which was six years younger than the median. Notably, individuals 
who attended for the vascular and physical performance assessments were on 
average five years younger and had higher DASI scores than the questionnaire only 
participants. Consequently prevalence and severity of functional capacity 
impairment for the renal unit as a whole is probably under-represented. It is also 
speculated the relative contribution of age and perhaps HD vintage to arterial 
stiffness may be amplified. Therefore findings pertaining to physical function and 
arterial stiffness should be inferred cautiously to the wider HD population. 
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Participant uptake is infrequently reported for studies employing physical 
performance and accelerometer outcomes but appears to be less than 20% (Mercer 
et al. 1998; Baria et al. 2011). Although the present sample was larger than most 
single centre observational studies in stage 5 CKD, participants undertaking the 
assessments represent just 40% (33% with complete datasets) of the Monklands 
renal unit population. Questionnaire response rate was higher (70%) and similar to 
that of Mingardi et al. (1999). Uptake reported for these studies reflects a perennial 
challenge faced by researchers working with clinical populations. North American 
and European surveys reveal most people agree health research is important but 
significant barriers to recruitment exist due to: low awareness; low public trust in 
government bodies; reduced confidence due to media depictions (Getz 2008; Team 
Consulting 2014). In addition, assessments necessitated a non-dialysis day 
appointment, which adversely impacted uptake and sample representativeness, and 
has been observed previously (Johansen et al. 2003a). If research findings and 
recommendations are to be more inclusive and effective for HD patients most at risk 
of poor outcomes, then these issues need to be urgently addressed.  
Table 7.8 Summary of research considerations arising from chapters 5 and 6. 
x Moderate sample size for multivariable analyses increases the risk of type II errors. 
x Cross-sectional studies therefore causation cannot be directly inferred. 
x Candidate biomarkers limited to routinely obtained clinical indices of health status. 
x Sample composed of self-selected participants with younger average age. 
compared to the resident renal unit and wider HD population.  
7.5.5 Recommendations for future vascular research in stage 5 CKD 
Clearly, the longer people remain on HD the greater their risk of accelerated 
vascular aging and premature mortality. This underscores the need for further 
research regarding health interventions to augment current medical management 
and reduce the impact of HD as a risk factor. Although these data suggest higher 
levels of habitual PA may not attenuate arterial stiffness of maintenance HD 
patients, manipulation of the PA variable via randomised control trial or prospective 
cohort study at least is necessary to test this hypothesis. Notably, a recent meta-
analysis concluded there was evidence that aerobic exercise interventions 
significantly reduced aortic PWV (Ashor et al. 2014). Moreover, a recently published 
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pilot study indicates 12 months of thrice weekly aerobic exercise ameliorates aortic 
stiffness in less severe CKD (Greenwood et al. 2015).  
Arteriosclerosis may be irreversible, but the effect of habitual PA on endothelial 
function, an important functional component of vascular stiffness in other clinical 
populations (Nigam et al. 2003; Ravikumar et al. 2002; McEniery et al. 2006; 
Wallace et al. 2007; Bruno et al. 2012) has not been explored in the HD population. 
Local improvement in endothelial function of HD patients has been observed 
following forearm strengthening (Rus et al. 2003), but it is not known whether a 
systemic improvement is provoked by chronic aerobic exercise. The prognostic 
utility of endothelial function determined by flow-mediated dilatation has been 
demonstrated in a recent meta-analysis (Xu et al. 2014). It is recommended that 
future studies investigating the effects of PA interventions on vascular health should 
include this outcome. Genetic markers implicated in arteriosclerosis and endothelial 
function should also be considered if the aim is to elucidate PA mediated reductions 
in CV mortality and morbidity. 
Presently there is conflicting evidence regarding improved arterial stiffness following 
structured PA interventions in stage 5 CKD. Studies are generally uncontrolled or 
insufficiently powered to detect a clinically meaningful change (Mustata et al. 2004; 
Toussaint et al. 2008a), or have not stringently regulated the PA stimulus with the 
objective of improving CRF (Koh et al. 2010). A phase two study in which HD 
patients were randomly assigned to 12 weeks of intra-dialytic aerobic exercise or an 
exercise wait-listed control group was also part of this project. Vascular outcome 
measures were aortic PWV and endothelial function. The study is now closed and it 
is intended that findings will be disseminated via an independent publication.   
Five-year mortality risk associated with CKD increases commensurate with 
reductions in renal function (Tonelli et al. 2006). Altered vascular structure and 
greater arterial stiffness has also been observed in people with stage 3 to 4 CKD 
compared to hypertensive peers with normal renal function (Briet et al. 2006). 
Moreover, prevalence of left ventricular hypertrophy in people with CKD increases 
from approximately 40% to 75% by the commencement of RRT (Foley et al. 1995; 
Levin et al. 1999). Research to determine whether CKD stage is predictive of arterial 
stiffness could strengthen the case for earlier targeted lifestyle intervention.  
The Vicorder device employed in the present study uses oscillometry and carries 
low operator burden. However, while measures are reliable they differ from those 
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obtained by applanation tonometry or Doppler flow devices (Hickson et al. 2009; van 
Leeuwen-Segarceanu et al. 2010; Kis et al. 2011) used in other CKD studies. 
Agreement between the Vicorder and more frequently used SphygmoCor (AtCor 
medical. Victoria, Australia) can be improved via a correction equation but values 
remain significantly different (Hickson et al. 2009). In addition, the prognostic utility 
of PWV has been demonstrated with devices other than Vicorder. Research 
exploring the prognostic utility of Vicorder and methods to facilitate comparison of 
similar vascular outcomes from different devices is warranted. 
Table 7.9 Summary of research suggestions arising from chapters 3 to 6. 
x Quantify bias of purposive data sampling from just three days accelerometer wear. 
x Reliability of PA monitoring technologies available to consumers. 
x Calibration studies using artificial neural networks to improve precision of 
accelerometer categorised PA outcomes specific to the CKD population.   
x Calibration studies for ActivPAL categorised PA intensity outcomes. 
x Feasibility studies for routine PA monitoring via readily available smart technology. 
x Dose-response health benefits of different metrics of objectively measured PA. 
x Accelerometer based PA and sedentary time guidelines for health in stage 5 CKD.  
x Determine prognostic utility and clinically important thresholds of physical 
performance tests specific to stage 5 CKD. 
x Correlates and relative contribution of PA to Human Activity Profile scores.  
x Exploration of interactions between changes in physical function and intermediate 
endpoints in prospective and intervention studies. 
x Effect of medications on phenotypic expression of genes associated with skeletal 
muscle response to PA. 
x Improving uptake of higher levels of PA among people with stage 5 CKD. 
x Inclusion of endothelial function as an outcome in PA health and intervention 
studies.   
x Effect of PA on phenotypic expression of genes implicated in arterial stiffness. 
x Independent contribution of different levels of CKD severity to arterial stiffness. 
x Methods to compare and pool arterial stiffness data obtained via different devices.  
x Prognostic utility of Vicorder measured arterial stiffness in stage 5 CKD. 
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7.6 Conclusions 
Assessment of PA via accelerometry is a rapidly expanding field in health research 
and guidance regarding data reduction criteria is urgently required. Based on the 
observations of this project, one dialysis day and two non-dialysis days and eight 
hours wear/day is the minimum required monitor wear time for reliable estimates of 
PA and sedentary behaviour (normalised to wear time). This rubric should allow 
90% sample retention for final analyses thereby preserving ecological validity.  
Selection of PA assessment method depends on the information content required. 
The Stanford Seven-Day Recall provides a broad indication of compliance with 
consensus PA guidelines but accelerometers are better able to characterise 
behaviour at the lower end of the activity spectrum, where the majority of the HD 
population operates. High compliance and low cost of wearable monitors now 
generally available demonstrates they are a feasible monitoring method.  
Similar outcomes from Actigraph GT3x and ActivPAL monitors cannot be used 
interchangeably in stage 5 CKD. If outcomes of interest are time seated or steps 
taken, ActivPAL will provide more precise estimates. Until research is undertaken to 
improve precision of categorised PA outcomes in the CKD population, Actigraph 
output should be reported as counts per minute only. Subjective and objectively 
estimated PA show limited agreement in stage 5 CKD due to recognised limitations 
of both methods, thus precluding direct comparison and pooling of existing data.     
Physical function of HD patients is lower than more aged non-uraemic individuals. 
Habitual PA is the most important independent predictor of physical performance 
measures of CRF and lower limb neuromuscular function and attenuates the effect 
of other risk factors. Self-reported functional status outcomes used in this study are 
unlikely to be sufficiently sensitive to PA behaviour change. A graded scale of 
physical performance testing can be employed to monitor physical function of young 
and older HD patients with STS5 and TUAG tasks as the minimum standard. 
Additional prognostic value of physical performance tests lies in their ability to help 
identify frail individuals at risk of dependency, hospitalisation and mortality. 
In light of high prevalence of functional decline and attendant increase in arterial 
stiffness with longer HD vintage, uraemia should be viewed as a model of 
accelerated aging. Habitual PA and higher CRF did not attenuate arterial stiffness of 
maintenance HD patients suggesting arteriosclerosis is not reversible, however this 
finding requires verification. Physical activity and CRF mediated benefits on survival 
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and morbidity in this population may instead be mediated via improved endothelial 
function and should be explored. Recognised limitations of AI and lack of 
association with PWV recommend the latter as the preferred arterial stiffness index. 
Findings from this project are intended to support renal healthcare providers and 
allied investigators with selection and standardisation of assessment methods to 
operationalise current government strategies and KDOQI recommendations. The 
value of these recommendations cannot be overstated in light of: the growing global 
health problem of severe kidney disease and substantial attendant burden of care 
and cost; poor long-term prognosis of stage 5 CKD; poor short-term prognosis for 
frail individuals initiating HD and those who subsequently become frail.   
Table 7.10 Summary of recommendations arising from this thesis for 
healthcare providers and investigators. 
1. Questionnaires can be used to screen for compliance with PA guidelines but 
cannot presently be directly compared to or pooled with objectively estimated PA. 
2. Accelerometry is feasible for routine PA monitoring and recommended for 
research seeking to elucidate behaviour mediated mechanisms of health. 
3. ActivPAL and Actigraph GT3x outcomes are not interchangeable. ActivPAL is 
preferred for estimating steps taken, time seated, and breaks in sedentary time.  
4. Actigraph GT3x output should be reported as activity counts per minute only for a 
gross measure of PA until precision of categorised outcomes is improved. 
5. Wear time: One dialysis day and two non-dialysis days with eight hours wear per 
day is the minimum requirement for characterising PA and sedentary behaviour. 
6. Weekend day/s: Inclusion is not a compulsory data reduction criterion. 
7. Data reduction criteria should be reported in PA studies for quality assurance. 
8. Physical function: Physical performance tests are preferred over functional status 
questionnaires for monitoring changes in PA behaviour and exercise interventions.  
9. Functional status questionnaires should only be used in tandem with physical 
performance measures.  
10. Frailty is easily assessed using expedient physical performance tests. 
11. Sit-to-stand five and Timed up-and-go tests are the minimum requirement for 
monitoring physical function in stage 5 CKD. 
12. Healthcare providers in nephrology now need to move forward with 
standardisation of physical function monitoring as a ‘sixth vital sign’.   
13. Pulse wave velocity is the preferred central arterial stiffness index in stage 5 CKD. 
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Appendix I c: Study information sheet. 
 
Participant Information Sheet 
The relationship of arterial stiffness to physical activity, aerobic fitness, and 
quality of life in people undergoing maintenance haemodialysis therapy for 
chronic kidney disease. 
Dear Sir/Madam 
 
My name is Sean Prescott and I am a PhD student from the School of Health 
Sciences at Queen Margaret University in Edinburgh.  As part of my PhD degree, I 
am doing some research projects.  One of these will take place at the renal unit in 
Monklands Hospital. It will look at factors related to arterial health (how well blood 
vessels work) and quality of life in people receiving haemodialysis.  
Before you decide to take part I need to be sure that you understand why this study 
is taking place, and what would be involved if you agree to take part.  
What is the purpose of the study? 
Heart problems are often seen with chronic kidney disease and may result in shorter 
life expectancies. It is believed that this may be due in part to increased arterial 
stiffness. In the general population higher levels of physical activity and fitness are 
related to lower arterial stiffness and reduced risk of heart problems. However little 
is known about relationships between arterial stiffness, physical activity, aerobic 
fitness in the haemodialysis population. Therefore, the aim of this study is to 
examine these relationships. It will also look at how quality of life and symptoms 
might be related to these factors.  
Who is able to take part? 
The study is open to men and women aged 18 years and over who receive 
haemodialysis therapy for chronic kidney disease. It is the aim of the research team 
to involve around 100 people in the study.  The study involves some physical 
activities and a quick assessment will decide if you can take part (form attached).   
Do I have to take part? 
You do not have to take part. If you decide that you do not wish to continue in the 
study you may withdraw at any time and you would not have to give a reason. This 
would not affect the standard of care you receive. You will be withdrawn from the 
study if you become unwell and are unable to give consent. Any data already 
collected will be retained.    
What will happen if I agree to take part? 
You will be asked to come to one appointment at Monklands Hospital renal unit on a 
non-dialysis day. The session should take no longer than one and a half hours. 
During this session your arterial stiffness will be measured after you have rested in a 
lying position for 15 minutes. This is a similar procedure to having your blood 
pressure taken. We ask that you do not eat or drink beverages containing caffeine 
such as tea or coffee in the three hours before your appointment, as this may affect 
measurement of your blood pressure and arterial stiffness. Alcohol can also affect 
these measures so please do not drink alcohol in the 10 hours before your 
appointment. 
Your height and weight will be measured and you will be given two short 
questionnaires on your current fitness level. These should take no longer than five 
minutes each to complete. You will also be asked to do the following three short 
physical activities: measuring your grip strength; standing up from a seated position 
five times; and getting up from a chair to walk three metres, return and sit down 
again. These activities will take 5-10 minutes to do.  
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The final activity is a graded shuttle walk on a short 10-metre course marked with 
cones. You will hear beeps that will pace you and prompt you to walk a bit quicker 
each minute until you decide to stop. Usual time for the shuttle walk is 5-12 minutes. 
You do not have to do this activity if you choose not to. The session will progress at 
a pace comfortable for you and allow time for rest periods. At the end of this session 
you will be given two small activity monitors to wear. One is attached on a belt and 
is to be worn during waking hours. The other monitor, which is similar in size to a 
credit card is positioned on the front of your thigh with non-allergenic tape and may 
be worn at night. Both monitors are to be worn over the following 8 days.  
Over the next three dialysis sessions you will be asked to complete three 
questionnaires. One questionnaire is on physical activity and the other two will ask 
you about aspects of quality of life and experience of symptoms with your condition. 
These will take approximately 10-20 minutes each to complete. The questionnaires 
do contain some personal questions. You do not have to answer these if you 
choose not to. The activity monitor will be collected after nine days when you come 
to the renal unit for dialysis. 
What if I would like to take part but have no personal transport or have special 
transport needs?  
If you need help with transport to attend the non-dialysis appointment a taxi can be 
arranged and you will be reimbursed for travel costs. 
How can I find out more information about this study? 
You can speak with me as the researcher. You are also welcome to contact Dr 
Claire Nolan, an independent person, who knows about this project but is not 
involved in it.  Dr Nolan is a consultant nephrologist at Monklands Hospital.  Her 
contact details are given at the end of this information sheet. 
What are the possible risks or disadvantages of taking part? 
Measurement of arterial stiffness and the physical activities used in the study will 
present little or no risk to you. There may be a small disruption to your daily routine 
in that you will be asked to make one visit to the renal unit outside of your normal 
times. However, this will be for one session only and will be at a time agreed 
between you and the researcher. Use of the activity monitor requires only that you 
remember to attach it to your belt during the day for 8 days.   
What are the benefits of taking part? 
There will be no immediate benefits to taking part in the study. However your taking 
part will help further knowledge about how physical activity and fitness might 
influence heart health and relate to quality of life. The project will be valuable as it 
will help guide improvements in health care and quality of life for this condition.   
What if there is a problem? 
If you have any concerns about any part of this study, you can speak with me as the 
researcher in the first instance or Dr Nolan. If you remain unhappy and wish to 
complain formally, you may do this by contacting: Dr Fiona Coutts, Dean of Health 
Sciences Queen Margaret University (details at end of information sheet); or 
through the NHS Complaints Procedure (details can be obtained from the hospital). 
Will my taking part be kept confidential? 
Your GP will be informed that you are taking part in the study, however all 
information about your taking part will be kept strictly confidential. If any concerns 
regarding your health arise during the study your medical team will be informed. 
Your name will be replaced with a unique code. It will not be possible for you to be 
identified in any reporting of the data gathered. The information collected will be for 
the researcher and the research team’s use only and will be stored securely 
according to the Data Protection Act 1998. The study data will be destroyed on 
completion of the study. 
What will happen to the results of the study? 
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The results will be used for presentation in a PhD thesis and may be published in a 
journal or presented at a conference. A summary of the information will be made 
available to you if you wish. You will not be identified in any publication or report. 
Who is organising and funding the research? 
This research is being organised by Professor Tom Mercer from Queen Margaret 
University (tmercer@qmu.ac.uk) and Dr Jamie Traynor and Dr Ilona Shilliday from 
Monklands Hospital. The project is being jointly funded by the UK Kidney Patients 
Foundation and Queen Margaret University.  
Who has reviewed this study? 
This study has been examined by the West of Scotland Research Ethics 
Committee, which has responsibility for protecting your safety, rights, wellbeing and 
dignity. It has met the standards set by this body and given a favourable ethical 
opinion. 
If you have read and understood this information sheet, and any questions you had 
have been answered, please now see the consent forms if you would like to take 
part in the study. You may keep one of the consent forms for your own records. 
Thank you for considering taking part in this study. 
 
Yours sincerely 
 
Sean Prescott 
 
Contact Information 
Sean Prescott, PhD Research Student, 
Physiotherapy, Health Sciences 
Queen Margaret University, Edinburgh 
Musselburgh 
East Lothian  EH21 6UU 
Email / Telephone: sprescott@qmu.ac.uk / 
0131 474 0000 
 
 
Dr Fiona Coutts 
Dean of Health Sciences 
Queen Margaret University, Edinburgh 
Musselburgh 
East Lothian  EH21 6UU 
Email / Telephone: fcoutts@qmu.ac.uk / 
0131 474 0000 
 
Independent adviser 
Dr Claire Nolan 
Consultant Nephrologist 
Monklands Hospital 
Monkscourt Avenue 
Airdrie 
ML6 0JS 
Email / Telephone: claire.nolan@lanarkshire.scot.nhs.uk / 0123 671 3167 
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Appendix I d: Participant consent form. 
 
 341 
Appendix I e: Participant recruitment pamphlet. 
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Appendix II: BORG’s rating of perceived exertion scale. 
Borg’s Rating of Perceived Exertion Scale 
6 No exertion at all 
7 Extremely light 
8  
9 Very light 
10  
11 Light 
12  
13 Somewhat hard 
14  
15 Hard (heavy) 
16  
17 Very Hard 
18  
19 Extremely hard 
20 Maximal exertion 
 
Instructions:  When you begin doing aerobic exercise, try to estimate how hard you 
feel the work is; that is, rate the degree of the perceived level of exertion you feel. 
Think of perceived exertion as the total amount of exertion and physical fatigue, 
combining all sensations and feelings of physical stress, effort, and fatigue. When 
rating how the whole body is feeling while exercising don’t concern yourself with any 
one factor such as leg pain, shortness of breath or work intensity, simply try to 
concentrate on your total inner feeling of exertion. Try to estimate as honestly and 
objectively as possible. Don’t underestimate the degree of exertion you feel, but 
don’t overestimate it either. Just try to estimate as accurately as possible (Borg 
1998).  
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Appendix III: Duke activity status index questionnaire. 
Duke Activity Status Index (DASI) 
 
Item Activity – Can you….. Yes No 
1 take care of yourself (eating dressing bathing or 
using the toilet)?  
 
 
 
 
2 walk indoors such as around your house?  
 
  
3 walk a block or two on level ground?  
 
  
4 climb a flight of stairs or walk up a hill?  
 
  
5 run a short distance?  
 
  
6 do light work around the house like dusting or 
washing dishes?  
 
  
7 do moderate work around the house like vacuuming 
sweeping floors or carrying in groceries?  
 
  
8 do heavy work around the house like scrubbing 
floors or lifting and moving heavy furniture?  
 
  
9 do yardwork like raking leaves weeding or pushing 
a power mower?  
 
  
10 have sexual relations?  
 
  
11 participate in moderate recreational activities like 
golf bowling dancing doubles tennis or throwing a 
baseball or football?  
 
  
12 participate in strenuous sports like swimming 
singles tennis football basketball or skiing?  
 
  
Answers are expressed as yes or no response with a 1 representing yes and 0 
representing a no response. The responses are then multiplied by the weight value 
for each question and a composite score obtained. 
Duke activity status index = SUM(values for all 12 questions) 
Interpretation:  
• maximum value 58.2  
• minimum value 0  
Estimated peak oxygen uptake in mL/min = (0.43 * (duke activity status index)) + 9.6  
 
Reference:  
Hlatky MA Boineau RE et al. 1989 A brief self-administered questionnaire to 
determine functional capacity (The Duke Activity Status Index). American Journal of 
Cardiology. 64: 651-654. 
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Appendix IV: Leicester uraemic symptom scale (part 1). 
 
THE LEICESTER URAEMIC SYMPTOM SCALE 
(LUSS) 
 
 
 
Part 1 
 
The following is a list of 10 symptoms commonly associated with 
kidney problems. Please tick the box which best describes how 
frequently you experience each symptom. 
 
 
SYMPTOM Never  
Less than 
once per 
week 
1-2 times 
per week 
Several 
times per 
week 
Every 
day 
Itching      
Sleep disturbance      
Loss of appetite      
Excessive tiredness      
Pain in bones/joints      
Poor concentration/ 
mental alertness 
     
Loss of muscle strength/ 
power 
     
Shortness of breath      
Muscle spasm/stiffness      
Restless legs      
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Appendix IV continued: Leicester uraemic symptom scale (part 2). 
 
LUSS Part 2 
 
Some of the symptoms that you ticked overleaf may be more 
intrusive than others. Please tick the boxes below which best 
describe how intrusive you find each symptom. 
If you do not experience a symptom, please tick the box marked 
N/A (not applicable). 
 
SYMPTOM N/A Not at all intrusive 
Slightly 
intrusive 
Quite 
intrusive 
Very 
intrusive 
Extremely 
intrusive 
Itching       
Sleep disturbance       
Loss of appetite       
Excessive tiredness       
Pain in bones/joints       
Poor concentration/ 
mental alertness 
      
Loss of muscle 
strength/power 
      
Shortness of breath       
Muscle 
spasms/stiffness 
      
Restless legs       
 
Thank you for completing this questionnaire 
 
For office use only: 
 
 
 
 
 
 
 
 
 
SCORE TABLE 
No. of uraemic 
symptoms identified 
 
Part 1 Total Score 
 
Part 2 Total Score 
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Appendix V a: Actigraph and ActivPAL wear instructions. 
 
Activity Monitors 
Thank you for wearing the activity monitors. They record different aspects of 
physical activity such as how much time you spend sitting, standing or walking.  
Please wear the monitors during waking hours for eight days including weekdays 
and weekends. You can take the monitors off at night when you go to bed, but 
please try to remember to put them on in the morning as soon as possible after you 
get up. The monitors must be removed for showering/bathing/swimming, but should 
be put back on immediately after. 
Both monitors record 8 days of activity starting from the time you were given them 
so please wear them from the day you receive them. 
After you have worn the monitors for eight days, please bring them back to the 
dialysis unit during your routine appointment on ______________________ and I 
will arrange to collect them.  
Wearing the Actigraph 
The Actigraph is worn on the belt provided with the monitor place on the non-
dominant hip, just above the boney point on the front of your pelvis. Please wear it 
with the wording on the monitor right side up.   
 
Applying the ActivPAL 
Please attach the monitor to the front of your thigh on the same side as the 
Actigraph. It should be positioned on the midline of the thigh, between the hip and 
the knee in the orientation indicated by the figure on the front panel of the monitor 
(the little man should be standing pointing upwards).  
You have been provided with special stickies to be used with the monitor, one for 
each day. The backings on the stickies indicate which side is to be attached to the 
monitor and which side adheres to your skin. The stickies can be removed and 
repositioned so when you remove the monitor to shower you should be able to put it 
back on using the same stickie.  
The activity monitors and tape are not waterproof and they should be removed for 
bathing or swimming. The skin should be thoroughly dried after bathing to 
maximise the adherence of the tape/gel. Further details can be found on the 
PALstickies instruction sheet provided. 
You’ve also been given some Hypafix tape. This can be used over the monitor, in 
addition to the stickies if you feel the monitor is not secure enough. 
 
Finally, please return the included form and note when you wore 
the monitors. 
 
If you have any questions regarding the monitor please contact 
me on 0131 4740000 say: ‘Sean Prescott’. You can also reach me 
at 07980338486. 
 
Thank you very much for helping with this study, 
 
Sean 
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Appendix V b: ActivPAL and Actigraph wear log. 
 
 
 
ActivPAL and Actigraph Usage 
 
 Date Time On Time Off 
Day 1    
Day 2    
Day 3    
Day 4    
Day 5    
Day 6    
Day 7    
Day 8    
 
 
 
Comments: 
 
 
 
 
 
 
 
 
 
 
Please fill in the date and the times above and return with the monitor in the 
addressed envelope 
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Appendix VI: Stanford Seven-Day Recall questionnaire.  
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Appendix VI b: Stanford Seven Day Recall interview script. 
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Appendix VI b: Stanford Seven Day Recall script continued. 
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Appendix VII: Normality of Actigraph physical activity data. 
Actigraph outcome variables. Participants with seven days wear greater than 
four hours wear/day.  
 7 days Dialysis Days Non-Dialysis Days 
Statistic df Sig. Statistic df Sig. Statistic df Sig. 
Wear (min) 0.099 51 0.200* 0.065 51 0.200* 0.071 51 0.200* 
Sedentary (min) 0.054 51 0.200* 0.067 51 0.200* 0.082 51 0.200* 
Sedentary (%) 0.126 51 0.042 0.125 51 0.046 0.106 51 0.200* 
MVPA (min) 0.245 51 0.000 0.296 51 0.000 0.236 51 0.000 
MVPA (%) 0.242 51 0.000 0.263 51 0.000 0.226 51 0.000 
TPA (min) 0.125 51 0.045 0.151 51 0.005 0.100 51 0.200* 
TPA (%) 0.126 51 0.042 0.125 51 0.046 0.106 51 0.200* 
Uniaxial cpd 0.209 51 0.000 0.269 51 0.000 0.180 51 0.000 
Uniaxial cpm 0.197 51 0.000 0.197 51 0.000 0.208 51 0.000 
Triaxial cpd 0.165 51 0.001 0.217 51 0.000 0.155 51 0.004 
Triaxial cpm 0.175 51 0.000 0.168 51 0.001 0.187 51 0.000 
Step count/day 0.192 51 0.000 0.276 51 0.000 0.183 51 0.000 
Step count/min 0.201 51 0.000 0.237 51 0.000 0.222 51 0.000 
*Lower bound of true significance (Kolmogorov-Smirnov test) 
cpd = counts per day, cpm =  counts per minute 
 
 
 
Actigraph PA variables. Participants with three dialysis days wear or four non-
dialysis days wear greater than four hours/day. 
 Dialysis Days (n = 63) Non-Dialysis Days (n = 54) 
Statistic df Sig. Statistic df Sig. 
Wear (min) 0.066 63 0.200* 0.074 54 0.200* 
Sedentary (min) 0.071 63 0.200* 0.088 54 0.200* 
Sedentary (%) 0.133 63 0.008 0.102 54 0.200* 
MVPA (min) 0.265 63 0.000 0.229 54 0.000 
MVPA (%) 0.238 63 0.000 0.218 54 0.000 
TPA (min) 0.153 63 0.001 0.096 54 0.200* 
TPA (%) 0.133 63 0.008 0.102 54 0.200* 
Uniaxial cpd 0.230 63 0.000 0.160 54 0.001 
Uniaxial cpm 0.179 63 0.000 0.201 54 0.000 
Triaxial cpd 0.204 63 0.000 0.139 54 0.011 
Triaxial cpm 0.160 63 0.000 0.165 54 0.001 
Step count/day 0.240 63 0.000 0.158 54 0.002 
Step count/min 0.205 63 0.000 0.192 54 0.000 
*Lower bound of true significance (Kolmogorov-Smirnov test) 
cpd = counts per day, cpm =  counts per minute 
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Appendix VIII:  Normality of ActivPAL physical activity data. 
 
ActivPAL outcome variables. Participants with seven days wear greater than 
four hours wear/day  
 7 days Dialysis Days Non-Dialysis Days 
Statistic df Sig. Statistic df Sig. Statistic df Sig. 
Wear minute  0.982 44 0.722 0.982 44 0.726 0.976 44 0.490 
Sit/Lie (min) 0.964 44 0.176 0.991 44 0.978 0.945 44 0.037 
Sit/Lie (%) 0.933 44 0.014 0.875 44 0.000 0.927 44 0.008 
Step time (min) 0.729 44 0.000 0.571 44 0.000 0.832 44 0.000 
Step time (%) 0.741 44 0.000 0.708 44 0.000 0.771 44 0.000 
Stand time (min) 0.954 44 0.076 0.835 44 0.000 0.961 44 0.141 
Stand time (%) 0.933 44 0.014 0.875 44 0.000 0.927 44 0.008 
Steps (day) 0.759 44 0.000 0.639 44 0.000 0.829 44 0.000 
Steps (min)  0.761 44 0.000 0.748 44 0.000 0.772 44 0.000 
Transitions (day)  0.978 44 0.561 0.971 44 0.336 0.972 44 0.369 
Transitions (hour) 0.893 44 0.001 0.949 44 0.051 0.895 44 0.001 
METmin (day)   0.987 44 0.893 0.918 44 0.004 0.962 44 0.161 
METmin (min)   0.792 44 0.000 0.781 44 0.000 0.805 44 0.000 
Shapiro-Wilk test of normality 
 
ActivPAL outcome variables. Participants with either three dialysis days wear 
or four non-dialysis days wear greater than four hours/day 
 Dialysis Days† Non-Dialysis Days†† 
Statistic df Sig. Statistic df Sig. 
Wear minute  0.071 55 0.200* 0.970 47 0.261 
Sit/Lie (min) 0.048 55 0.200* 0.950 47 0.043 
Sit/Lie (%) 0.088 55 0.200* 0.931 47 0.009 
Step time (min) 0.230 55 0.000 0.846 47 0.000 
Step time (%) 0.233 55 0.000 0.792 47 0.000 
Stand time (min) 0.125 55 0.033 0.964 47 0.151 
Stand time (%) 0.088 55 0.200* 0.932 47 0.009 
Steps (day) 0.233 55 0.000 0.845 47 0.000 
Steps (min)  0.260 55 0.000 0.793 47 0.000 
Transitions (day)  0.119 55 0.049 0.975 47 0.391 
Transitions (hour) 0.098 55 0.200* 0.906 47 0.001 
METmin (day)   0.082 55 0.200* 0.962 47 0.133 
METmin (min)   0.226 55 0.000 0.824 47 0.000 
*Lower bound of true significance 
† Dialysis Days n = 55 Kolmogorov-Smirnov normality test 
†† Non-Dialysis Days n =47 Shapiro-Wilk normality test 
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Appendix IX: Test of differences for Actigraph outcom
e variables.  Dialysis versus non-dialysis days. 
 W
ear tim
e 
>4 hours 
>5 hours 
>6 hours 
>7 hours 
>8 hours 
>9 hours 
>10 hours 
n =  
51 
49 
49 
47 
37 
35 
29 
W
ear tim
e 
(m
in) 
t(50) = 11.40  
p < 0.001 d = 1.60 
t(48) = 12.90  
p < 0.001 d = 1.84 
t(48) = 12.90  
p < 0.001 d = 1.84 
t(46) = 12.40  
p < 0.001 d = 1.81 
t(36) = 11.40  
p < 0.001 d = 1.87 
t(34) = 11.31  
p < 0.001 d = 1.91 
t(28) = 10.68  
p < 0.001 d = 1.98 
S
edentary 
tim
e (m
in) 
t(50) = 8.69  
p < 0.001 d = 1.22 
t(48) = 8.57  
p < 0.001 d = 1.22  
t(48) = 8.57  
p < 0.001 d = 1.22  
t(46) = 8.21  
p < 0.001 d = 1.20 
t(36) = 7.18  
  p < 0.001 d = 1.18 
t(34) = 7.11  
p < 0.001 d = 1.20 
t(28) = 6.52  
p < 0.001 d = 1.21 
S
edentary 
tim
e (%
) 
Z = -5.04    
p < 0.001 r = 0.71 
Z = -4.85  
p < 0.001 r = 0.69 
Z = -4.85  
p < 0.001 r = 0.69 
Z = -4.68  
p < 0.001 r = 0.68 
Z = -3.99  
p < 0.001 r = 0.66 
Z = -4.01  
p < 0.001 r = 0.68 
Z = -3.75  
p < 0.001 r = 0.70 
M
V
P
A
 tim
e 
(m
in) 
Z = -2.89    
p = 0.004 r = 0.40 
Z = -3.01  
p = 0.003 r = 0.43 
Z = -3.01  
p = 0.003 r = 0.43 
Z = -3.00  
p = 0.003 r = 0.44 
Z = -2.50  
p = 0.013 r = 0.41 
Z = -2.65  
p = 0.008 r = 0.45 
Z = -2.24  
p = 0.025 r = 0.42 
M
V
P
A
 tim
e 
(%
) 
Z = -3.21    
p = 0.001 r = 0.45 
Z = -3.23  
p = 0.001 r = 0.46 
Z = -3.23  
p = 0.001 r = 0.46 
Z = -3.22  
p = 0.001 r = 0.47 
Z = -2.30  
p = 0.021 r = 0.38 
Z = -2.51  
p = 0.012 r = 0.42 
Z = -2.20  
p = 0.028 r = 0.41 
LV
P
A
 tim
e 
(m
in) 
Z = -2.93    
p = 0.003 r = 0.41 
Z = -3.12  
p = 0.002 r = 0.45 
Z = -3.12  
p = 0.002 r = 0.45 
Z = -3.08  
p = 0.002 r = 0.45 
Z = -3.18  
p = 0.001 r = 0.52 
Z = -3.23  
p = 0.001 r = 0.55 
Z = -2.93  
p = 0.003 r = 0.54 
LV
P
A
 tim
e 
(%
) 
Z = -5.04    
p < 0.001 r = 0.71 
Z = -4.85  
p < 0.001 r = 0.69 
Z = -4.85  
p < 0.001 r = 0.69 
Z = -4.68  
p < 0.001 r = 0.68 
Z = -3.99  
p <0.001 r = 0.66 
Z = -4.01  
p <0.001 r = 0.68 
Z = -3.75  
p <0.001 r = 0.70 
U
niaxial 
C
ounts/day 
Z = -3.403  
p = 0.001 r = 0.48 
Z = -3.59  
p < 0.001 r = 0.51 
Z = -3.59  
p < 0.001 r = 0.51 
Z = 3.52  
p < 0.001 r = 0.51 
Z = -3.18  
p = 0.001 r = 0.52 
Z = -3.24  
p = 0.001 r = 0.55 
Z = -2.91  
p = 0.004 r = 0.60 
U
niaxial 
C
ounts/m
in 
Z = -4.705  
p <0.001 r = 0.66 
Z = -4.49  
p < 0.001 r = 0.64 
Z = -4.49  
p < 0.001 r = 0.64 
Z = -4.349  
p < 0.001 r = 0.63 
Z = -3.61  
p < 0.001 r = 0.59 
Z = -3.65  
p < 0.001 r = 0.62 
Z = -3.32  
p = 0.001 r = 0.62 
Triaxial 
C
ounts/day 
Z = -3.77    
p < 0.001 r = 0.53 
Z = -3.99  
p <0.001 r = 0.57 
Z = -3.99  
p <0.001 r = 0.57 
Z = 3.852  
p <0.001 r = 0.56 
Z = -3.75  
p <0.001 r = 0.62 
Z = -3.77  
p <0.001 r = 0.64 
Z = -3.49  
p <0.001 r = 0.65 
Triaxial 
C
ounts/m
in 
Z = -5.54    
p < 0.001 r = 0.78 
Z = -5.38  
p < 0.001 r = 0.77 
Z = -5.38  
p < 0.001 r = 0.77 
Z = -5.21  
p <0.001 r = 0.76 
Z = -4.64  
p < 0.001 r = 0.76 
Z = -4.65  
p < 0.001 r = 0.79 
Z = -4.23  
p < 0.001 r = 0.78 
S
tep 
count/day 
Z = -3.05    
p = 0.002 r = 0.43 
Z = -3.19  
p < 0.001 r = 0.46 
Z = -3.19  
p <0.001 r = 0.46 
Z = -3.19  
p = 0.001 r = 0.46 
Z = -2.95  
p = 0.003 r = 0.48 
Z = -3.05  
p = 0.002 r = 0.52 
Z = -2.63  
p = 0.009 r = 0.49 
S
tep 
count/m
in 
Z = -4.04    
p < 0.001 r = 0.57 
Z = -3.92  
p < 0.001 r = 0.56 
Z = -3.92  
p < 0.001 r = 0.56 
Z = -3.83  
p < 0.001 r = 0.56 
Z = -3.36  
p = 0.001 r = 0.55 
Z = -3.44  
p = 0.001 r = 0.58 
Z = -3.02  
p = 0.003 r = 0.56 
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Appendix X. Test of differences for ActivPAL outcom
e variables.  Dialysis versus Non-Dialysis days. 
 
W
ear tim
e 
>4 hours 
>5 hours 
>6 hours 
>7 hours 
>8 hours 
>9 hours 
>10 hours 
n =  
44 
42 
39 
38 
35 
32 
22 
W
ear (m
in)  
T(43 )=5.565  
p < 0.001 d = 1.20 
t(41) = 5.508  
p < 0.001 d = 1.22 
t(38) = 5.719 
p < 0.001 d = 1.32 
t(37) = 5.750 
p < 0.001 d = 1.34   
t(34) = 5.496 
p < 0.001  d = 1.33 
t(31) = 4.752 
p < 0.001  d = 1.21 
t(21) = 3.274 
p < 0.001 d = 1.01 
S
it/Lie (m
in)  
Z = -5.532  
p < 0.001  r = 0.83 
Z = -5.383  
p < 0.001  r = 0.83 
Z = -5.233 p < 0.001  
r = 0.84 
Z = -5.156  
p < 0.001  r = 0.84 
Z = -4.914 p<0.001   
r = 0.83 
Z = -4.656 p< 0.001    
r = 0.84 
Z = -4.010 p < 
0.001  r = 0.85 
S
it/Lie (%
) 
Z = -5.053    
p < 0.001  r = 0.76 
Z = -4.870    
p < 0.001 r = 0.75 
Z = -4.856    
p < 0.001  r = 0.78 
Z = -4.764    
p < 0.001  r = 0.77 
Z = -4.472    
p < 0.001  r = 0.76 
Z = -4.637    
p < 0.001  r = 0.82 
Z = -4.107    
p < 0.001  r = 0.88 
S
tand (m
in) 
Z = -4.260    
p < 0.001  r = 0.64 
Z = -4.508    
p < 0.001  r = 0.70 
Z = -4.410    
p < 0.001  r = 0.71 
Z = -4.300    
p < 0.001  r = 0.70 
Z = -4.013    
p < 0.001   r = 0.68 
Z = -4.544   
p < 0.001   r = 0.80  
Z = -3.977    
p < 0.001  r = 0.85  
S
tand (%
) 
Z = -5.053    
p < 0.001  r = 0.76 
Z = -4.870    
p < 0.001  r = 0.75 
Z = -4.856    
p < 0.001  r = 0.78 
Z = -4.764    
p < 0.001  r = 0.77 
Z = -4.472    
p < 0.001   r = 0.76 
Z = -4.637    
p < 0.001   r = 0.82 
Z = -4.107    
p < 0.001  r = 0.88 
S
tep 
Tim
e 
(m
in)  
Z = -3.980     
p < 0.001  r = 0.60   
Z = -4.245    
p < 0.001  r = 0.66 
Z = -4.117     
p < 0.001  r = 0.66 
Z = -4.010     
p < 0.001  r = 0.65 
Z = -3.653     
p < 0.001   r = 0.62 
Z = -4.207     
p < 0.001   r = 0.74  
Z = -3.847     
p < 0.001   r = 0.82  
S
tep Tim
e (%
) 
Z = -4.878    
p < 0.001  r = 0.74 
Z = -4.683    
p < 0.001  r = 0.72  
Z = -4.591    
p < 0.001  r = 0.74 
Z = -4.488    
p < 0.001  r = 0.73 
Z = -4.193   
p < 0.001   r = 0.71 
Z = -4.376   
p < 0.001  r = 0.77 
Z = -3.912    
p < 0.001  r = 0.83 
Transitions 
(day) 
T(43 )= -2.842  
p = 0.007 d = 0.61 
T(41 )= -3.525  
p =0.001 d = 0.78 
T(38 )= -4.132  
p < 0.001 d = 0.95 
T(37 )= -3.974  
p < 0.001  d = 0.92 
T(34 )= -4.212  
p < 0.001   d = 1.02 
T(31 )= -3.908   
P
 < 0.001   d = 0.99 
T(21 )= -4.778   
p < 0.001 d = 1.47 
Transitions 
(hr)  
Z = -5.123    
p < 0.001  r = 0.77  
Z = -4.983    
p < 0.001  r = 0.77  
Z = -5.177    
p < 0.001  r = 0.83  
Z = -5.098    
p < 0.001  r = 0.83 
Z = -4.848    
p < 0.001   r = 0.82 
Z = -4.581    
p < 0.001  r = 0.81 
Z = -3.912    
p < 0.001  r = 0.83 
S
teps/day 
Z = -3.769    
p < 0.001  r = 0.57 
Z = -3.982    
p < 0.001  r = 0.61 
Z = -3.852   
p < 0.001  r = 0.62 
Z = -3.734    
p < 0.001  r = 0.61 
Z = -3.358    
p < 0.001   r = 0.57 
Z = -3.964   
p < 0.001  r = 0.70 
Z = -3.587    
p < 0.001  r = 0.76 
S
teps/m
in 
Z = -4.621    
p < 0.001  r = 0.70 
Z = -4.408    
p < 0.001  r = 0.68 
Z = -4.312    
p < 0.001  r = 0.69 
Z = -4.213    
p < 0.001  r = 0.68 
Z = -3.882    
p < 0.001   r = 0.66 
Z = -4.226    
p < 0.001  r = 0.75 
Z = -3.750    
p < 0.001  r = 0.80 
M
E
Tm
in/day 
Z = -3.349   
p = 0.001  r = 0.50 
Z = -3.057    
p = 0.002  r = 0.47 
Z = -3.000    
p = 0.003  r = 0.48 
Z = -3.125    
p = 0.002  r = 0.51 
Z = -2.948    
p = 0.003   r = 0.50 
Z = -2.412    
p = 0.016  r = 0.43 
Z = -1.347    
p = 0.178  r = 0.29 
M
E
Tm
in/m
in 
Z = -4.831    
p < 0.001  r = 0.73 
Z = -4.633   
p < 0.001  r = 0.71 
Z = -4.549   
p < 0.001  r = 0.73 
Z = -4.459    
p < 0.001  r = 0.72 
Z = -4.160   
p < 0.001   r = 0.70 
Z = -4.506    
p < 0.001  r = 0.80  
Z = -4.042    
p < 0.001  r = 0.86 
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Appendix XI: Single measure reliability values for Actigraph 
 
 
Actigraph outcome variables single measure intra-class correlation coefficients 
(dialysis days).  
Hours of wear >4 >5 >6 >7 >8 >9 >10 
Cases (n =) 63 63 62 60 57 55 53 
Sedentary mins 0.394 0.394 0.452 0.522 0.636 0.614 0.591 
Sedentary % 0.771 0.771 0.777 0.801 0.803 0.801 0.806 
Total PA mins 0.756 0.756 0.776 0.781 0.786 0.784 0.783 
Total PA % 0.799 0.799 0.810 0.814 0.818 0.819 0.818 
MVPA mins 0.794 0.794 0.805 0.800 0.796 0.793 0.791 
MVPA % 0.776 0.776 0.780 0.776 0.781 0.779 0.779 
Triaxial counts/day 0.799 0.799 0.810 0.814 0.818 0.819 0.818 
Triaxial counts/min 0.815 0.815 0.818 0.832 0.833 0.834 0.839 
Steps/day 0.861 0.861 0.872 0.873 0.869 0.868 0.867 
Steps/min 0.860 0.860 0.861 0.867 0.869 0.870 0.871 
 
 
 
Actigraph outcome variables single measure intra-class correlation coefficients 
(non-dialysis days).  
Hours of wear >4 >5 >6 >7 >8 >9 >10 
Cases (n =) 54 52 52 51 40 38 32 
Sedentary mins 0.544 0.524 0.524 0.534 0.595 0.592 0.571 
Sedentary % 0.760 0.768 0.768 0.775 0.747 0.744 0.670 
Total PA mins 0.746 0.766 0.766 0.770 0.737 0.730 0.701 
Total PA % 0.797 0.797 0.797 0.805 0.784 0.791 0.740 
MVPA mins 0.811 0.812 0.812 0.821 0.816 0.802 0.805 
MVPA % 0.815 0.812 0.812 0.822 0.818 0.808 0.805 
Triaxial counts/day 0.796 0.811 0.811 0.811 0.774 0.766 0.761 
Triaxial counts/min 0.840 0.838 0.838 0.841 0.821 0.821 0.802 
Steps/day 0.841 0.850 0.850 0.850 0.825 0.827 0.821 
Steps/min 0.856 0.860 0.860 0.863 0.846 0.852 0.833 
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Appendix XII: Single measure reliability values for ActivPAL 
 
 
ActivPAL outcome variables single measure intra-class correlation coefficients 
(dialysis days).  
 
Hours of wear >4 >5 >6 >7 >8 >9 >10 
Cases (n =) 55 55 52 51 51 49 44 
Sit/Lie mins 0.459 0.459 0.565 0.591 0.591 0.595 0.689 
Sit/Lie % 0.834 0.834 0.834 0.836 0.836 0.829 0.847 
Stand mins 0.681 0.681 0.692 0.700 0.700 0.662 0.683 
Stand % 0.833 0.833 0.834 0.836 0.836 0.829 0.847 
Walking mins 0.743 0.743 0.783 0.795 0.795 0.770 0.781 
Walking % 0.766 0.766 0.774 0.781 0.781 0.761 0.769 
Steps/day 0.741 0.741 0.788 0.797 0.797 0.773 0.780 
Steps/min 0.763 0.763 0.777 0.781 0.781 0.762 0.768 
Transitions/day 0.527 0.527 0.582 0.564 0.564 0.535 0.600 
Transitions/hr 0.555 0.555 0.592 0.580 0.580 0.569 0.581 
METmin/day 0.539 0.539 0.685 0.712 0.712 0.692 0.787 
METmin/min 0.812 0.812 0.828 0.831 0.831 0.824 0.852 
 
 
ActivPAL outcome variables single measure intra-class correlation coefficients 
(non-dialysis days). 
 
Hours of wear >4 >5 >6 >7 >8 >9 >10 
Cases (n =) 47 45 43 43 37 34 24 
Sit/Lie mins 0.575 0.540 0.561 0.561 0.496 0.514 0.454 
Sit/Lie % 0.697 0.692 0.675 0.675 0.638 0.611 0.667 
Stand mins 0.667 0.696 0.657 0.657 0.649 0.585 0.692 
Stand % 0.711 0.703 0.647 0.647 0.618 0.584 0.640 
Walking mins 0.722 0.740 0.734 0.734 0.718 0.694 0.727 
Walking % 0.762 0.757 0.749 0.749 0.727 0.722 0.722 
Steps/day 0.749 0.766 0.760 0.760 0.742 0.716 0.733 
Steps/min 0.778 0.778 0.770 0.770 0.747 0.739 0.727 
Transitions/day 0.538 0.558 0.542 0.542 0.540 0.442 0.406 
Transitions/hr 0.652 0.669 0.660 0.660 0.663 0.619 0.560 
EE/day 0.367 0.491 0.520 0.520 0.510 0.424 0.544 
EE/min 0.772 0.791 0.794 0.794 0.751 0.739 0.725 
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Appendix XIII Computed wear times Actigraph. 
XIII a: Computed wear times Actigraph Sedentary time (mins). 
Dialysis Day Sedentary mins Non-Dialysis Day Sedentary mins 
n = 
Wear 
hours 
Days required for 
desired reliability n = 
Wear 
hours 
Days required for 
desired reliability 
    0.7 0.8 0.9    0.7 0.8 0.9 
63 4h 3.59 6.15 13.84 54 4h 1.96 3.36 7.56 
63 5h 3.59 6.15 13.84 52 5h 2.12 3.63 8.17 
62 6h 2.83 4.85 10.92 52 6h 2.12 3.63 8.17 
60 7h 2.14 3.66 8.24 51 7h 2.04 3.49 7.86 
57 8h 1.33 2.29 5.14 40 8h 1.59 2.72 6.12 
55 9h 1.47 2.51 5.66 38 9h 1.61 2.75 6.2 
53 10h 1.61 2.76 6.22 32 10h 1.75 3.01 6.76 
 
XIII b: Computed wear times Actigraph Total PA (mins). 
Dialysis Day Total PA mins Non-Dialysis Day Total PA mins 
n = 
Wear 
hours 
Days required for 
desired reliability n = 
Wear 
hours 
Days required for 
desired reliability 
    0.7 0.8 0.9     0.7 0.8 0.9 
63 4h 0.75 1.29 2.91 54 4h 0.79 1.36 3.06 
63 5h 0.75 1.29 2.91 52 5h 0.71 1.22 2.75 
62 6h 0.67 1.15 2.60 52 6h 0.71 1.22 2.75 
60 7h 0.66 1.12 2.53 51 7h 0.70 1.19 2.69 
57 8h 0.64 1.09 2.45 40 8h 0.83 1.43 3.21 
55 9h 0.64 1.10 2.47 38 9h 0.86 1.48 3.33 
53 10h 0.65 1.11 2.50 32 10h 1.00 1.71 3.84 
 
XIII c: Computed wear times Actigraph MVPA (mins). 
Dialysis Day MVPA mins Non-Dialysis Day MVPA mins 
n = 
Wear 
hours 
Days required to 
achieve reliability n = 
Wear 
hours 
Days required to 
achieve reliability 
    0.7 0.8 0.9     0.7 0.8 0.9 
63 4h 0.60 1.04 2.33 54 4h 0.54 0.93 2.09 
63 5h 0.60 1.04 2.33 52 5h 0.54 0.93 2.08 
62 6h 0.57 0.97 2.19 52 6h 0.54 0.93 2.08 
60 7h 0.58 1.00 2.25 51 7h 0.51 0.87 1.97 
57 8h 0.60 1.02 2.30 40 8h 0.53 0.90 2.03 
55 9h 0.61 1.05 2.35 38 9h 0.58 0.99 2.23 
53 10h 0.62 1.06 2.38 32 10h 0.57 0.97 2.18 
 
 
 358 
 
Appendix XIV Computed wear times Actigraph 
XIV a: Computed wear times Actigraph MVPA (% of wear time). 
Dialysis Day MVPA % Non-Dialysis Day MVPA % 
n = 
Wear 
hours 
Days required to 
achieve reliability n = 
Wear 
hours 
Days required to 
achieve reliability 
    0.7 0.8 0.9     0.7 0.8 0.9 
63 4h 0.67 1.15 2.59 54 4h 0.53 0.91 2.05 
63 5h 0.67 1.15 2.59 52 5h 0.54 0.93 2.09 
62 6h 0.66 1.12 2.53 52 6h 0.54 0.93 2.09 
60 7h 0.67 1.16 2.60 51 7h 0.51 0.87 1.95 
57 8h 0.66 1.12 2.53 40 8h 0.52 0.89 2.00 
55 9h 0.66 1.14 2.56 38 9h 0.55 0.95 2.13 
53 10h 0.66 1.14 2.56 32 10h 0.56 0.97 2.18 
 
XIV b: Computed wear times Actigraph Triaxial counts/day. 
Dialysis Day Triaxial counts/day Non-Dialysis Day Triaxial counts/day 
n = 
Wear 
hours 
Days required to 
achieve reliability n = 
Wear 
hours 
Days required to 
achieve reliability 
    0.7 0.8 0.9     0.7 0.8 0.9 
63 4h 0.59 1.01 2.26 54 4h 0.60 1.02 2.30 
63 5h 0.59 1.01 2.26 52 5h 0.54 0.93 2.10 
62 6h 0.55 0.94 2.11 52 6h 0.54 0.93 2.10 
60 7h 0.53 0.91 2.05 51 7h 0.54 0.93 2.10 
57 8h 0.52 0.89 2.00 40 8h 0.68 1.17 2.63 
55 9h 0.51 0.88 1.98 38 9h 0.71 1.22 2.74 
53 10h 0.52 0.89 2.00 32 10h 0.73 1.26 2.83 
 
XIV c: Computed wear times Actigraph Steps/day. 
Dialysis Day Steps/day Non-Dialysis Day Steps/day 
n = 
Wear 
hours 
Days required to 
achieve reliability n = 
Wear 
hours 
Days required to 
achieve reliability 
    0.7 0.8 0.9     0.7 0.8 0.9 
63 4h 0.38 0.65 1.45 54 4h 0.90 1.54 3.47 
63 5h 0.38 0.65 1.45 52 5h 0.38 0.65 1.45 
62 6h 0.34 0.59 1.32 52 6h 0.38 0.65 1.45 
60 7h 0.34 0.58 1.31 51 7h 0.34 0.59 1.32 
57 8h 0.35 0.61 1.36 40 8h 0.34 0.58 1.31 
55 9h 0.35 0.61 1.37 38 9h 0.35 0.61 1.36 
53 10h 0.36 0.61 1.38 32 10h 0.35 0.61 1.37 
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Appendix XV Computed wear times ActivPAL. 
  XV a: Computed wear times ActivPAL Sit/Lie (minutes). 
Dialysis Day Sit/Lie (mins) Non-Dialysis Day Sit/Lie (mins) 
N= 
Wear 
hours 
Days required to 
achieve reliability N= 
Wear 
hours 
Days required to 
achieve reliability 
    0.7 0.8 0.9     0.7 0.8 0.9 
55 4h 2.75 4.72 10.61 47 4h 1.72 2.95 6.64 
55 5h 2.75 4.72 10.61 45 5h 1.98 3.40 7.66 
52 6h 1.80 3.08 6.93 43 6h 1.82 3.12 7.03 
51 7h 1.62 2.77 6.23 43 7h 1.82 3.12 7.03 
51 8h 1.62 2.77 6.23 37 8h 2.38 4.07 9.16 
49 9h 1.59 2.72 6.11 34 9h 2.21 3.79 8.52 
44 10h 1.05 1.80 4.05 24 10h 2.81 4.82 10.84 
 
XV b: Computed wear times ActivPAL Stand time (minutes). 
Dialysis Day Stand time (mins) Non-Dialysis Day Stand time (mins) 
n = 
Wear 
hours 
Days required to 
achieve reliability n = 
Wear 
hours 
Days required to 
achieve reliability 
    0.7 0.8 0.9     0.7 0.8 0.9 
55 4h 1.09 1.87 4.21 47 4h 1.16 2.00 4.49 
55 5h 1.09 1.87 4.21 45 5h 1.02 1.74 3.92 
52 6h 1.04 1.78 4.01 43 6h 1.22 2.08 4.69 
51 7h 1.00 1.71 3.86 43 7h 1.22 2.08 4.69 
51 8h 1.00 1.71 3.86 37 8h 1.26 2.16 4.86 
49 9h 1.19 2.04 4.59 34 9h 1.65 2.84 6.38 
44 10h 1.09 1.86 4.19 24 10h 1.04 1.78 4.01 
 
XV c:  Computed wear times ActivPAL Stepping time (minutes). 
Dialysis Day Stepping time (mins) Non-Dialysis Day Stepping time (mins) 
n = 
Wear 
hours 
Days required to 
achieve reliability n = 
Wear 
hours 
Days required to 
achieve reliability 
    0.7 0.8 0.9     0.7 0.8 0.9 
55 4h 0.81 1.38 3.11 47 4h 0.90 1.54 3.47 
55 5h 0.81 1.38 3.11 45 5h 0.82 1.41 3.17 
52 6h 0.65 1.11 2.49 43 6h 0.85 1.45 3.27 
51 7h 0.60 1.03 2.32 43 7h 0.85 1.45 3.27 
51 8h 0.60 1.03 2.32 37 8h 0.91 1.57 3.53 
49 9h 0.70 1.19 2.69 34 9h 1.03 1.77 3.97 
44 10h 0.66 1.12 2.53 24 10h 0.88 1.50 3.38 
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Appendix XVI Computed wear times ActivPAL. 
XVI a: Computed wear times ActivPAL Stepping time (% of wear time). 
Dialysis Day Stepping time (%) Non-Dialysis Day Stepping time (%) 
n = 
Wear 
hours 
Days required to 
achieve reliability n = 
Wear 
hours 
Days required to 
achieve reliability 
    0.7 0.8 0.9     0.7 0.8 0.9 
55 4h 0.71 1.22 2.75 47 4h 0.73 1.25 2.80 
55 5h 0.71 1.22 2.75 45 5h 0.75 1.28 2.89 
52 6h 0.68 1.17 2.63 43 6h 0.78 1.34 3.02 
51 7h 0.65 1.12 2.52 43 7h 0.78 1.34 3.02 
51 8h 0.65 1.12 2.52 37 8h 0.88 1.51 3.39 
49 9h 0.73 1.26 2.83 34 9h 0.90 1.54 3.47 
44 10h 0.70 1.20 2.71 24 10h 0.90 1.54 3.47 
 
XVI b: Computed wear times ActivPAL Steps/day. 
Dialysis Day Steps/day Non-Dialysis Day Steps/day 
n = 
Wear 
hours 
Days required to 
achieve reliability n = 
Wear 
hours 
Days required to 
achieve reliability 
    0.7 0.8 0.9     0.7 0.8 0.9 
55 4h 0.82 1.40 3.14 47 4h 0.78 1.34 3.01 
55 5h 0.82 1.40 3.14 45 5h 0.71 1.22 2.75 
52 6h 0.63 1.08 2.42 43 6h 0.74 1.26 2.84 
51 7h 0.59 1.02 2.29 43 7h 0.74 1.26 2.84 
51 8h 0.59 1.02 2.29 37 8h 0.81 1.39 3.13 
49 9h 0.69 1.17 2.64 34 9h 0.93 1.59 3.57 
44 10h 0.66 1.13 2.54 24 10h 0.85 1.46 3.28 
 
XVI c: Computed wear times ActivPAL Transitions/day. 
Dialysis Day Transitions/day Non-Dialysis Day Transitions/day 
n = 
Wear 
hours 
Days required to 
achieve reliability n = 
Wear 
hours 
Days required to 
achieve reliability 
    0.7 0.8 0.9     0.7 0.8 0.9 
55 4h 2.09 3.59 8.08 47 4h 2.00 3.44 7.73 
55 5h 2.09 3.59 8.08 45 5h 1.85 3.17 7.14 
52 6h 1.67 2.87 6.45 43 6h 1.97 3.38 7.60 
51 7h 1.80 3.09 6.95 43 7h 1.97 3.38 7.60 
51 8h 1.80 3.09 6.95 37 8h 1.99 3.41 7.67 
49 9h 2.03 3.48 7.82 34 9h 2.94 5.05 11.36 
44 10h 1.55 2.67 6.00 24 10h 3.41 5.85 13.17 
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Appendix XVII Computed wear times ActivPAL. 
XVII a: Computed wear times ActivPAL Transitions/hour. 
Dialysis Day Transitions/hour Non-Dialysis Day Transitions/hour 
n = 
Wear 
hours 
Days required to 
achieve reliability n = 
Wear 
hours 
Days required to 
achieve reliability 
    0.7 0.8 0.9     0.7 0.8 0.9 
55 4h 1.87 3.21 7.23 47 4h 1.25 2.14 4.81 
55 5h 1.87 3.21 7.23 45 5h 1.15 1.98 4.45 
52 6h 1.61 2.76 6.20 43 6h 1.20 2.06 4.63 
51 7h 1.69 2.90 6.52 43 7h 1.20 2.06 4.63 
51 8h 1.69 2.90 6.52 37 8h 1.18 2.03 4.57 
49 9h 1.77 3.03 6.82 34 9h 1.44 2.46 5.54 
44 10h 1.68 2.88 6.49 24 10h 1.83 3.14 7.06 
 
 
XVII b: Computed wear times ActivPAL Energy Expenditure per day. 
Dialysis Day EE/day Non-Dialysis Day EE/day 
n = 
Wear 
hours 
Days required to 
achieve reliability n = 
Wear 
hours 
Days required to 
achieve reliability 
    0.7 0.8 0.9     0.7 0.8 0.9 
55 4h 2.00 3.42 7.70 47 4h 4.02 6.89 15.50 
55 5h 2.00 3.42 7.70 45 5h 2.42 4.14 9.32 
52 6h 1.07 1.84 4.14 43 6h 2.15 3.69 8.31 
51 7h 0.95 1.62 3.65 43 7h 2.15 3.69 8.31 
51 8h 0.95 1.62 3.65 37 8h 2.24 3.85 8.66 
49 9h 1.04 1.78 4.00 34 9h 3.17 5.44 12.24 
44 10h 0.63 1.08 2.43 24 10h 1.96 3.36 7.55 
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Appendix XVIII: Results of normality testing of sedentary and PA 
outcomes. 
 
 
Outcome ActivPAL Actigraph Seven Day recall 
 Statistic df Sig. Statistic df Sig. Statistic df Sig. 
Sedentary (min) 0.977 37 0.636 0.985 37 0.885   
Sedentary (%) 0.915 37 0.008 0.898 37 0.003   
Light PA (min)   0.969 39 0.361 0.942 69 0.003 
Moderate PA 
(min)   0.858 39 0 0.753 39 0 
Vigorous PA (min)   0.227 39 0 0.609 39 0 
MVPA (min)   0.869 39 0 0.755 39 0 
Total PA (min) 0.939 37 0.042 0.917 37 0.009   
Total PA (%) 0.915 37 0.008 0.898 37 0.003   
Steps / day 0.771 37 0 0.764 37 0   
Steps / minute 0.774 37 0 0.765 37 0   
Counts/day 0.787 37 0 0.757 37 0   
Counts/min 0.786 37 0 0.769 37 0   
EE (kcals)   0.631 39 0 0.845 39 0 
EE (MET mins) 0.969 35 0.411   0.935 35 0.039 
EE (MET mins) 0.980 37 0.736 0.962 37 0.237   
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Appendix XIX – Concordance ActivPAL/Actigraph 
XIX a: Dialysis day - ActivPAL v Actigraph 
Sedentary (min) 
XIX b: Dialysis day - ActivPAL & Actigraph 
Sedentary (min) LOA 
   
 
XIX c: Non-dialysis day - ActivPAL v 
Actigraph Sedentary (min) 
XIX d: Dialysis day - ActivPAL & Actigraph 
Sedentary (min) LOA 
    
 
XIX e: Dialysis day - ActivPAL v Actigraph 
Sedentary (%) 
XIX f: Dialysis day - ActivPAL & Actigraph 
Sedentary (%) LOA 
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Appendix XIX continued 
 
XIX g: Non-dialysis day ActivPAL v 
Actigraph Sedentary (%) 
XIX h: Non-dialysis day ActivPAL & 
Actigraph Sedentary (%) LOA 
    
XIX i: Dialysis day Actigraph v ActivPAL total 
PA (mins) 
XIX j: Dialysis day Actigraph v ActivPAL total 
PA (mins) LOA 
       
XIX k: Non-dialysis day Actigraph v ActivPAL 
total PA (mins) 
XIX l: Non-dialysis day Actigraph v 
ActivPAL total PA (mins) LOA  
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Appendix XIX continued 
XIX m: Dialysis day Actigraph v ActivPAL total 
PA (%) 
XIX n: Dialysis day Actigraph & ActivPAL total 
PA (%) LOA 
       
 
 
XIX o: Non-dialysis day Actigraph v ActivPAL 
total PA (%) 
 
XIX p: Non-dialysis day Actigraph & ActivPAL 
total PA (%) LOA  
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Appendix XX - Concordance ActivPAL/Actigraph 
XX a: Dialysis day Actigraph v ActivPAL 
steps/day 
XX b: Dialysis day Actigraph v ActivPAL 
steps/day  
     
 
XX c: Non-dialysis day Actigraph v ActivPAL 
steps/day 
 
XX d: Non-dialysis day Actigraph & ActivPAL 
steps/day  
       
 
XX e: Dialysis day Actigraph v ActivPAL 
uniaxial counts/day 
 
XX f: Dialysis day Actigraph &ActivPAL 
uniaxial counts/day LOA  
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Appendix XX continued 
XX g: Non-Dialysis day Actigraph v ActivPAL 
uniaxial counts/day 
XX h: Non-Dialysis day Actigraph v ActivPAL 
uniaxial counts/day  
     
 
XX i: Dialysis day Actigraph v ActivPAL 
uniaxial counts/min 
 
XX j: Dialysis day Actigraph & ActivPAL 
uniaxial counts/min LOA 
            
 
XX k: Non-Dialysis day Actigraph v ActivPAL 
uniaxial counts/min 
 
XX l: Non-Dialysis day Actigraph v ActivPAL 
uniaxial counts/min  
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Appendix XXI Concordance 7DR/Actigraph  
XXI a: Dialysis day 7DR v Actigraph MVPA (min)  XXI b: Dialysis day 7DR & Actigraph MVPA 
(min) LOA 
      
 
XXI c: Non-dialysis day 7DR v Actigraph MVPA 
(min)  
 
XXI d: Non-dialysis day 7DR & Actigraph 
MVPA (min) LOA 
     
  
 
XXI e: Dialysis day 7DR v Actigraph EE/day 
(METmin) 
 
XXI f: Dialysis day 7DR & Actigraph EE/day 
LOA (METmin) 
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Appendix XXI continued 
XXI g: Non-dialysis day 7DR v Actigraph 
EE/day (METmin)  
XXI h: Non-dialysis day 7DR & Actigraph EE/day 
LOA (METmin) 
     
XXI i: Dialysis day 7DR v ActivPAL EE/day 
(METmin) 
XXI j: Dialysis day 7DR & ActivPAL EE/day 
(METmin) LOA 
       
 
XXI k: Non-dialysis day 7DR v ActivPAL 
EE/day (METmin) 
 
XXI l: Non-dialysis day 7DR & ActivPAL 
EE/day (METmin) LOA  
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Appendix XXI continued 
XXI m: Dialysis day 7DR v Actigraph MVPA 
EE/day (kcals)  
XXI n: Dialysis day 7DR & Actigraph MVPA 
EE/day (kcals) LOA 
       
 
XXI o: Non-dialysis day 7DR v Actigraph 
MVPA EE/day (kcals)  
XXI p: Non-dialysis day 7DR & Actigraph 
MVPA EE/day (kcals) LOA 
 
     
 
 
 371 
Appendix XXII Participant characteristics chapter 5  
Appendix XXII a: Participant characteristics. 
Participant Characteristic Total sample Sample with sufficient PA data 
Age (years) 55.6 ± 15.6 57.5 ± 15.5 
Gender M/F (%) 48/25 (66/34) 40 / 23 (63/37) 
Body Mass Index (kg/m2) 28.5 ± 6.3 28.7 ± 6.3 
Resting Heart rate (bpm) 72.0 ± 13.0 71.7 ± 12.4 
Systolic (mmHg) 135.6 ± 24.5 134.7 ± 23.8 
Diastolic  (mmHg) 77.6 ± 12.0 75.5 ± 9.8 
Systemic pulse pressure  (mmHg) 52 (43 - 70) 53 (43 - 70) 
Mean arterial pressure (mmHg) 96.9 ± 13.8 95.2 ± 11.9 
Haemodialysis Vintage (months) 16.8 (6.7 - 32.7) 14.8 (6.8 - 31.4) 
Renal Replacement Therapy Vintage (months) 25.9 (8.1 - 68.8) 25.9 (8.3 - 69.3) 
Haemoglobin (g/dL) 11.2 ± 1.0 11.2 ± 1.0 
Haematocrit  (%) 33.9 ± 3.2 33.9 ± 3.2 
C-reactive protein (mg/L)  0 (0 - 10.0) 0 (0 – 10.0) 
Dialysis Adequacy  (%) 71 (66 - 75) 71 (66 - 75) 
Albumin   (g/L) 39.0 (36.0 - 42.0) 39.0 (36.0 - 41.0) 
Troponin T   (ng/L) 37 (20.5 - 69.5) 37.0 (21.0 - 69.0) 
Corrected Calcium serum level  (mmol/L) 2.36 ± 0.17 2.37 ± 0.17 
Phosphate   (mmol/L) 1.43 ± 0.41 1.40 ± 0.33 
Parathyroid level  (mmol/L) 16.8 (9.9 - 30.6) 16.4 (9.7 - 30.9) 
Creatinine pre-dialysis   (mmol/L) 683 (558 - 672) 644 (546 - 856) 
Total number of medications 9 (7 - 12) 10 (8 - 12) 
Number of comorbidities,  (N) 1.0 ± 0.8 1.0 ± 0.8 
x Hypertension (%) 42 (58) 35 (56) 
x Diabetes mellitus (%) 16 (22) 16 (24) 
x Cardiovascular disease (%) 14 (19) 13 (21) 
 
Appendix XXII b: Determination of physical performance, functional status 
outcome, and physical activity differences between male and female 
participants. 
Outcome n = Recruited sample n = Sample with PA data 
Hand grip strength  72 t(70)=7.43, p <0.001, d =0.88 63 t(61) = 6.62, p <0.001, d = 
0.83 
Sit-to-stand 5 70 Z = -0.65, p =0.52, 61 Z = -0.40, P = 0.69 
Timed up-and-go 72 Z = 0, p = 1.0 63 Z = -0.36, p = 0.72 
ISWT 69 Z = -0.10, p = 0.92 61 Z = -0.28, p = 0.78 
Duke  73 Z = -2.62, p = 0.01, r = 0.31 63 Z = -2.321, p = 0.02, r = 0.29 
KDQOL-SF PCS 65 Z = -2.20, p = 0.03, r = 0.27 58 Z = -2.129, p = 0.03, r = 0.28 
Physical activity    63 Z = -2.027, p = 0.04, r = 0.26 
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Appendix XXIII Shuttle W
alk Test outcom
es 
Appendix XXIII a: Results of m
ultiple regression analyses for Increm
ental Shuttle W
alk Test outcom
e variables.  
Variable 
Shuttle walk test distance 
(m
) 
Shuttle walk test gait speed 
(m
/s) 
Shuttle walk test fitness 
(M
ETs) 
 
U
nstandardized β C
oefficient 
(Low
er, U
pper bound) 
U
nstandardized β C
oefficient  
(Low
er, U
pper bound) 
U
nstandardized β C
oefficient 
(Low
er, U
pper bound) 
Age 
-5.98*** (-8.85, -3.1) 
-0.01*** (-0.02, -0.01) 
-0.04** (-0.07, -0.02) 
B
M
I 
-8.62* (-15.54, -1.70) 
-0.02** (-0.032, -0.004) 
-0.07* (-0.14, -0.01) 
M
edications 
-17.29* (-31.14, -3.44) 
-0.04** (-0.07, -0.01) 
-0.19** (-0.32, -0.05) 
r 
0.63 
0.64 
0.59 
r 2 
0.40 
0.41 
0.35 
r 2 adjusted 
0.37 
0.38 
0.32 
 Appendix XXIII b: Results of Increm
ental Shuttle W
alk Test m
ultiple regression analyses with physical activity as additional 
predictor variable. 
Variable 
Shuttle walk test distance 
(m
) 
Shuttle walk test gait speed 
(m
/s) 
Shuttle walk test fitness 
(M
ETs) 
 
U
nstandardized β C
oefficient 
(Low
er, U
pper bound) 
U
nstandardized β C
oefficient  
(Low
er, U
pper bound) 
U
nstandardized β C
oefficient 
(Low
er, U
pper bound) 
Age 
-3.568** (-6.09, -1.04) 
-0.008** (-0.014, -0.002) 
-0.029* (-0.056, -0.002) 
B
M
I 
-6.91* (-12.59, -1.23) 
-0.015** (-0.028, -0.002) 
-0.063* (-0.123, -0.002) 
M
edications 
-11.51* (-22.58, -0.44) 
-0.026** (-0.051, -0.002) 
-0.145* (-0.263, -0.027) 
PA 
0.47 *** (0.31, 0.64) 
0.001*** (0.001, 0.001) 
0.003** (0.001, 0.005) 
r 
0.79 
0.76 
0.69 
r 2 
0.62 
0.57 
0.48 
r 2 adjusted 
0.59 
0.54 
0.44 
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Appendix XXIV Participant characteristics chapter 6 
 
Participant characteristics whole sample and participants with sufficient PA data 
for final analyses.  
Characteristic 
Total sample 
n = 73 
Sample with 
sufficient PA data n 
= 63 
Age (years) 55.6 ± 15.6 57.5 ± 15.5 
Gender M/F (%) 48/25 (66/34) 40 / 23 (63/37) 
Weight 81.0 ±17.5 80.5 ± 16.4 
Height 167.7 ± 16.6 166.5 ± 17.2 
Body Mass Index (kg/m2) 28.5 ± 6.3 28.7 ± 6.3 
Resting Heart rate (bpm) 72.0 ± 13.0 71.7 ± 12.4 
Systolic (mmHg) 135.6 ± 24.5 134.7 ± 23.8 
Diastolic  (mmHg) 77.6 ± 12.0 75.5 ± 9.8 
Systemic pulse pressure  (mmHg) 52 (43 - 70) 53 (43 - 70) 
Mean arterial pressure (mmHg) 96.9 ±13.8 95.2 ± 11.9 
Haemodialysis Vintage (months) 16.8 (6.7 - 32.7) 14.8 (6.8 - 31.4) 
Renal Replacement Therapy Vintage 
(months) 
25.9 (8.1 - 68.8) 25.9 (8.3 - 69.3) 
Haemoglobin (g/dL) 11.2 ± 1.0 11.2 ± 1.0 
Haematocrit  (%) 33.9 ± 3.2 33.9 ± 3.2 
C-reactive protein (mg/L)  0 (0 - 10.0) 0 (0 - 10.0) 
Dialysis Adequacy  (%) 71 (66 - 75) 71 (66 - 75) 
Albumin   (g/L) 39.0 (36.0 - 42.0) 39.0 (36.0 - 41.0) 
Troponin T   (ng/L) 37 (20.5 - 69.5) 37.0 (21.0 - 69.0) 
Corrected Calcium serum level  (mmol/L) 2.36 ± 0.17 2.37 ± 0.17 
Phosphate   (mmol/L) 1.43 ± 0.41 1.40 ± 0.33 
Parathyroid level  (mmol/L) 16.8 (9.9 - 30.6) 16.4 (9.7 - 30.9) 
Creatinine pre-dialysis   (mmol/L) 683 (558 - 672) 644 (546 - 856) 
Number of vasoactive medications 2 (1 - 3.5) 2 (1 - 3) 
Number of comorbidities,  (N) 1.0 ± 0.8 1.0 ± 0.8 
x Hypertension (%) 42 (58) 35 (56) 
x Diabetes mellitus (%) 16 (22) 16 (24) 
x Cardiovascular disease (%) 14 (19) 13 (21) 
Shuttle walk test distance  280 (170 - 440)¥ 280 (150 - 430)¥¥ 
Pulse wave velocity 7.50 (6.3 - 9.0)  
8.03 ± 2.3† 
7.6 (6.4 - 9.4) 
8.10 ± 2.3† 
Augmentation Index 20.4 ± 7.5 20.9 ± 6.9 
†data non-normally distributed, mean ± std dev presented for comparison 
¥n = 69, ¥¥n = 61 
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Appendix XXV PWV univariable associations 
Appendix XXV a: Univariable associations with pulse wave velocity participants 
with sufficient PA data (n = 63). 
Variable Unstandardized β 
(Lower, Upper) 
Pearson r 
Age 0.10*** (0.07, 0.13) 0.45*** 
Systolic Bp 0.05*** (0.02, 0.07) 0.23*** 
Troponin-T  0.01** (0, 0.02) 0.11** 
Serum phosphate  -2.19* (-3.89, -0.48) -0.10** 
Diabetic status 1.57* (0.26, 2.88) 0.09*  
HD Vintage 0.02* (0, 0.04) 0.08* 
Vasoactive Medications 0.42* (0.05, 0.78) 0.09* 
Creatinine (predialysis) -0.003* (-0.006, 0) -0.07* 
Creatinine (postdialysis) -0.006  (-0.013, 0) -0.06, p = 0.07 
Comorbidity number 0.7  (-0.03, 1.42) 0.06, p = 0.06 
Gender -1.09  (-2.27, 0.09) -0.05, p = 0.07 
   
Physical Activity -0.003*(-0.005, -0.001) -0.09** 
ISWT † -0.005** (-0.007, -0.002) -0.18*** 
†n = 61 
 
Appendix XXV b: Univariable associations with augmentation index participants 
with sufficient PA data (n = 63). 
Variable Unstandardized β 
(Lower, Upper) 
Pearson r 
Heart rate -0.18* (-0.31, -0.04) -0.11** 
Height -0.106* (-0.205, -0.007) -0.07* 
Age 0.1 (-0.013, 0.214) 0.05, p = 0.08 
BMI 0.24 (-0.035, 0.513) 0.05, p = 0.09 
Haematocrit † 0.48 (-0.07, 1.03) 0.05, p = 0.08 
Haemoglobin 1.16 (-0.60, 2.93) 0.03, p = 0.19 
Physical activity† -0.005 (-0.012, 0.003) 0.05, p = 0.11 
ISWT †† -0.008* (-0.017, 0) 0.07* 
†n = 62   ††n = 61 
 
 
 375 
Appendix XXVI PWV multivariable regression 
 
Appendix XXVI a: Results of pulse wave velocity multivariable regression 
analysis with model adjusted for MAP, gender, heart rate.   
Variable Unstandardized β (Lower, Upper) 
Age 0.08*** (0.054, 0.106) 
Troponin T  0.01** (0.003, 0.016) 
Creatinine (post-dialysis) -0.004* (-0.008, 0.000) 
HD Vintage 0.015* (0.001, 0.029) 
Mean arterial pressure 0.038* (0.008, 0.068) 
r  0.77 
r2 0.60 
r2 (adjusted) 0.57 
*p < 0.05, ** p < 0.01, ***p < 0.001, n = 71 
 
 
Appendix XXVI b: Results of AI multivariable regression analysis with model 
adjusted for MAP.   
Variable Unstandardized β (Lower, Upper) 
Age 0.13** (0.04, 0.23) 
Height -0.15** (-0.24, -0.07) 
Body mass index 0.313* (0.07, 0.56) 
Resting heart rate -0.19** (-0.31, -0.07) 
Haemoglobin 1.69* (0.31, 3.07) 
Mean arterial pressure 0.12* (0.01, 0.22) 
r  0.66 
r2 0.44 
r2 (adjusted) 0.38 
*p < 0.05, ** p < 0.01, ***p < 0.001, n = 71 
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Appendix XXVII Boxplot and scatterplot behavioural outliers  
Appendix XXVII a: Boxplot of participant physical activity level. 
 
 
 
Appendix XXVII b: Scatterplot of PWV versus habitual PA 
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Appendix XXVIII Smart technology vs research accelerometer price 
 
Research accelerometers 
used in this study 
Manufacturer Price per unit and 
ancillaries 
ActivPAL PAL Technologies Ltd, Glasgow £405 – 465 + £390 
(software licence) + £7 
for 10 ‘stickies’/week 
Actigraph GT3X Actigraphcorp, Pensacola, Florida £452 (monitor 
+software licence) 
 
Consumer wearables  Price range 
Apple Watch Apple Inc, California, USA £479 - 949 
Fitbit Fitbit Inc, San Francisco, USA £99 - 119 
Nike Fuelband Nike Inc, Beaverton, USA £60 - 179 
Samsung Gearfit Samsung Group, Korea £58 - 129 
Sony Smartband SWR10 Sony Corp, Tokyo, Japan £25 - 100 
Jawbone UP3 Jawbone, San Francisco, USA £130 - 150 
Withings Activite and Pulse 
Ox 
Issy-les-Moulineaux, France £70 
 
 
 
 
 
Appendix XXIX Fried Frailty criteria 
 
Application of adapted Fried et al. (2001) frailty criteria. 
 
Frailty is determined by an individual meeting three of the five criteria for frailty 
proposed by Fried et al. (2001): unintentional weight loss; weakness (grip strength); 
slow gait; exhaustion; low physical activity.  
 
x The KDQOL-SF ‘vitality’ subscale was substituted for self-reported 
exhaustion from the Centre for Epidemiological Studies Depression scale 
(Johansen et al. 2007; Bao et al 2012; Painter and Kuskowski 2013).  
x Instead of the original 15 foot average gait speed test, terminal gait speed 
from the incremental shuttle walk test was employed. If a participant’s 
terminal gait speed was below 1.2 m/s, the threshold required to walk across 
a pedestrian crossing safely (Asher et al 2012) they were classified as 
having ‘slow gait’.  
x A body mass index below 18.5 kg/m2 was used as a surrogate for ‘shrinkage’ 
or unintentional weight loss as previously used by Painter and Kuskowski 
2013. 
x Participants’ Actigraph data were employed to classify individuals with ‘low 
PA’. Accumulation of less than 50 minutes/day of all PA (defined as >100 
cpm), which is predictive of mobility deterioration in stage 5 CKD (Kutsuna et 
al 2010) was employed.  
 
